"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtWith_AU_IN_FIRST","meanArtWith_AU_IN_LAST","meanArtWith_AU_IN_CORR","mean_articles_per_internal_author","mean_articles_per_internal_first_author","mean_articles_per_internal_last_author","mean_articles_per_internal_corresponding_author","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","meanCitationTrend","InternCoauthorship","AffCoauthorship","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"IRCCS_TUMORIMILAN",2000,222,7.85585585585586,3.5045045045045,0.59009009009009,0.468468468468468,0.59009009009009,1.86124401913876,1.22429906542056,1.44444444444444,1.22429906542056,0.202702702702703,9,90,37,31,53,0.41,0.17,0.14,0.24,46.34,1.02231067527539,NA,0.292792792792793,0.599099099099099,0.453,0.353,0.436,0.36,"MARCO A. PIEROTTI;FRANCO BERRINO;EMILIO BOMBARDIERI;ELIA BIGANZOLI;EMILIO BAJETTA;MARIO P. COLOMBO;TOMMASO A. DRAGANI;GIANFRANCESCO GALLINO;S TURA;FILIBERTO BELLI;EMANUELA OTTAVIANI;MARIA GRAZIA DAIDONE;FRANCO ZUNINO;CAROLINA TERRAGNA;NICOLETTA TESTONI;PATRIZIA BORACCHI;VITTORIO MONTEFUSCO;FEDERICO BOZZETTI;ELDA TAGLIABUE;SALVATORE ANDREOLA","14;10;10;9;9;9;8;8;8;7;7;7;7;7;7;7;7;7;7;7","MARCO A. PIEROTTI;GIORGIO PARMIANI;FRANCO BERRINO;FRANCA FORMELLI;MONICA BINASCHI;EMILIO BOMBARDIERI;GIANNI BONADONNA;FEDERICO BOZZETTI;ELIA BIGANZOLI;GEMMA GATTA;CARLO GAMBACORTI‐PASSERINI;PATRIZIA BORACCHI;SANTE BASSO RICCI;MARIO P. COLOMBO;EMILIO BAJETTA;FRANCO ZUNINO;MARIA GRAZIA DAIDONE;GIANFRANCESCO GALLINO;IGNAZIO CATALDO;TOMMASO A. DRAGANI","1.77;1.6;1.56;1.5;1.5;1.49;1.45;1.45;1.4;1.22;1.21;1.18;1.17;1.16;1.14;1.11;1.1;1.06;1.06;1.04","MARCO A. PIEROTTI;FRANCO BERRINO;EMILIO BOMBARDIERI;ELIA BIGANZOLI;EMILIO BAJETTA;MARIO P. COLOMBO;TOMMASO A. DRAGANI;GIANFRANCESCO GALLINO;FILIBERTO BELLI;MARIA GRAZIA DAIDONE;FRANCO ZUNINO;PATRIZIA BORACCHI;VITTORIO MONTEFUSCO;FEDERICO BOZZETTI;ELDA TAGLIABUE;SALVATORE ANDREOLA;SILVANA PILOTTI;SYLVIE MÉNARD;IGNAZIO CATALDO;GABRIELLA SOZZI","14;10;10;9;9;9;8;8;7;7;7;7;7;7;7;7;7;7;6;6","MARCO A. PIEROTTI;GIORGIO PARMIANI;FRANCO BERRINO;FRANCA FORMELLI;MONICA BINASCHI;EMILIO BOMBARDIERI;GIANNI BONADONNA;FEDERICO BOZZETTI;ELIA BIGANZOLI;GEMMA GATTA;CARLO GAMBACORTI‐PASSERINI;PATRIZIA BORACCHI;SANTE BASSO RICCI;MARIO P. COLOMBO;EMILIO BAJETTA;FRANCO ZUNINO;MARIA GRAZIA DAIDONE;GIANFRANCESCO GALLINO;IGNAZIO CATALDO;TOMMASO A. DRAGANI","1.77;1.6;1.56;1.5;1.5;1.49;1.45;1.45;1.4;1.22;1.21;1.18;1.17;1.16;1.14;1.11;1.1;1.06;1.06;1.04","FRANCO BERRINO;ANDREA MICHELI;CARLO GAMBACORTI‐PASSERINI;GEMMA GATTA;MARCO A. PIEROTTI;GABRIELLA SOZZI;ROSANNA SUPINO;EMILIO BOMBARDIERI;MARIO P. COLOMBO;ARDUINO VERDECCHIA;LYNN A. G. RIES;MICHEL P. COLEMAN;MILENA SANT;RICCARDO CAPOCACCIA;BARBARA PASINI;BARBARA WEBER;CARYN LERMAN;DOMINIQUE STOPPA-LYONNET;HENRY T. LYNCH;JEAN-SÉBASTIEN BRUNET","984;872;861;836;785;616;616;611;611;560;560;560;560;560;534;534;534;534;534;534","FRANCO BERRINO;ANDREA MICHELI;CARLO GAMBACORTI‐PASSERINI;GEMMA GATTA;MARCO A. PIEROTTI;GABRIELLA SOZZI;ROSANNA SUPINO;MARIO P. COLOMBO;MILENA SANT;BARBARA PASINI;VINCENZO MAZZAFERRO;E. ̃TASSI;EDOARDO MARCHESI;GONÇALO J. M. CABRITA;LUCA MOLOGNI;MARILEILA VARELLA‐GARCIA;PHILIPP LE COUTRE;ROSSELLA BARNI;F GARBAGNATI;ALFONSO MARCHIANÒ","984;872;838;836;699;616;616;611;560;534;533;507;507;507;507;507;507;507;494;480","MARCO A. PIEROTTI;FRANCO ZUNINO;MARIO P. COLOMBO;ELIA BIGANZOLI;FRANCO BERRINO;ELDA TAGLIABUE;EMILIO BAJETTA;FEDERICO BOZZETTI;GIANFRANCESCO GALLINO;SALVATORE ANDREOLA;SILVANA PILOTTI;TOMMASO A. DRAGANI;SYLVIE MÉNARD;VITTORIO MONTEFUSCO;EMILIO BOMBARDIERI;MARIA GRAZIA DAIDONE;FILIBERTO BELLI;GABRIELLA SOZZI;GIORGIO PARMIANI;LUIGI MARIANI","12;10;9;9;9;7;7;7;7;7;7;7;7;7;6;6;6;6;6;6","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;MATHEMATICS;ECONOMICS;ENGINEERING;HISTORY;SOCIOLOGY;MATERIALS SCIENCE;PHILOSOPHY;PSYCHOLOGY;ART;GEOGRAPHY","161;121;32;19;9;6;5;3;3;3;2;2;2;1;1","INTERNAL MEDICINE;GENETICS;CANCER RESEARCH;ONCOLOGY;BIOCHEMISTRY;PATHOLOGY;IMMUNOLOGY;SURGERY;MOLECULAR BIOLOGY;RADIOLOGY;CELL BIOLOGY;ENDOCRINOLOGY;GASTROENTEROLOGY;PALEONTOLOGY;ENVIRONMENTAL HEALTH;GYNECOLOGY;PHARMACOLOGY;ORGANIC CHEMISTRY;VIROLOGY;NUCLEAR MEDICINE","120;67;63;51;50;50;46;44;35;22;21;21;18;15;10;10;10;9;9;8","CANCER;GENE;CHEMOTHERAPY;CELL CULTURE;MELANOMA;RADIATION THERAPY;IN VITRO;ANTIGEN;CARCINOMA;DISEASE;IMMUNOHISTOCHEMISTRY;RECEPTOR;CELL;IMMUNE SYSTEM;DNA;LYMPH NODE;POPULATION;SIGNAL TRANSDUCTION;HORMONE;STAGE (STRATIGRAPHY);TRANSPLANTATION","89;59;28;17;15;15;14;13;13;13;13;13;12;11;10;10;10;10;9;9;9","BREAST CANCER;COLORECTAL CANCER;TYROSINE KINASE;CARCINOGENESIS;METASTASIS;CELL CYCLE;CHROMOSOME;CD8;CISPLATIN;NEUTROPENIA;RECOMBINANT DNA;ALLELE;CYTOTOXIC T CELL;GENE EXPRESSION;MUTATION;T CELL;TRANSFECTION;TRANSGENE;ADENOCARCINOMA;BREAKPOINT CLUSTER REGION;CANCER REGISTRY;CHROMOSOMAL TRANSLOCATION;EXON;MONOCLONAL ANTIBODY;RECEPTOR TYROSINE KINASE","34;13;12;11;11;8;8;7;7;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;5","TAMOXIFEN;ABL;AROMATASE;GENETICALLY MODIFIED MOUSE;MAMMARY GLAND;COLONOSCOPY;CTL*;CYTOGENETICS;FEBRILE NEUTROPENIA;KARYOTYPE;METASTATIC BREAST CANCER;PHILADELPHIA CHROMOSOME;RELATIVE SURVIVAL;TRK RECEPTOR;TUMOR SUPPRESSOR GENE;ANTHRACYCLINE;AUTOPHOSPHORYLATION;CD59;COMPLEMENT MEMBRANE ATTACK COMPLEX;CORPUS UTERI;CYCLIN;DNA METHYLATION;FOLATE RECEPTOR;FUSION PROTEIN;FUSION TRANSCRIPT;LOSS OF HETEROZYGOSITY;MAMMOGRAPHY;MASTECTOMY;MICROSATELLITE;MUCOSA-ASSOCIATED LYMPHOID TISSUE;RETINOID;RNA SPLICING;SENTINEL NODE;TELOMERASE REVERSE TRANSCRIPTASE;THYMIDINE KINASE;TROPOMYOSIN RECEPTOR KINASE A;VINCRISTINE;VINORELBINE","8;5;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;BREAST NEOPLASMS;MIDDLE AGED;MALE;ADULT;AGED;MELANOMA;LUNG NEOPLASMS;ANTINEOPLASTIC AGENTS;TUMOR CELLS, CULTURED;ANIMALS;;NEOPLASM PROTEINS;MICE;ADENOCARCINOMA;NEOPLASMS;SKIN NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CARCINOMA","169;109;102;72;66;58;58;54;47;45;42;39;38;34;32;30;30;30;29;29","IMMUNOBIOLOGY OF DENDRITIC CELLS;EFFICACY AND RESISTANCE IN CML TREATMENT;THE P53 SIGNALING NETWORK IN CANCER RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;MECHANISMS OF ESTROGEN RECEPTOR SIGNALING;MELANOMA;MOLECULAR RESEARCH ON BREAST CANCER;ROLE OF RETINOIC ACID IN BIOLOGICAL PROCESSES;SARCOMA RESEARCH AND TREATMENT;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DNA TOPOISOMERASES: STRUCTURE, FUNCTION, AND INHIBITION;ENDOSCOPIC SKULL BASE SURGERY TECHNIQUES;GASTRIC CANCER RESEARCH AND TREATMENT;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;ADVANCES IN METABOLOMICS RESEARCH;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ENGINEERING BACTERIA FOR CANCER TREATMENT;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;LYMPHOID NEOPLASMS","14;7;7;6;6;6;6;5;5;4;4;4;4;4;3;3;3;3;3;3","ANTIGEN PRESENTATION;BREAST CANCER;MELANOMA;RADIOTHERAPY;CANCER RISK;CANCER THERAPY;NEUROENDOCRINE TUMORS;ABL;BREAKPOINT CLUSTER REGION;MEMORY T CELLS;PANCREATIC NEUROENDOCRINE TUMORS;REGIMEN;T CELL IMMUNITY;TUMOR MICROENVIRONMENT;CANCER IMMUNOTHERAPY;IMMUNOPHENOTYPING;MICROTUBULE-TARGETING AGENTS;SURGICAL ONCOLOGY;TRANSGENE EXPRESSION;TUMOR SUPPRESSION","9;8;8;8;7;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4","BREAST CANCER;CANCER PATIENTS;LUNG CANCER;HODGKINS DISEASE;LYMPH NODE;CANCER INSTITUTE;CELL LUNG;COLORECTAL CANCER;HUMAN MELANOMA;MELANOMA CELLS;NODE-POSITIVE BREAST;OVARIAN CANCER;PERIPHERAL BLOOD;STEM CELL;TUMORS INVOLVING;CANCER CELLS;CARCINOMA CELL;CELL CARCINOMA;CELL TRANSPLANTATION;CHRONIC MYELOID;CUTANEOUS MELANOMA;GENE PRODUCT;HUMAN BREAST;HUMAN OVARIAN;LEUKEMIA PATIENTS;MULTIPLE MYELOMA;MYELOID LEUKEMIA;NEUROENDOCRINE TUMOURS;PATIENTS RECEIVING;PATIENTS TREATED","26;10;6;5;5;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","PUBMED SCOPUS;CROSSREF PUBMED;HODGKINS DISEASE;BREAST CANCER;CELL LINES;BREAST CARCINOMA;GP TRK;ISTITUTO NAZIONALE;NAZIONALE TUMORI;TUMORI MILAN;FHIT PROTEIN;KINASE ACTIVITY;TYROSINE KINASE;EXPERIMENTAL ONCOLOGY;HUMAN BREAST;MILAN ITALYSEARCH;CANCER CELL;CARCINOMA CELLS;MAPK ACTIVATION;NIHTPTC CELLS;SCIENCEGOOGLE SCHOLAR;TYROSINASE-RELATED PROTEIN-;CELL LINE;GROWTH FACTOR;THOMAS HODGKIN;PUBMED GOOGLE;TYROSINE PHOSPHORYLATION;CANCER CELLS;CANCER RES;CARCINOMA SPECIMENS","93;82;52;50;40;38;35;24;24;24;22;22;21;20;19;18;17;16;16;16;15;15;14;14;14;13;13;12;12;12",40,0.18,6,5.25,1.75,1,0,1,7,1,1,6,0,0,3,0,2,2,1,1.5,0,0,0,42.75,42.75,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,4,0.51,6,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CARMINATI PAOLO;MERLINI LUCIO;PENCO SERGIO;ZUNINO FRANCO","1;1;1;1","CARMINATI, PAOLO;ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI;MERLINI, LUCIO;PENCO, SERGIO;SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.;ZUNINO, FRANCO","1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY","2;1","CANCER","1",NA,NA,"A61K31/435;A61K31/4745;A61P31/12;A61P33/06;A61P35/00;C07D209/00;C07D221/00;C07D311/00;C07D491/22","1;1;1;1;1;1;1;1;1","A61P31/00;A61P31/12;A61P33/06;A61P35/00;A61P35/04;C07D491/22","1;1;1;1;1;1",4,7.33,359,1.04,0,0,13.5,0,0,2,0,2,0,0,0,0,4,0,0,0,0,0,0,0,3,1,0,4,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY","4;4;2;1","CANCER;CLINICAL RESEARCH;RARE DISEASES;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;ORPHAN DRUG;STEM CELL RESEARCH;BREAST CANCER;LUNG;LUNG CANCER;LYMPHOMA;PATIENT SAFETY;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;TRANSPLANTATION","4;4;3;2;2;2;2;1;1;1;1;1;1;1","CANCER","4","6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY","4;2;1;1","BLOOD CANCER;LEUKEMIA / LEUKAEMIA;BREAST CANCER;HODGKIN'S DISEASE;LUNG CANCER;NON-HODGKIN'S LYMPHOMA","2;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","3;1;1",4,1219989,209260.62,4,5.25,3.5,0.75,10.6666666666667,211111.739583333,1.05157581685489,"FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;BRUNEL UNIVERSITY LONDON;DE DUVE INSTITUTE;GERMAN CANCER RESEARCH CENTER;KAROLINSKA INSTITUTET;LEIDEN UNIVERSITY;LEIDEN UNIVERSITY MEDICAL CENTER;MOLMED (ITALY);NATIONAL AGENCY FOR NEW TECHNOLOGIES, ENERGY AND SUSTAINABLE ECONOMIC DEVELOPMENT;NATIONAL RESEARCH COUNCIL;NUCLEAR RESEARCH AND CONSULTANCY GROUP;PUBLIC HEALTH ENGLAND;ST GEORGE'S, UNIVERSITY OF LONDON;UNIVERSITY OF COLOGNE;UNIVERSITY OF PARIS-SUD;UNIVERSITY OF ROSTOCK;UNIVERSITY OF TÜBINGEN;WISE & MUNRO LEARNING RESEARCH","4;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","4","COALITION S;EC & ERC - EUROPEAN UNION","4;4","CSC - COST-SHARING CONTRACTS (FUNDING SCHEME);FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME);FP5-EAECTP C - RESEARCH AND TRAINING PROGRAMME (EURATOM) IN THE FIELD OF NUCLEAR ENERGY (1998 TO 2002) (PROGRAMME);RGI - RESEARCH GRANTS (INDIVIDUAL FELLOWSHIPS) (FUNDING SCHEME)","3;3;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY","4;3;1;1;1;1;1","BIOTECHNOLOGY;CANCER;GENETICS;PREVENTION;RARE DISEASES;CLIMATE-RELATED EXPOSURES AND CONDITIONS;HEMATOLOGY;HUMAN GENOME;IMMUNIZATION;LUNG;VACCINE RELATED","3;3;3;2;2;1;1;1;1;1;1","CANCER","3","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;3.4 VACCINES;5.1 PHARMACEUTICALS","2;1;1","MELANOMA;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;SKIN CANCER","2;1;1;1;1","2.2 ENDOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;1.2 CANCER INITIATION: ALTERATIONS IN CHROMOSOMES;1.4 CANCER PROGRESSION AND METASTASIS;2.3 INTERACTIONS OF GENES AND/OR GENETIC POLYMORPHISMS WITH EXOGENOUS AND/OR ENDOGENOUS FACTORS;2.4 RESOURCES AND INFRASTRUCTURE RELATED TO ETIOLOGY;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","2;1;1;1;1;1","A01 CLINICAL MEDICINE;A06 AGRICULTURE, VETERINARY AND FOOD SCIENCE","3;1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIMILAN",2001,209,7.50239234449761,3.7511961722488,0.593301435406699,0.5311004784689,0.598086124401914,1.73835920177384,1.1588785046729,1.44155844155844,1.16822429906542,0.291866028708134,7,101,21,27,52,0.48,0.1,0.13,0.25,52.41,1.14704961796317,NA,0.253588516746411,0.631578947368421,0.437,0.367,0.392,0.358,"MARCO A. PIEROTTI;EMILIO BOMBARDIERI;MARIA GRAZIA DAIDONE;GEMMA GATTA;GRAZIELLA PRATESI;PINUCCIA VALAGUSSA;ANDREA FERRARI;SYLVIE MÉNARD;FRANCO ZUNINO;FRANCO BERRINO;ALBERTO AZZARELLI;MICHELA CASANOVA;SILVANA CANEVARI;GABRIELLA SOZZI;PAOLA PEREGO;LUCA GIANNI;GIORGIO PARMIANI;LUIGI MARIANI;SILVANA PILOTTI;S. PILOTTI","14;10;9;8;8;8;8;8;7;7;7;6;6;6;6;6;6;6;6;6","EMILIO BOMBARDIERI;FRANCO BERRINO;MARCO A. PIEROTTI;MILENA SANT;JUAN ROSAÍ;GEMMA GATTA;MARIA GRAZIA DAIDONE;SYLVIE MÉNARD;FERNANDO RAVAGNANI;ANTONIO RUSSO;PINUCCIA VALAGUSSA;EGIDIO RIGGIO;NATALE CASCINELLI;GIORGIO PARMIANI;FRANCO ZUNINO;ETTORE MARUBINI;GRAZIELLA PRATESI;EMILIO BAJETTA;ETTORE SEREGNI;SILVANA CANEVARI","2.78;1.96;1.67;1.66;1.59;1.46;1.46;1.31;1.3;1.19;1.14;1;0.97;0.96;0.9;0.88;0.87;0.86;0.84;0.8","MARCO A. PIEROTTI;EMILIO BOMBARDIERI;MARIA GRAZIA DAIDONE;GEMMA GATTA;GRAZIELLA PRATESI;PINUCCIA VALAGUSSA;ANDREA FERRARI;SYLVIE MÉNARD;FRANCO ZUNINO;FRANCO BERRINO;ALBERTO AZZARELLI;MICHELA CASANOVA;SILVANA CANEVARI;GABRIELLA SOZZI;PAOLA PEREGO;LUCA GIANNI;GIORGIO PARMIANI;LUIGI MARIANI;SILVANA PILOTTI;S. PILOTTI","14;10;9;8;8;8;8;8;7;7;7;6;6;6;6;6;6;6;6;6","EMILIO BOMBARDIERI;FRANCO BERRINO;MARCO A. PIEROTTI;MILENA SANT;JUAN ROSAÍ;GEMMA GATTA;MARIA GRAZIA DAIDONE;SYLVIE MÉNARD;FERNANDO RAVAGNANI;ANTONIO RUSSO;PINUCCIA VALAGUSSA;EGIDIO RIGGIO;NATALE CASCINELLI;GIORGIO PARMIANI;FRANCO ZUNINO;ETTORE MARUBINI;GRAZIELLA PRATESI;EMILIO BAJETTA;ETTORE SEREGNI;SILVANA CANEVARI","2.78;1.96;1.67;1.66;1.59;1.46;1.46;1.31;1.3;1.19;1.14;1;0.97;0.96;0.9;0.88;0.87;0.86;0.84;0.8","LUIGI MARIANI;MARCO A. PIEROTTI;FRANCO DE CONNO;SEBASTIANO MERCADANTE;CARLA RIPAMONTI;EIJA KALSO;G.W. HANKS;H J MCQUAY;J. CASAS;J. MEYNADIER;JULIETTE SÄWE;LUKAS RADBRUCH;MAGDI HANNA;NATHAN I. CHERNY;P. POULAIN;ROBERT TWYCROSS;V. VENTAFRIDDA;ALBERTO AZZARELLI;FRANCO BERRINO;LUCA GIANNI","1060;977;976;925;895;851;851;851;851;851;851;851;851;851;851;851;851;757;661;626","LUIGI MARIANI;FRANCO DE CONNO;MARCO A. PIEROTTI;CARLA RIPAMONTI;ALBERTO AZZARELLI;FRANCO BERRINO;SILVANA PILOTTI;EMILIO BOMBARDIERI;PINUCCIA VALAGUSSA;ANDREA MICHELI;LUCA GIANNI;ANDREA FERRARI;GABRIELLA SOZZI;GIANNI BONADONNA;CECILIA GAVAZZI;CLAUDIA LOMBARDO;DOMENICO DELIA;SALVATORE LO VULLO;FRANCO ZUNINO;VALERIA PALA","1060;976;873;851;699;661;582;565;551;550;548;531;506;501;479;453;453;438;421;413","MARCO A. PIEROTTI;EMILIO BOMBARDIERI;FRANCO ZUNINO;MARIA GRAZIA DAIDONE;GEMMA GATTA;SYLVIE MÉNARD;PINUCCIA VALAGUSSA;FRANCO BERRINO;ANDREA FERRARI;GABRIELLA SOZZI;ROSANNA SUPINO;SILVANA CANEVARI;SILVANA PILOTTI;GRAZIELLA PRATESI;CLAUDIA LOMBARDO;LUCA GIANNI;ALBERTO AZZARELLI;ETTORE SEREGNI;GIORGIO PARMIANI;LUIGI MARIANI","13;9;9;8;8;8;8;7;7;6;6;6;6;6;5;5;5;5;5;5","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;SOCIOLOGY;MATHEMATICS;ENGINEERING;BUSINESS;MATERIALS SCIENCE;PHILOSOPHY;POLITICAL SCIENCE;ECONOMICS;PSYCHOLOGY;ART;ENVIRONMENTAL SCIENCE;GEOGRAPHY;GEOLOGY","163;107;27;14;10;10;9;4;3;3;3;3;2;2;1;1;1;1","INTERNAL MEDICINE;GENETICS;PATHOLOGY;CANCER RESEARCH;BIOCHEMISTRY;SURGERY;ONCOLOGY;MOLECULAR BIOLOGY;IMMUNOLOGY;RADIOLOGY;CELL BIOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;PALEONTOLOGY;ENDOCRINOLOGY;NUCLEAR MEDICINE;PHARMACOLOGY;DEMOGRAPHY;PEDIATRICS;UROLOGY","129;61;57;54;50;47;39;33;26;25;23;16;15;14;13;12;12;9;9;9","CANCER;GENE;CHEMOTHERAPY;CELL CULTURE;RADIATION THERAPY;IN VITRO;POPULATION;APOPTOSIS;MELANOMA;CONFIDENCE INTERVAL;CARCINOMA;IMMUNOHISTOCHEMISTRY;DISEASE;DNA;RECEPTOR;STAGE (STRATIGRAPHY);CELL;SARCOMA;LYMPH NODE;TOXICITY","94;48;44;21;17;16;16;15;14;13;12;12;11;11;11;10;9;9;8;8","BREAST CANCER;CISPLATIN;CELL CYCLE;CANCER REGISTRY;CYTOTOXIC T CELL;ALLELE;COLORECTAL CANCER;METASTASIS;OVARIAN CANCER;PACLITAXEL;DNA DAMAGE;DOXORUBICIN;MUTATION;CARCINOGENESIS;PROGRAMMED CELL DEATH;TOLERABILITY;ADENOCARCINOMA;CHROMOSOME;CYCLOPHOSPHAMIDE;GENE EXPRESSION;HUMAN LEUKOCYTE ANTIGEN","37;14;13;10;9;8;8;8;8;8;7;7;7;6;6;6;5;5;5;5;5","RELATIVE SURVIVAL;ANTHRACYCLINE;CELL CYCLE CHECKPOINT;GENE MAPPING;GERMLINE MUTATION;IFOSFAMIDE;MAMMARY GLAND;MAMMOGRAPHY;MASTECTOMY;MICROSATELLITE;OVARIAN CARCINOMA;PROPIDIUM IODIDE;RETINOID;SENTINEL LYMPH NODE;TAXANE;TUMOR SUPPRESSOR GENE;VINORELBINE;ABL;AJCC STAGING SYSTEM;ALTERNATIVE SPLICING;ATAXIA-TELANGIECTASIA;CARBOPLATIN;CASPASE;CASPASE 3;CYCLIN-DEPENDENT KINASE 1;DUCTAL CARCINOMA;EPIRUBICIN;FOLATE RECEPTOR;FUSION TRANSCRIPT;GENE DELIVERY;HAPLOTYPE;LOSS OF HETEROZYGOSITY;MEDULLARY THYROID CANCER;METASTATIC BREAST CANCER;MHC CLASS I;MONOCLONAL;NUCLEOTIDE EXCISION REPAIR;ONCOGENE;PHILADELPHIA CHROMOSOME;REPORTER GENE;RNA SPLICING;SENTINEL NODE;SPIRILLACEAE;TAMOXIFEN;VINCRISTINE;VIRAL VECTOR","9;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;BREAST NEOPLASMS;MALE;MIDDLE AGED;ADULT;OVARIAN NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ANTINEOPLASTIC AGENTS;AGED;LUNG NEOPLASMS;MELANOMA;NEOPLASMS;APOPTOSIS;ANIMALS;PACLITAXEL;TUMOR CELLS, CULTURED;BIOMARKERS, TUMOR;SKIN NEOPLASMS;DOXORUBICIN","171;111;81;63;58;54;52;51;49;48;48;38;38;37;32;32;32;31;29;28","THE P53 SIGNALING NETWORK IN CANCER RESEARCH;IMMUNOBIOLOGY OF DENDRITIC CELLS;SARCOMA RESEARCH AND TREATMENT;MELANOMA;MOLECULAR RESEARCH ON BREAST CANCER;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DNA TOPOISOMERASES: STRUCTURE, FUNCTION, AND INHIBITION;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;EPIDEMIOLOGY OF MULTIPLE PRIMARY CANCERS;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;MOLECULAR MECHANISMS OF DNA DAMAGE RESPONSE;ROLE OF RETINOIC ACID IN BIOLOGICAL PROCESSES;TESTICULAR GERM CELL TUMORS AND TREATMENT;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HEPATOCELLULAR CARCINOMA;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;MOLECULAR MECHANISMS OF ANGIOGENESIS AND VASCULAR FUNCTION;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;BREAST PATHOLOGY AND IMAGING TECHNIQUES","10;8;8;6;6;5;4;4;4;4;4;4;4;3;3;3;3;3;2;2","BREAST CANCER;RELATIVE SURVIVAL;MELANOMA;CHILDHOOD CANCER;REGIMEN;TOLERABILITY;CANCER;CANCER THERAPY;RADIOTHERAPY;ANTIGEN PRESENTATION;BONE METASTASIS;CAMPTOTHECIN;CANCER REGISTRY DATA;CHILDHOOD CANCER SURVIVOR STUDY;CLINICAL SIGNIFICANCE;HISTOLOGY;METASTATIC BREAST CANCER;P53;PACLITAXEL;SURGICAL ONCOLOGY","10;9;7;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4","BREAST CANCER;CELL LINES;CANCER CELL;CANCER PATIENTS;LUNG CANCER;OVARIAN CANCER;OVARIAN CARCINOMA;CELL CYCLE;CELL LINE;HUMAN MELANOMA;MELANOMA CELLS;CANCER CELLS;CANCER SURVIVAL;CARCINOMA CELLS;CELL CARCINOMA;CLASS II;GERM CELL;SYNOVIAL SARCOMA;ADJUVANT CHEMOTHERAPY;ANTITUMOR ACTIVITY;BONE PAIN;CANCER MODIFIER;CANCER PAIN;CELL LUNG;CELL PROLIFERATION;CELL TUMORS;CELLS EXPRESSING;CHRONIC MYELOID;COLON CARCINOMA;COLORECTAL CANCER","24;7;6;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;BREAST CANCER;CELL LINES;CELL CYCLE;CELL LINE;PUBMED GOOGLE;IGROVPT CELLS;MOL CELL;CANCER RESEARCH;IGROV CELLS;RESEARCH CAMPAIGN;AIRAKSINEN MS;CELL NEUROSCI;MOLECULAR BIOCHEMICALS;NEUROSCI -CROSSREF;ROCHE MOLECULAR;THYROID CARCINOMA;GDNF FAMILY;HUMAN GFRA;SCIENCE -CROSSREF;CAMPAIGN HTTPWWWBJCANCERCOM;CELLS FIG;HUMAN GFRΑ;MOCK-TRANSFECTED CELLS;NEURO-A CELLS;CANCER RES;HER-TRANSFECTED IGROV;INVASIVE CARCINOMA;MS MOL","57;51;23;23;17;14;13;12;12;11;11;11;10;10;10;10;10;10;9;9;9;8;8;8;8;8;7;7;7;7",44,0.21,6,5.25,7,0,0,0,6,0,1.5,5.25,0,0,1.5,0,4,0,1,2,0,0,0,49,46.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,13,529,1.41,2,0.33,14.5,0,0,2,0,3,0,0,1,0,5,1,0,0,0,0,0,0,6,0,0,6,0,0,0,0,0,0,0,0,0,"Belgium;United Kingdom;United States","3;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY","6;6;3;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;ORPHAN DRUG;PATIENT SAFETY;DIGESTIVE DISEASES;BIOTECHNOLOGY;DENTAL/ORAL AND CRANIOFACIAL DISEASE;GENETIC TESTING;GENETICS;HEMATOLOGY;HUMAN GENOME;NEUROBLASTOMA;NEUROSCIENCES;PANCREATIC CANCER;PEDIATRIC;PEDIATRIC RESEARCH INITIATIVE;PREVENTION;STEM CELL RESEARCH","6;6;5;5;4;4;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER","5","6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS","5;2;1;1","GASTROINTESTINAL TRACT;HEAD AND NECK CANCER;MELANOMA;NEUROBLASTOMA;PANCREATIC CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER;SARCOMA;SMALL INTESTINE CANCER;STOMACH CANCER","1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.2 ENDOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;2.3 INTERACTIONS OF GENES AND/OR GENETIC POLYMORPHISMS WITH EXOGENOUS AND/OR ENDOGENOUS FACTORS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","4;1;1;1;1",2,1279091.5,174060.93,3.5,7.5,6,1,14,317041.525297619,0.659219639458281,"FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;EKSPERIMENTAALSE JA KLIINILISE MEDITSIINI INSTITUUT;GERMAN CANCER RESEARCH CENTER;INSTITUTE OF ONCOLOGY LJUBLJANA;JOSEPH FOURIER UNIVERSITY;KU LEUVEN;MAASTRICHT UNIVERSITY;MARIO NEGRI SUD FOUNDATION;NATIONAL RESEARCH COUNCIL;SHEBA MEDICAL CENTER;ST GEORGE'S, UNIVERSITY OF LONDON;UNIVERSITY OF ABERDEEN;UNIVERSITY OF ST ANDREWS;UNIVERSITY OF STRASBOURG","2;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","CSC - COST-SHARING CONTRACTS (FUNDING SCHEME);FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME)","2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;3210 NUTRITION AND DIETETICS;3211 ONCOLOGY AND CARCINOGENESIS;4203 HEALTH SERVICES AND SYSTEMS;4206 PUBLIC HEALTH","2;2;1;1;1;1","GENETICS;NUTRITION;PREVENTION;AGING;BREAST CANCER;CANCER;CARDIOVASCULAR;GENETIC TESTING","2;2;2;1;1;1;1;1","CANCER;CARDIOVASCULAR","1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","BREAST CANCER","1","2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;2.2 ENDOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;2.3 INTERACTIONS OF GENES AND/OR GENETIC POLYMORPHISMS WITH EXOGENOUS AND/OR ENDOGENOUS FACTORS;3.2 NUTRITIONAL SCIENCE IN CANCER PREVENTION","1;1;1;1","A01 CLINICAL MEDICINE;A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE","1;1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIMILAN",2002,204,8.04411764705882,3.65686274509804,0.549019607843137,0.480392156862745,0.558823529411765,1.82843137254902,1.27272727272727,1.50769230769231,1.26666666666667,0.28921568627451,14,91,24,29,53,0.45,0.12,0.14,0.26,91.01,1.64966342460168,NA,0.308823529411765,0.637254901960784,0.47,0.415,0.443,0.41,"FRANCO BERRINO;VITTORIO KROGH;MICHELA CASANOVA;EMILIO BAJETTA;EMILIO BOMBARDIERI;MAURA MASSIMINO;ANDREA FERRARI;SYLVIE MÉNARD;MARIA GRAZIA DAIDONE;GRAZIELLA CEFALO;FEDERICO BOZZETTI;MARIO P. COLOMBO;ETTORE SEREGNI;ALESSANDRO M. GIANNI;FILIPPO SPREAFICO;ETTORE MARUBINI;ANTONIA MARTINETTI;NADIA ZAFFARONI;ANDREA MICHELI;L. FERRARI","16;11;10;10;9;9;9;9;8;8;8;8;8;8;7;7;7;7;7;6","FEDERICO BOZZETTI;FRANCO BERRINO;COSIMO LEQUAGLIE;MARIO P. COLOMBO;ETTORE MARUBINI;VITTORIO KROGH;MARCO GUZZO;CINZIA PELLIZZARO;ELIA BIGANZOLI;SYLVIE MÉNARD;MARIA GRAZIA DAIDONE;MARCO LADETTO;PATRIZIA BORACCHI;EMILIO BAJETTA;BÁRBARA CONTI;F. BOZZETTI;ANTONINO CARBONE;PATRIZIA OLMI;FELICIA STEFANIA FALVELLA;MICHELA CASANOVA","4.53;3.81;1.77;1.69;1.56;1.47;1.38;1.2;1.18;1.17;1.13;1.13;1.07;1.06;1.02;1;1;1;1;0.98","FRANCO BERRINO;VITTORIO KROGH;MICHELA CASANOVA;EMILIO BAJETTA;EMILIO BOMBARDIERI;MAURA MASSIMINO;ANDREA FERRARI;SYLVIE MÉNARD;MARIA GRAZIA DAIDONE;GRAZIELLA CEFALO;FEDERICO BOZZETTI;MARIO P. COLOMBO;ETTORE SEREGNI;ALESSANDRO M. GIANNI;FILIPPO SPREAFICO;ETTORE MARUBINI;ANTONIA MARTINETTI;NADIA ZAFFARONI;ANDREA MICHELI;L. FERRARI","16;11;10;10;9;9;9;9;8;8;8;8;8;8;7;7;7;7;7;6","FEDERICO BOZZETTI;FRANCO BERRINO;COSIMO LEQUAGLIE;MARIO P. COLOMBO;ETTORE MARUBINI;VITTORIO KROGH;MARCO GUZZO;CINZIA PELLIZZARO;ELIA BIGANZOLI;SYLVIE MÉNARD;MARIA GRAZIA DAIDONE;MARCO LADETTO;EMILIO BAJETTA;BÁRBARA CONTI;F. BOZZETTI;ANTONINO CARBONE;PATRIZIA OLMI;FELICIA STEFANIA FALVELLA;MICHELA CASANOVA;EMILIO BOMBARDIERI","4.53;3.81;1.77;1.69;1.56;1.47;1.38;1.2;1.18;1.17;1.13;1.13;1.06;1.02;1;1;1;1;0.98;0.95","ETTORE MARUBINI;LUIGI MARIANI;NATALE CASCINELLI;UMBERTO VERONESI;MARCO GRECO;ALBERTO LUINI;MARISEL AGUILAR;ROBERTO SACCOZZI;ALESSANDRO M. GIANNI;MASSIMO DI NICOLA;MICHELE MAGNI;CARMELO CARLO‐STELLA;PAOLA MATTEUCCI;SALVATORE GRISANTI;MARCO MILANESI;PAOLO LONGONI;PAOLA PEREGO;EMILIO BAJETTA;ROSANNA SUPINO;FRANCO BERRINO","4772;4445;4314;4275;4205;4181;4181;4181;3753;3250;3250;3234;3227;3177;3163;3163;1138;923;855;835","LUIGI MARIANI;NATALE CASCINELLI;MARCO GRECO;ALBERTO LUINI;MARISEL AGUILAR;ROBERTO SACCOZZI;UMBERTO VERONESI;ALESSANDRO M. GIANNI;MASSIMO DI NICOLA;MICHELE MAGNI;CARMELO CARLO‐STELLA;PAOLA MATTEUCCI;SALVATORE GRISANTI;MARCO MILANESI;PAOLO LONGONI;PAOLA PEREGO;FRANCO BERRINO;ROSANNA SUPINO;CHIARA CASTELLI;EMILIO BAJETTA","4306;4228;4205;4181;4181;4181;4181;3753;3250;3250;3234;3227;3177;3163;3163;1138;828;820;808;779","FRANCO BERRINO;VITTORIO KROGH;MICHELA CASANOVA;ANDREA FERRARI;MAURA MASSIMINO;ALESSANDRO M. GIANNI;EMILIO BAJETTA;EMILIO BOMBARDIERI;ETTORE SEREGNI;GRAZIELLA CEFALO;ANTONIA MARTINETTI;FRANCO ZUNINO;MARIA GRAZIA DAIDONE;FEDERICO BOZZETTI;FILIPPO SPREAFICO;MARIO P. COLOMBO;ANDREA MICHELI;NADIA ZAFFARONI;PAOLA PEREGO;DANIELA POLASTRI","15;11;10;9;9;8;8;8;8;8;7;7;7;7;7;7;6;6;6;5","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;SOCIOLOGY;COMPUTER SCIENCE;MATHEMATICS;ART;ENGINEERING;PHILOSOPHY;PSYCHOLOGY;BUSINESS;ECONOMICS;ENVIRONMENTAL SCIENCE;POLITICAL SCIENCE;GEOGRAPHY;HISTORY;MATERIALS SCIENCE","162;104;27;14;11;9;9;7;6;4;4;2;2;2;2;1;1;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;BIOCHEMISTRY;PATHOLOGY;GENETICS;SURGERY;IMMUNOLOGY;MOLECULAR BIOLOGY;ENDOCRINOLOGY;CELL BIOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;RADIOLOGY;PALEONTOLOGY;DEMOGRAPHY;GYNECOLOGY;PHARMACOLOGY;LITERATURE;OPTICS","126;62;58;53;47;46;44;32;26;21;20;18;17;17;10;9;8;8;7;7","CANCER;CHEMOTHERAPY;GENE;RADIATION THERAPY;RECEPTOR;IN VITRO;CARCINOMA;IMMUNE SYSTEM;IMMUNOHISTOCHEMISTRY;APOPTOSIS;MELANOMA;LUNG CANCER;ANTIGEN;CELL CULTURE;CONFIDENCE INTERVAL;LYMPHOMA;COHORT;REGIMEN;SARCOMA;DISEASE;EPIC;POPULATION;STAGE (STRATIGRAPHY)","85;50;44;21;20;17;15;14;12;11;11;10;9;9;9;9;8;8;8;7;7;7;7","BREAST CANCER;CISPLATIN;COLORECTAL CANCER;CYCLOPHOSPHAMIDE;MUTATION;OVARIAN CANCER;CD8;GENE EXPRESSION;T CELL;CARCINOGENESIS;CYTOTOXIC T CELL;METASTASIS;TYROSINE KINASE;CANCER REGISTRY;ADENOCARCINOMA;HAZARD RATIO;MAJOR HISTOCOMPATIBILITY COMPLEX;RECEPTOR TYROSINE KINASE;BLEOMYCIN;FLUOROURACIL;GROWTH FACTOR;NEUTROPENIA;PACLITAXEL;PHENOTYPE;PROSTATE CANCER;RHABDOMYOSARCOMA;TOPOTECAN","33;17;14;10;10;10;9;9;9;8;8;7;7;6;5;5;5;5;4;4;4;4;4;4;4;4;4","VINCRISTINE;MAMMARY GLAND;MASTECTOMY;OVARIAN CARCINOMA;CA15-3;CARBOPLATIN;DNA METHYLATION;DUCTAL CARCINOMA;EPIRUBICIN;GERMLINE MUTATION;POINT MUTATION;REED–STERNBERG CELL;TAMOXIFEN;TUMOR SUPPRESSOR GENE;ABL;ALTERNATIVE SPLICING;ANTIGEN PRESENTATION;AROMATASE;BREAST CARCINOMA;CD3;CTL*;FAS LIGAND;GENETICALLY MODIFIED MOUSE;GENOMICS;INSULIN-LIKE GROWTH FACTOR;INTERLEUKIN 21;IRINOTECAN;MAMMOGRAPHY;MHC CLASS I;MHC CLASS II;NODULAR SCLEROSIS;PRIMARY TUMOR;RELATIVE SURVIVAL;TARTRATE-RESISTANT ACID PHOSPHATASE;TRK RECEPTOR;VASCULAR ENDOTHELIAL GROWTH FACTOR A;VINORELBINE","7;5;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;BREAST NEOPLASMS;MALE;MIDDLE AGED;ADULT;AGED;LUNG NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;NEOPLASMS;TUMOR CELLS, CULTURED;OVARIAN NEOPLASMS;ADENOCARCINOMA;ANIMALS;APOPTOSIS;CELL DIVISION;ADOLESCENT;ANTINEOPLASTIC AGENTS;ITALY;AGED, 80 AND OVER","162;110;95;79;73;69;63;53;43;43;40;34;32;29;28;28;25;25;25;24","LYMPHOID NEOPLASMS;IMMUNOBIOLOGY OF DENDRITIC CELLS;SARCOMA RESEARCH AND TREATMENT;MOLECULAR RESEARCH ON BREAST CANCER;GASTRIC CANCER RESEARCH AND TREATMENT;NATURAL KILLER CELLS IN IMMUNITY;COLORECTAL CANCER RESEARCH AND TREATMENT;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;HER2 SIGNALING IN BREAST CANCER TREATMENT;MOLECULAR MECHANISMS OF APOPTOSIS AND CELL DEATH;ADVANCEMENTS IN LUNG CANCER RESEARCH;DNA TOPOISOMERASES: STRUCTURE, FUNCTION, AND INHIBITION;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;SALIVARY GLAND TUMORS AND CARCINOMAS;TESTICULAR GERM CELL TUMORS AND TREATMENT;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;CANCER OF UNKNOWN PRIMARY SITE;CELLULAR SENESCENCE AND AGING-RELATED DISEASES;CHEMOMETRICS IN ANALYTICAL CHEMISTRY AND FOOD TECHNOLOGY;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA","10;8;7;6;5;5;4;4;4;4;3;3;3;3;3;2;2;2;2;2","BREAST CANCER;REGIMEN;CANCER INCIDENCE;CHEMOTHERAPY;SURGICAL ONCOLOGY;ANTIGEN PRESENTATION;TUMOR MICROENVIRONMENT;BREAST CANCER SCREENING;CANCER THERAPY;RADIOTHERAPY;RECTAL CANCER;RHABDOMYOSARCOMA;TOPOTECAN;TREATMENT;ANAL CANCER;CANCER REGISTRY DATA;CARBOPLATIN;CHEMORADIOTHERAPY;CHEMOTHERAPY REGIMEN;CHILDHOOD CANCER SURVIVOR STUDY","9;8;7;6;6;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3","BREAST CANCER;CANCER PATIENTS;GROWTH FACTOR;LUNG CANCER;OVARIAN CANCER;PATIENTS TREATED;TUMOR CELL;ADVANCED BREAST;GASTRIC CANCER;LOCALLY ADVANCED;PREOPERATIVE CHEMORADIATION;RECTAL CANCER;ANTITUMOR ACTIVITY;BREAST CARCINOMAS;CANCER PREVALENCE;CANCER RESULTS;CELL LINE;CELL TUMORS;EPIC COHORT;GERM CELL;HODGKINS DISEASE;MELANOMA CELLS;MUCOEPIDERMOID CARCINOMA;OVARIAN CARCINOMA;REED-STERNBERG CELLS;SALIVARY GLANDS;SQUAMOUS CELL;ACID PHOSPHATASE-B;ALPHA-FETOPROTEIN AFP;BCL- EXPRESSION","15;7;6;6;6;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;ORGANOTYPIC CULTURES;PUBMED GOOGLE;MELANOMA CELLS;PAPILLARY CARCINOMA;CELL LINES;THYROID NODULES;GROWTH FACTOR;HUMAN MELANOMA;CISPLATIN-INDUCED APOPTOSIS;CROSSREF SCOPUS;GENE TRANSFER;OVARIAN CANCER;PAPILLARY THYROID;THYROID NODULE;HUMAN PAPILLOMAVIRUS;SURVIVAL RATE;NORMAL KERATINOCYTES;RES -PUBMED;WELL-DEVELOPED PTC-NC;BREAST CANCER;CARCINOMA CELL;CELL LINE;EPIDERMAL GROWTH;FACTOR RECEPTOR;MHC CLASS;RETTK IMMUNOREACTIVITY;THERAPY -CROSSREF;TUMOR CELLS","55;47;37;33;31;25;22;20;18;16;15;13;13;13;13;13;12;12;11;11;11;10;10;10;10;10;10;10;10;10",41,0.2,6,8,1,3,0,6,12.5,1,1.75,8,0,1,1,0,3.75,1,1,1,2,0,0,72,72,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,13.5,1257.67,0.8,1,0.33,55,0,0,1,0,2,0,0,0,0,3,0,0,0,0,0,0,0,1,2,0,2,0,0,1,0,0,0,0,0,0,"Belgium;Switzerland","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES","3;3;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;BREAST CANCER;NEUROBLASTOMA;NEUROSCIENCES;ORPHAN DRUG;PATIENT SAFETY;PEDIATRIC;PREVENTION","3;3;3;2;1;1;1;1;1;1;1","CANCER","3","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","2;1;1;1","BREAST CANCER;ENDOMETRIAL CANCER;NEUROBLASTOMA","1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","3;1",2,1902512.5,144259.2,4.5,13.5,9,1,3,377459.492330586,0.54045534459982,"FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;AMSTERDAM UMC LOCATION VUMC;AUTONOMOUS UNIVERSITY OF BARCELONA;BELFAST CITY HOSPITAL;CANISIUS-WILHELMINA ZIEKENHUIS;CENTRE HOSPITALIER UNIVERSITAIRE DE NANCY;FRENCH NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;GERMAN CANCER RESEARCH CENTER;INSTITUTO DE BIOLOGIA EXPERIMENTAL TECNOLÓGICA;IRCCS OSPEDALE SAN RAFFAELE;KAROLINSKA INSTITUTET INNOVATIONS (SWEDEN);MEDICAL UNIVERSITY OF BIAŁYSTOK;PAUL EHRLICH INSTITUT;ROYAL HOLLOWAY UNIVERSITY OF LONDON;TECHNICAL UNIVERSITY OF MUNICH;THORAXKLINIK HEIDELBERG;TRINITY COLLEGE DUBLIN;UNIVERSITY HOSPITAL OF LAUSANNE;UNIVERSITY OF EASTERN FINLAND;UNIVERSITY OF EDINBURGH","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME);CON - COORDINATION OF RESEARCH ACTIONS (FUNDING SCHEME);CSC - COST-SHARING CONTRACTS (FUNDING SCHEME)","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3206 MEDICAL BIOTECHNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","2;1;1;1;1","GENETICS;CANCER;GENE THERAPY;GENETIC TESTING;HUMAN GENOME;LUNG;LUNG CANCER;PREVENTION;RARE DISEASES","2;1;1;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE","1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","1;1","LUNG CANCER","1",NA,NA,"A01 CLINICAL MEDICINE;B11 COMPUTER SCIENCE AND INFORMATICS","1;1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIMILAN",2003,240,9.8875,3.49583333333333,0.55,0.404166666666667,0.554166666666667,1.83552631578947,1.32,1.53968253968254,1.31683168316832,0.370833333333333,11,130,29,22,52,0.54,0.12,0.09,0.22,75.07,1.41828155351667,NA,0.4625,0.75,0.497,0.45,0.447,0.449,"FRANCO BERRINO;­ROSARIO ­TUMINO;DOMENICO PALLI;GIORGIO PARMIANI;VITTORIO KROGH;EMILIO BOMBARDIERI;ANDREA MICHELI;SALVATORE PANICO;NADIA ZAFFARONI;SILVANA PILOTTI;SYLVIE MÉNARD;VALERIA PALA;MARIA GRAZIA DAIDONE;CARLOTTA SACERDOTE;SABINA SIERI;LICIA RIVOLTINI;COSIMO LEQUAGLIE;PAOLO VINEIS;GIOVANNA MASALA;MARCO A. PIEROTTI","25;16;15;14;13;12;12;11;11;10;10;9;9;9;9;9;9;9;8;7","FRANCO BERRINO;COSIMO LEQUAGLIE;SYLVIE MÉNARD;NADIA ZAFFARONI;MAURIZIO COLECCHIA;TOMMASO A. DRAGANI;IGNAZIO CATALDO;FEDERICO BOZZETTI;PAOLO BIDOLI;MARIA GRAZIA DAIDONE;SILVANA PILOTTI;BÁRBARA CONTI;GIORGIO PARMIANI;PAOLO CORRADINI;EMILIO BOMBARDIERI;JUDITH DIMENT;MARCO FOLINI;RAFFAELLA VILLA;ANDREA MICHELI;GEMMA GATTA","2.89;2.75;2.09;1.85;1.73;1.64;1.5;1.49;1.43;1.41;1.4;1.3;1.3;1.29;1.25;1.17;1.06;1.06;1.01;1.01","FRANCO BERRINO;GIORGIO PARMIANI;VITTORIO KROGH;EMILIO BOMBARDIERI;ANDREA MICHELI;SALVATORE PANICO;NADIA ZAFFARONI;SILVANA PILOTTI;SYLVIE MÉNARD;VALERIA PALA;MARIA GRAZIA DAIDONE;SABINA SIERI;LICIA RIVOLTINI;COSIMO LEQUAGLIE;MARCO A. PIEROTTI;GEMMA GATTA;IGNAZIO CATALDO;CHIARA CASTELLI;EMILIO BAJETTA;MAURIZIO COLECCHIA","25;14;13;12;12;11;11;10;10;9;9;9;9;9;7;7;7;7;7;7","FRANCO BERRINO;COSIMO LEQUAGLIE;SYLVIE MÉNARD;NADIA ZAFFARONI;MAURIZIO COLECCHIA;TOMMASO A. DRAGANI;IGNAZIO CATALDO;FEDERICO BOZZETTI;PAOLO BIDOLI;MARIA GRAZIA DAIDONE;SILVANA PILOTTI;BÁRBARA CONTI;GIORGIO PARMIANI;PAOLO CORRADINI;EMILIO BOMBARDIERI;JUDITH DIMENT;MARCO FOLINI;RAFFAELLA VILLA;ANDREA MICHELI;GEMMA GATTA","2.89;2.75;2.09;1.85;1.73;1.64;1.5;1.49;1.43;1.41;1.4;1.3;1.3;1.29;1.25;1.17;1.06;1.06;1.01;1.01","FRANCO BERRINO;HENRIK MØLLER;GEMMA GATTA;MILENA SANT;ANDREA MICHELI;RICCARDO CAPOCACCIA;A. VERDECCHIA;MARIANO SANTAQUILANI;TIIU AARELEID;PASCALE GROSCLAUDE;FEDERICA PERRONE;P. ROAZZI;VITTORIO KROGH;MARIO P. COLOMBO;JEAN FAIVRE;MAGDALENA BIELSKA‐LASOTA;­ROSARIO ­TUMINO;DOMENICO PALLI;GIORGIO PARMIANI;DANIELE LISI","3554;2423;2052;1922;1904;1693;1616;1580;1478;1359;1265;1249;1243;1223;1166;1166;1166;1111;1092;1019","FRANCO BERRINO;GEMMA GATTA;MILENA SANT;ANDREA MICHELI;VITTORIO KROGH;MARIO P. COLOMBO;LUIGI MARIANI;CHIARA SACCO;CIRO GALLO;E. PIAZZA;FABIANA CASTIGLIONE;FRANCESCO FERRAÙ;FRANCESCO ROSETTI;FRANCO VITO PIANTEDOSI;L. FRONTINI;M. CLERICI;M.R. MIGLIORINO;OSCAR BERTETTO;S. CIGOLARI;SANTI BARBERA","3554;2052;1922;1869;1243;1223;915;798;798;798;798;798;798;798;798;798;798;798;798;798","FRANCO BERRINO;VITTORIO KROGH;ANDREA MICHELI;NADIA ZAFFARONI;SABINA SIERI;VALERIA PALA;EMILIO BOMBARDIERI;SILVANA PILOTTI;MARIA GRAZIA DAIDONE;MAURIZIO COLECCHIA;SYLVIE MÉNARD;FRANCO ZUNINO;GEMMA GATTA;LUIGI MARIANI;MARIO P. COLOMBO;TOMMASO A. DRAGANI;E. MUGNO;GIANNI BONADONNA;PINUCCIA VALAGUSSA;ROSANNA SUPINO","25;13;11;9;9;9;8;8;7;7;7;7;7;6;6;6;6;6;6;6","MEDICINE;BIOLOGY;CHEMISTRY;SOCIOLOGY;PHYSICS;COMPUTER SCIENCE;ART;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE;PSYCHOLOGY;ECONOMICS;GEOGRAPHY;ENVIRONMENTAL SCIENCE;MATERIALS SCIENCE","195;118;24;20;18;10;6;6;4;4;4;3;3;1;1","INTERNAL MEDICINE;GENETICS;ONCOLOGY;CANCER RESEARCH;PATHOLOGY;SURGERY;BIOCHEMISTRY;IMMUNOLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;MOLECULAR BIOLOGY;GASTROENTEROLOGY;RADIOLOGY;DEMOGRAPHY;ENDOCRINOLOGY;GYNECOLOGY;NUCLEAR MEDICINE;OPTICS;PALEONTOLOGY;PHARMACOLOGY","158;61;60;56;56;52;51;38;26;26;26;23;20;19;17;16;13;12;10;8","CANCER;GENE;CHEMOTHERAPY;IN VITRO;POPULATION;IMMUNE SYSTEM;LUNG CANCER;ANTIGEN;CONFIDENCE INTERVAL;RADIATION THERAPY;IMMUNOHISTOCHEMISTRY;APOPTOSIS;CARCINOMA;INCIDENCE (GEOMETRY);LUNG;CELL CULTURE;DNA;SARCOMA;STAGE (STRATIGRAPHY);MELANOMA;PROSPECTIVE COHORT STUDY;STEM CELL","113;49;37;22;20;18;18;16;14;14;13;12;12;12;12;11;11;10;10;9;9;9","BREAST CANCER;CANCER REGISTRY;T CELL;CISPLATIN;CYTOTOXIC T CELL;CD8;GENE EXPRESSION;COLORECTAL CANCER;CYCLOPHOSPHAMIDE;CARCINOGENESIS;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;IMMUNOTHERAPY;OVARIAN CANCER;DOXORUBICIN;METASTASIS;TELOMERASE;ADENOCARCINOMA;DNA DAMAGE;PROSTATE CANCER;ALLELE;CELL CYCLE;HAZARD RATIO;LOCUS (GENETICS);MUTATION;PACLITAXEL;PROSTATE;RETINOIC ACID;RHABDOMYOSARCOMA","42;12;12;11;11;10;10;9;9;8;8;8;8;7;7;7;6;6;6;5;5;5;5;5;5;5;5;5","RELATIVE SURVIVAL;BREAST CARCINOMA;CARBOPLATIN;RETINOID;TUMOR ANTIGEN;VINCRISTINE;MAMMARY GLAND;MAMMOGRAPHY;TAMOXIFEN;DNA METHYLATION;ELISPOT;ESTROGEN RECEPTOR;IMATINIB MESYLATE;LOSS OF HETEROZYGOSITY;PERFORIN;PRIMARY TUMOR;SENTINEL LYMPH NODE;SEX HORMONE-BINDING GLOBULIN;TELOMERASE REVERSE TRANSCRIPTASE;ADJUVANT CHEMOTHERAPY;ALVEOLAR RHABDOMYOSARCOMA;ANDROSTENEDIONE;ANTIGEN-PRESENTING CELL;AROMATASE;AXILLARY LYMPH NODES;CANCER VACCINE;CD99;CELL CYCLE CHECKPOINT;COLPOSCOPY;CYTOREDUCTIVE SURGERY;FLUORESCENCE IN SITU HYBRIDIZATION;GENE PRODUCT;GERMLINE MUTATION;GRANZYME B;IFOSFAMIDE;LNCAP;METASTATIC BREAST CANCER;OSTEOCALCIN;OVARIAN CARCINOMA;PAPILLARY CARCINOMA;RIBOZYME;SENTINEL NODE;SINGLE-NUCLEOTIDE POLYMORPHISM;T-CELL RECEPTOR;TAXANE;TRASTUZUMAB;TRK RECEPTOR;TUMOR SUPPRESSOR GENE","10;7;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MIDDLE AGED;MALE;BREAST NEOPLASMS;LUNG NEOPLASMS;ADULT;AGED;NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ANTINEOPLASTIC AGENTS;MELANOMA;TUMOR CELLS, CULTURED;ITALY;CARCINOMA, NON-SMALL-CELL LUNG;OVARIAN NEOPLASMS;EUROPE;PROGNOSIS;BIOMARKERS, TUMOR;ANIMALS","203;144;104;101;94;91;81;79;78;61;51;50;38;37;36;33;31;31;30;29","IMMUNOBIOLOGY OF DENDRITIC CELLS;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;LYMPHOID NEOPLASMS;HER2 SIGNALING IN BREAST CANCER TREATMENT;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;SARCOMA RESEARCH AND TREATMENT;ADVANCEMENTS IN LUNG CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF LUNG CANCER;MOLECULAR RESEARCH ON BREAST CANCER;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;MECHANISMS OF ESTROGEN RECEPTOR SIGNALING;MOLECULAR MECHANISMS OF DNA DAMAGE RESPONSE;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;EFFICACY AND RESISTANCE IN CML TREATMENT;ENDOSCOPIC SKULL BASE SURGERY TECHNIQUES;GASTRIC CANCER RESEARCH AND TREATMENT;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER","12;9;9;7;6;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3","BREAST CANCER;RELATIVE SURVIVAL;BREAST CARCINOMA;CANCER INCIDENCE;HEALTHY EATING INDEX;CANCER;CANCER REGISTRY DATA;IMAGING;REGIMEN;CANCER RISK;CARBOPLATIN;HER2;NON-SMALL CELL LUNG CANCER;T CELL THERAPY;TUMOR ANTIGEN;ANTIGEN PRESENTATION;CANCER IMAGING;CANCER SURVIVORSHIP;DNA DAMAGE;ESTROGEN","15;10;7;7;7;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4","BREAST CANCER;LUNG CANCER;CANCER PATIENTS;CANCER SURVIVAL;OVARIAN CARCINOMA;CELL LUNG;GROWTH FACTOR;BREAST CARCINOMA;CELL LINES;COLORECTAL CANCER;EUROPEAN PROSPECTIVE;HUMAN MELANOMA;NON-SMALL CELL;OVARIAN CANCER;PROCEDURE GUIDELINES;PROSPECTIVE INVESTIGATION;TUMOUR IMAGING;CANCER PREVALENCE;CARCINOMA CELLS;CELL TRANSPLANTATION;DENDRITIC CELLS;ELDERLY PATIENTS;EUROPREVAL STUDY;FACTOR RECEPTOR;HODGKINS DISEASE;NEURAL NETWORK;NUTRITION EPIC;PARENTERAL NUTRITION;PEPTIDE NUCLEIC;POSTMENOPAUSAL WOMEN","21;13;10;7;6;5;5;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","PUBMED SCOPUS;CROSSREF PUBMED;CABOT MC;GIULIANO AE;HAN TY;CELL LINES;NF MICRODELETION;PUBMED GOOGLE;TY GIULIANO;BIOL CHEM;BREAST CANCER;YY HAN;AE CABOT;LIU YY;MALIGNANT PERIPHERAL;NERVE SHEATH;PERIPHERAL NERVE;CHEM -GOOGLE;SCHOLAR LIU;NEUROFIBROMATOSIS TYPE;AL LEROY;UOS CELLS;AL WU;HUMAN MELANOMA;RES -GOOGLE;MELANOMA CELLS;RESISTANT CELLS;TUMOR CELLS;AL BIRINDELLI;BIOL -CROSSREF","137;124;62;52;46;39;39;36;34;33;32;32;30;30;29;29;29;28;28;27;26;25;22;20;20;19;19;19;18;18",44,0.18,6,4.25,4,1.25,0,1,4,0,1,4.25,0,1,3.25,1,1.75,0,1,2.5,0,0,0,64.5,75.75,2,1,2,0,0,0,0,0,0,0,0,0,3,0,0,0,10,3.58,12.3333333333333,0,3,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"MARZI MAURO;PISANO CLAUDIO;TINTI MARIA ORNELLA;VESCI LOREDANA;ZUNINO FRANCO;ALPEGIANI MARCO;CABRI WALTER;DANELLI TAMARA;MARASTONI ELENA;PATRICIO MARTIN GOMEZ","3;3;3;3;3;2;2;2;2;2","MARZI, MAURO;PISANO, CLAUDIO;TINTI, MARIA ORNELLA;VESCI, LOREDANA;ZUNINO, FRANCO;ALPEGIANI, MARCO;CABRI, WALTER;DANELLI, TAMARA;INSTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI;MARASTONI, ELENA","3;3;3;3;3;2;2;2;2;2","34 CHEMICAL SCIENCES;3402 INORGANIC CHEMISTRY;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY","6;2;1",NA,NA,NA,NA,"A61P31/12;A61P33/00;A61P35/00;A61P43/00;C07D491/22;A61K31/4745;A61K31/4375;A61K31/47;C07D209/00;C07D221/00","3;3;3;3;3;2;1;1;1;1","A61P31/12;A61P33/00;A61P35/00;A61P43/00;C07D491/22;A61P31/00","3;3;3;3;3;1",4,10.5,507.5,1,0,0,64.5,0,0,0,0,3,0,0,1,0,4,0,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,0,0,0,0,"United States","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY","4;2;2;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;PREVENTION;BREAST CANCER;COLO-RECTAL CANCER;DIGESTIVE DISEASES;LUNG;LYMPHOMA;ORPHAN DRUG;PEDIATRIC;PEDIATRIC CANCER","4;4;3;3;2;2;1;1;1;1;1;1;1;1","CANCER","1","6.1 PHARMACEUTICALS","4","COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;OVARIAN CANCER;STOMACH CANCER","1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","2;2",2,457287,23901.49,2.5,19,7.5,0.5,8,363567.402240496,0.660125188674761,"FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;DANISH MINISTRY OF FOOD, AGRICULTURE AND FISHERIES;FINNISH INSTITUTE FOR HEALTH AND WELFARE;FRIEDRICH SCHILLER UNIVERSITY JENA;GERMAN INSTITUTE OF HUMAN NUTRITION;HAROKOPIO UNIVERSITY;INTEGRATED CARDIO METABOLIC CENTRE;ISTITUTO NAZIONALE DI RICERCA PER GLI ALIMENTI E LA NUTRIZIONE;KAROLINSKA INSTITUTET;LEATHERHEAD FOOD RESEARCH;LUDWIK HIRSZFELD INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY;MAX RUBNER INSTITUT;MEDICAL RESEARCH COUNCIL;NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS;NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT;NATIONAL RESEARCH INSTITUTE FOR AGRICULTURE, FOOD AND ENVIRONMENT;NESTLÉ (SWITZERLAND);NETHERLANDS ORGANISATION FOR APPLIED SCIENTIFIC RESEARCH;SAPIENZA UNIVERSITY OF ROME;SPANISH NATIONAL RESEARCH COUNCIL","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;SWISS NATIONAL SCIENCE FOUNDATION","1;1","COALITION S;EC & ERC - EUROPEAN UNION","2;1","CAREERS (FUNDING INSTRUMENT HIERARCHY);FELLOWSHIPS (FUNDING INSTRUMENT HIERARCHY);FELLOWSHIPS FOR PROSPECTIVE RESEARCHERS (FUNDING INSTRUMENT);FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME);THN - THEMATIC NETWORK CONTRACTS (FUNDING SCHEME)","1;1;1;1;1","30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3006 FOOD SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES","1;1;1","OSTEOPOROSIS","1",NA,NA,NA,NA,NA,NA,NA,NA,"A06 AGRICULTURE, VETERINARY AND FOOD SCIENCE","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIMILAN",2004,235,8.8936170212766,4.37021276595745,0.608510638297872,0.527659574468085,0.736170212765957,2.3265306122449,1.34905660377358,1.67567567567568,1.384,0.327659574468085,9,148,23,30,23,0.63,0.1,0.13,0.1,76.03,1.61581188563382,NA,0.370212765957447,0.714893617021277,0.484,0.434,0.413,0.421,"EMILIO BAJETTA;MARCO A. PIEROTTI;ALESSANDRO GRONCHI;MARIA GRAZIA DAIDONE;PAOLO G. CASALI;PAOLA COLLINI;CARMELO CARLO‐STELLA;GIORGIO PARMIANI;SILVANA PILOTTI;PAOLO CORRADINI;ANTONIA MARTINETTI;EMILIO BOMBARDIERI;LUIGI MARIANI;MAURA MASSIMINO;ALESSANDRO M. GIANNI;FRANCO BERRINO;PINUCCIA VALAGUSSA;MASSIMO DI NICOLA;MARIO P. COLOMBO;ETTORE SEREGNI","17;16;13;12;12;12;11;11;11;10;10;9;9;9;9;8;8;8;8;8","GIORGIO PARMIANI;MAURA MASSIMINO;EMILIO BAJETTA;ALESSANDRO GRONCHI;GEMMA GATTA;PAOLO G. CASALI;MARCO A. PIEROTTI;PAOLA COLLINI;JUAN ROSAÍ;EMILIO BOMBARDIERI;NADIA ZAFFARONI;MARIA GRAZIA DAIDONE;CARMELO CARLO‐STELLA;FEDERICO BOZZETTI;MARCO FOLINI;LUIGI MARIANI;MARIO P. COLOMBO;MILENA CALATI;DE PALO G;ANTONIA MARTINETTI","3.16;3.06;1.91;1.86;1.73;1.66;1.6;1.49;1.46;1.45;1.41;1.33;1.19;1.12;1.08;1.01;1;1;1;0.99","EMILIO BAJETTA;MARCO A. PIEROTTI;ALESSANDRO GRONCHI;MARIA GRAZIA DAIDONE;PAOLO G. CASALI;PAOLA COLLINI;CARMELO CARLO‐STELLA;GIORGIO PARMIANI;SILVANA PILOTTI;PAOLO CORRADINI;ANTONIA MARTINETTI;EMILIO BOMBARDIERI;LUIGI MARIANI;MAURA MASSIMINO;ALESSANDRO M. GIANNI;FRANCO BERRINO;PINUCCIA VALAGUSSA;MASSIMO DI NICOLA;MARIO P. COLOMBO;ETTORE SEREGNI","17;16;13;12;12;12;11;11;11;10;10;9;9;9;9;8;8;8;8;8","GIORGIO PARMIANI;MAURA MASSIMINO;EMILIO BAJETTA;ALESSANDRO GRONCHI;GEMMA GATTA;PAOLO G. CASALI;MARCO A. PIEROTTI;PAOLA COLLINI;JUAN ROSAÍ;EMILIO BOMBARDIERI;NADIA ZAFFARONI;MARIA GRAZIA DAIDONE;CARMELO CARLO‐STELLA;FEDERICO BOZZETTI;MARCO FOLINI;LUIGI MARIANI;MARIO P. COLOMBO;MILENA CALATI;DE PALO G;ANTONIA MARTINETTI","3.16;3.06;1.91;1.86;1.73;1.66;1.6;1.49;1.46;1.45;1.41;1.33;1.19;1.12;1.08;1.01;1;1;1;0.99","EMILIO BAJETTA;SILVANA PILOTTI;PATRIZIA OLMI;ALESSANDRO GRONCHI;PAOLO G. CASALI;ALAN L. STEWART;ALAN S. COATES;CLAIRE SNOWDON;DAVID DODWELL;E. MICKIEWICZ;EMMA HALL;GIANFILIPPO BERTELLI;GIORGIO COCCONI;GIORGIO MASSIMINI;ISABEL ÁLVAREZ;JACEK JASSEM;JUDITH M. BLISS;JØRN ANDERSEN;LESLEY FALLOWFIELD;LORNA J. GIBSON","2099;1864;1789;1771;1754;1743;1743;1743;1743;1743;1743;1743;1743;1743;1743;1743;1743;1743;1743;1743","EMILIO BAJETTA;PATRIZIA OLMI;ALESSANDRO GRONCHI;PAOLO G. CASALI;ROSSELLA BERTULLI;MARCO A. PIEROTTI;SILVANA PILOTTI;LUIGI MARIANI;FRANCO BERRINO;PAOLA COLLINI;ROSALBA MICELI;MAURIZIO COLECCHIA;ANGELA GRECO;GIORGIO PARMIANI;LAURA LOZZA;ELENA TAMBORINI;VITTORIO KROGH;SYLVIE MÉNARD;CARLO SPREAFICO;MILO FRATTINI","2040;1789;1754;1754;1470;1467;1459;1415;1344;1213;1050;1028;997;849;838;780;779;766;751;690","EMILIO BAJETTA;MARIA GRAZIA DAIDONE;PAOLA COLLINI;ALESSANDRO GRONCHI;PAOLO G. CASALI;MARCO A. PIEROTTI;ANTONIA MARTINETTI;PAOLO CORRADINI;GIORGIO PARMIANI;LUIGI MARIANI;ETTORE SEREGNI;FRANCO ZUNINO;MARIO P. COLOMBO;MAURA MASSIMINO;PINUCCIA VALAGUSSA;ALESSANDRO M. GIANNI;ANDREA FERRARI;CARMELO CARLO‐STELLA;FRANCO BERRINO;MICHELA CASANOVA","15;12;12;12;12;11;10;10;10;9;8;8;8;8;8;8;8;8;8;7","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;SOCIOLOGY;ECONOMICS;MATHEMATICS;ENGINEERING;PHILOSOPHY;MATERIALS SCIENCE;PSYCHOLOGY;HISTORY;POLITICAL SCIENCE;BUSINESS;GEOGRAPHY","181;114;25;16;9;8;7;7;6;5;4;4;3;3;2;1","INTERNAL MEDICINE;CANCER RESEARCH;SURGERY;GENETICS;ONCOLOGY;PATHOLOGY;BIOCHEMISTRY;IMMUNOLOGY;MOLECULAR BIOLOGY;CELL BIOLOGY;GASTROENTEROLOGY;PALEONTOLOGY;RADIOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;GYNECOLOGY;PHARMACOLOGY;ANESTHESIA;NUCLEAR MEDICINE;UROLOGY","136;64;62;61;55;54;50;37;33;29;27;17;17;16;10;10;10;9;9;9","CANCER;GENE;CHEMOTHERAPY;CELL CULTURE;RECEPTOR;IN VITRO;STAGE (STRATIGRAPHY);IMMUNE SYSTEM;RADIATION THERAPY;MELANOMA;SARCOMA;STEM CELL;APOPTOSIS;CONFIDENCE INTERVAL;DNA;TRANSPLANTATION;DISEASE;IMMUNOHISTOCHEMISTRY;LEUKEMIA;LUNG CANCER;SIGNAL TRANSDUCTION","102;51;48;17;17;16;16;15;14;13;13;13;12;12;12;12;10;9;9;9;9","BREAST CANCER;METASTASIS;CISPLATIN;COLORECTAL CANCER;CARCINOGENESIS;MUTATION;PROSTATE CANCER;CYTOTOXIC T CELL;GENE EXPRESSION;CELL CYCLE;CYCLOPHOSPHAMIDE;OVARIAN CANCER;CD8;HAEMATOPOIESIS;PROGRAMMED CELL DEATH;T CELL;THYROID CARCINOMA;ALLELE;CD34;DOXORUBICIN;HAZARD RATIO;IMMUNOTHERAPY;RNA;TOLERABILITY","33;13;12;11;10;10;10;9;9;8;8;8;7;7;7;7;7;6;6;6;6;6;6;6","GERMLINE MUTATION;ESTROGEN RECEPTOR;TAXANE;FLUDARABINE;HEMATOPOIETIC GROWTH FACTOR;TAMOXIFEN;CASPASE;CTL*;ELISPOT;IMATINIB MESYLATE;LNCAP;MASTECTOMY;METASTATIC BREAST CANCER;ONCOGENE;PRIMARY TUMOR;RIBOZYME;SEX HORMONE-BINDING GLOBULIN;STEM CELL FACTOR;THIOTEPA;TUMOR SUPPRESSOR GENE","6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","HUMANS;FEMALE;MIDDLE AGED;BREAST NEOPLASMS;MALE;ADULT;AGED;;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;MELANOMA;LUNG NEOPLASMS;ANTINEOPLASTIC AGENTS;ANIMALS;ADENOCARCINOMA;NEOPLASMS;SARCOMA;OVARIAN NEOPLASMS;RNA, MESSENGER;MICE;CELL LINE, TUMOR","165;102;78;74;72;64;61;54;50;48;46;41;33;32;30;30;29;29;28;26","IMMUNOBIOLOGY OF DENDRITIC CELLS;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;MECHANISMS OF ESTROGEN RECEPTOR SIGNALING;SARCOMA RESEARCH AND TREATMENT;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEMATOPOIETIC STEM CELL BIOLOGY;DNA TOPOISOMERASES: STRUCTURE, FUNCTION, AND INHIBITION;ENDOSCOPIC SKULL BASE SURGERY TECHNIQUES;GLIOMAS;HER2 SIGNALING IN BREAST CANCER TREATMENT;MOLECULAR RESEARCH ON BREAST CANCER;THE P53 SIGNALING NETWORK IN CANCER RESEARCH;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CELLULAR SENESCENCE AND AGING-RELATED DISEASES;CHALLENGES IN PAIN MANAGEMENT AND TREATMENT;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;DIAGNOSIS AND TREATMENT OF LUNG CANCER;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GYNECOLOGIC ONCOLOGY","10;9;9;9;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3","BREAST CANCER;NEUROENDOCRINE TUMORS;RADIOTHERAPY;SOFT TISSUE SARCOMA;TREATMENT;CANCER IMMUNOTHERAPY;CANCER THERAPY;ESTROGEN;TOLERABILITY;HORMONE THERAPY;PAIN MANAGEMENT;TAXANE;ADJUVANT THERAPY;CAMPTOTHECIN;CANCER INCIDENCE;CANCER PAIN;HEMATOPOIETIC GROWTH FACTOR;METASTATIC BREAST CANCER;METASTATIC COLORECTAL CANCER;MINIMAL RESIDUAL DISEASE","8;8;7;7;7;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4","BREAST CANCER;CANCER PATIENTS;LUNG CANCER;STEM CELL;CELL TRANSPLANTATION;COLON CANCER;GENE EXPRESSION;GROWTH FACTOR;NEUROENDOCRINE TUMORS;PHASE II;CANCER RECURRENCE;DENDRITIC CELLS;HUMAN OVARIAN;II STUDY;PROSTATE CANCER;RECOMBINANT HUMAN;SOFT TISSUE;CANCER CELLS;CANCER PAIN;CELL LINE;COLONY-STIMULATING FACTOR;CYTOREDUCTIVE SURGERY;DIETARY PATTERNS;ELDERLY BREAST;ESTROGEN RECEPTOR;FACTOR RECEPTOR;GRANULOCYTE COLONY-STIMULATING;HYPERTHERMIC PERFUSION;LYMPH NODE;MALIGNANT MELANOMA","22;9;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","PUBMED SCOPUS;CROSSREF PUBMED;COLON CANCERS;BREAST CANCER;SURVIVIN EXPRESSION;CELL LINES;MSI COLON;NUCLEAR Β-CATENIN;TYROSINE KINASE;BIOL -CROSSREF;CELL BIOL;CELL PROLIFERATION;PIEROTTI MA;TRK-T ONCOPROTEIN;TRANSFORMING ACTIVITY;ARTERY BYPASS;BYPASS GRAFTING;CELL LINE;CORONARY ARTERY;DIETARY PATTERNS;TUMOR CELLS;WILD TYPE;Β-CATENIN STAINING;Β-CATENINTCF- SIGNALING;CANCER PATIENTS;COILED-COIL DOMAIN;COLON CANCER;HEKT CELLS;LATE TOX;NEEL BG","33;28;24;22;19;16;14;14;14;12;12;12;12;11;10;9;9;9;9;9;9;9;9;9;8;8;8;8;8;8",60,0.26,6.25,4.25,1,1,0,2.25,6.75,1,1,5,0,0,3,1,2,1,1.75,6.5,1,0,0,73.25,73.25,3,2,1,0,0,0,0,0,0,0,0,0,3,0,0,0,5,1.46,6.66666666666667,0,3,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BERNER MARKUS;CARRARA MAURO;DALLAVALLE SABRINA;DONELLA-DEANA ARIANNA;GAMBACORTI PASSERINI CARLO;GUNBY ROSALIND;MARCHESINI RENATO ANGELO;MARIN ORIANO;MOLOGNI LUCA;PENCO SERGIO","1;1;1;1;1;1;1;1;1;1","ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI;BERNER, MARKUS;CARRARA, MAURO;DALLAVALLE, SABRINA;DONELLA-DEANA, ARIANNA;GAMBACORTI PASSERINI, CARLO;GUNBY, ROSALIND;MARCHESINI, RENATO ANGELO;MARIN, ORIANO;MHT S.R.L.","3;1;1;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;46 INFORMATION AND COMPUTING SCIENCES;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;4611 MACHINE LEARNING","4;2;1;1;1;1","CANCER","1",NA,NA,"A61B5/103;A61B5/107;A61K31/00;A61K31/437;A61K31/5395;A61P35/00;C07D209/00;C07D211/00;C07D221/00;C07D311/00","1;1;1;1;1;1;1;1;1;1","A61B5/0059;A61B5/444;A61B5/445;A61B5/7264;A61K31/5395;A61P25/00;A61P31/12;A61P33/06;A61P35/00;A61P35/02","1;1;1;1;1;1;1;1;1;1",3,10,516,0.71,0,0,22,0,0,1,0,1,0,0,1,0,2,1,0,0,0,0,0,0,2,1,0,3,0,0,0,0,0,0,0,0,0,"Belgium","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES","3;3;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;BREAST CANCER;DIGESTIVE DISEASES;HEMATOLOGY;LYMPHOMA;PATIENT SAFETY","3;2;2;2;1;1;1;1;1","CANCER","3","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY","3;1;1","BREAST CANCER;GASTROINTESTINAL TRACT;HODGKIN'S DISEASE;NON-HODGKIN'S LYMPHOMA;STOMACH CANCER","1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","2",2,5140000,271904.76,5,19,8.5,1,62,241764.490038115,0.972020332526714,"FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;AARHUS UNIVERSITY;ARISTOTLE UNIVERSITY OF THESSALONIKI;ASTON UNIVERSITY;BRUNEL UNIVERSITY LONDON;FORTHNET (GREECE);GERMAN CANCER RESEARCH CENTER;HELLENIC MEDITERRANEAN UNIVERSITY;KU LEUVEN;LIVERPOOL JOHN MOORES UNIVERSITY;MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH;NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS;NOTTINGHAM TRENT UNIVERSITY;QUEEN MARY UNIVERSITY OF LONDON;QUEEN'S UNIVERSITY BELFAST;RADBOUD UNIVERSITY NIJMEGEN;SHEFFIELD HALLAM UNIVERSITY;SPANISH NATIONAL CANCER RESEARCH CENTRE;TAMPERE UNIVERSITY;TELECOMMUNICATION SYSTEMS RESEARCH INSTITUTE","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","FP6-2002-LIFESCIHEALTH (CALL FOR PROPOSAL);FP6-IST - INFORMATION SOCIETY TECHNOLOGIES: THEMATIC PRIORITY UNDER THE SPECIFIC PROGRAMME ""INTEGRATING AND STRENGTHENING THE EUROPEAN RESEARCH AREA"" (2002-2006). (PROGRAMME);FP6-LIFESCIHEALTH - LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH: THEMATIC PRIORITY 1 UNDER THE FOCUSING AND INTEGRATING COMMUNITY RESEARCH PROGRAMME 2002-2006. (PROGRAMME);IP - INTEGRATED PROJECT (FUNDING SCHEME);NOE - NETWORK OF EXCELLENCE (FUNDING SCHEME)","1;1;1;1;1","31 BIOLOGICAL SCIENCES;3105 GENETICS;32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;46 INFORMATION AND COMPUTING SCIENCES;4602 ARTIFICIAL INTELLIGENCE","2;1;1;1;1;1","BIOTECHNOLOGY;CANCER;CLINICAL RESEARCH;GENETICS;NETWORKING AND INFORMATION TECHNOLOGY R&D (NITRD);PREVENTION","1;1;1;1;1;1","CANCER","2","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.9 RESOURCES AND INFRASTRUCTURE (TREATMENT EVALUATION)","1;1;1","NOT SITE-SPECIFIC CANCER","1",NA,NA,"A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;B11 COMPUTER SCIENCE AND INFORMATICS","1;1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIMILAN",2005,237,10.9957805907173,3.93248945147679,0.459915611814346,0.426160337552743,0.506329113924051,2.03501094091904,1.23863636363636,1.578125,1.26315789473684,0.40084388185654,5,145,36,20,28,0.61,0.15,0.08,0.12,107.89,2.03790925854849,NA,0.40084388185654,0.755274261603376,0.501,0.453,0.379,0.452,"ANDREA FERRARI;FRANCO BERRINO;PAOLA COLLINI;MONICA TERENZIANI;LUIGI MARIANI;MICHELA CASANOVA;MARCO A. PIEROTTI;FILIPPO SPREAFICO;ELIO RÍBOLI;SILVANA PILOTTI;LICIA RIVOLTINI;MAURA MASSIMINO;JUAN ROSAÍ;MARIO P. COLOMBO;CRISTINA MEAZZA;­ROSARIO ­TUMINO;ANTONINO CARBONE;PAOLO CORRADINI;GIANNI BISOGNO;VITTORIO KROGH","17;16;16;14;14;13;12;12;11;11;10;10;9;9;8;8;8;8;8;8","ANTONINO CARBONE;FRANCO BERRINO;MARIO P. COLOMBO;PAOLA COLLINI;ANDREA FERRARI;LUIGI MARIANI;GIORGIO PARMIANI;SYLVIE MÉNARD;MONICA TERENZIANI;JUAN ROSAÍ;MARIA GRAZIA DAIDONE;VALERIA BERNO;GIOVANNI LUCA BERETTA;FRANCO ZUNINO;MICHELA CASANOVA;MARCO A. PIEROTTI;FILIPPO SPREAFICO;PATRIZIA BORACCHI;SILVANA PILOTTI;ANNUNZIATA GLOGHINI","2.84;1.81;1.73;1.65;1.52;1.51;1.44;1.41;1.39;1.32;1.19;1.17;1.17;1.17;1.16;1.14;1.04;1.03;1.03;1.01","ANDREA FERRARI;FRANCO BERRINO;PAOLA COLLINI;MONICA TERENZIANI;LUIGI MARIANI;MICHELA CASANOVA;MARCO A. PIEROTTI;FILIPPO SPREAFICO;ELIO RÍBOLI;SILVANA PILOTTI;LICIA RIVOLTINI;MAURA MASSIMINO;JUAN ROSAÍ;MARIO P. COLOMBO;CRISTINA MEAZZA;­ROSARIO ­TUMINO;ANTONINO CARBONE;PAOLO CORRADINI;VITTORIO KROGH;MARIA GRAZIA DAIDONE","17;16;16;14;14;13;12;12;11;11;10;10;9;9;8;8;8;8;8;7","ANTONINO CARBONE;FRANCO BERRINO;MARIO P. COLOMBO;PAOLA COLLINI;ANDREA FERRARI;LUIGI MARIANI;GIORGIO PARMIANI;SYLVIE MÉNARD;MONICA TERENZIANI;JUAN ROSAÍ;MARIA GRAZIA DAIDONE;VALERIA BERNO;GIOVANNI LUCA BERETTA;FRANCO ZUNINO;MICHELA CASANOVA;MARCO A. PIEROTTI;FILIPPO SPREAFICO;PATRIZIA BORACCHI;SILVANA PILOTTI;ANNUNZIATA GLOGHINI","2.84;1.81;1.73;1.65;1.52;1.51;1.44;1.41;1.39;1.32;1.19;1.17;1.17;1.17;1.16;1.14;1.04;1.03;1.03;1.01","LUCA GIANNI;JOSÉ BASELGA;ARON GOLDHIRSCH;BRIAN LEYLAND‐JONES;CARLOS H. BARRIOS;CAROL WARD;CAROLINE LOHRISCH;CAROLYN STRAEHLE;CHIUN‐SHENG HUANG;CHRISTIAN JACKISCH;CHRISTOPH THOMSSEN;DAVID CAMERON;ELEANOR MCFADDEN;GÜNTHER STEGER;HIROJI IWATA;IAN SMITH;ISTVÁN LÁNG;JOSEF RÜSCHOFF;MARION PROCTER;MARTINE PICCART","5215;5064;4907;4907;4907;4907;4907;4907;4907;4907;4907;4907;4907;4907;4907;4907;4907;4907;4907;4907","LUCA GIANNI;SYLVIE MÉNARD;MANUELA CAMPIGLIO;FRANCO BERRINO;SILVANA PILOTTI;PAOLA COLLINI;VITTORIO KROGH;LUIGI MARIANI;MARCO A. PIEROTTI;ANDREA FERRARI;MONICA TERENZIANI;MARIO P. COLOMBO;LICIA RIVOLTINI;PAOLO G. CASALI;ALEXANDRA NIETERS;ANJA OLSEN;ANNE TJØNNELAND;ANTONIA TRICHOPOULOU;BERTRAND HÉMON;CARLOS A. GONZÁLEZ","5215;4070;3973;2494;1610;1208;1189;1104;1049;1009;957;896;871;846;839;839;839;839;839;839","ANDREA FERRARI;FRANCO BERRINO;PAOLA COLLINI;MONICA TERENZIANI;MICHELA CASANOVA;LUIGI MARIANI;FILIPPO SPREAFICO;MAURA MASSIMINO;FRANCA FOSSATI‐BELLANI;JUAN ROSAÍ;SILVANA PILOTTI;LICIA RIVOLTINI;MARIO P. COLOMBO;CRISTINA MEAZZA;VITTORIO KROGH;MARCO A. PIEROTTI;ELENA TAMBORINI;NADIA ZAFFARONI;FRANCO ZUNINO;MARIO CATANZARO","17;15;15;14;13;13;12;10;9;9;9;9;9;8;8;7;7;7;7;7","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;MATHEMATICS;PHYSICS;ENGINEERING;PSYCHOLOGY;SOCIOLOGY;GEOGRAPHY;PHILOSOPHY;ART;MATERIALS SCIENCE;POLITICAL SCIENCE","182;117;26;17;13;12;6;6;6;4;3;2;2;2","INTERNAL MEDICINE;GENETICS;CANCER RESEARCH;SURGERY;ONCOLOGY;PATHOLOGY;BIOCHEMISTRY;IMMUNOLOGY;GASTROENTEROLOGY;MOLECULAR BIOLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;ENDOCRINOLOGY;PALEONTOLOGY;UROLOGY;RADIOLOGY;GYNECOLOGY;STATISTICS;OPTICS;ORGANIC CHEMISTRY","129;66;60;57;54;54;53;40;26;25;23;17;16;12;11;10;9;9;8;8","CANCER;GENE;CHEMOTHERAPY;IMMUNE SYSTEM;SARCOMA;IN VITRO;POPULATION;RADIATION THERAPY;CARCINOMA;CONFIDENCE INTERVAL;RECEPTOR;REGIMEN;TRANSPLANTATION;ANTIGEN;CELL CULTURE;DNA;IMMUNOHISTOCHEMISTRY;LYMPHOMA;MELANOMA;APOPTOSIS;CELL;LUNG CANCER;STEM CELL","86;63;36;20;15;14;13;13;12;11;11;11;11;10;10;10;10;10;10;9;9;9;9","BREAST CANCER;CYCLOPHOSPHAMIDE;GENE EXPRESSION;CD8;T CELL;CARCINOGENESIS;CELL CYCLE;COLORECTAL CANCER;CYTOTOXIC T CELL;ETOPOSIDE;GENOTYPE;MUTATION;OVARIAN CANCER;RHABDOMYOSARCOMA;RNA;CISPLATIN;METASTASIS;CANCER REGISTRY;DNA REPAIR;HEAT SHOCK PROTEIN;IMATINIB;PACLITAXEL;PHENOTYPE;PROGRAMMED CELL DEATH;RETINOIC ACID;SOFT TISSUE SARCOMA","35;13;11;10;10;8;8;8;8;8;8;8;7;7;7;6;6;5;5;5;5;5;5;5;5;5","RETINOID;THIOTEPA;VINCRISTINE;GERMLINE MUTATION;MISSENSE MUTATION;ONCOGENE;ADJUVANT CHEMOTHERAPY;ALTERNATIVE SPLICING;ESTROGEN RECEPTOR;FLUDARABINE;HSP70;IL-2 RECEPTOR;IMATINIB MESYLATE;INSULIN-LIKE GROWTH FACTOR;INTERLEUKIN 21;MICROARRAY ANALYSIS TECHNIQUES;RELATIVE SURVIVAL;SINGLE-NUCLEOTIDE POLYMORPHISM;TELOMERASE REVERSE TRANSCRIPTASE;TUMOR SUPPRESSOR GENE","5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","HUMANS;FEMALE;MALE;BREAST NEOPLASMS;MIDDLE AGED;ADULT;AGED;LUNG NEOPLASMS;;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ANTINEOPLASTIC AGENTS;MELANOMA;ADOLESCENT;CARCINOMA, SQUAMOUS CELL;SARCOMA;BIOMARKERS, TUMOR;NEOPLASMS;ADENOCARCINOMA;OVARIAN NEOPLASMS;TREATMENT OUTCOME","177;123;86;82;76;69;61;56;52;45;35;34;30;30;30;29;29;27;27;27","SARCOMA RESEARCH AND TREATMENT;IMMUNOBIOLOGY OF DENDRITIC CELLS;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;MOLECULAR RESEARCH ON BREAST CANCER;LYMPHOID NEOPLASMS;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;CELLULAR SENESCENCE AND AGING-RELATED DISEASES;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MELANOMA;ROLE OF RETINOIC ACID IN BIOLOGICAL PROCESSES;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GLIOMAS;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;INSULIN-LIKE GROWTH FACTORS IN HEALTH AND DISEASE;MECHANISMS AND APPLICATIONS OF RNA INTERFERENCE;MICROARRAY DATA ANALYSIS AND GENE EXPRESSION PROFILING","11;9;6;6;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3","BREAST CANCER;REGIMEN;CANCER RISK;SOFT TISSUE SARCOMA;CANCER IMMUNOTHERAPY;RHABDOMYOSARCOMA;ANTIGEN PRESENTATION;CANCER THERAPY;SURGICAL ONCOLOGY;THIOTEPA;TUMOR REGRESSION;CANCER SUSCEPTIBILITY;CHEMOTHERAPY;CHEMOTHERAPY REGIMEN;CUMULATIVE INCIDENCE;EPITHELIOID SARCOMA;HEAT SHOCK PROTEINS;MELANOMA;RADIOTHERAPY;SALVAGE THERAPY","13;11;8;8;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4","BREAST CANCER;STEM CELL;CANCER RISK;CELL TRANSPLANTATION;COLORECTAL CANCER;LUNG CANCER;SOFT TISSUE;EUROPEAN PROSPECTIVE;PROSPECTIVE INVESTIGATION;REDUCED-INTENSITY CONDITIONING;CANCER PATIENTS;PERIPHERAL BLOOD;ALLOGENEIC STEM;HUMAN BREAST;NON-HODGKINS LYMPHOMA;TISSUE SARCOMAS;ADJUVANT CHEMOTHERAPY;CANCER CELL;CANCER CELLS;CARCINOID TUMOR;CELL CARCINOMA;CELL LINES;DENDRITIC CELLS;DNA DAMAGE;GENE EXPRESSION;GROWTH FACTOR;HIGH-DOSE CHEMOTHERAPY;PHASE II;PROGNOSTIC FACTORS;PROSTATE CANCER","25;10;9;8;7;7;7;6;6;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","BREAST CANCER;PUBMED SCOPUS;CROSSREF PUBMED;COLORECTAL CANCER;OVARIAN CARCINOMA;SEQUENCING PRIMER;GENE EXPRESSION;MULTIPLE SEQUENCING;PUBMED GOOGLE;TUMOR CELLS;CANCER RISK;SEVEN-PRIMER POOL;TGFBR FSPKO;AMPLIFICATION PRODUCTS;DNA SEQUENCING;HUMAN PAPILLOMAVIRUS;CANCER PATIENTS;CARCINOMA CELLS;NONSPECIFIC AMPLIFICATION;OVARIAN CANCER;CANCER CENTER;CENTER YORK;HR CI;KETTERING CANCER;MEMORIAL SLOAN;NECK SERVICE;SERVICE MEMORIAL;SLOAN KETTERING;YORK AVENUE;YORK NY","60;57;50;23;21;21;20;19;17;17;16;16;16;15;14;14;13;13;13;13;12;12;12;12;12;12;12;12;12;12",51,0.22,9.53,8,7,1.25,0,6,9,1,2,9,2,1,14.5,5,3.5,1.5,6.25,9,4,0,0,124,124.5,6,5,4,0,0,0,0,0,0,0,0,0,9,0,0,36,6.33333333333333,6.13,6.55555555555556,0,6,3,1,7,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ZUNINO FRANCO;BAKER JOFFRE B;GIANNI LUCA;GIANNINI GIUSEPPE;MERLINI LUCIO;PENCO SERGIO;PISANO CLAUDIO;SHAK STEVEN;TINTI MARIA ORNELLA;VESCI LOREDANA","5;4;4;4;4;4;4;4;4;4","ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI;ZUNINO, FRANCO;GIANNINI, GIUSEPPE;MERLINI, LUCIO;PENCO, SERGIO;PISANO, CLAUDIO;SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.;VESCI, LOREDANA;ALLOATTI, DOMENICO;DAL POZZO, ALMA","5;5;4;4;4;4;4;4;3;3","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;34 CHEMICAL SCIENCES;3405 ORGANIC CHEMISTRY;46 INFORMATION AND COMPUTING SCIENCES;4613 THEORY OF COMPUTATION","9;6;3;3;2;1;1;1","CANCER;BIOTECHNOLOGY;GENETICS;INFECTIOUS DISEASES","3;2;2;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","2;1","A61P35/00;C12Q1/68;A61K47/48;A61P31/12;A61P33/00;A61P35/04;A61K31/00;A61K31/282;A61K31/337;A61K31/404","4;4;2;2;2;2;1;1;1;1","A61P35/00;A61P43/00;A61P31/12;A61P33/00;A61P35/04;C12Q1/6886;C12Q2600/106;G01N2474/20;A61K47/64;A61K31/00","9;7;4;4;4;4;4;4;2;1",7,5.43,911.83,1.6,2,0.29,28.71,0,1,2,1,2,0,0,1,0,7,0,0,0,0,0,0,0,5,1,1,6,0,0,1,0,0,0,0,0,0,"Italy;United States","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY","7;6;3;2;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;TRANSPLANTATION;AGING;BIOENGINEERING;BIOMEDICAL IMAGING;CHRONIC PAIN;DIGESTIVE DISEASES;HEMATOLOGY;LUNG;LUNG CANCER;LYMPHOMA;PAIN RESEARCH;PANCREATIC CANCER;PREVENTION;PROSTATE CANCER;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN","5;5;3;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER","5","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","4;1","BREAST CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;PANCREATIC CANCER;PROSTATE CANCER;RESPIRATORY SYSTEM","1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","5;1",2,538188.5,59144.02,4,12.5,5.5,0.5,12,209074.323371448,1.13356817890515,"FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;AALBORG UNIVERSITY HOSPITAL;ANDALUSIAN SCHOOL OF PUBLIC HEALTH;BASQUE FOUNDATION FOR HEALTH INNOVATION AND RESEARCH;CANCER RESEARCH UK;DANISH CANCER SOCIETY;GERMAN CANCER RESEARCH CENTER;GERMAN INSTITUTE OF HUMAN NUTRITION;IMPERIAL COLLEGE LONDON;INSTITUT CATALÀ D'ONCOLOGIA;INSTITUT GUSTAVE ROUSSY;INSTITUTO DE SALUD PÚBLICA DE NAVARRA;INTERNATIONAL AGENCY FOR RESEARCH ON CANCER;ISTITUTO PER LO STUDIO E LA PREVENZIONE ONCOLOGICA;LUND UNIVERSITY;MEDICAL RESEARCH COUNCIL;NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS;NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT;UIT THE ARCTIC UNIVERSITY OF NORWAY;UMEÅ UNIVERSITY","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","CA - COORDINATION ACTION (FUNDING SCHEME);FP6-2002-MOBILITY-12 (CALL FOR PROPOSAL);FP6-2003-SSP-3 (CALL FOR PROPOSAL);FP6-MOBILITY - HUMAN RESOURCES AND MOBILITY IN THE SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ""STRUCTURING THE EUROPEAN RESEARCH AREA"" UNDER THE SIXTH FRAMEWORK PROGRAMME 2002-2006 (PROGRAMME);FP6-POLICIES - POLICY SUPPORT: SPECIFIC ACTIVITIES COVERING WIDER FIELD OF RESEARCH UNDER THE FOCUSING AND INTEGRATING COMMUNITY RESEARCH PROGRAMME 2002-2006. (PROGRAMME);IRG - MARIE CURIE ACTIONS-INTERNATIONAL RE-INTEGRATION GRANTS (FUNDING SCHEME)","1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3210 NUTRITION AND DIETETICS;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4202 EPIDEMIOLOGY;4203 HEALTH SERVICES AND SYSTEMS;4206 PUBLIC HEALTH","2;1;1;1;1;1;1;1","CANCER;BEHAVIORAL AND SOCIAL SCIENCE;BREAST CANCER;CARDIOVASCULAR;HEART DISEASE;NUTRITION;OBESITY;PREVENTION;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN","2;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;STROKE","2;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;2.3 PSYCHOLOGICAL, SOCIAL AND ECONOMIC FACTORS;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;5.2 CELLULAR AND GENE THERAPIES","2;1;1;1;1","BREAST CANCER;COLON AND RECTAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;LUNG CANCER;NOT SITE-SPECIFIC CANCER","2;1;1;1;1","1.3 CANCER INITIATION: ONCOGENES AND TUMOR SUPPRESSOR GENES;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;3.2 NUTRITIONAL SCIENCE IN CANCER PREVENTION;6.2 SURVEILLANCE","1;1;1;1","A01 CLINICAL MEDICINE;A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE","1;1","3 GOOD HEALTH AND WELL BEING","1",1,"AMERICAN ASSOCIATION FOR CANCER RESEARCH","1","31 BIOLOGICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","2;1;1;1",NA,NA,"CANCER","1",NA,NA,NA,NA,"BASIC SCIENCE","1","BREAST CANCER","1",NA,NA
"IRCCS_TUMORIMILAN",2006,281,11.7188612099644,4.11743772241993,0.462633451957295,0.462633451957295,0.512455516014235,2.08468468468468,1.25,1.60493827160494,1.21008403361345,0.359430604982206,3,168,50,30,23,0.6,0.18,0.11,0.08,79.92,1.56462322931372,NA,0.398576512455516,0.786476868327402,0.434,0.463,0.42,0.437,"MARCO A. PIEROTTI;­ROSARIO ­TUMINO;DOMENICO PALLI;ELIO RÍBOLI;ALESSANDRO M. GIANNI;SALVATORE PANICO;SHEILA BINGHAM;KIM OVERVAD;JAKOB LINSEISEN;ANTONIA TRICHOPOULOU;ANNE TJØNNELAND;LUIGI MARIANI;ANTONINO CARBONE;HEINER BOEING;FRANÇOISE CLAVEL‐CHAPELON;FRANCO BERRINO;PAOLA COLLINI;PAOLO CORRADINI;CARLOTTA SACERDOTE;ANJA OLSEN","21;17;16;16;16;15;15;14;14;14;14;14;13;13;12;12;12;12;11;11","MARCO A. PIEROTTI;PAOLA COLLINI;LUIGI MARIANI;ALESSANDRO M. GIANNI;ANDREA FERRARI;FILIPPO SPREAFICO;ANTONINO CARBONE;SILVANA CANEVARI;MARIA GRAZIA DAIDONE;GIORGIO SECRETO;AMEDEO VITTORIO BEDINI;MAURA MASSIMINO;PAOLO G. CASALI;PAOLA PEREGO;EMILIO BAJETTA;MASSIMO DI NICOLA;ELIA BIGANZOLI;GIORGIO PARMIANI;MARIO SANTINAMI;TOMMASO A. DRAGANI","3.55;1.49;1.44;1.34;1.19;1.15;1.13;1.06;1.02;1;1;0.95;0.94;0.94;0.93;0.92;0.92;0.91;0.9;0.9","MARCO A. PIEROTTI;­ROSARIO ­TUMINO;DOMENICO PALLI;ELIO RÍBOLI;ALESSANDRO M. GIANNI;SALVATORE PANICO;SHEILA BINGHAM;KIM OVERVAD;JAKOB LINSEISEN;ANTONIA TRICHOPOULOU;ANNE TJØNNELAND;LUIGI MARIANI;ANTONINO CARBONE;HEINER BOEING;FRANÇOISE CLAVEL‐CHAPELON;FRANCO BERRINO;PAOLA COLLINI;PAOLO CORRADINI;CARLOTTA SACERDOTE;ANJA OLSEN","21;17;16;16;16;15;15;14;14;14;14;14;13;13;12;12;12;12;11;11","MARCO A. PIEROTTI;PAOLA COLLINI;LUIGI MARIANI;ALESSANDRO M. GIANNI;ANDREA FERRARI;FILIPPO SPREAFICO;ANTONINO CARBONE;SILVANA CANEVARI;MARIA GRAZIA DAIDONE;GIORGIO SECRETO;AMEDEO VITTORIO BEDINI;MAURA MASSIMINO;PAOLO G. CASALI;PAOLA PEREGO;EMILIO BAJETTA;MASSIMO DI NICOLA;ELIA BIGANZOLI;GIORGIO PARMIANI;MARIO SANTINAMI;TOMMASO A. DRAGANI","3.55;1.49;1.44;1.34;1.19;1.15;1.13;1.06;1.02;1;1;0.95;0.94;0.94;0.93;0.92;0.92;0.91;0.9;0.9","PAOLO G. CASALI;ALLAN T. VAN OOSTEROM;IAN JUDSON;JAAP VERWEIJ;­ROSARIO ­TUMINO;DOMENICO PALLI;ELIO RÍBOLI;SHEILA BINGHAM;SALVATORE PANICO;CARLO L. BELLO;CHARLES M. BAUM;CHRISTOPHER D.�M. FLETCHER;CHRISTOPHER R. GARRETT;GEORGE D. DEMETRI;GRANT A. MCARTHUR;JAYESH DESAI;JEFFREY A. MORGAN;MANISHA H. SHAH;MARTIN E. BLACKSTEIN;MICHAEL C. HEINRICH","4261;3439;3439;3439;2601;2582;2582;2507;2481;2480;2480;2480;2480;2480;2480;2480;2480;2480;2480;2480","PAOLO G. CASALI;MARIO P. COLOMBO;FRANCO BERRINO;SILVANA CANEVARI;MARCO A. PIEROTTI;SABINA SIERI;FEDERICO BOZZETTI;LUIGI MARIANI;VITTORIO KROGH;ALESSANDRO GRONCHI;ALESSANDRO M. GIANNI;ANDREA FERRARI;PAOLA COLLINI;SILVANA PILOTTI;ROSALBA MICELI;PAOLO CORRADINI;SYLVIE MÉNARD;GIORGIO PARMIANI;PATRIZIA OLMI;ANTONINO CARBONE","4261;1858;1840;1413;1092;950;901;858;852;834;716;702;684;663;632;571;531;521;517;489","MARCO A. PIEROTTI;ALESSANDRO M. GIANNI;LUIGI MARIANI;FRANCO BERRINO;ANTONINO CARBONE;FILIPPO SPREAFICO;PAOLO CORRADINI;PAOLA COLLINI;PAOLO G. CASALI;ANDREA FERRARI;MASSIMO DI NICOLA;EMILIO BAJETTA;CARMELO CARLO‐STELLA;MICHELE MAGNI;SILVANA CANEVARI;FRANCO ZUNINO;MARIO P. COLOMBO;MAURA MASSIMINO;PAOLA PEREGO;MARIA GRAZIA DAIDONE","21;15;13;12;10;10;10;10;10;9;9;9;8;8;8;7;7;7;7;7","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;MATHEMATICS;SOCIOLOGY;PSYCHOLOGY;ECONOMICS;PHILOSOPHY;ART;ENGINEERING;MATERIALS SCIENCE;POLITICAL SCIENCE;HISTORY;BUSINESS","215;147;32;21;18;11;11;6;4;4;3;3;3;3;2;1","INTERNAL MEDICINE;CANCER RESEARCH;GENETICS;SURGERY;ONCOLOGY;BIOCHEMISTRY;IMMUNOLOGY;GASTROENTEROLOGY;PATHOLOGY;MOLECULAR BIOLOGY;CELL BIOLOGY;RADIOLOGY;ENDOCRINOLOGY;PALEONTOLOGY;ENVIRONMENTAL HEALTH;ARTIFICIAL INTELLIGENCE;UROLOGY;COMPUTATIONAL BIOLOGY;GYNECOLOGY;OPTICS;PHARMACOLOGY","171;86;86;71;61;53;47;45;44;40;24;23;21;20;19;12;12;11;11;10;10","CANCER;GENE;CHEMOTHERAPY;CONFIDENCE INTERVAL;RECEPTOR;CELL CULTURE;IN VITRO;APOPTOSIS;POPULATION;PROSPECTIVE COHORT STUDY;RADIATION THERAPY;STAGE (STRATIGRAPHY);IMMUNE SYSTEM;LYMPHOMA;ANTIGEN;REGIMEN;MELANOMA;STEM CELL;TOXICITY;TRANSPLANTATION","114;70;44;23;23;22;18;17;16;15;15;15;14;14;13;13;12;12;12;12","BREAST CANCER;COLORECTAL CANCER;GENE EXPRESSION;CYCLOPHOSPHAMIDE;TRANSFECTION;CISPLATIN;CARCINOGENESIS;CELL CYCLE;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;MUTATION;OVARIAN CANCER;CYTOTOXIC T CELL;HAZARD RATIO;ALLELE;CD8;GENOTYPE;PROGRAMMED CELL DEATH;RECEPTOR TYROSINE KINASE;T CELL;GROWTH FACTOR;IMMUNOTHERAPY;NEUTROPENIA;TYROSINE KINASE","25;21;16;13;13;12;11;11;11;10;10;9;9;8;8;8;8;8;8;7;7;7;7","OXALIPLATIN;CAPECITABINE;IMATINIB MESYLATE;IRINOTECAN;ONCOGENE;TUMOR SUPPRESSOR GENE;VINCRISTINE;MICROARRAY;MICROARRAY ANALYSIS TECHNIQUES;PROSTATECTOMY;SEX HORMONE-BINDING GLOBULIN;VINORELBINE;CD3;FEBRILE NEUTROPENIA;FLUDARABINE;GENE EXPRESSION PROFILING;GERMLINE MUTATION;GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR;IL-2 RECEPTOR;INSULIN-LIKE GROWTH FACTOR;MAMMOGRAPHY;MEASLES VIRUS;MISSENSE MUTATION;PARAMYXOVIRIDAE;PLATELET-DERIVED GROWTH FACTOR RECEPTOR;RELATIVE SURVIVAL;RETINOID;SINGLE-NUCLEOTIDE POLYMORPHISM;TRASTUZUMAB;VIROTHERAPY","6;5;5;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","HUMANS;FEMALE;MIDDLE AGED;MALE;ADULT;BREAST NEOPLASMS;AGED;ANTINEOPLASTIC AGENTS;MELANOMA;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ADENOCARCINOMA;;NEOPLASMS;LUNG NEOPLASMS;ANIMALS;CELL LINE, TUMOR;MICE;NEOPLASM PROTEINS;STOMACH NEOPLASMS;EUROPE","217;142;104;100;93;87;83;75;58;55;52;51;43;42;39;36;34;32;31;29","IMMUNOBIOLOGY OF DENDRITIC CELLS;LYMPHOID NEOPLASMS;MICROARRAY DATA ANALYSIS AND GENE EXPRESSION PROFILING;SARCOMA RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;GYNECOLOGIC ONCOLOGY;HER2 SIGNALING IN BREAST CANCER TREATMENT;INSULIN-LIKE GROWTH FACTORS IN HEALTH AND DISEASE;MELANOMA;MOLECULAR BASIS OF RETT SYNDROME AND RELATED DISORDERS;MOLECULAR CHAPERONES IN PROTEIN FOLDING AND DISEASE;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;MOLECULAR MECHANISMS OF DNA DAMAGE RESPONSE;MOLECULAR MECHANISMS OF KIDNEY DEVELOPMENT AND DISEASE;ROLE OF RETINOIC ACID IN BIOLOGICAL PROCESSES","11;11;7;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4","REGIMEN;BREAST CANCER;CANCER RISK;ANTIGEN PRESENTATION;CANCER THERAPY;CONCOMITANT;MELANOMA;TREATMENT;CANCER;CANCER IMMUNOTHERAPY;GASTRIC CANCER;IMATINIB MESYLATE;MELPHALAN;NEUROENDOCRINE TUMORS;PANCREATIC NEUROENDOCRINE TUMORS;TUMOR REGRESSION;CAMPTOTHECIN;CANCER INCIDENCE;DNA DAMAGE;FHIT","13;12;9;8;8;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4","BREAST CANCER;CELL TRANSPLANTATION;EUROPEAN PROSPECTIVE;LUNG CANCER;PROSPECTIVE INVESTIGATION;STEM CELL;CANCER PATIENTS;OVARIAN CANCER;CELL CARCINOMA;CELL LINES;GASTRIC CANCER;CANCER CELLS;CANCER RISK;NEUROENDOCRINE TUMORS;RECTAL CANCER;SQUAMOUS CELL;ALLOGENEIC STEM;BONE MARROW;LONG-TERM RESULTS;MELANOMA CELLS;PROGNOSTIC FACTORS;ADVANCED GASTROINTESTINAL;ANTITUMOR ACTIVITY;CANCER CELL;CANCER TREATED;CELL LUNG;COLON CANCER;COLORECTAL CANCER;GASTROINTESTINAL STROMAL;GENE EXPRESSION","17;9;9;9;9;8;7;7;6;6;6;5;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3","PUBMED SCOPUS;BREAST CANCER;CROSSREF PUBMED;CANCER RISK;OVARIAN CANCER;CANCER PATIENTS;SECONDARY ALCOHOL;CELL LINES;GROWTH FACTOR;TYROSINE KINASE;ALCOHOL METABOLITES;EUROPEAN PROSPECTIVE;GENE EXPRESSION;PROSPECTIVE INVESTIGATION;CONFIDENCE INTERVAL;DNA DAMAGE;RR CI;MYOCARDIAL STRIPS;ODDS RATIO;POSTMENOPAUSAL WOMEN;STATISTICALLY SIGNIFICANT;TUMOR GROWTH;BODY MASS;COLON CANCER;CUSACK BJ;GASTRIC CANCER;HR CI;INCREASED RISK;LOGISTIC REGRESSION;MELANOMA CELLS","33;32;31;22;19;14;13;12;12;12;11;11;11;11;10;10;10;9;9;9;9;9;8;8;8;8;8;8;8;8",71,0.25,9,8,2.25,1,0,5,11,1,2,8.5,0,1.25,7,2.75,2.5,2,1.5,4.75,1.25,0,0,84,84,1,0,2,0,0,0,0,0,0,0,0,0,2,0,0,11,1,0.17,1,2,0,2,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"FORMELLI FRANCA","2","ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DIE TUMORI","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","4;2","BREAST CANCER;CANCER;ORPHAN DRUG;RARE DISEASES","2;2;2;2","5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","2;2","A61K31/167;A61P35/00;C07C233/00;A61K31/16","2;2;2;1","A61K31/167;A61P35/00;A61P43/00","2;2;2",6,6.25,319,1.27,0,0,37.83,0,1,2,1,2,0,0,0,0,6,0,0,0,0,0,0,0,4,2,0,6,0,0,0,0,0,0,0,0,0,"United Kingdom;United States","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES","6;5;2;2;1","CANCER;CLINICAL RESEARCH;RARE DISEASES;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;OVARIAN CANCER;PATIENT SAFETY;PEDIATRIC;PREVENTION;TRANSPLANTATION;COLO-RECTAL CANCER;DIGESTIVE DISEASES;IMMUNIZATION;LYMPHOMA;MIND AND BODY;ORPHAN DRUG;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;VACCINE RELATED","6;6;5;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER","6","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.4 SURGERY;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","5;2;1;1;1","OVARIAN CANCER;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;MYELOMA;NON-HODGKIN'S LYMPHOMA;SARCOMA","2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","3;3;2",9,5970943.11,364809.55,4.88888888888889,14.4444444444444,6.55555555555556,1,34.3333333333333,853514.257597639,0.329227072071323,"FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;MEDICAL RESEARCH COUNCIL;UNIVERSITY OF OXFORD;ERASMUS MC;GERMAN CANCER RESEARCH CENTER;IMPERIAL COLLEGE LONDON;INSERM;INSTITUTE CURIE;UNIVERSITY OF GLASGOW;UNIVERSITY OF MILAN;UNIVERSITY OF ROME TOR VERGATA;AALBORG UNIVERSITY HOSPITAL;ANDALUSIAN SCHOOL OF PUBLIC HEALTH;ARTTIC (FRANCE);ASKLEPIOS KLINIK ST. GEORG;BASQUE FOUNDATION FOR HEALTH INNOVATION AND RESEARCH;CANCER RESEARCH UK;CATHOLIC UNIVERSITY OF THE SACRED HEART;CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES;CENTRO DI RIFERIMENTO ONCOLOGICO","9;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;MEDICAL RESEARCH COUNCIL","7;2","COALITION S;EC & ERC - EUROPEAN UNION;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;UKRI - UK RESEARCH AND INNOVATION","9;7;2;2","FP6-LIFESCIHEALTH - LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH: THEMATIC PRIORITY 1 UNDER THE FOCUSING AND INTEGRATING COMMUNITY RESEARCH PROGRAMME 2002-2006. (PROGRAMME);IP - INTEGRATED PROJECT (FUNDING SCHEME);STREP - SPECIFIC TARGETED RESEARCH PROJECT (FUNDING SCHEME);FP6-2004-LIFESCIHEALTH-5 (CALL FOR PROPOSAL);FP6-2005-LIFESCIHEALTH-6 (CALL FOR PROPOSAL);FP6-IST - INFORMATION SOCIETY TECHNOLOGIES: THEMATIC PRIORITY UNDER THE SPECIFIC PROGRAMME ""INTEGRATING AND STRENGTHENING THE EUROPEAN RESEARCH AREA"" (2002-2006). (PROGRAMME);FELLOWSHIP (PROJECT CATEGORY);FP6-2004-FOOD-3-A (CALL FOR PROPOSAL);FP6-FOOD - FOOD QUALITY AND SAFETY: THEMATIC PRIORITY 5 UNDER THE FOCUSING AND INTEGRATING COMMUNITY RESEARCH PROGRAMME 2002-2006. (PROGRAMME);NOE - NETWORK OF EXCELLENCE (FUNDING SCHEME);RESEARCH GRANT (PROJECT CATEGORY)","4;3;3;2;2;2;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3101 BIOCHEMISTRY AND CELL BIOLOGY;3105 GENETICS;4203 HEALTH SERVICES AND SYSTEMS;4206 PUBLIC HEALTH;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3210 NUTRITION AND DIETETICS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4205 NURSING","7;4;4;3;2;2;2;2;1;1;1;1;1;1;1","CANCER;GENETICS;CLINICAL RESEARCH;PREVENTION;BEHAVIORAL AND SOCIAL SCIENCE;BIOTECHNOLOGY;DIABETES;HUMAN GENOME;NUTRITION;OBESITY;BIOMEDICAL IMAGING;CHRONIC PAIN;CLIMATE-RELATED EXPOSURES AND CONDITIONS;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DEPRESSION;GENETIC TESTING;IMMUNIZATION;MENTAL HEALTH;ORPHAN DRUG;PAIN RESEARCH","6;4;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;METABOLIC AND ENDOCRINE;CARDIOVASCULAR;GENERIC HEALTH RELEVANCE;ORAL AND GASTROINTESTINAL;STROKE","5;2;1;1;1;1","5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.3 PSYCHOLOGICAL, SOCIAL AND ECONOMIC FACTORS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;3.4 VACCINES;7.2 END OF LIFE CARE","4;3;2;1;1;1;1;1","NOT SITE-SPECIFIC CANCER;MELANOMA;SARCOMA","4;1;1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;1.2 CANCER INITIATION: ALTERATIONS IN CHROMOSOMES;1.3 CANCER INITIATION: ONCOGENES AND TUMOR SUPPRESSOR GENES;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;6.6 END-OF-LIFE CARE;6.9 RESOURCES AND INFRASTRUCTURE RELATED TO CANCER CONTROL, SURVIVORSHIP, AND OUTCOMES RESEARCH","2;1;1;1;1;1;1;1;1","A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE;A05 BIOLOGICAL SCIENCES;B12 ENGINEERING;C23 EDUCATION","3;3;1;1;1;1","3 GOOD HEALTH AND WELL BEING","1",3,"THE CAMBRIDGE STRUCTURAL DATABASE;PUBLIC LIBRARY OF SCIENCE","2;1","31 BIOLOGICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS","2;1;1","BIOTECHNOLOGY;GENETICS","1;1","GENERIC HEALTH RELEVANCE","1",NA,NA,NA,NA,"BASIC SCIENCE","1","NOT SITE-SPECIFIC CANCER","1",NA,NA
"IRCCS_TUMORIMILAN",2007,252,11.265873015873,3.82539682539683,0.428571428571429,0.444444444444444,0.503968253968254,2.16666666666667,1.16129032258065,1.53424657534247,1.20952380952381,0.337301587301587,3,150,38,31,25,0.6,0.15,0.12,0.1,89.16,1.68938050372434,NA,0.345238095238095,0.76984126984127,0.45,0.412,0.393,0.421,"FRANCO BERRINO;MARCO A. PIEROTTI;EMILIO BAJETTA;PAOLO CORRADINI;­ROSARIO ­TUMINO;ANDREA MICHELI;PAOLA COLLINI;KIM OVERVAD;PAOLO G. CASALI;ELIO RÍBOLI;ANNE TJØNNELAND;RICCARDO CAPOCACCIA;ROBERTA DE ANGELIS;JAKOB LINSEISEN;RICCARDO INGHELMANN;DOMENICO PALLI;ALESSANDRO GRONCHI;ENRICO GRANDE;SHEILA BINGHAM;PAOLO BAILI","16;15;15;14;13;13;12;11;11;11;11;11;10;10;10;10;10;10;10;9","MARCO A. PIEROTTI;FRANCO BERRINO;ALESSANDRO GRONCHI;NADIA ZAFFARONI;ANDREA MICHELI;EMILIO BAJETTA;ROBERTA DE ANGELIS;PAOLO CORRADINI;PAOLO BAILI;FRANCO ZUNINO;RICCARDO CAPOCACCIA;PAOLA COLLINI;SILVIA FRANCISCI;PAOLO G. CASALI;RICCARDO INGHELMANN;ENRICO GRANDE;GIORGIO PARMIANI;LUIGI MARIANI;MILENA SANT;ARDUINO VERDECCHIA","2.48;1.96;1.91;1.77;1.7;1.65;1.41;1.27;1.19;1.17;1.15;1.12;1.08;1.03;1.02;1.02;1.02;1.01;1;0.99","FRANCO BERRINO;MARCO A. PIEROTTI;EMILIO BAJETTA;PAOLO CORRADINI;ANDREA MICHELI;PAOLA COLLINI;PAOLO G. CASALI;ALESSANDRO GRONCHI;PAOLO BAILI;GIORGIO PARMIANI;ALESSANDRO M. GIANNI;MARIA GRAZIA DAIDONE;NADIA ZAFFARONI;LUIGI MARIANI;SILVANA PILOTTI;SYLVIE MÉNARD;R. VALDAGNI;ANTONINO CARBONE;LICIA RIVOLTINI;ELENA TAMBORINI","16;15;15;14;13;12;11;10;9;9;9;8;8;8;8;8;7;7;7;7","MARCO A. PIEROTTI;FRANCO BERRINO;ALESSANDRO GRONCHI;NADIA ZAFFARONI;ANDREA MICHELI;EMILIO BAJETTA;PAOLO CORRADINI;PAOLO BAILI;FRANCO ZUNINO;PAOLA COLLINI;PAOLO G. CASALI;GIORGIO PARMIANI;LUIGI MARIANI;MILENA SANT;SYLVIE MÉNARD;SILVANA PILOTTI;ROSALBA MICELI;UGO PASTORINO;LICIA RIVOLTINI;T. RANCATI","2.48;1.96;1.91;1.77;1.7;1.65;1.27;1.19;1.17;1.12;1.03;1.02;1.01;1;0.95;0.91;0.82;0.81;0.8;0.8","GIORGIO PARMIANI;CHIARA CASTELLI;ANDREW SHELTON;AUSTIN GURNEY;DIANE M. SIMEONE;EMINA H. HUANG;IN-KYUNG PARK;MICHAEL F. CLARKE;PIERO DALERBA;ROBERT W. CHO;RUI LIU;SCOTT J. DYLLA;TIMOTHY HOEY;XINHAO WANG;GEMMA GATTA;ANDREA MICHELI;ARDUINO VERDECCHIA;SILVIA FRANCISCI;FRANCO BERRINO;LUCÌA MANGONE","2884;2786;2098;2098;2098;2098;2098;2098;2098;2098;2098;2098;2098;2098;2075;2041;1907;1893;1673;1665","GIORGIO PARMIANI;CHIARA CASTELLI;ANDREA MICHELI;FRANCO BERRINO;GABRIELLA MARIANI;PAOLO G. CASALI;EMILIO BAJETTA;ALESSANDRO GRONCHI;MARIA GRAZIA DAIDONE;PAOLA COLLINI;MILENA SANT;LUIGI MARIANI;NADIA ZAFFARONI;SIMONETTA VIVIANI;LICIA RIVOLTINI;RAFFAELLA VILLA;UGO PASTORINO;MARIO SANTINAMI;LORENZO PILLA;MANUELA IERO","2852;2786;2039;1673;1497;1479;1291;1196;1011;959;935;839;821;814;786;721;719;703;661;650","FRANCO BERRINO;EMILIO BAJETTA;MARCO A. PIEROTTI;ANDREA MICHELI;PAOLA COLLINI;PAOLO CORRADINI;PAOLO G. CASALI;ALESSANDRO GRONCHI;FRANCO ZUNINO;ALESSANDRO M. GIANNI;PAOLO BAILI;GIORGIO PARMIANI;LUIGI MARIANI;MARIA GRAZIA DAIDONE;R. VALDAGNI;ELENA TAMBORINI;NADIA ZAFFARONI;SYLVIE MÉNARD;LICIA RIVOLTINI;MARIO SANTINAMI","16;15;14;12;12;12;11;10;8;8;8;8;8;7;7;7;7;7;7;7","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;SOCIOLOGY;MATHEMATICS;COMPUTER SCIENCE;ECONOMICS;GEOGRAPHY;PSYCHOLOGY;MATERIALS SCIENCE;ART;ENGINEERING;POLITICAL SCIENCE;BUSINESS;ENVIRONMENTAL SCIENCE;PHILOSOPHY","216;100;30;26;19;16;13;6;5;5;4;3;3;2;1;1;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;PATHOLOGY;SURGERY;GENETICS;BIOCHEMISTRY;GASTROENTEROLOGY;IMMUNOLOGY;CELL BIOLOGY;RADIOLOGY;ENVIRONMENTAL HEALTH;MOLECULAR BIOLOGY;DEMOGRAPHY;ENDOCRINOLOGY;OPTICS;GYNECOLOGY;PALEONTOLOGY;NUCLEAR MEDICINE;UROLOGY","173;77;68;62;61;57;46;32;31;30;25;23;21;18;17;17;12;12;11;11","CANCER;CHEMOTHERAPY;GENE;IN VITRO;POPULATION;INCIDENCE (GEOMETRY);TRANSPLANTATION;CONFIDENCE INTERVAL;APOPTOSIS;RADIATION THERAPY;RECEPTOR;CELL CULTURE;LYMPHOMA;SARCOMA;DNA;STEM CELL;IMMUNE SYSTEM;LUNG CANCER;MELANOMA;PROSPECTIVE COHORT STUDY;STROMAL CELL;TOXICITY","121;50;37;20;20;19;17;16;15;15;15;14;14;14;13;13;12;12;12;12;12;12","BREAST CANCER;COLORECTAL CANCER;CANCER REGISTRY;PROSTATE CANCER;OVARIAN CANCER;CYCLOPHOSPHAMIDE;CISPLATIN;GENE EXPRESSION;GIST;IMATINIB;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;MELPHALAN;METASTASIS;MUTATION;PROSTATE;RELATIVE RISK;CANCER CELL;CELL CYCLE;CHEMOTHERAPY REGIMEN;CYTOTOXIC T CELL;HAZARD RATIO;PHASES OF CLINICAL RESEARCH;PROGRAMMED CELL DEATH;RITUXIMAB;SOFT TISSUE SARCOMA;TELOMERE;TOLERABILITY;TRANSFECTION;TYROSINE KINASE","37;22;16;15;12;11;9;9;9;8;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6;6;6","RELATIVE SURVIVAL;IMATINIB MESYLATE;ANTHRACYCLINE;BREAST RECONSTRUCTION;CYTOREDUCTIVE SURGERY;FLUDARABINE;FLUORESCENCE IN SITU HYBRIDIZATION;PDGFRA;BREAST SURGERY;CARBOPLATIN;ESTROGEN RECEPTOR;IRINOTECAN;KRAS;LNCAP;MAMMOGRAPHY;MASTECTOMY;MYELOID-DERIVED SUPPRESSOR CELL;ONCOGENE;OVARIAN CARCINOMA;OXALIPLATIN;SMALL INTERFERING RNA;TELOMERASE REVERSE TRANSCRIPTASE;TRASTUZUMAB","11;6;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;BREAST NEOPLASMS;AGED;;ANTINEOPLASTIC AGENTS;COLORECTAL NEOPLASMS;NEOPLASMS;ITALY;ADENOCARCINOMA;MELANOMA;LUNG NEOPLASMS;EUROPE;ADOLESCENT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;GASTROINTESTINAL STROMAL TUMORS;PROSTATIC NEOPLASMS","182;119;96;94;89;84;73;63;57;50;50;45;39;36;35;33;32;32;31;31","GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;SARCOMA RESEARCH AND TREATMENT;LYMPHOID NEOPLASMS;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;IMMUNOBIOLOGY OF DENDRITIC CELLS;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;TESTICULAR GERM CELL TUMORS AND TREATMENT;BREAST RECONSTRUCTION TECHNIQUES AND OUTCOMES;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;MANAGEMENT OF PERITONEAL CARCINOMATOSIS FROM DIGESTIVE TRACT;MECHANISMS OF ESTROGEN RECEPTOR SIGNALING;MOLECULAR RESEARCH ON BREAST CANCER;RADIOTHERAPY PHYSICS AND TECHNOLOGY;ROLE OF RETINOIC ACID IN BIOLOGICAL PROCESSES;THE P53 SIGNALING NETWORK IN CANCER RESEARCH;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;DNA TOPOISOMERASES: STRUCTURE, FUNCTION, AND INHIBITION;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER","12;12;11;10;6;6;5;5;4;4;4;4;4;4;4;4;3;3;3;3","BREAST CANCER;CANCER INCIDENCE;RELATIVE SURVIVAL;SOFT TISSUE SARCOMA;BREAST CANCER SCREENING;MELPHALAN;PROSTATE CANCER;CANCER;CHEMOTHERAPY REGIMEN;IMATINIB MESYLATE;MELANOMA;METASTATIC COLORECTAL CANCER;RADIOTHERAPY;TOLERABILITY;TREATMENT;CANCER RISK;EWING'S SARCOMA;HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY;STOMACH CANCER;STROMAL TUMOR","16;11;11;10;7;7;7;6;6;6;6;6;6;6;6;5;5;5;5;5","BREAST CANCER;PROSTATE CANCER;COLORECTAL CANCER;STEM CELL;CANCER RISK;CELL TRANSPLANTATION;EUROPEAN PROSPECTIVE;GASTROINTESTINAL STROMAL;LUNG CANCER;PROSPECTIVE INVESTIGATION;CANCER BURDEN;REGIONAL ESTIMATES;OVARIAN CANCER;CELL CARCINOMA;LATE RECTAL;LIVER TRANSPLANTATION;MELANOMA PATIENTS;PERIPHERAL BLOOD;PHASE II;PROGNOSTIC FACTORS;RETROSPECTIVE ANALYSIS;SEQUENTIAL CHEMOTHERAPY;SOFT TISSUE;STEM CELLS;ALLOGENEIC STEM;ANTITUMOR ACTIVITY;CANCER CELLS;CANCER SURVIVAL;CARCINOMA CELLS;CELL LINES","15;10;9;9;8;7;7;7;7;7;6;6;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3","BREAST CANCER;DE COMPOSTELA;SANTIAGO DE;PIT- EXPRESSION;CELL LINE;SPAIN SEARCH;CANCER RISK;COMPOSTELA SPAIN;MEDICINE UNIVERSITY;PHYSIOLOGY SCHOOL;PROSTATE CANCER;COMPOSTELA SANTIAGO;BOOSTEREXPRESS REAGENT;PIT- MRNA;PIT- PROMOTER;CD CELLS;CELL LINES;PROTEIN EXPRESSION;OVARIAN CANCER;TYROSINE KINASE;EXPRESSION FIGURE;GHC CELLS;PROGRESSION-FREE SURVIVAL;RET-INDUCED APOPTOSIS;CANCER CELLS;KINASE ACTIVITY;LUNG CANCER;MRNA EXPRESSION;BONE MARROW;CASPASE- ACTIVITY","38;32;32;20;19;18;16;16;16;16;16;15;14;14;14;13;13;12;10;10;9;9;9;9;8;8;8;8;7;7",60,0.24,6,3.25,1,2,0,3.25,5.5,1,1,4,0,1,1,2.5,2.5,0,1,1,1,0,0,79.75,79.75,2,0,0,0,0,0,0,1,1,0,0,0,1,1,0,12,2,0.42,1,1,0,2,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BAKER JOFFRE B;FORMELLI FRANCA;GIANNI LUCA;SHAK STEVEN","1;1;1;1","FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES","4;2;1","CANCER;BREAST CANCER;GENETICS;NEUROBLASTOMA;NEUROSCIENCES;ORPHAN DRUG;RARE DISEASES","2;1;1;1;1;1;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","1;1;1","A61K31/167;A61K31/195;A61P35/00;C07C233/00;C07C233/09;C12Q1/68","1;1;1;1;1;1","A61P35/00;A61P43/00;A61K31/167;C12Q1/6886;C12Q2600/106;G01N2474/20","2;2;1;1;1;1",12,6.58,190.75,2.86,4,0.33,24.67,2,1,5,0,2,0,0,2,0,12,0,0,0,0,0,0,0,10,2,0,12,0,0,0,0,0,0,0,0,0,"United States;Switzerland","3;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY","12;9;6;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;ORPHAN DRUG;PATIENT SAFETY;BREAST CANCER;LUNG;LUNG CANCER;PEDIATRIC;BIOENGINEERING;BIOTECHNOLOGY;DIGESTIVE DISEASES;HEMATOLOGY;KIDNEY DISEASE;LIVER CANCER;LIVER DISEASE;LYMPHOMA;OVARIAN CANCER;PEDIATRIC CANCER","12;9;7;7;4;4;3;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER","10","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY","8;2;1;1","BREAST CANCER;LUNG CANCER;SARCOMA;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;ENDOMETRIAL CANCER;HODGKIN'S DISEASE;KIDNEY CANCER;LIVER CANCER;MELANOMA;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;PROSTATE CANCER","3;2;2;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.1 LOCALIZED THERAPIES - DISCOVERY AND DEVELOPMENT;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","10;2;2;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,"AMERICAN ASSOCIATION FOR CANCER RESEARCH","4","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","8;4",NA,NA,"CANCER","4",NA,NA,NA,NA,"CLINICAL MEDICINE AND SCIENCE","4","OVARIAN CANCER","4",NA,NA
"IRCCS_TUMORIMILAN",2008,315,11.2412698412698,3.84126984126984,0.415873015873016,0.441269841269841,0.463492063492064,2.12302284710018,1.14912280701754,1.51086956521739,1.23728813559322,0.384126984126984,3,184,54,39,28,0.58,0.17,0.12,0.09,101.33,1.84672642034737,NA,0.441269841269841,0.819047619047619,0.478,0.432,0.418,0.429,"LUIGI MARIANI;MARCO A. PIEROTTI;FRANCO ZUNINO;ANDREA FERRARI;PAOLA COLLINI;CRISTINA MEAZZA;MICHELA CASANOVA;SIRANOUSH MANOUKIAN;ANTONINO CARBONE;PAOLO CORRADINI;ANDREA BALSARI;FILIPPO SPREAFICO;FRANCO BERRINO;­ROSARIO ­TUMINO;PAOLO RADICE;ELIO RÍBOLI;EMILIO BAJETTA;ANNE TJØNNELAND;ALESSANDRO M. GIANNI;KIM OVERVAD","16;15;15;14;13;13;12;12;12;12;12;11;11;11;11;10;10;10;10;9","LUIGI MARIANI;MARCO A. PIEROTTI;FRANCO ZUNINO;ANTONINO CARBONE;ELIA BIGANZOLI;ANDREA BALSARI;GIORGIO PIZZOCARO;TOMMASO A. DRAGANI;PATRIZIA BORACCHI;ANDREA FERRARI;CRISTINA MEAZZA;ANNUNZIATA GLOGHINI;PAOLA COLLINI;M. CARRARA;G. GAMBARINI;MARIA GRAZIA DAIDONE;EMILIO BAJETTA;MICHELA CASANOVA;NICOLA NICOLAI;IRCCS ISTITUTO","2.21;1.97;1.8;1.7;1.65;1.53;1.38;1.37;1.32;1.3;1.27;1.24;1.23;1.21;1.21;1.17;1.12;1.11;1.05;1","LUIGI MARIANI;MARCO A. PIEROTTI;FRANCO ZUNINO;ANDREA FERRARI;PAOLA COLLINI;CRISTINA MEAZZA;MICHELA CASANOVA;SIRANOUSH MANOUKIAN;ANTONINO CARBONE;PAOLO CORRADINI;ANDREA BALSARI;FILIPPO SPREAFICO;FRANCO BERRINO;­ROSARIO ­TUMINO;PAOLO RADICE;ELIO RÍBOLI;EMILIO BAJETTA;ANNE TJØNNELAND;ALESSANDRO M. GIANNI;KIM OVERVAD","16;15;15;14;13;13;12;12;12;12;12;11;11;11;11;10;10;10;10;9","LUIGI MARIANI;MARCO A. PIEROTTI;FRANCO ZUNINO;ANTONINO CARBONE;ELIA BIGANZOLI;ANDREA BALSARI;GIORGIO PIZZOCARO;TOMMASO A. DRAGANI;ANDREA FERRARI;CRISTINA MEAZZA;ANNUNZIATA GLOGHINI;PAOLA COLLINI;M. CARRARA;MARIA GRAZIA DAIDONE;EMILIO BAJETTA;MICHELA CASANOVA;NICOLA NICOLAI;IRCCS ISTITUTO;CARLA RIPAMONTI;GIANNI VIRGILI","2.21;1.97;1.8;1.7;1.65;1.53;1.38;1.37;1.3;1.27;1.24;1.23;1.21;1.17;1.12;1.11;1.05;1;1;1","VINCENZO MAZZAFERRO;JORDI BRUIX;JOSEP M. LLOVET;ALEJANDRO FORNER;ANDRÉ COSME DE OLIVEIRA;ARMANDO SANTORO;CAMILLO PORTA;D. VOLIOTIS;DIETER HÄUSSINGER;EDWARD GANE;IVAN BORBATH;JEAN FRANÇOIS SEITZ;JEAN FRÉDÉRIC BLANC;JEAN‐LUC RAOUL;LUIGI BOLONDI;M. MOSCOVICI;MINGHUA SHAN;MYRON SCHWARTZ;PETER R. GALLE;PHILIP HILGARD","11801;11719;11719;11718;11718;11718;11718;11718;11718;11718;11718;11718;11718;11718;11718;11718;11718;11718;11718;11718","VINCENZO MAZZAFERRO;FRANCO BERRINO;GEMMA GATTA;ANDREA MICHELI;SIRANOUSH MANOUKIAN;MILENA SANT;PAOLO BAILI;LUIGI MARIANI;PAOLO RADICE;MARIO P. COLOMBO;PAOLO G. CASALI;PAOLA COLLINI;LUCIO BERTARIO;MARCO A. PIEROTTI;SALVATORE LO VULLO;SILVIA PICONESE;ALESSANDRO GRONCHI;EMILIO BAJETTA;MARIO SANTINAMI;MARCO FIORE","11789;2629;2111;2081;1848;1769;1715;1633;1023;974;949;863;843;814;770;756;732;698;671;658","FRANCO ZUNINO;LUIGI MARIANI;ANDREA FERRARI;MARCO A. PIEROTTI;CRISTINA MEAZZA;PAOLA COLLINI;SIRANOUSH MANOUKIAN;MICHELA CASANOVA;PAOLO CORRADINI;FILIPPO SPREAFICO;FRANCO BERRINO;PAOLO RADICE;ANTONINO CARBONE;MAURA MASSIMINO;ALESSANDRO M. GIANNI;MONICA TERENZIANI;ROBERTO LUKSCH;TOMMASO A. DRAGANI;EMILIO BAJETTA;ELIA BIGANZOLI","16;15;14;13;13;12;12;12;12;11;10;9;9;9;9;8;8;8;8;7","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;SOCIOLOGY;MATHEMATICS;MATERIALS SCIENCE;PSYCHOLOGY;ENGINEERING;POLITICAL SCIENCE;GEOGRAPHY;PHILOSOPHY;BUSINESS;ECONOMICS;ENVIRONMENTAL SCIENCE;HISTORY","249;151;47;29;18;14;11;10;9;6;6;4;2;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;GENETICS;CANCER RESEARCH;SURGERY;PATHOLOGY;BIOCHEMISTRY;IMMUNOLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;RADIOLOGY;MOLECULAR BIOLOGY;OPTICS;ENDOCRINOLOGY;GYNECOLOGY;NUCLEAR MEDICINE;PALEONTOLOGY;DEMOGRAPHY;PHARMACOLOGY","191;101;83;76;74;65;60;46;33;32;29;28;19;18;17;16;15;14;11;11","CANCER;GENE;CHEMOTHERAPY;POPULATION;RADIATION THERAPY;CONFIDENCE INTERVAL;IMMUNE SYSTEM;IN VITRO;LYMPHOMA;APOPTOSIS;RECEPTOR;CELL CULTURE;SARCOMA;IMMUNOHISTOCHEMISTRY;INCIDENCE (GEOMETRY);REGIMEN;TRANSPLANTATION;MULTIPLE MYELOMA;DISEASE;DNA;LUNG CANCER;PROPORTIONAL HAZARDS MODEL","140;72;51;30;25;24;20;20;20;17;17;15;15;13;13;13;13;12;11;11;11;11","BREAST CANCER;COLORECTAL CANCER;GENE EXPRESSION;MUTATION;HAZARD RATIO;OVARIAN CANCER;PROSTATE CANCER;ALLELE;CYCLOPHOSPHAMIDE;T CELL;CARCINOGENESIS;METASTASIS;CELL CYCLE;CISPLATIN;MONOCLONAL ANTIBODY;PROGRAMMED CELL DEATH;RHABDOMYOSARCOMA;CANCER REGISTRY;CYTOTOXIC T CELL;IMATINIB;IMMUNOTHERAPY;PROSTATE","47;22;17;17;16;15;14;12;12;12;11;11;10;10;8;8;8;7;7;7;7;7","GERMLINE MUTATION;DNA METHYLATION;ESTROGEN RECEPTOR;FLUDARABINE;TAMOXIFEN;THIOTEPA;HISTONE DEACETYLASE;RADIOIMMUNOTHERAPY;RELATIVE SURVIVAL;TUMOR SUPPRESSOR GENE;VINCRISTINE;CARBOPLATIN;CETUXIMAB;CYCLIN D1;IL-2 RECEPTOR;IRINOTECAN;OVARIAN CARCINOMA;TRASTUZUMAB;BRCA MUTATION;CASPASE;CYTOREDUCTIVE SURGERY;ERLOTINIB;GENE EXPRESSION PROFILING;HAPLOTYPE;HORMONE THERAPY;IMATINIB MESYLATE;INHIBITOR OF APOPTOSIS;KRAS;LOSS OF HETEROZYGOSITY;MAMMOGRAPHY;MASTECTOMY;MICROARRAY;PDGFRA;PROPIDIUM IODIDE;SINGLE-NUCLEOTIDE POLYMORPHISM;TLR2","9;8;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","HUMANS;FEMALE;BREAST NEOPLASMS;MIDDLE AGED;MALE;AGED;ADULT;ANTINEOPLASTIC AGENTS;NEOPLASMS;;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;NEOPLASM RECURRENCE, LOCAL;OVARIAN NEOPLASMS;LUNG NEOPLASMS;ANIMALS;ADENOCARCINOMA;BIOMARKERS, TUMOR;MICE;ADOLESCENT","235;150;110;97;96;82;81;75;73;65;57;49;41;41;38;37;35;32;32;31","SARCOMA RESEARCH AND TREATMENT;LYMPHOID NEOPLASMS;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MOLECULAR RESEARCH ON BREAST CANCER;DNA TOPOISOMERASES: STRUCTURE, FUNCTION, AND INHIBITION;ROLE OF HISTONE DEACETYLASES IN CELLULAR REGULATION;ADVANCEMENTS IN LUNG CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HER2 SIGNALING IN BREAST CANCER TREATMENT;IMMUNOBIOLOGY OF DENDRITIC CELLS;INNATE IMMUNE RECOGNITION AND SIGNALING PATHWAYS;MALE CIRCUMCISION FOR HIV PREVENTION AND PENILE HEALTH;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;MELANOMA;MICROARRAY DATA ANALYSIS AND GENE EXPRESSION PROFILING","14;12;11;6;6;6;6;6;5;5;4;4;4;4;4;4;4;4;4;4","BREAST CANCER;CANCER RISK;REGIMEN;RADIOTHERAPY;CANCER SUSCEPTIBILITY;BRCA1;CANCER SURVIVORSHIP;RHABDOMYOSARCOMA;SOFT TISSUE SARCOMA;CANCER INCIDENCE;FOLLICULAR LYMPHOMA;MELANOMA;REFRACTORY (PLANETARY SCIENCE);THIOTEPA;THYROID NODULES;TREATMENT;BRCA2;CAMPTOTHECIN;CANCER;DOSIMETRY","22;13;13;12;11;7;7;7;7;6;6;6;6;6;6;6;5;5;5;5","BREAST CANCER;LUNG CANCER;MULTIPLE MYELOMA;EUROPEAN PROSPECTIVE;PHASE II;PROSPECTIVE INVESTIGATION;SOFT TISSUE;CANCER PATIENTS;CANCER RISK;GASTROINTESTINAL STROMAL;PROSTATE CANCER;GENE EXPRESSION;HEPATOCELLULAR CARCINOMA;II STUDY;MUTATION CARRIERS;OVARIAN CANCER;BRCA MUTATION;CANCER CELLS;CELL CARCINOMA;CELL LINES;COLORECTAL CANCER;HISTONE DEACETYLASE;NON-HODGKINS LYMPHOMA;PHASE III;STEM CELL;STROMAL TUMORS;TISSUE SARCOMA;ALLOGENEIC STEM;CANCER THERAPY;CELL LUNG","24;8;8;7;7;7;7;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3","BREAST CANCER;CANCER RISK;BRCA MUTATION;NON-HODGKINS LYMPHOMA;PROSTATE CANCER;GROWTH FACTOR;MUTATION CARRIERS;CELL LINES;HR CI;CANCER SURVIVAL;GENE EXPRESSION;MULTIPLE MYELOMA;OVARIAN CANCER;FACTOR RECEPTOR;CANCER PATIENTS;COLORECTAL CANCER;FATTY ACIDS;HAZARD RATIO;POSTMENOPAUSAL WOMEN;RR CI;CONFIDENCE INTERVAL;ARTIFICIAL ANTIGEN-PRESENTING;DENDRITIC CELLS;EUROPEAN PROSPECTIVE;PROSPECTIVE INVESTIGATION;TREG CELLS;ANTIGEN-PRESENTING CELLS;BRCA CARRIERS;CANCER CELLS;CELL CYCLE","93;34;29;18;18;17;17;16;15;14;13;13;13;12;11;11;11;11;11;10;9;8;8;8;8;8;7;7;7;7",73,0.23,6,4,1,2,2,3,3,1,2,5,0,1,5.5,1,2,3,1,5,2,0,0,106,106,1,1,1,0,0,0,0,0,0,0,0,0,2,0,0,0,2,0.33,1,0,0,2,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BOGNI ANNA;PASCALI CLAUDIO","2;2","FOND IRCCS;INDIVIDUAL","1;1","51 PHYSICAL SCIENCES;5110 SYNCHROTRONS AND ACCELERATORS","4;2",NA,NA,NA,NA,"C07B59/00;C07B63/00","2;2","A61K51/0491;C07B59/005;C07B63/00","2;2;2",15,5.47,376.07,3.11,1,0.07,42.47,1,0,4,0,5,0,0,5,0,13,2,0,0,0,0,0,0,13,2,0,15,0,0,0,0,0,0,0,0,0,"Italy;United States","4;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;3210 NUTRITION AND DIETETICS;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","15;8;6;3;3;2;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;PEDIATRIC;PEDIATRIC CANCER;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;AGING;BIOMEDICAL IMAGING;BIOTECHNOLOGY;DIGESTIVE DISEASES;NUTRITION;PATIENT SAFETY;PREVENTION;TRANSPLANTATION;BEHAVIORAL AND SOCIAL SCIENCE;BREAST CANCER","14;13;9;8;4;3;3;3;3;3;2;2;2;2;2;2;2;2;1;1","CANCER;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;MUSCULOSKELETAL;ORAL AND GASTROINTESTINAL","13;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;7.1 INDIVIDUAL CARE NEEDS;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","10;3;2;2;1;1","COLON AND RECTAL CANCER;MYELOMA;NON-HODGKIN'S LYMPHOMA;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;BREAST CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;GASTROINTESTINAL TRACT;HEAD AND NECK CANCER;HODGKIN'S DISEASE;KIDNEY CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;MELANOMA;OVARIAN CANCER;SARCOMA;STOMACH CANCER","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;3.1 INTERVENTIONS TO PREVENT CANCER: PERSONAL BEHAVIORS THAT AFFECT CANCER RISK;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","9;3;3;2;1;1;1",1,8981796,690907.38,6,13,10,1,31,890255.706662088,0.35383092480368,"ACIES CONSULTING GROUP (FRANCE);AGILENT TECHNOLOGIES (DENMARK);ERASMUS MC;EUROPEAN COMMITTEE FOR STANDARDIZATION;FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;INSTITUTE OF BIOTECHNOLOGY;INTERUNIVERSITY CONSORTIUM FOR MAGNETIC RESONANCE;MEDICAL UNIVERSITY OF GRAZ;NEL (NORWAY);QIAGEN (GERMANY);TATAA BIOCENTER (SWEDEN);TECHNICAL UNIVERSITY OF MUNICH;UNIVERSITY OF FLORENCE","1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CP-IP - LARGE-SCALE INTEGRATING PROJECT (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2007-B (CALL FOR PROPOSAL)","1;1;1","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY","1;1",NA,NA,"GENERIC HEALTH RELEVANCE","1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION)","1;1","NOT SITE-SPECIFIC CANCER","1","4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS","1","A01 CLINICAL MEDICINE","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIMILAN",2009,356,13.2949438202247,3.6938202247191,0.446629213483146,0.443820224719101,0.564606741573034,2.23089983022071,1.30327868852459,1.68085106382979,1.43571428571429,0.421348314606742,9,209,61,37,33,0.59,0.17,0.1,0.09,63.17,1.36559300993859,NA,0.457865168539326,0.817415730337079,0.477,0.423,0.411,0.409,"ELIO RÍBOLI;PAOLO CORRADINI;NADIA SLIMANI;SHEILA BINGHAM;PAOLO G. CASALI;ANTONIA TRICHOPOULOU;ANNE TJØNNELAND;KIM OVERVAD;MARCO A. PIEROTTI;JONAS MANJER;­ROSARIO ­TUMINO;MAZDA JENAB;ALESSANDRO GRONCHI;RUDOLF KAAKS;HEINER BOEING;JAKOB LINSEISEN;CARLO MOROSI;KAY‐TEE KHAW;SABINE ROHRMANN;DOMENICO PALLI","26;24;22;22;18;18;17;16;16;16;16;16;16;15;15;14;14;13;13;13","EMILIO BAJETTA;PAOLO CORRADINI;ALESSANDRO GRONCHI;HEIDI BLÜMHUBER;PAOLO G. CASALI;ANTONINO CARBONE;MARCO A. PIEROTTI;M. CARRARA;FRANCO ZUNINO;CARLO MOROSI;ANDREA FERRARI;MARIA GRAZIA DAIDONE;LUIGI MARIANI;PAOLA COLLINI;AUGUSTO CARACENI;G. GAMBARINI;MASSIMO MAFFEZZINI;LAURA FRIGERIO;PATRIZIA CASALINI;EMILIO BOMBARDIERI","3.34;2.27;2.02;2;1.76;1.72;1.7;1.68;1.57;1.56;1.36;1.31;1.17;1.14;1.11;1.1;1.09;1.08;1.07;1.06","PAOLO CORRADINI;PAOLO G. CASALI;MARCO A. PIEROTTI;ALESSANDRO GRONCHI;CARLO MOROSI;ANDREA FERRARI;UGO PASTORINO;FRANCO BERRINO;PAOLA COLLINI;R. VALDAGNI;FRANCO ZUNINO;EMILIO BAJETTA;MARIO SANTINAMI;LUIGI MARIANI;GABRIELLA SOZZI;LICIA RIVOLTINI;SILVANA PILOTTI;CLAUDIA AGNOLI;ANTONINO CARBONE;LUCA GIANNI","24;18;16;16;14;12;11;11;11;10;10;10;10;10;9;9;9;8;8;8","EMILIO BAJETTA;PAOLO CORRADINI;ALESSANDRO GRONCHI;HEIDI BLÜMHUBER;PAOLO G. CASALI;ANTONINO CARBONE;MARCO A. PIEROTTI;M. CARRARA;FRANCO ZUNINO;CARLO MOROSI;ANDREA FERRARI;MARIA GRAZIA DAIDONE;LUIGI MARIANI;PAOLA COLLINI;AUGUSTO CARACENI;MASSIMO MAFFEZZINI;LAURA FRIGERIO;PATRIZIA CASALINI;EMILIO BOMBARDIERI;VALENTINA ZUCO","3.34;2.27;2.02;2;1.76;1.72;1.7;1.68;1.57;1.56;1.36;1.31;1.17;1.14;1.11;1.09;1.08;1.07;1.06;1.05","ELIO RÍBOLI;NADIA SLIMANI;RICCARDO CAPOCACCIA;SHEILA BINGHAM;ANTONIA TRICHOPOULOU;MARIO SANTINAMI;ANNE TJØNNELAND;PAOLO G. CASALI;CLAUDIA ALLEMANI;LICIA RIVOLTINI;MILENA SANT;MARIANO SANTAQUILANI;LUIGI MARIANI;JONAS MANJER;­ROSARIO ­TUMINO;EILIV LUND;ALESSANDRO GRONCHI;GABRIELLA SOZZI;ARNOLD KNIJN;F MARCHESI","2338;1998;1929;1869;1714;1714;1704;1699;1665;1599;1538;1531;1527;1510;1476;1467;1444;1398;1344;1344","MARIO SANTINAMI;CLAUDIA ALLEMANI;LICIA RIVOLTINI;MILENA SANT;ALESSANDRO GRONCHI;PAOLO G. CASALI;LUIGI MARIANI;F MARCHESI;UGO PASTORINO;DOMENICO DELIA;GABRIELLA SOZZI;ALESSANDRA FABBRI;SALVATORE LO VULLO;ENRICO FONTANELLA;SYLVIE MÉNARD;ELISA CALABRÒ;ELDA TAGLIABUE;VERONICA HUBER;LAURA GATTI;PAOLA PEREGO","1714;1665;1599;1538;1444;1418;1417;1344;1332;1140;1116;1047;1041;1023;1013;976;915;886;835;835","PAOLO CORRADINI;ALESSANDRO GRONCHI;PAOLO G. CASALI;MARCO A. PIEROTTI;CARLO MOROSI;FRANCO ZUNINO;ANDREA FERRARI;UGO PASTORINO;FRANCO BERRINO;MARIO SANTINAMI;R. VALDAGNI;EMILIO BAJETTA;LICIA RIVOLTINI;SILVANA PILOTTI;LUCA GIANNI;DOMENICO DELIA;LUIGI MARIANI;PAOLA COLLINI;M. CARRARA;MONICA RODOLFO","22;16;16;15;12;12;11;11;10;10;10;10;9;9;8;8;8;8;7;7","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;SOCIOLOGY;COMPUTER SCIENCE;MATHEMATICS;MATERIALS SCIENCE;POLITICAL SCIENCE;PHILOSOPHY;ART;ECONOMICS;BUSINESS;ENGINEERING;PSYCHOLOGY;GEOGRAPHY;ENVIRONMENTAL SCIENCE;HISTORY","307;164;50;34;21;18;17;10;9;8;5;5;4;3;3;2;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CANCER RESEARCH;GENETICS;PATHOLOGY;BIOCHEMISTRY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;CELL BIOLOGY;RADIOLOGY;PALEONTOLOGY;PHARMACOLOGY;NUCLEAR MEDICINE;OPTICS;DEMOGRAPHY;GYNECOLOGY;MOLECULAR BIOLOGY;UROLOGY","248;118;91;83;76;76;63;46;45;40;35;28;26;23;19;19;18;18;17;16","CANCER;GENE;CHEMOTHERAPY;POPULATION;RADIATION THERAPY;PROSPECTIVE COHORT STUDY;STEM CELL;TRANSPLANTATION;CONFIDENCE INTERVAL;LUNG CANCER;MELANOMA;DISEASE;APOPTOSIS;IN VITRO;MULTIPLE MYELOMA;REGIMEN;SARCOMA;STROMAL CELL;STAGE (STRATIGRAPHY);IMMUNE SYSTEM;INCIDENCE (GEOMETRY);RECEPTOR","164;73;71;32;28;27;20;20;19;19;18;16;15;15;15;15;15;15;14;13;13;13","BREAST CANCER;COLORECTAL CANCER;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;PROSTATE CANCER;CYCLOPHOSPHAMIDE;MUTATION;ALLELE;HAZARD RATIO;GENOTYPE;CISPLATIN;METASTASIS;OVARIAN CANCER;CARCINOGENESIS;CUMULATIVE INCIDENCE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;CANCER REGISTRY;GENE EXPRESSION;PHENOTYPE;DNA DAMAGE;PROGRESSIVE DISEASE;T CELL","51;25;23;16;15;14;13;13;12;11;11;11;10;10;10;9;9;9;8;8;8","SINGLE-NUCLEOTIDE POLYMORPHISM;TRASTUZUMAB;RELATIVE SURVIVAL;FLUDARABINE;GERMLINE MUTATION;CAPECITABINE;IMATINIB MESYLATE;KRAS;OXALIPLATIN;THIOTEPA;CASPASE;DNA MISMATCH REPAIR;GENE EXPRESSION PROFILING;GENOTYPING;HISTONE DEACETYLASE;INHIBITOR OF APOPTOSIS;IRINOTECAN;METASTATIC BREAST CANCER;PRIMARY TUMOR;PROSTATE-SPECIFIC ANTIGEN;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RETINOID;SENTINEL NODE;TRABECTEDIN;VINCRISTINE","9;9;8;7;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4","HUMANS;FEMALE;MIDDLE AGED;MALE;AGED;ADULT;;NEOPLASMS;BREAST NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;MELANOMA;EUROPE;LUNG NEOPLASMS;ANTINEOPLASTIC AGENTS;OVARIAN NEOPLASMS;CARCINOMA, SQUAMOUS CELL;YOUNG ADULT;ADOLESCENT;ITALY;ADENOCARCINOMA","256;165;131;128;106;98;92;92;78;70;68;62;59;54;50;47;45;42;42;41","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;SARCOMA RESEARCH AND TREATMENT;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;LYMPHOID NEOPLASMS;ADVANCEMENTS IN LUNG CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;CLINICOPATHOLOGY OF FIBROUS TUMORS AND TREATMENT STRATEGIES;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEMATOPOIETIC STEM CELL BIOLOGY;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;RADIOTHERAPY PHYSICS AND TECHNOLOGY;ROLE OF RETINOIC ACID IN BIOLOGICAL PROCESSES;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM;DIAGNOSIS AND TREATMENT OF LUNG CANCER;DNA TOPOISOMERASES: STRUCTURE, FUNCTION, AND INHIBITION;ENDOSCOPIC SKULL BASE SURGERY TECHNIQUES","13;11;10;9;8;7;7;7;6;5;5;5;5;5;5;5;4;4;4;4","BREAST CANCER;REGIMEN;DIETARY PATTERNS;HEALTHY EATING INDEX;CANCER RISK;CUMULATIVE INCIDENCE;CANCER SUSCEPTIBILITY;RADIOTHERAPY;SOFT TISSUE SARCOMA;HEMATOPOIETIC CELL TRANSPLANTATION;RELATIVE SURVIVAL;SNP;CANCER SURVIVORSHIP;CANCER THERAPY;MELANOMA;REFRACTORY (PLANETARY SCIENCE);CANCER SURVIVAL;DOSIMETRY;INTERNATIONAL MYELOMA WORKING GROUP;MELPHALAN","17;15;13;13;11;10;9;9;9;8;8;8;7;7;7;7;6;6;6;6","BREAST CANCER;EUROPEAN PROSPECTIVE;PROSPECTIVE INVESTIGATION;STEM CELL;CANCER PATIENTS;LUNG CANCER;PROSTATE CANCER;CELL TRANSPLANTATION;MULTIPLE MYELOMA;CANCER RISK;RETROSPECTIVE ANALYSIS;CELL CARCINOMA;OVARIAN CANCER;ALLOGENEIC STEM;CARCINOMA CELLS;COLORECTAL CANCER;GASTROINTESTINAL STROMAL;MELANOMA PATIENTS;NUTRITION EPIC;PHASE II;LOCALLY ADVANCED;METASTATIC BREAST;MYELOMA PATIENTS;PATIENTS UNDERGOING;REDUCED INTENSITY;REDUCED-INTENSITY CONDITIONING;SQUAMOUS CELL;TUMOR RESPONSE;ALLOGENEIC TRANSPLANTATION;ANTITUMOR ACTIVITY","26;22;22;17;12;12;12;10;10;9;8;7;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;3;3","BREAST CANCER;LUNG CANCER;PUBMED SCOPUS;CANCER RISK;CROSSREF PUBMED;GROWTH FACTOR;CELL LINES;EML-ALK FUSION;CANCER PATIENTS;PROSTATE CANCER;FACTOR RECEPTOR;CONFIDENCE INTERVAL;MUTATION CARRIERS;CELL CARCINOMA;EPIDERMAL GROWTH;EUROPEAN PROSPECTIVE;FUSION GENE;PROSPECTIVE INVESTIGATION;GENE EXPRESSION;HR CI;MULTIPLE MYELOMA;SITU HYBRIDIZATION;STEM CELL;BRCA MUTATION;CELL LINE;CELL LUNG;ENERGY INTAKE;PERIPHERAL BLOOD;SQUAMOUS CELL;LOGISTIC REGRESSION","89;50;41;40;33;26;25;25;21;20;18;17;16;15;15;15;15;15;14;14;14;14;14;12;12;12;12;12;12;11",80,0.22,7,4,1.25,1.5,0,2,6,1,1.5,5,0,1,3,1,1,0,1,2,1.75,0,0,112,107.5,2,0,1,0,0,0,0,0,1,0,0,0,2,0,0,5,8,1.22,2,0,2,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BELVISI LAURA;BOLOGNESI MARTINO;CANEVARI SILVANA;CATTOZZO MARGHERITA;DELIA DOMENICO;DI CIOCCIO VITO;DRAGO CARMELO;FIGINI MARIANGELA;MANZONI LEONARDO PIERPAOLO;MARTIN FRANCK","1;1;1;1;1;1;1;1;1;1","DOMPE PHARMA SPA;FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DIE TUMORI;UNIVERSITA DEGLI STUDI DI MILANO","1;1;1;1","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","3;2;1;1;1","CANCER;BIOTECHNOLOGY;BRAIN DISORDERS;COMPLEMENTARY AND INTEGRATIVE HEALTH;OVARIAN CANCER;RARE DISEASES","2;1;1;1;1;1","5.1 PHARMACEUTICALS","1","A61K31/5517;A61P35/00;C07D487/04;C07K16/28","1;1;1;1","A61P35/00;A61K39/395;A61P43/00;C07D487/04;C07K16/28;C07K16/3069;C07K2317/21;C07K2317/54;C07K2317/92;C07K5/0808","2;1;1;1;1;1;1;1;1;1",18,6.47,345.22,3.38,2,0.11,48.44,1,0,5,0,8,0,0,4,0,16,2,0,0,0,0,0,0,13,3,2,18,0,0,0,0,0,0,0,0,0,"United States;Japan","3;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3209 NEUROSCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","18;16;11;3;1;1;1;1","CLINICAL RESEARCH;CANCER;RARE DISEASES;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;UROLOGIC DISEASES;AGING;LYMPHOMA;PROSTATE CANCER;STEM CELL RESEARCH;BIOTECHNOLOGY;BREAST CANCER;COLO-RECTAL CANCER;DIGESTIVE DISEASES;OVARIAN CANCER;PATIENT SAFETY;PEDIATRIC;CARDIOVASCULAR;CERVICAL CANCER;CHRONIC PAIN","17;16;11;10;4;4;3;3;3;3;2;2;2;2;2;2;2;1;1;1","CANCER;INFECTION;ORAL AND GASTROINTESTINAL","14;1;1","6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;6.2 CELLULAR AND GENE THERAPIES;3.4 VACCINES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.4 SURGERY","15;4;2;1;1;1","NON-HODGKIN'S LYMPHOMA;LUNG CANCER;OVARIAN CANCER;PROSTATE CANCER;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;BREAST CANCER;BLADDER CANCER;CERVICAL CANCER;COLON AND RECTAL CANCER;HEAD AND NECK CANCER;HODGKIN'S DISEASE;LARYNGEAL CANCER;LEUKEMIA / LEUKAEMIA;MELANOMA;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER;SARCOMA","4;3;3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","13;3;3;1;1;1;1",2,1754817,203166.11,4,6,3.5,1,4,735757.282455739,0.483855217595371,"FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;AUGUST PI I SUNYER BIOMEDICAL RESEARCH INSTITUTE;CIC NANOGUNE;COMPLUTENSE UNIVERSITY OF MADRID;DANA-FARBER CANCER INSTITUTE;DOMPÉ (ITALY);FRENCH NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;ITALIAN INSTITUTE OF TECHNOLOGY;NATIONAL RESEARCH COUNCIL;UNIVERSITY OF SANTIAGO DE COMPOSTELA;UNIVERSITY OF TWENTE","2;1;1;1;1;1;1;1;1;1;1","AMERICAN ASSOCIATION FOR CANCER RESEARCH;EUROPEAN COMMISSION","1;1","COALITION S;EC & ERC - EUROPEAN UNION;HRA - HEALTH RESEARCH ALLIANCE","1;1;1","CP-FP - SMALL OR MEDIUM-SCALE FOCUSED RESEARCH PROJECT (FUNDING SCHEME);FP7-NMP - SPECIFIC PROGRAMME ""COOPERATION"": NANOSCIENCES, NANOTECHNOLOGIES, MATERIALS AND NEW PRODUCTION TECHNOLOGIES (PROGRAMME);FP7-NMP-2008-SMALL-2 (CALL FOR PROPOSAL);THE LANDON FOUNDATION-AACR INNOVATOR AWARD FOR INTERNATIONAL COLLABORATION IN CANCER RESEARCH (OLD) (PROGRAM)","1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","2;1;1;1","CANCER;RARE DISEASES;BIOENGINEERING;BIOTECHNOLOGY;CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL RESEARCH;DIGESTIVE DISEASES;GENETICS;HUMAN GENOME;LIVER CANCER;LIVER DISEASE;NANOTECHNOLOGY;OVARIAN CANCER;PREVENTION","2;2;1;1;1;1;1;1;1;1;1;1;1;1","CANCER","2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","LIVER CANCER;OVARIAN CANCER","1;1","4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.1 LOCALIZED THERAPIES - DISCOVERY AND DEVELOPMENT","1;1","A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1;1",NA,NA,4,"PUBLIC LIBRARY OF SCIENCE;AMERICAN ASSOCIATION FOR CANCER RESEARCH","3;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;49 MATHEMATICAL SCIENCES;51 PHYSICAL SCIENCES;5106 NUCLEAR AND PLASMA PHYSICS","6;2;2;1;1;1;1","CANCER;BIOTECHNOLOGY;BREAST CANCER;CLINICAL RESEARCH;GENETICS","2;1;1;1;1","CANCER","2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","2","BIOMEDICAL","1","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE","2;1","BREAST CANCER;MELANOMA","1;1",NA,NA
"IRCCS_TUMORIMILAN",2010,336,13.7172619047619,3.72321428571429,0.422619047619048,0.407738095238095,0.523809523809524,2.23035714285714,1.16393442622951,1.55681818181818,1.23076923076923,0.467261904761905,7,184,61,35,30,0.55,0.18,0.1,0.09,65.56,1.45066799001092,NA,0.49702380952381,0.797619047619048,0.457,0.375,0.389,0.401,"­ROSARIO ­TUMINO;ANTONIA TRICHOPOULOU;KIM OVERVAD;ELIO RÍBOLI;ANNE TJØNNELAND;RUDOLF KAAKS;HEINER BOEING;DOMENICO PALLI;KAY‐TEE KHAW;EVA ARDANÁZ;PAOLO VINEIS;SALVATORE PANICO;JONAS MANJER;NADIA SLIMANI;PAOLA COLLINI;MARÍA‐JOSÉ SÁNCHEZ;MARCO A. PIEROTTI;CARMEN NAVARRO;CARLOTTA SACERDOTE;NICHOLAS J. WAREHAM","31;25;24;24;24;20;20;20;19;18;17;16;16;15;15;15;14;14;14;14","FRANCO BERRINO;PAOLO G. CASALI;UGO PASTORINO;MARCO A. PIEROTTI;SILVANA CANEVARI;ANDREA FERRARI;ANTONINO CARBONE;ALESSANDRO GRONCHI;MAURA MASSIMINO;TOMMASO A. DRAGANI;NADIA ZAFFARONI;VINCENZO MAZZAFERRO;FLAVIO CRIPPA;PAOLA COLLINI;MANUELA GARIBOLDI;M. CARRARA;LUCA TAVECCHIO;SILVANA PILOTTI;DOMENICO DELIA;­ROSARIO ­TUMINO","2.67;2.05;1.88;1.88;1.53;1.45;1.38;1.36;1.33;1.27;1.26;1.23;1.19;1.18;1.17;1.12;1.1;1.08;1.02;1.01","PAOLA COLLINI;MARCO A. PIEROTTI;PAOLO G. CASALI;FRANCO BERRINO;VITTORIO KROGH;ALESSANDRO GRONCHI;SILVANA CANEVARI;ANDREA FERRARI;SILVANA PILOTTI;PAOLO CORRADINI;SABINA SIERI;GIOVANNA MASALA;MAURA MASSIMINO;FILIPPO SPREAFICO;MONICA TORTORETO;M. CARRARA;NADIA ZAFFARONI;LUIGI MARIANI;PAOLO RADICE;VALERIA PALA","15;14;13;13;13;12;11;11;11;10;10;10;10;9;9;9;9;9;9;8","FRANCO BERRINO;PAOLO G. CASALI;UGO PASTORINO;MARCO A. PIEROTTI;SILVANA CANEVARI;ANDREA FERRARI;ANTONINO CARBONE;ALESSANDRO GRONCHI;MAURA MASSIMINO;TOMMASO A. DRAGANI;NADIA ZAFFARONI;VINCENZO MAZZAFERRO;FLAVIO CRIPPA;PAOLA COLLINI;MANUELA GARIBOLDI;M. CARRARA;LUCA TAVECCHIO;SILVANA PILOTTI;DOMENICO DELIA;FRANCO DE CONNO","2.67;2.05;1.88;1.88;1.53;1.45;1.38;1.36;1.33;1.27;1.26;1.23;1.19;1.18;1.17;1.12;1.1;1.08;1.02;1","ELIO RÍBOLI;ANNE TJØNNELAND;­ROSARIO ­TUMINO;PAOLO G. CASALI;PETRA H. PEETERS;RUDOLF KAAKS;FRANCO BERRINO;KIM OVERVAD;VITTORIO KROGH;ANTONIA TRICHOPOULOU;LUCA GIANNI;DOMENICO PALLI;HEINER BOEING;MARIE‐CHRISTINE BOUTRON‐RUAULT;JOSÉ BASELGA;KAY‐TEE KHAW;PANCRAS C.W. HOGENDOORN;ALESSANDRO GRONCHI;SALVATORE PANICO;MILVIA ZAMBETTI","2163;2161;2061;1854;1831;1751;1722;1604;1567;1543;1527;1468;1438;1406;1397;1374;1342;1262;1247;1236","PAOLO G. CASALI;FRANCO BERRINO;VITTORIO KROGH;LUCA GIANNI;ALESSANDRO GRONCHI;MILVIA ZAMBETTI;LISA LICITRA;PAOLO CORRADINI;LUIGI MARIANI;MILENA SANT;CLAUDIA ALLEMANI;MARCO FIORE;CARMEN ŢEREANU;ROSALBA MICELI;SIRANOUSH MANOUKIAN;SABINA SIERI;PAOLA COLLINI;ANDREA FERRARI;S. BIELACK;S. FERRARI","1849;1722;1567;1292;1248;1207;1105;1030;1013;975;960;885;884;881;824;731;722;703;671;671","PAOLA COLLINI;FRANCO BERRINO;MARCO A. PIEROTTI;VITTORIO KROGH;PAOLO G. CASALI;ANDREA FERRARI;SILVANA CANEVARI;PAOLO CORRADINI;ALESSANDRO GRONCHI;MAURA MASSIMINO;SABINA SIERI;FILIPPO SPREAFICO;M. CARRARA;DOMENICO DELIA;LUIGI MARIANI;MICHELA CASANOVA;MONICA TORTORETO;ROSALBA MICELI;SILVANA PILOTTI;VALERIA PALA","15;13;13;13;12;11;11;10;10;10;10;9;9;8;8;8;8;8;8;8","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;SOCIOLOGY;COMPUTER SCIENCE;POLITICAL SCIENCE;MATERIALS SCIENCE;ENGINEERING;GEOGRAPHY;PHILOSOPHY;PSYCHOLOGY;ART;MATHEMATICS;ECONOMICS;BUSINESS;ENVIRONMENTAL SCIENCE;HISTORY;GEOLOGY","270;162;38;37;26;17;10;9;7;6;6;6;5;5;4;3;2;2;1","INTERNAL MEDICINE;GENETICS;ONCOLOGY;CANCER RESEARCH;PATHOLOGY;BIOCHEMISTRY;SURGERY;ENVIRONMENTAL HEALTH;CELL BIOLOGY;IMMUNOLOGY;RADIOLOGY;GASTROENTEROLOGY;OPTICS;NUCLEAR MEDICINE;DEMOGRAPHY;ENDOCRINOLOGY;MOLECULAR BIOLOGY;PALEONTOLOGY;MEDICAL PHYSICS;FAMILY MEDICINE;GYNECOLOGY","199;90;87;83;70;59;59;43;42;42;34;28;26;22;21;21;19;18;15;12;12","CANCER;GENE;CHEMOTHERAPY;RADIATION THERAPY;POPULATION;CONFIDENCE INTERVAL;PROSPECTIVE COHORT STUDY;INCIDENCE (GEOMETRY);LYMPHOMA;DISEASE;IN VITRO;CELL CULTURE;PROPORTIONAL HAZARDS MODEL;IMMUNOHISTOCHEMISTRY;RECEPTOR;STEM CELL;APOPTOSIS;SIGNAL TRANSDUCTION;IMMUNE SYSTEM;COHORT STUDY;SARCOMA;STAGE (STRATIGRAPHY)","144;79;47;36;35;34;28;24;22;19;19;18;18;17;16;16;15;15;14;13;13;13","BREAST CANCER;GENE EXPRESSION;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;HAZARD RATIO;COLORECTAL CANCER;PROSTATE CANCER;GENOTYPE;MICRORNA;CARCINOGENESIS;CELL CYCLE;CERVICAL CANCER;METASTASIS;PI3K/AKT/MTOR PATHWAY;PHENOTYPE;CHROMOSOME;CLINICAL ENDPOINT;CYCLOPHOSPHAMIDE;HEAD AND NECK CANCER;LOWER RISK;PROGRAMMED CELL DEATH;PROSTATE;RELATIVE RISK;T CELL;TRANSCRIPTION FACTOR","37;22;20;19;16;13;12;12;10;10;9;9;9;8;7;7;7;7;7;7;7;7;7;7","SINGLE-NUCLEOTIDE POLYMORPHISM;ONCOGENE;ESTROGEN RECEPTOR;PROMOTER;PTEN;TRASTUZUMAB;GERMLINE MUTATION;IMATINIB MESYLATE;PDGFRA;CASPASE;DNA METHYLATION;FLUORESCENCE IN SITU HYBRIDIZATION;GENE EXPRESSION PROFILING;INHIBITOR OF APOPTOSIS;MICROARRAY;NEOADJUVANT THERAPY;PENETRANCE;TRIPLE-NEGATIVE BREAST CANCER;TUMOR SUPPRESSOR GENE;VINCRISTINE","10;7;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;;ANTINEOPLASTIC AGENTS;BREAST NEOPLASMS;EUROPE;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;NEOPLASMS;BIOMARKERS, TUMOR;CARCINOMA, SQUAMOUS CELL;TREATMENT OUTCOME;UTERINE CERVICAL NEOPLASMS;ITALY;LUNG NEOPLASMS;ADOLESCENT;YOUNG ADULT","242;160;120;108;100;90;85;78;78;58;52;49;45;43;42;42;38;37;35;35","LYMPHOID NEOPLASMS;SARCOMA RESEARCH AND TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GYNECOLOGIC ONCOLOGY;MOLECULAR RESEARCH ON BREAST CANCER;GLIOMAS;NEUROBLASTOMA RESEARCH AND TREATMENT;RADIOTHERAPY PHYSICS AND TECHNOLOGY;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;TESTICULAR GERM CELL TUMORS AND TREATMENT;ACUTE MYELOID LEUKEMIA;CANCER STEM CELLS AND TUMOR METASTASIS;CELLULAR SENESCENCE AND AGING-RELATED DISEASES;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GLOBAL TRENDS IN COLORECTAL CANCER RESEARCH;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY","13;12;11;8;8;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4","BREAST CANCER;CANCER RISK;SOFT TISSUE SARCOMA;NEUROENDOCRINE TUMORS;CANCER;CANCER INCIDENCE;CANCER THERAPY;PANCREATIC NEUROENDOCRINE TUMORS;CANCER SUSCEPTIBILITY;HEALTHY EATING INDEX;SURGICAL ONCOLOGY;CLINICAL ENDPOINT;LOWER RISK;REGIMEN;TUMOR CLASSIFICATION;MICRORNAS;BRCA1;BREAST CANCER SCREENING;DOSIMETRY;GENOME-WIDE ASSOCIATION STUDY","20;14;11;10;9;9;9;9;8;8;8;7;7;7;7;6;5;5;5;5","BREAST CANCER;EUROPEAN PROSPECTIVE;PROSPECTIVE INVESTIGATION;CANCER RISK;PROSTATE CANCER;CERVICAL CANCER;CANCER PATIENTS;COLORECTAL CANCER;CLINICAL PRACTICE;DIAGNOSIS TREATMENT;PRACTICE GUIDELINES;SOFT TISSUE;STEM CELL;CANCER CELLS;CANCER INCIDENCE;CELL CARCINOMA;EPITHELIAL OVARIAN;GENETIC VARIANTS;NON-HODGKIN LYMPHOMA;OVARIAN CANCER;ALLOGENEIC STEM;BRAIN TUMORS;CELL TRANSPLANTATION;CLINICAL ACTIVITY;DNA DAMAGE;ESMO CLINICAL;EXPRESSION PROFILE;ISTITUTO NAZIONALE;LUNG CANCER;NAZIONALE TUMORI","27;16;16;11;10;9;8;7;6;6;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4","BREAST CANCER;OVARIAN CANCER;CANCER RISK;CELL LINES;RADIATION THERAPY;STAGE III;LUNG CANCER;STANDARD TREATMENT;PUBMED SCOPUS;LYMPH NODES;EUROPEAN PROSPECTIVE;HR CI;SOFT TISSUE;STANDARD APPROACH;ESTIMATED DOSES;TUMOUR SIZE;PROSPECTIVE INVESTIGATION;CT SCAN;CANCER CELLS;RED MARROW;GROWTH FACTOR;STATISTICALLY SIGNIFICANT;CONFIDENCE INTERVAL;GENE EXPRESSION;TUMOUR RESPONSE;ADJUVANT CHEMOTHERAPY;ENDOMETRIAL CANCER;INCREASED RISK;LYMPH NODE;MUTATIONAL ANALYSIS","79;42;33;31;30;27;23;22;21;20;19;19;19;19;18;18;17;16;15;15;14;14;13;13;13;12;12;12;12;12",81,0.24,9,5,1.75,1,1.5,2,6.25,1,2,6,0,1,3,3,2,1,1,2,1.25,0,0,116,117,4,1,5,0,0,1,0,0,1,0,0,0,7,1,0,2,3.375,2.16,1.5,0,4,4,3,1,3,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BAKER JOFFRE B;BOGNI ANNA;GIANNI LUCA;PASCALI CLAUDIO;SHAK STEVEN;BELVISI LAURA;BOLOGNESI MARTINO;CARLO-STELLA CARMELO;DELIA DOMENICO;DRAGO CARMELO","3;3;3;3;3;1;1;1;1;1","FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;GENOMIC HEALTH INC;FONDAZIONE IRCSS;FOND IRCCS;UNIVERSITA DEGLI STUDI DI MILANO","5;3;2;1;1","51 PHYSICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;5110 SYNCHROTRONS AND ACCELERATORS;3211 ONCOLOGY AND CARCINOGENESIS;3101 BIOCHEMISTRY AND CELL BIOLOGY;34 CHEMICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY","6;4;3;3;2;1;1;1","CANCER;GENETICS","2;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","1;1","C12Q1/68;C07B59/00;C07B63/00;A61K31/4412;A61K31/502;A61K31/5517;A61K39/395;A61P35/00;A61P7/10;A61P9/00","3;2;2;1;1;1;1;1;1;1","A61P35/00;A61P43/00;A61K51/0491;C07B59/005;C07B63/00;C12Q1/6886;C12Q2600/106;G01N2474/20;A61K31/404;A61K31/44","4;4;3;3;3;3;3;3;1;1",20,5.35,140.55,3.91,3,0.15,24.15,0,1,12,0,2,0,0,5,0,17,3,0,0,0,0,0,0,14,4,2,19,0,0,1,0,0,0,0,0,0,"United States;Canada;France;Italy;United Kingdom","2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","20;19;6;5;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;PATIENT SAFETY;LYMPHOMA;STEM CELL RESEARCH;TRANSPLANTATION;DIGESTIVE DISEASES;OVARIAN CANCER;PEDIATRIC;PEDIATRIC RESEARCH INITIATIVE;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN;UROLOGIC DISEASES;BIOENGINEERING;BIOTECHNOLOGY;CARDIOVASCULAR;COLO-RECTAL CANCER","18;17;13;11;5;5;3;3;3;2;2;2;2;2;2;2;1;1;1;1","CANCER;CARDIOVASCULAR","18;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","17;7;2;1;1;1;1","NON-HODGKIN'S LYMPHOMA;OVARIAN CANCER;LEUKEMIA / LEUKAEMIA;SARCOMA;BLADDER CANCER;COLON AND RECTAL CANCER;GASTROINTESTINAL TRACT;HEAD AND NECK CANCER;HODGKIN'S DISEASE;LARYNGEAL CANCER;MELANOMA;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;PROSTATE CANCER;SALIVARY GLAND CANCER","4;3;2;2;1;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","12;2;2;1;1;1;1",2,4499445,466608.27,4.5,9.5,5.5,1,19.5,844638.733943834,0.397803210410598,"FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;AUGUST PI I SUNYER BIOMEDICAL RESEARCH INSTITUTE;BROAD INSTITUTE;DIAGENODE (BELGIUM);DÉLÉGATION PARIS 11;ESAOTE (ITALY);GERMAN CANCER RESEARCH CENTER;HELMHOLTZ CENTRE FOR INFECTION RESEARCH;ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI;INSTITUT D'INVESTIGACIÓ BIOMÉDICA DE BELLVITGE;KAROLINSKA INSTITUTET;ROYAL INSTITUTE OF TECHNOLOGY;SINTEF;SURFLAY NANOTEC (GERMANY);UNIVERSITY COLLEGE DUBLIN;UNIVERSITY OF BAYREUTH;UNIVERSITY OF ROME TOR VERGATA;UNIVERSITY OF TÜBINGEN","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","CP-FP - SMALL OR MEDIUM-SCALE FOCUSED RESEARCH PROJECT (FUNDING SCHEME);CP-IP - LARGE-SCALE INTEGRATING PROJECT (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2010-TWO-STAGE (CALL FOR PROPOSAL);FP7-NMP - SPECIFIC PROGRAMME ""COOPERATION"": NANOSCIENCES, NANOTECHNOLOGIES, MATERIALS AND NEW PRODUCTION TECHNOLOGIES (PROGRAMME);FP7-NMP-2009-LARGE-3 (CALL FOR PROPOSAL)","1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","2;1;1;1","BIOENGINEERING;BIOMEDICAL IMAGING;CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;GENETICS;HUMAN GENOME;LIVER CANCER;LIVER DISEASE;ORPHAN DRUG;RARE DISEASES","1;1;1;1;1;1;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE","1;1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1;1","LIVER CANCER;NOT SITE-SPECIFIC CANCER","1;1","1.3 CANCER INITIATION: ONCOGENES AND TUMOR SUPPRESSOR GENES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD","1;1;1","A01 CLINICAL MEDICINE;B12 ENGINEERING","1;1","3 GOOD HEALTH AND WELL BEING","1",17,"PUBLIC LIBRARY OF SCIENCE","17","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3105 GENETICS;3211 ONCOLOGY AND CARCINOGENESIS;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;42 HEALTH SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3202 CLINICAL SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3215 REPRODUCTIVE MEDICINE;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4203 HEALTH SERVICES AND SYSTEMS","21;15;7;5;3;3;2;2;1;1;1;1;1","GENETICS;CANCER;BIOTECHNOLOGY;BREAST CANCER;PREVENTION;DIGESTIVE DISEASES;HUMAN GENOME;RARE DISEASES;BRAIN DISORDERS;CLINICAL RESEARCH;COLO-RECTAL CANCER;DIGESTIVE DISEASES - (PEPTIC ULCER);EMERGING INFECTIOUS DISEASES;HEMATOLOGY;INFECTIOUS DISEASES;LYMPHOMA;NEUROSCIENCES;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN","7;6;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;INFECTION;NEUROLOGICAL","6;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES","5;1;1;1","BIOMEDICAL","5","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE","5;2","BREAST CANCER;NOT SITE-SPECIFIC CANCER;COLON AND RECTAL CANCER;STOMACH CANCER;THYROID CANCER","2;2;1;1;1",NA,NA
"IRCCS_TUMORIMILAN",2011,373,16.686327077748,3.36193029490617,0.380697050938338,0.378016085790885,0.546916890080429,2.24775583482944,1.20338983050847,1.56666666666667,1.47826086956522,0.447721179624665,2,205,75,45,29,0.55,0.2,0.12,0.08,62.56,1.4708209813815,NA,0.501340482573727,0.863270777479893,0.463,0.416,0.446,0.434,"­ROSARIO ­TUMINO;ELIO RÍBOLI;ANNE TJØNNELAND;DOMENICO PALLI;KIM OVERVAD;RUDOLF KAAKS;SALVATORE PANICO;CARLOTTA SACERDOTE;ANTONIA TRICHOPOULOU;NICHOLAS J. WAREHAM;KAY‐TEE KHAW;HEINER BOEING;VITTORIO KROGH;PAOLO VINEIS;MAZDA JENAB;AURELIO BARRICARTE;PETRA H. PEETERS;MARIE‐CHRISTINE BOUTRON‐RUAULT;FRANÇOISE CLAVEL‐CHAPELON;NADIA SLIMANI","46;39;39;35;34;32;28;28;27;26;25;24;23;22;21;21;21;20;19;17","NADIA ZAFFARONI;GIUSEPPE PROCOPIO;PAOLO G. CASALI;MARIA GRAZIA DAIDONE;ELDA TAGLIABUE;­ROSARIO ­TUMINO;SILVANA CANEVARI;VITTORIO KROGH;ROSALBA MICELI;CINZIA DE MARCO;DOMENICO PALLI;ANDREA FERRARI;GIOVANNI INVERNIZZI;LICIA RIVOLTINI;FRANCO BERRINO;R. VALDAGNI;MARCO A. PIEROTTI;SALVATORE PANICO;CARLO CHIESA;CARLOTTA SACERDOTE","2.33;2.13;1.72;1.71;1.64;1.47;1.42;1.37;1.32;1.31;1.27;1.25;1.21;1.19;1.18;1.17;1.14;1.1;1.06;1.06","DOMENICO PALLI;VITTORIO KROGH;NADIA ZAFFARONI;PAOLO G. CASALI;PAOLO CORRADINI;FRANCO BERRINO;SABINA SIERI;VALERIA PALA;ELDA TAGLIABUE;SILVANA CANEVARI;SARA GRIONI;PAOLO RADICE;MARCO A. PIEROTTI;SIRANOUSH MANOUKIAN;VITTORIO MONTEFUSCO;BERNARD PEISSEL;CINZIA DE MARCO;FRANCO ZUNINO;GIOVANNA MASALA;PAOLO PETERLONGO","35;23;17;16;16;15;15;14;14;13;13;13;11;11;11;11;10;10;10;10","NADIA ZAFFARONI;GIUSEPPE PROCOPIO;PAOLO G. CASALI;MARIA GRAZIA DAIDONE;ELDA TAGLIABUE;SILVANA CANEVARI;VITTORIO KROGH;ROSALBA MICELI;CINZIA DE MARCO;DOMENICO PALLI;ANDREA FERRARI;GIOVANNI INVERNIZZI;LICIA RIVOLTINI;FRANCO BERRINO;R. VALDAGNI;MARCO A. PIEROTTI;CARLO CHIESA;EMILIO BAJETTA;PAOLO CORRADINI;FRANCO ZUNINO","2.33;2.13;1.72;1.71;1.64;1.42;1.37;1.32;1.31;1.27;1.25;1.21;1.19;1.18;1.17;1.14;1.06;1.04;1.03;1.01","­ROSARIO ­TUMINO;ANNE TJØNNELAND;ELIO RÍBOLI;DOMENICO PALLI;KIM OVERVAD;HEINER BOEING;SALVATORE PANICO;RUDOLF KAAKS;NICHOLAS J. WAREHAM;ANTONIA TRICHOPOULOU;CARLOTTA SACERDOTE;AURELIO BARRICARTE;MAZDA JENAB;KAY‐TEE KHAW;AÑA LLUCH;LUCA GIANNI;PINUCCIA VALAGUSSA;SEMIGLAZOV VF;PAOLO MORANDI;CARLOS A. GONZÁLEZ","4288;3582;3572;3477;3031;2907;2818;2655;2621;2537;2398;2265;2226;2181;2161;2161;2161;2161;2105;2104","GIULIA BIANCHI;VITTORIO KROGH;VALERIA PALA;PAOLO G. CASALI;SARA GRIONI;MARIA GRAZIA DAIDONE;SABINA SIERI;FRANCO BERRINO;UGO PASTORINO;LUCIO BERTARIO;GEMMA GATTA;ANNALISA TRAMA;LISA LICITRA;ELDA TAGLIABUE;ELISA CALABRÒ;MICHELANDREA DE CESARE;PAOLA PEREGO;SERENELLA M. PUPA;SYLVIE MÉNARD;LICIA RIVOLTINI","2057;2056;1740;1537;1294;1265;1143;1028;946;900;876;736;736;713;679;656;619;597;584;577","VITTORIO KROGH;NADIA ZAFFARONI;VALERIA PALA;ELDA TAGLIABUE;FRANCO BERRINO;SARA GRIONI;SABINA SIERI;SILVANA CANEVARI;PAOLO CORRADINI;PAOLO G. CASALI;MARCO A. PIEROTTI;BERNARD PEISSEL;VITTORIO MONTEFUSCO;SIRANOUSH MANOUKIAN;ROBERTO MAZZA;R. VALDAGNI;FRANCO ZUNINO;CINZIA DE MARCO;ITALIA BONGARZONE;MICHELANDREA DE CESARE","21;15;14;13;13;13;13;13;12;12;11;10;10;10;9;9;9;8;8;8","MEDICINE;BIOLOGY;CHEMISTRY;SOCIOLOGY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;ENGINEERING;PHILOSOPHY;GEOGRAPHY;BUSINESS;POLITICAL SCIENCE;PSYCHOLOGY;ART;MATERIALS SCIENCE;ECONOMICS;ENVIRONMENTAL SCIENCE;HISTORY","307;166;45;34;29;23;14;10;10;8;7;7;7;6;6;5;4;2","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;GENETICS;PATHOLOGY;SURGERY;BIOCHEMISTRY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;CELL BIOLOGY;DEMOGRAPHY;ENDOCRINOLOGY;RADIOLOGY;OPTICS;PALEONTOLOGY;NUCLEAR MEDICINE;PHARMACOLOGY;MOLECULAR BIOLOGY;GYNECOLOGY","245;109;98;92;83;75;70;50;48;45;44;27;23;21;19;19;16;15;14;13","CANCER;GENE;CHEMOTHERAPY;PROSPECTIVE COHORT STUDY;POPULATION;CONFIDENCE INTERVAL;RADIATION THERAPY;COHORT;CELL CULTURE;COHORT STUDY;ODDS RATIO;RECEPTOR;APOPTOSIS;INCIDENCE (GEOMETRY);MULTIPLE MYELOMA;STEM CELL;IN VIVO;LUNG CANCER;LYMPHOMA;SARCOMA","175;82;50;37;34;30;26;23;20;20;20;19;18;17;17;17;16;16;16;16","BREAST CANCER;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;COLORECTAL CANCER;GENOTYPE;PROSTATE CANCER;HAZARD RATIO;CANCER CELL;GENE EXPRESSION;MUTATION;ALLELE;CARCINOGENESIS;PI3K/AKT/MTOR PATHWAY;SOFT TISSUE SARCOMA;CANCER REGISTRY;CLINICAL ENDPOINT;BORTEZOMIB;CELL CYCLE;MICRORNA;CISPLATIN;EPIDERMAL GROWTH FACTOR RECEPTOR;LENALIDOMIDE;OVARIAN CANCER","44;34;28;19;15;14;12;12;12;11;11;11;11;10;10;9;9;9;8;8;8;8","SINGLE-NUCLEOTIDE POLYMORPHISM;RELATIVE SURVIVAL;ESTROGEN RECEPTOR;GERMLINE MUTATION;TRASTUZUMAB;CAPECITABINE;DNA METHYLATION;HISTONE DEACETYLASE;MASTECTOMY;ONCOGENE;TRABECTEDIN;TUMOR SUPPRESSOR GENE;CXCR4;GENOTYPING;IFOSFAMIDE;IMATINIB MESYLATE;METASTATIC BREAST CANCER;PENETRANCE;PRIMARY TUMOR;PROMOTER;PTEN;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RIBAVIRIN;SEX HORMONE-BINDING GLOBULIN;TAXANE","17;10;7;7;7;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","HUMANS;FEMALE;MALE;MIDDLE AGED;BREAST NEOPLASMS;AGED;ADULT;ANTINEOPLASTIC AGENTS;;NEOPLASMS;EUROPE;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;LUNG NEOPLASMS;ITALY;RISK FACTORS;PROSPECTIVE STUDIES;CELL LINE, TUMOR;BIOMARKERS, TUMOR;TREATMENT OUTCOME;ANIMALS","271;195;155;149;116;114;108;98;95;80;78;63;51;50;46;43;42;40;38;37","SARCOMA RESEARCH AND TREATMENT;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;HER2 SIGNALING IN BREAST CANCER TREATMENT;LYMPHOID NEOPLASMS;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;SMOKING CESSATION AND HEALTH EFFECTS OF TOBACCO;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;RADIOTHERAPY PHYSICS AND TECHNOLOGY;ADVANCEMENTS IN LUNG CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;PATHOGENESIS AND TREATMENT OF ALCOHOLIC LIVER DISEASE;ROLE OF LONG NONCODING RNAS IN CANCER AND DEVELOPMENT;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;INTEGRATION OF PALLIATIVE CARE IN END-OF-LIFE;ROLE OF HISTONE DEACETYLASES IN CELLULAR REGULATION;ADVANCEMENTS IN PROSTATE CANCER RESEARCH","16;14;11;10;10;9;7;6;6;5;5;5;5;5;5;4;4;4;4;3","BREAST CANCER;CANCER RISK;HEALTHY EATING INDEX;DIETARY PATTERNS;CANCER;SOFT TISSUE SARCOMA;CANCER SUSCEPTIBILITY;CLINICAL ENDPOINT;RELATIVE SURVIVAL;DIET QUALITY;HER2;MELANOMA;REGIMEN;BRCA1;CANCER THERAPY;GENOME-WIDE ASSOCIATION STUDY;TREATMENT;TUMOR MICROENVIRONMENT;CONCOMITANT;METASTATIC GASTRIC CANCER","26;25;14;13;12;11;10;10;10;9;8;8;8;6;6;6;6;6;5;5","BREAST CANCER;EUROPEAN PROSPECTIVE;PROSPECTIVE INVESTIGATION;CANCER RISK;CANCER PATIENTS;PROSTATE CANCER;LUNG CANCER;MULTIPLE MYELOMA;COLORECTAL CANCER;GASTRIC CANCER;STEM CELL;EPIC COHORT;NUTRITION EPIC;OVARIAN CANCER;CELL TRANSPLANTATION;PHASE II;RISK FACTORS;ALLOGENEIC STEM;PHASE III;ASSOCIATION STUDY;CANCER SURVIVAL;CELL CARCINOMA;CELL LINES;PANCREATIC CANCER;SOFT TISSUE;BRCA MUTATION;GASTROINTESTINAL STROMAL;GENOME-WIDE ASSOCIATION;HODGKIN LYMPHOMA;II STUDY","31;21;21;19;13;13;11;11;10;10;10;8;8;8;7;7;7;6;6;5;5;5;5;5;5;4;4;4;4;4","BREAST CANCER;PUBMED SCOPUS;SITU FL;CANCER RISK;CROSSREF PUBMED;EUROPEAN PROSPECTIVE;PROSPECTIVE INVESTIGATION;CELL LINES;LUNG CANCER;PANCREATIC CANCER;ALCOHOL CONSUMPTION;BONE MARROW;MUTATION CARRIERS;OVERT FL;BRCA MUTATION;HR CI;NUTRITION EPIC;COLORECTAL CANCER;CONFIDENCE INTERVAL;RISK FACTORS;EUROPEAN COUNTRIES;HEPATOCELLULAR CARCINOMA;LYMPH NODE;INTERV RADIOL;RADIOL -ABSTRACT;VASC INTERV;LIVER TUMORS;RELATIVE SURVIVAL;CELL LINE;LOGISTIC REGRESSION","66;61;47;43;35;31;31;29;28;26;22;22;22;22;20;20;18;17;17;17;16;16;16;14;14;14;13;13;12;12",124,0.33,6.35,4,1,1,4,4,5.5,1,2,5,0,1,3,1.5,2,1,1.25,3,2,0,0,108.25,109.25,6,1,3,0,0,2,1,0,1,0,0,0,5,3,0,16,2.75,1.76,1.625,1,5,3,3,0,4,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,1,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BAKER JOFFRE B;LUCA GIANNI;SHAK STEVEN;STEVEN SHAK;BOGNI ANNA;CANEVARI SILVANA;CARMELO CARLO-STELLA;CINGARLINI SARA;COLOMBATTI MARCO;FIGINI MARIANGELA","4;2;2;2;1;1;1;1;1;1","FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;GENOMIC HEALTH INC;FONDAZIONE IRCSS;INSTITUTO NAZIONALE TUMORI;UNIVERSITA DEGLI STUDI DI VERONA","6;4;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;51 PHYSICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;34 CHEMICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;5110 SYNCHROTRONS AND ACCELERATORS","11;5;3;2;1;1;1;1","CANCER;GENETICS;BIOTECHNOLOGY;CERVICAL CANCER;GENETIC TESTING;PROSTATE CANCER;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN;UROLOGIC DISEASES","6;3;1;1;1;1;1;1;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","2","C12Q1/68;A61K39/395;A61K31/4412;A61K31/502;A61K9/70;A61P7/10;A61P9/00;C07B59/00;C07B63/00;C07H21/04","4;2;1;1;1;1;1;1;1;1","A61P35/00;A61P43/00;C12Q1/6886;C12Q2600/106;G01N2474/20;A61K31/404;A61K31/44;A61K31/502;A61K47/6827;A61K47/6869","5;4;3;3;3;1;1;1;1;1",23,6.23,444.26,4.67,6,0.26,47,1,0,12,0,5,0,1,4,0,21,2,0,0,0,0,0,0,20,3,0,23,0,0,0,0,0,0,0,0,0,"Italy;United Kingdom;United States;Australia;Belgium;Canada;Norway;Spain","4;2;2;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;31 BIOLOGICAL SCIENCES;3105 GENETICS;3204 IMMUNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","22;15;9;4;1;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;RARE DISEASES;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;HEMATOLOGY;NEUROSCIENCES;TRANSPLANTATION;GENETICS;ORPHAN DRUG;PEDIATRIC;PEDIATRIC RESEARCH INITIATIVE;BREAST CANCER;CHRONIC PAIN;DIGESTIVE DISEASES;LIVER CANCER;LIVER DISEASE;LUNG;LYMPHOMA;OVARIAN CANCER","21;18;17;15;7;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2","CANCER;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM","14;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;6.4 SURGERY;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;7.2 END OF LIFE CARE","17;4;3;3;2;1;1","NON-HODGKIN'S LYMPHOMA;BREAST CANCER;LEUKEMIA / LEUKAEMIA;LIVER CANCER;MYELOMA;OVARIAN CANCER;SARCOMA;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;BRAIN TUMOR;HODGKIN'S DISEASE;KIDNEY CANCER;LUNG CANCER;NEUROBLASTOMA;NOT SITE-SPECIFIC CANCER;SKIN CANCER","4;2;2;2;2;2;2;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;1.2 CANCER INITIATION: ALTERATIONS IN CHROMOSOMES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.6 END-OF-LIFE CARE;6.9 RESOURCES AND INFRASTRUCTURE RELATED TO CANCER CONTROL, SURVIVORSHIP, AND OUTCOMES RESEARCH","14;2;1;1;1;1",6,3546347.5,242610.78,5,9.5,5,0.666666666666667,26.6,942214.240942391,0.395875994855406,"FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;INSTITUT GUSTAVE ROUSSY;EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER;LEIDEN UNIVERSITY MEDICAL CENTER;UNIVERSITY OF OXFORD;ANDALUSIAN HEALTH SERVICE;ANTONI VAN LEEUWENHOEK HOSPITAL;CHRISTIE HOSPITAL NHS FOUNDATION TRUST;CLAUDE BERNARD UNIVERSITY LYON 1;DANISH CANCER SOCIETY;ECANCER;ERASMUS MC;EUROPEAN CANCER ORGANISATION;EUROPEAN INSTITUTE OF ONCOLOGY;EUROPEAN MOLECULAR BIOLOGY LABORATORY;FUNDACIÓN INSTITUTO VALENCIANO DE ONCOLOGÍA;GERMAN CANCER RESEARCH CENTER;HEIDELBERG UNIVERSITY;HOSPITAL UNIVERSITARIO SON ESPASES;INSTITUT BERGONIÉ","6;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;WORLDWIDE CANCER RESEARCH","5;1","COALITION S;EC & ERC - EUROPEAN UNION;AMRC - ASSOCIATION OF MEDICAL RESEARCH CHARITIES;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP","5;5;1;1","FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);CP-FP - SMALL OR MEDIUM-SCALE FOCUSED RESEARCH PROJECT (FUNDING SCHEME);FP7-PEOPLE - SPECIFIC PROGRAMME ""PEOPLE"" IMPLEMENTING THE SEVENTH FRAMEWORK PROGRAMME OF THE EUROPEAN COMMUNITY FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ACTIVITIES (2007 TO 2013) (PROGRAMME);FP7-HEALTH-2010-SINGLE-STAGE (CALL FOR PROPOSAL);FP7-HEALTH-2010-TWO-STAGE (CALL FOR PROPOSAL);FP7-HEALTH-2011-TWO-STAGE (CALL FOR PROPOSAL);FP7-PEOPLE-2009-IRSES (CALL FOR PROPOSAL);FP7-PEOPLE-2010-RG (CALL FOR PROPOSAL);MC-IRG - INTERNATIONAL RE-INTEGRATION GRANTS (IRG) (FUNDING SCHEME);MC-IRSES - INTERNATIONAL RESEARCH STAFF EXCHANGE SCHEME (IRSES) (FUNDING SCHEME);NOE - NETWORK OF EXCELLENCE (FUNDING SCHEME)","3;2;2;1;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3206 MEDICAL BIOTECHNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","6;2;2;1;1;1;1;1;1","RARE DISEASES;CANCER;BIOTECHNOLOGY;GENETICS;HEMATOLOGY;ORPHAN DRUG;BIOENGINEERING;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;LUNG;NANOTECHNOLOGY;PANCREATIC CANCER;PREVENTION;REGENERATIVE MEDICINE;TRANSPLANTATION","4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;INFLAMMATORY AND IMMUNE SYSTEM","5;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.9 RESOURCES AND INFRASTRUCTURE (TREATMENT EVALUATION);2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","2;2;1;1;1;1;1","NOT SITE-SPECIFIC CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;MELANOMA;MYELOMA;PANCREATIC CANCER;SARCOMA","3;2;2;2;1;1;1;1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;1.1 NORMAL FUNCTIONING;1.2 CANCER INITIATION: ALTERATIONS IN CHROMOSOMES;1.3 CANCER INITIATION: ONCOGENES AND TUMOR SUPPRESSOR GENES;3.6 RESOURCES AND INFRASTRUCTURE RELATED TO PREVENTION;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.1 LOCALIZED THERAPIES - DISCOVERY AND DEVELOPMENT;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","3;2;1;1;1;1;1;1;1","A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;A05 BIOLOGICAL SCIENCES","4;1;1",NA,NA,28,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;AMERICAN CHEMICAL SOCIETY","20;5;3","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3105 GENETICS;4203 HEALTH SERVICES AND SYSTEMS;49 MATHEMATICAL SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3001 AGRICULTURAL BIOTECHNOLOGY;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3206 MEDICAL BIOTECHNOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4202 EPIDEMIOLOGY;4905 STATISTICS","41;22;21;9;7;6;2;1;1;1;1;1;1;1;1;1","CANCER;GENETICS;BIOTECHNOLOGY;RARE DISEASES;BREAST CANCER;DIGESTIVE DISEASES;HUMAN GENOME;OVARIAN CANCER;STEM CELL RESEARCH;UROLOGIC DISEASES;AGING;ALCOHOLISM, ALCOHOL USE AND HEALTH;CLINICAL RESEARCH;DENTAL/ORAL AND CRANIOFACIAL DISEASE;LIVER CANCER;LIVER DISEASE;PREVENTION;PROSTATE CANCER;REGENERATIVE MEDICINE;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN","14;9;5;4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE","18;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES","7;3;1","BIOMEDICAL","12","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE","10;2","BREAST CANCER;NOT SITE-SPECIFIC CANCER;MELANOMA;ORAL CAVITY AND LIP CANCER;OVARIAN CANCER;COLON AND RECTAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;LIVER CANCER;PHARYNGEAL CANCER;PROSTATE CANCER","7;3;2;2;2;1;1;1;1;1;1;1",NA,NA
"IRCCS_TUMORIMILAN",2012,526,14.3155893536122,3.56083650190114,0.444866920152091,0.427756653992395,0.560836501901141,2.53315290933694,1.47169811320755,1.89075630252101,1.56084656084656,0.452471482889734,11,341,83,50,34,0.65,0.16,0.1,0.06,47.08,1.12712050800052,7.77930442249893,0.522813688212928,0.85361216730038,0.513,0.489,0.508,0.481,"­ROSARIO ­TUMINO;ANNE TJØNNELAND;KIM OVERVAD;ELIO RÍBOLI;ANTONIA TRICHOPOULOU;DOMENICO PALLI;NICHOLAS J. WAREHAM;MARÍA‐JOSÉ SÁNCHEZ;KAY‐TEE KHAW;FILIPPO DE BRAUD;PAOLO G. CASALI;RUDOLF KAAKS;SALVATORE PANICO;EVA ARDANÁZ;BIRGIT TEUCHER;HEINER BOEING;GIUSEPPE PROCOPIO;FRANÇOISE CLAVEL‐CHAPELON;NADIA ZAFFARONI;LISA LICITRA","55;44;42;40;39;35;35;32;31;30;30;28;27;25;24;24;22;21;20;19","GIUSEPPE PROCOPIO;FILIPPO DE BRAUD;CARLA RIPAMONTI;PAOLO G. CASALI;ALBERTO LAFFRANCHI;MAURA MASSIMINO;AUGUSTO CARACENI;ELENA VERZONI;ANDREA FERRARI;LISA LICITRA;NADIA ZAFFARONI;­ROSARIO ­TUMINO;FILIPPO PIETRANTONIO;ALESSANDRO GRONCHI;LUIGI MARIANI;ROBERTO SALVIONI;LARRY JUNCK;PAMELA BIONDANI;UGO PASTORINO;ISABELLA TESTA","3.78;3.78;3.53;3.2;3.1;2.95;2.88;2.83;2.55;2.29;2.17;1.76;1.69;1.67;1.61;1.52;1.5;1.5;1.48;1.44","FILIPPO DE BRAUD;PAOLO G. CASALI;GIUSEPPE PROCOPIO;NADIA ZAFFARONI;LISA LICITRA;PAOLO CORRADINI;MAURA MASSIMINO;ANDREA FERRARI;SABINA SIERI;ALESSANDRO GRONCHI;LUIGI MARIANI;ROBERTO SALVIONI;ALESSANDRO M. GIANNI;ELENA VERZONI;R. VALDAGNI;VALERIA PALA;FRANCO BERRINO;NICOLA NICOLAI;CARLO MOROSI;VITTORIO KROGH","30;30;22;20;19;18;18;18;17;17;17;16;16;15;14;14;14;14;14;14","GIUSEPPE PROCOPIO;FILIPPO DE BRAUD;CARLA RIPAMONTI;PAOLO G. CASALI;ALBERTO LAFFRANCHI;MAURA MASSIMINO;AUGUSTO CARACENI;ELENA VERZONI;ANDREA FERRARI;LISA LICITRA;NADIA ZAFFARONI;FILIPPO PIETRANTONIO;ALESSANDRO GRONCHI;LUIGI MARIANI;ROBERTO SALVIONI;PAMELA BIONDANI;UGO PASTORINO;ISABELLA TESTA;R. VALDAGNI;EMILIO BOMBARDIERI","3.78;3.78;3.53;3.2;3.1;2.95;2.88;2.83;2.55;2.29;2.17;1.69;1.67;1.61;1.52;1.5;1.48;1.44;1.41;1.4","­ROSARIO ­TUMINO;PAOLO G. CASALI;ANNE TJØNNELAND;KIM OVERVAD;ELIO RÍBOLI;PETER HOHENBERGER;PATRICK SCHÖFFSKI;AXEL LE CESNE;JEAN‐YVES BLAY;GEORGE D. DEMETRI;HEINER BOEING;KAY‐TEE KHAW;HANS GELDERBLOM;DOMENICO PALLI;ANTONIA TRICHOPOULOU;SALVATORE PANICO;NICHOLAS J. WAREHAM;MARÍA‐JOSÉ SÁNCHEZ;RUDOLF KAAKS;BIRGIT TEUCHER","4522;4298;4098;3817;3779;3569;3432;3350;3350;3335;3229;3203;3171;3135;3131;3017;2963;2865;2817;2446","PAOLO G. CASALI;SABINA SIERI;VITTORIO KROGH;VALERIA PALA;ANNALISA TRAMA;LUIGI MARIANI;VINCENZO MAZZAFERRO;PAOLO A. ASCIERTO;CARLO MOROSI;FRANCO BERRINO;CARLO SPOSITO;SHERRIE BHOORI;R. VALDAGNI;SARA GRIONI;LICIA RIVOLTINI;ALESSANDRO GRONCHI;PAOLA FILIPAZZI;NADIA ZAFFARONI;CLAUDIA AGNOLI;RODOLFO LANOCITA","4298;1601;1147;1095;1087;988;911;878;863;856;828;828;780;754;747;719;717;706;702;641","PAOLO G. CASALI;FILIPPO DE BRAUD;GIUSEPPE PROCOPIO;NADIA ZAFFARONI;LISA LICITRA;PAOLO CORRADINI;SABINA SIERI;LUIGI MARIANI;MAURA MASSIMINO;ALESSANDRO GRONCHI;ANDREA FERRARI;ALESSANDRO M. GIANNI;VITTORIO KROGH;VALERIA PALA;ROBERTO SALVIONI;R. VALDAGNI;ELENA VERZONI;CARLO MOROSI;NICOLA NICOLAI;FILIPPO PIETRANTONIO","31;28;20;19;19;18;17;17;17;16;16;16;14;14;14;13;13;13;12;11","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;SOCIOLOGY;COMPUTER SCIENCE;MATHEMATICS;POLITICAL SCIENCE;PSYCHOLOGY;ECONOMICS;PHILOSOPHY;BUSINESS;MATERIALS SCIENCE;ENGINEERING;ART;GEOGRAPHY;ENVIRONMENTAL SCIENCE;GEOLOGY;HISTORY","478;185;54;52;39;31;18;16;16;14;12;11;11;7;6;5;1;1;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;SURGERY;PATHOLOGY;GENETICS;BIOCHEMISTRY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;OPTICS;CELL BIOLOGY;DEMOGRAPHY;GYNECOLOGY;ENDOCRINOLOGY;PALEONTOLOGY;RADIOLOGY;UROLOGY;FAMILY MEDICINE;NUCLEAR MEDICINE","405;228;117;111;110;93;66;65;64;36;33;32;32;30;29;27;25;23;21;20","CANCER;GENE;CHEMOTHERAPY;CONFIDENCE INTERVAL;POPULATION;PROSPECTIVE COHORT STUDY;RADIATION THERAPY;CLINICAL TRIAL;DISEASE;INCIDENCE (GEOMETRY);COHORT;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;SARCOMA;LUNG CANCER;PROPORTIONAL HAZARDS MODEL;TRANSPLANTATION;COHORT STUDY;HEPATOCELLULAR CARCINOMA;STAGE (STRATIGRAPHY);STROMAL CELL","290;85;82;51;48;46;33;29;29;28;27;24;23;23;22;22;21;19;19;19;19","BREAST CANCER;COLORECTAL CANCER;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;HAZARD RATIO;PROSTATE CANCER;SUNITINIB;CLINICAL ENDPOINT;CANCER REGISTRY;PHASES OF CLINICAL RESEARCH;GENE EXPRESSION;SOFT TISSUE SARCOMA;OVARIAN CANCER;PROSTATE;SORAFENIB;METASTASIS;CARCINOGENESIS;PLACEBO;CYCLOPHOSPHAMIDE;GIST;HEMATOPOIETIC STEM CELL TRANSPLANTATION;IMMUNOTHERAPY;PROGRESSIVE DISEASE","78;56;33;32;28;25;22;19;17;15;15;14;14;14;13;12;12;11;11;11;11;11","ESTROGEN RECEPTOR;PAZOPANIB;RELATIVE SURVIVAL;CETUXIMAB;METASTATIC BREAST CANCER;CAPECITABINE;IRINOTECAN;KRAS;MASTECTOMY;OXALIPLATIN;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;SINGLE-NUCLEOTIDE POLYMORPHISM;REGORAFENIB;CYTOREDUCTIVE SURGERY;FLUORESCENCE IN SITU HYBRIDIZATION;GERMLINE MUTATION;IPILIMUMAB;TRABECTEDIN;FLUDARABINE;GENE EXPRESSION PROFILING;GENE SIGNATURE;GENOTYPING;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;HISTONE DEACETYLASE;SOLITARY FIBROUS TUMOR;SUNITINIB MALATE;THIOTEPA;TRASTUZUMAB","12;10;10;9;8;7;7;7;7;7;7;7;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4","HUMANS;;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;BREAST NEOPLASMS;NEOPLASMS;EUROPE;ANTINEOPLASTIC AGENTS;ADOLESCENT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;PROSPECTIVE STUDIES;LUNG NEOPLASMS;AGED, 80 AND OVER;PROSTATIC NEOPLASMS;SARCOMA;YOUNG ADULT","296;224;206;172;161;145;129;124;101;94;74;61;61;61;58;53;50;49;47;47","SARCOMA RESEARCH AND TREATMENT;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;RENAL CELL CARCINOMA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;GLIOMAS;MOLECULAR RESEARCH ON BREAST CANCER;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;LYMPHOID NEOPLASMS;ADVANCEMENTS IN LUNG CANCER RESEARCH;CANCER STEM CELLS AND TUMOR METASTASIS;CHALLENGES IN PAIN MANAGEMENT AND TREATMENT;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;TESTICULAR GERM CELL TUMORS AND TREATMENT;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;INTEGRATION OF PALLIATIVE CARE IN END-OF-LIFE;PROSTATE CANCER RESEARCH AND TREATMENT","18;15;14;13;10;10;10;9;9;8;8;8;8;8;8;8;7;7;7;7","BREAST CANCER;CANCER RISK;TREATMENT;CLINICAL ENDPOINT;HEALTHY EATING INDEX;DIETARY PATTERNS;SOFT TISSUE SARCOMA;REFRACTORY (PLANETARY SCIENCE);TUMOR MICROENVIRONMENT;CANCER SUSCEPTIBILITY;REGIMEN;TUMOR REGRESSION;CANCER THERAPY;BREAST CANCER SCREENING;DIET QUALITY;PAZOPANIB;RADIOTHERAPY;RELATIVE SURVIVAL;MEDITERRANEAN DIET;STROMAL TUMOR","35;26;26;24;22;20;15;13;13;12;12;12;11;10;10;10;10;10;9;9","BREAST CANCER;EUROPEAN PROSPECTIVE;PROSPECTIVE INVESTIGATION;PROSTATE CANCER;COLORECTAL CANCER;CANCER RISK;PHASE II;CELL CARCINOMA;PHASE III;CANCER PATIENTS;LUNG CANCER;STEM CELL;GASTROINTESTINAL STROMAL;SOFT TISSUE;CELL TRANSPLANTATION;PANCREATIC CANCER;TISSUE SARCOMA;RENAL CELL;SQUAMOUS CELL;STROMAL TUMOR;III TRIAL;MULTIPLE MYELOMA;NUTRITION EPIC;OVARIAN CANCER;PHASE TRIAL;CELL LUNG;FINAL RESULTS;II STUDY;RANDOMIZED PHASE;SURVIVAL OS","54;29;28;23;18;17;17;15;14;13;12;12;11;11;10;9;9;8;8;8;7;7;7;7;7;6;6;6;6;6","BREAST CANCER;PROSTATE CANCER;COLORECTAL CANCER;CANCER RISK;PANCREATIC CANCER;EUROPEAN PROSPECTIVE;PROSPECTIVE INVESTIGATION;HAZARD RATIO;HR CI;PROGRESSION-FREE SURVIVAL;LUNG CANCER;CANCER CELLS;CANCER PATIENTS;LOGISTIC REGRESSION;MEDIAN FOLLOW-UP;ADVERSE EVENTS;EUROPEAN COUNTRIES;PATIENTS PTS;TYPE DIABETES;CONFIDENCE INTERVAL;PATIENTS TREATED;RESPONSE RATE;RISK FACTORS;SURVIVAL OS;ADVISORY BOARD;CI -P;MEDIAN AGE;MELANOMA CELLS;PHASE III;RARE CANCERS","98;43;41;35;31;29;29;27;26;25;24;23;23;20;20;19;19;19;19;17;17;17;17;17;15;15;15;15;15;15",175,0.33,7.62,4,2,1.5,3,3,3,1,1,5,0,1,4,1,2,1,2,4,2,0,0,106.5,107.5,8,1,4,0,2,3,1,0,1,0,0,0,8,4,0,1.33333333333333,2.83333333333333,1.82,1.41666666666667,2,5,6,2,2,3,0,1,3,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,7,1,0,2,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CANEVARI SILVANA;FIGINI MARIANGELA;BAKER JOFFRE B;CARLO-STELLA CARMELO;CINGARLINI SARA;COLOMBATTI MARCO;COUKOS GEORGE;FRACASSO GIULIO;GIANNI ALESSANDRO MASSIMO;GIANNI LUCA","3;3;2;2;2;2;2;2;2;2","FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;GENOMIC HEALTH INC;UNIVERSITY OF PENNSYLVANIA PENN;FONDAZIONE IRCSS;UNIVERSITA DEGLI STUDI DI VERONA","11;2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;34 CHEMICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;51 PHYSICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;5110 SYNCHROTRONS AND ACCELERATORS","19;7;3;3;2;1;1","CANCER;RARE DISEASES;GENETICS;OVARIAN CANCER;BIOTECHNOLOGY;BREAST CANCER;CERVICAL CANCER;GENETIC TESTING;ORPHAN DRUG;PROSTATE CANCER","7;3;2;2;1;1;1;1;1;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","2;1;1","A61K39/395;A61P35/00;A61K31/4412;A61K31/502;A61K35/17;A61K39/00;A61P7/10;A61P9/00;C07K16/30;C12Q1/68","4;4;2;2;2;2;2;2;2;2","A61P35/00;A61P43/00;C07K2317/622;A61K31/404;A61K31/44;A61K31/502;A61P7/10;A61P9/00;A61K2035/124;A61K2039/505","6;4;4;3;3;3;3;3;2;2",25,6.2,1102.56,3.71,10,0.4,46.12,0,2,10,0,6,0,1,6,0,22,3,0,0,0,0,0,0,20,5,0,25,0,0,0,0,0,0,0,0,0,"France;Italy;United Kingdom;Germany;Belgium;United States;Denmark;Spain;Netherlands;Norway;Sweden;Switzerland","8;8;8;5;3;3;2;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;34 CHEMICAL SCIENCES;3401 ANALYTICAL CHEMISTRY;3210 NUTRITION AND DIETETICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","25;18;9;3;2;2;2;2;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;PATIENT SAFETY;PREVENTION;HEMATOLOGY;BIOMEDICAL IMAGING;BREAST CANCER;GENETICS;NEUROSCIENCES;NUTRITION;PEDIATRIC;BIOTECHNOLOGY;IMMUNIZATION;LYMPHOMA;OVARIAN CANCER;PAIN RESEARCH;SUBSTANCE MISUSE;AGING","25;22;16;12;6;6;4;3;3;3;3;3;3;2;2;2;2;2;2;1","CANCER;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;STROKE","19;2;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.2 END OF LIFE CARE","16;6;4;3;2;1;1;1;1;1","BREAST CANCER;NOT SITE-SPECIFIC CANCER;COLON AND RECTAL CANCER;MELANOMA;NON-HODGKIN'S LYMPHOMA;OVARIAN CANCER;BLADDER CANCER;ENDOMETRIAL CANCER;HEAD AND NECK CANCER;LIVER CANCER;LUNG CANCER;MYELOMA;NEUROBLASTOMA;PANCREATIC CANCER;PROSTATE CANCER;SARCOMA","4;4;2;2;2;2;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;3.2 NUTRITIONAL SCIENCE IN CANCER PREVENTION;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.6 END-OF-LIFE CARE","13;2;2;2;2;2;2;2;1;1",5,3521832.8,268026.69,4.2,31.8,10.8,0.8,145.5,1091099.22243307,0.482082645817543,"FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;UNIVERSITY MEDICAL CENTER UTRECHT;AARHUS UNIVERSITY;ANDALUSIAN SCHOOL OF PUBLIC HEALTH;GHENT UNIVERSITY;IMPERIAL COLLEGE LONDON;INSTITUTO DE SALUD PÚBLICA DE NAVARRA;INTERNATIONAL AGENCY FOR RESEARCH ON CANCER;LUND UNIVERSITY;NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT;UMEÅ UNIVERSITY;UNIVERSITY OF BRISTOL;UNIVERSITY OF CAMBRIDGE;UNIVERSITY OF COPENHAGEN;UNIVERSITY OF HELSINKI;UNIVERSITY OF OXFORD;AALBORG UNIVERSITY HOSPITAL;ACADEMIC MEDICAL CENTER;ADDENBROOKE'S HOSPITAL;AGE UK","5;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","EUROPEAN COMMISSION;ECONOMIC AND SOCIAL RESEARCH COUNCIL;MESOTHELIOMA APPLIED RESEARCH FOUNDATION","3;1;1","COALITION S;EC & ERC - EUROPEAN UNION;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;UKRI - UK RESEARCH AND INNOVATION","4;3;1;1","CP-FP - SMALL OR MEDIUM-SCALE FOCUSED RESEARCH PROJECT (FUNDING SCHEME);CP-IP - LARGE-SCALE INTEGRATING PROJECT (FUNDING SCHEME);CSA-SA - SUPPORT ACTIONS (FUNDING SCHEME);FELLOWSHIP (PROJECT CATEGORY);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2011-TWO-STAGE (CALL FOR PROPOSAL);FP7-INCO - SPECIFIC PROGRAMME ""CAPACITIES"": INTERNATIONAL CO-OPERATION (PROGRAMME);FP7-INCO-2011-7 (CALL FOR PROPOSAL);FP7-KBBE - SPECIFIC PROGRAMME ""COOPERATION"": FOOD, AGRICULTURE AND BIOTECHNOLOGY (PROGRAMME);FP7-KBBE-2010-4 (CALL FOR PROPOSAL);MESOTHELIOMA RESEARCH GRANTS (PROGRAM)","1;1;1;1;1;1;1;1;1;1;1","42 HEALTH SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;4206 PUBLIC HEALTH;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3105 GENETICS;3210 NUTRITION AND DIETETICS;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY","4;3;3;2;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CARDIOVASCULAR;GENETICS;PREVENTION;AGING;BEHAVIORAL AND SOCIAL SCIENCE;BIOTECHNOLOGY;BRAIN DISORDERS;HEALTH SERVICES;HEART DISEASE;HUMAN GENOME;MENTAL HEALTH;NUTRITION;OBESITY;RARE DISEASES","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;STROKE;GENERIC HEALTH RELEVANCE;MENTAL HEALTH;ORAL AND GASTROINTESTINAL","3;2;2;2;1;1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.3 PSYCHOLOGICAL, SOCIAL AND ECONOMIC FACTORS;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);5.1 PHARMACEUTICALS;6.9 RESOURCES AND INFRASTRUCTURE (TREATMENT EVALUATION)","2;2;2;1;1;1","NOT SITE-SPECIFIC CANCER","1","6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;6.2 SURVEILLANCE","1;1","A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE;A01 CLINICAL MEDICINE;A06 AGRICULTURE, VETERINARY AND FOOD SCIENCE;D25 AREA STUDIES","2;1;1;1",NA,NA,57,"PUBLIC LIBRARY OF SCIENCE","57","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;4206 PUBLIC HEALTH;3210 NUTRITION AND DIETETICS;3211 ONCOLOGY AND CARCINOGENESIS;49 MATHEMATICAL SCIENCES;4202 EPIDEMIOLOGY;3105 GENETICS;34 CHEMICAL SCIENCES;4905 STATISTICS;3101 BIOCHEMISTRY AND CELL BIOLOGY;44 HUMAN SOCIETY;3402 INORGANIC CHEMISTRY;4403 DEMOGRAPHY;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3103 ECOLOGY;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;4203 HEALTH SERVICES AND SYSTEMS","53;41;22;19;13;13;10;8;6;4;4;3;3;2;2;1;1;1;1;1","CANCER;NUTRITION;PREVENTION;GENETICS;OBESITY;BREAST CANCER;SUBSTANCE MISUSE;ALCOHOLISM, ALCOHOL USE AND HEALTH;DIABETES;AGING;BIOTECHNOLOGY;CLINICAL RESEARCH;COLO-RECTAL CANCER;CONTRACEPTION/REPRODUCTION;DIGESTIVE DISEASES;TOBACCO;TOBACCO SMOKE AND HEALTH;BEHAVIORAL AND SOCIAL SCIENCE;BRAIN CANCER;BRAIN DISORDERS","15;14;14;10;7;5;5;4;4;3;3;2;2;2;2;2;2;1;1;1","CANCER;CARDIOVASCULAR;STROKE;ORAL AND GASTROINTESTINAL;GENERIC HEALTH RELEVANCE;METABOLIC AND ENDOCRINE;RESPIRATORY","29;15;13;8;4;4;3","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;2.3 PSYCHOLOGICAL, SOCIAL AND ECONOMIC FACTORS;2.5 RESEARCH DESIGN AND METHODOLOGIES (AETIOLOGY);3.3 NUTRITION AND CHEMOPREVENTION;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","5;2;1;1;1;1;1;1","POPULATION & SOCIETY;BIOMEDICAL;CLINICAL","12;5;5","PUBLIC HEALTH;CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","15;8;6","NOT SITE-SPECIFIC CANCER;BREAST CANCER;COLON AND RECTAL CANCER;LUNG CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;MELANOMA;BRAIN TUMOR;LARYNGEAL CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER","10;7;6;4;2;2;1;1;1;1","7 AFFORDABLE AND CLEAN ENERGY;3 GOOD HEALTH AND WELL BEING;10 REDUCED INEQUALITIES","3;2;1"
"IRCCS_TUMORIMILAN",2013,559,14.9749552772809,3.7298747763864,0.384615384615385,0.409660107334526,0.493738819320215,2.76026490066225,1.47260273972603,1.95726495726496,1.54189944134078,0.43649373881932,6,323,92,79,29,0.58,0.16,0.14,0.05,45.52,1.30443852804381,7.81914491108587,0.477638640429338,0.86046511627907,0.542,0.491,0.471,0.476,"­ROSARIO ­TUMINO;ELIO RÍBOLI;ANNE TJØNNELAND;FILIPPO DE BRAUD;KIM OVERVAD;PAOLO G. CASALI;KAY‐TEE KHAW;ANTONIA TRICHOPOULOU;SILVIA ROSSI;DOMENICO PALLI;NICHOLAS J. WAREHAM;HEINER BOEING;ALESSANDRO GRONCHI;MARÍA‐JOSÉ SÁNCHEZ;SALVATORE PANICO;LUIGI MARIANI;FRANÇOISE CLAVEL‐CHAPELON;AURELIO BARRICARTE;ROBERTO FOSCHI;TIMOTHY J. KEY","47;39;39;35;33;32;31;31;30;26;26;24;24;24;23;23;22;22;21;21","SILVIA ROSSI;ANDREA FERRARI;ROBERTO FOSCHI;ALESSANDRO GRONCHI;FILIPPO DE BRAUD;MAURA MASSIMINO;PAOLO G. CASALI;GEMMA GATTA;LUIGI MARIANI;RICCARDO CAPOCACCIA;NADIA ZAFFARONI;LARRY JUNCK;­ROSARIO ­TUMINO;SILVANA CANEVARI;MARIO P. COLOMBO;ROBERTA DE ANGELIS;UGO PASTORINO;FRANCESCO RASPAGLIESI;PAOLO CORRADINI;MARCO A. PIEROTTI","5.21;3.69;3.6;3.58;3.48;3.32;3.23;2.84;2.05;2.03;2;2;1.77;1.76;1.74;1.69;1.65;1.59;1.49;1.3","FILIPPO DE BRAUD;PAOLO G. CASALI;SILVIA ROSSI;ALESSANDRO GRONCHI;MARÍA‐JOSÉ SÁNCHEZ;SALVATORE PANICO;LUIGI MARIANI;ROBERTO FOSCHI;NADIA ZAFFARONI;VITTORIO KROGH;GEMMA GATTA;GIUSEPPE PROCOPIO;VALERIA PALA;SABINA SIERI;ANDREA NECCHI;FEDERICA PERRONE;SILVANA CANEVARI;SILVIA STACCHIOTTI;ANDREA FERRARI;MAURA MASSIMINO","35;32;30;24;24;23;23;21;21;19;18;17;16;16;16;15;15;15;15;14","SILVIA ROSSI;ANDREA FERRARI;ROBERTO FOSCHI;ALESSANDRO GRONCHI;FILIPPO DE BRAUD;MAURA MASSIMINO;PAOLO G. CASALI;GEMMA GATTA;LUIGI MARIANI;RICCARDO CAPOCACCIA;NADIA ZAFFARONI;SILVANA CANEVARI;MARIO P. COLOMBO;UGO PASTORINO;FRANCESCO RASPAGLIESI;PAOLO CORRADINI;MARCO A. PIEROTTI;GIUSEPPE PROCOPIO;R. VALDAGNI;FEDERICA PERRONE","5.21;3.69;3.6;3.58;3.48;3.32;3.23;2.84;2.05;2.03;2;1.76;1.74;1.65;1.59;1.49;1.3;1.28;1.22;1.22","ANNE TJØNNELAND;ANTONIA TRICHOPOULOU;­ROSARIO ­TUMINO;ELIO RÍBOLI;TIMOTHY J. KEY;MARÍA‐JOSÉ SÁNCHEZ;PETRA H. PEETERS;MILENA SANT;CARLOTTA SACERDOTE;KIM OVERVAD;PILAR AMIANO;ANNALISA TRAMA;KAY‐TEE KHAW;HERMANN BRENNER;MAGDALENA BIELSKA‐LASOTA;VITTORIO KROGH;DOMENICO PALLI;EVA ARDANÁZ;OTTO VISSER;PAOLO G. CASALI","4751;3879;3711;3618;3541;3458;3378;3283;3267;3129;3101;2987;2970;2895;2824;2772;2751;2709;2693;2588","MILENA SANT;ANNALISA TRAMA;VITTORIO KROGH;SARA GRIONI;FRANCO BERRINO;PAOLO G. CASALI;PAOLO BAILI;ALESSANDRO GRONCHI;PAOLO RADICE;GEMMA GATTA;VALERIA PALA;SILVANA PILOTTI;PAMELA MINICOZZI;ROBERTA SANFILIPPO;SABINA SIERI;FILIPPO DE BRAUD;LAURA BOTTA;LUIGI MARIANI;ANDREA ANICHINI;CHIARA COLOMBO","3283;2987;2772;2249;2109;2086;1859;1806;1664;1292;1265;1113;1085;1040;966;954;924;873;806;802","FILIPPO DE BRAUD;PAOLO G. CASALI;ALESSANDRO GRONCHI;LUIGI MARIANI;ROBERTO FOSCHI;NADIA ZAFFARONI;VITTORIO KROGH;GEMMA GATTA;ANDREA NECCHI;GIUSEPPE PROCOPIO;SILVANA CANEVARI;VALERIA PALA;FEDERICA PERRONE;SABINA SIERI;SILVANA PILOTTI;ANDREA FERRARI;SARA GRIONI;MAURA MASSIMINO;SILVIA STACCHIOTTI;UGO PASTORINO","33;29;23;22;21;20;19;18;15;15;15;15;15;15;14;14;13;13;13;13","MEDICINE;BIOLOGY;PHYSICS;SOCIOLOGY;CHEMISTRY;COMPUTER SCIENCE;MATHEMATICS;POLITICAL SCIENCE;PSYCHOLOGY;BUSINESS;ECONOMICS;ENGINEERING;PHILOSOPHY;MATERIALS SCIENCE;GEOGRAPHY;ART;ENVIRONMENTAL SCIENCE;GEOLOGY;HISTORY","513;209;69;65;44;25;19;10;10;9;9;8;8;7;6;5;2;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CANCER RESEARCH;PATHOLOGY;GENETICS;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;DEMOGRAPHY;BIOCHEMISTRY;OPTICS;RADIOLOGY;IMMUNOLOGY;ENDOCRINOLOGY;PALEONTOLOGY;GYNECOLOGY;CELL BIOLOGY;UROLOGY;PHARMACOLOGY;NUCLEAR MEDICINE","432;244;132;130;118;110;92;65;61;57;54;48;46;39;38;37;33;26;22;21","CANCER;CHEMOTHERAPY;GENE;POPULATION;CONFIDENCE INTERVAL;INCIDENCE (GEOMETRY);LUNG CANCER;COHORT;RADIATION THERAPY;PROSPECTIVE COHORT STUDY;PROPORTIONAL HAZARDS MODEL;ADVERSE EFFECT;SARCOMA;DISEASE;MORTALITY RATE;STAGE (STRATIGRAPHY);CLINICAL TRIAL;MELANOMA;REGIMEN;RANDOMIZED CONTROLLED TRIAL","318;114;87;74;57;51;47;44;41;39;31;30;30;29;27;27;26;26;26;25","BREAST CANCER;COLORECTAL CANCER;PROSTATE CANCER;CANCER REGISTRY;PROSTATE;HAZARD RATIO;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;OVARIAN CANCER;CISPLATIN;CERVIX;CLINICAL ENDPOINT;GENE EXPRESSION;METASTASIS;CERVICAL CANCER;GENOTYPE;MUTATION;NEUTROPENIA;STOMACH CANCER;SUNITINIB;MICRORNA;SOFT TISSUE SARCOMA;UNIVARIATE ANALYSIS","115;79;60;36;33;31;29;28;26;24;24;23;23;16;15;15;15;15;15;14;14;14","RELATIVE SURVIVAL;CETUXIMAB;KRAS;SINGLE-NUCLEOTIDE POLYMORPHISM;ESTROGEN RECEPTOR;NEOADJUVANT THERAPY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;TRASTUZUMAB;DNA METHYLATION;EPIDEMIOLOGY OF CANCER;MASTECTOMY;TRABECTEDIN;ANDROGEN DEPRIVATION THERAPY;CYTOREDUCTIVE SURGERY;IPILIMUMAB;ANTHRACYCLINE;BRCA MUTATION;CARBOPLATIN;IFOSFAMIDE;PAZOPANIB;TAXANE","26;15;15;13;12;11;11;10;9;9;9;8;7;7;7;6;6;6;6;6;6","HUMANS;FEMALE;MALE;BREAST NEOPLASMS;MIDDLE AGED;;ADULT;AGED;NEOPLASMS;ITALY;LUNG NEOPLASMS;COLORECTAL NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;PROSTATIC NEOPLASMS;MELANOMA;AGED, 80 AND OVER;OVARIAN NEOPLASMS;SKIN NEOPLASMS;ANTINEOPLASTIC AGENTS;SURVIVAL RATE","366;272;226;205;204;186;177;174;168;138;121;114;104;100;86;80;79;76;75;74","GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;SARCOMA RESEARCH AND TREATMENT;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;PROSTATE CANCER RESEARCH AND TREATMENT;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GLOBAL TRENDS IN OBESITY AND OVERWEIGHT RESEARCH;HEPATOCELLULAR CARCINOMA;MANAGEMENT OF PERITONEAL CARCINOMATOSIS FROM DIGESTIVE TRACT;RENAL CELL CARCINOMA;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;TESTICULAR GERM CELL TUMORS AND TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;MAMMALIAN MAP KINASE SIGNALING PATHWAYS","38;22;12;9;9;9;8;8;8;8;8;8;8;8;8;8;7;7;7;7","CANCER INCIDENCE;BREAST CANCER;RELATIVE SURVIVAL;REGIMEN;CLINICAL ENDPOINT;CANCER RISK;TREATMENT;SOFT TISSUE SARCOMA;HEALTHY EATING INDEX;STOMACH CANCER;UNIVARIATE ANALYSIS;CANCER SUSCEPTIBILITY;MELANOMA;NEOADJUVANT THERAPY;PROGRESSION-FREE SURVIVAL;PROSTATE CANCER;CANCER REGISTRY DATA;NEUROENDOCRINE TUMORS;CANCER;CUMULATIVE INCIDENCE","40;30;27;26;25;21;19;17;15;15;15;14;14;12;11;11;10;10;9;9","BREAST CANCER;CANCER BURDEN;COLORECTAL CANCER;EUROPEAN PROSPECTIVE;OVARIAN CANCER;PROSPECTIVE INVESTIGATION;PROSTATE CANCER;CANCER RISK;PHASE II;PHASE III;CANCER PATIENTS;CELL CARCINOMA;LUNG CANCER;NUTRITION EPIC;PATIENTS PTS;EPIC COHORT;ABSTRACT P--;CANCER CELLS;COHORT STUDY;HEPATOCELLULAR CARCINOMA;PATIENTS TREATED;SOFT TISSUE;CANCER SURVIVAL;CYTOREDUCTIVE SURGERY;GENE EXPRESSION;HYPERTHERMIC INTRAPERITONEAL;II STUDY;PRELIMINARY RESULTS;SQUAMOUS CELL;BRCA MUTATION","52;34;21;19;19;19;19;16;15;14;13;13;11;11;11;9;8;8;8;8;8;8;7;7;7;7;7;7;7;6","BREAST CANCER;HR CI;CANCER RISK;GENE EXPRESSION;CANCER CELLS;EUROPEAN PROSPECTIVE;PROSPECTIVE INVESTIGATION;CELL LINES;COLORECTAL CANCER;LUNG CANCER;OVARIAN CANCER;REGRESSION MODELS;TYPE DIABETES;CONFIDENCE INTERVAL;BRCA MUTATION;PROSTATE CANCER;EUROPEAN COUNTRIES;INTERNAL MAMMARY;PATIENTS TREATED;CANCER PATIENTS;GROWTH FACTOR;INTERVAL CI;PROGRESSION-FREE SURVIVAL;TUMOR CELLS;HAZARD RATIO;COX REGRESSION;LOGISTIC REGRESSION;PHASE II;STEM CELL;BODY MASS","122;39;35;32;25;25;25;23;23;23;23;22;22;20;19;18;17;17;17;16;16;16;16;16;15;14;14;14;14;13",191,0.34,6.35,5,3,2,2,6.25,3,1,1,5,1,1,4,4.25,2,2.25,2,3,2,0,0,90,90,7,1,2,0,0,2,0,0,2,2,0,0,5,4,0,8,2.55555555555556,1.1,1.66666666666667,2,5,5,4,0,2,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,1,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"BAKER JOFFRE B;GIANNI LUCA;SHAK STEVEN;RASPAGLIESI FRANCESCO;BELLONE MATTEO;BOGNI ANNA;BOGNI, ANNA;CANEVARI SILVANA;CINGARLINI SARA;COLOMBATTI MARCO","3;3;3;2;1;1;1;1;1;1","FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;GENOMIC HEALTH INC;ISTITUTO SUPERIORE DI SANITA ISS;OSPEDALE SAN RAFFAELE SRL;UNI DEGLI STUDI DI VERONA","9;3;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;51 PHYSICAL SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;5106 NUCLEAR AND PLASMA PHYSICS;5110 SYNCHROTRONS AND ACCELERATORS;3101 BIOCHEMISTRY AND CELL BIOLOGY;3204 IMMUNOLOGY","11;4;3;3;2;2;2;1;1","CANCER;GENETICS;BIOTECHNOLOGY;CERVICAL CANCER;CLINICAL RESEARCH;INFECTIOUS DISEASES;PREVENTION;SEXUALLY TRANSMITTED INFECTIONS;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN","6;3;2;2;2;2;2;2;2;2","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","2;1","C12Q1/68;A61M31/00;C07B59/00;C07B63/00;A61K31/4439;A61K39/395;A61K9/00;C07K16/30;C12N15/09","3;2;2;2;1;1;1;1;1","A61K2039/505;A61K31/337;A61K31/4965;A61K31/517;A61K9/0036;A61L27/54;A61M31/002;A61P35/00;A61K31/4439;A61K45/06","2;2;2;2;2;2;2;2;1;1",48,5.88,424.66,7.27,16,0.33,42.52,2,2,17,1,11,0,2,13,0,36,5,0,0,0,0,0,0,35,9,4,40,7,0,1,0,0,0,0,0,0,"United States;Italy;Germany;United Kingdom;France;Japan;Switzerland","9;6;2;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3210 NUTRITION AND DIETETICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","48;36;25;6;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;PATIENT SAFETY;HEMATOLOGY;BREAST CANCER;DIGESTIVE DISEASES;LYMPHOMA;ORPHAN DRUG;LUNG;AGING;BIOMEDICAL IMAGING;COLO-RECTAL CANCER;LUNG CANCER;OVARIAN CANCER;PREVENTION;TRANSPLANTATION;BIOTECHNOLOGY;DENTAL/ORAL AND CRANIOFACIAL DISEASE","40;39;24;18;10;7;6;6;6;6;5;4;3;3;3;3;3;3;2;2","CANCER;BLOOD;CONGENITAL;INFECTION;ORAL AND GASTROINTESTINAL;RESPIRATORY","32;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","30;9;5;3;2;1","BREAST CANCER;NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;LUNG CANCER;OVARIAN CANCER;LIVER CANCER;MELANOMA;NOT SITE-SPECIFIC CANCER;HODGKIN'S DISEASE;SARCOMA;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;BRAIN TUMOR;HEAD AND NECK CANCER;LEUKEMIA / LEUKAEMIA;NEUROBLASTOMA;ORAL CAVITY AND LIP CANCER;PROSTATE CANCER;STOMACH CANCER;TESTICULAR CANCER","7;6;4;4;4;3;3;3;2;2;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","23;5;4;2;2;1;1",6,4695992.33,683731.14,6.5,32.5,9.5,0.833333333333333,403,1621526.80094705,0.34473682437658,"FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;UNIVERSITY OF CAMBRIDGE;CARDIFF UNIVERSITY;GERMAN CANCER RESEARCH CENTER;GHENT UNIVERSITY;HEIDELBERG UNIVERSITY;IMPERIAL COLLEGE LONDON;JOHNS HOPKINS UNIVERSITY;KAROLINSKA INSTITUTET;KU LEUVEN;NEWCASTLE UNIVERSITY;OREGON HEALTH & SCIENCE UNIVERSITY;TECHNICAL UNIVERSITY OF MUNICH;UNIVERSITY COLLEGE LONDON;UNIVERSITY MEDICAL CENTER HAMBURG-EPPENDORF;UNIVERSITY OF BRISTOL;UNIVERSITY OF EDINBURGH;UNIVERSITY OF GLASGOW;UNIVERSITY OF LEICESTER;UNIVERSITY OF SOUTHAMPTON","6;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","EUROPEAN COMMISSION;MEDICAL RESEARCH COUNCIL;EUROPEAN RESEARCH COUNCIL","3;2;1","COALITION S;EC & ERC - EUROPEAN UNION;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;UKRI - UK RESEARCH AND INNOVATION","5;4;2;2","CP-FP - SMALL OR MEDIUM-SCALE FOCUSED RESEARCH PROJECT (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2013-INNOVATION-1 (CALL FOR PROPOSAL);RESEARCH GRANT (PROJECT CATEGORY);ERC-2012-ADG_20120314 (CALL FOR PROPOSAL);ERC-AG - ERC ADVANCED GRANT (FUNDING SCHEME);FP7-IDEAS-ERC - SPECIFIC PROGRAMME: ""IDEAS"" IMPLEMENTING THE SEVENTH FRAMEWORK PROGRAMME OF THE EUROPEAN COMMUNITY FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ACTIVITIES (2007 TO 2013) (PROGRAMME)","3;3;3;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;3210 NUTRITION AND DIETETICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4205 NURSING;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","4;4;3;2;1;1;1;1;1;1","CLINICAL RESEARCH;AGING;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;GENETICS;PREVENTION;BEHAVIORAL AND SOCIAL SCIENCE;BRAIN DISORDERS;ACQUIRED COGNITIVE IMPAIRMENT;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);BASIC BEHAVIORAL AND SOCIAL SCIENCE;BREAST CANCER;COMPLEMENTARY AND INTEGRATIVE HEALTH;DEMENTIA;DEPRESSION;DIABETES;HUMAN GENOME;LUNG;MENTAL HEALTH","4;3;3;3;3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE;MENTAL HEALTH;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;NEUROLOGICAL","4;2;2;1;1;1","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;1.2 PSYCHOLOGICAL AND SOCIOECONOMIC PROCESSES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.3 PSYCHOLOGICAL, SOCIAL AND ECONOMIC FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;3.3 NUTRITION AND CHEMOPREVENTION;7.1 INDIVIDUAL CARE NEEDS;8.4 RESEARCH DESIGN AND METHODOLOGIES (HEALTH SERVICES)","3;2;2;1;1;1;1;1;1;1","NOT SITE-SPECIFIC CANCER;BREAST CANCER;LUNG CANCER;OVARIAN CANCER;PROSTATE CANCER","3;1;1;1;1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;3.2 NUTRITIONAL SCIENCE IN CANCER PREVENTION;3.3 CHEMOPREVENTION;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","2;1;1;1;1;1","A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;A04 PSYCHOLOGY, PSYCHIATRY AND NEUROSCIENCE","2;2;2",NA,NA,119,"PUBLIC LIBRARY OF SCIENCE","119","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3105 GENETICS;4206 PUBLIC HEALTH;3210 NUTRITION AND DIETETICS;4202 EPIDEMIOLOGY;4203 HEALTH SERVICES AND SYSTEMS;3202 CLINICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3215 REPRODUCTIVE MEDICINE;49 MATHEMATICAL SCIENCES;41 ENVIRONMENTAL SCIENCES;4105 POLLUTION AND CONTAMINATION;34 CHEMICAL SCIENCES;4905 STATISTICS;51 PHYSICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3204 IMMUNOLOGY","136;62;58;30;20;15;13;11;11;8;6;6;6;4;4;3;3;3;2;2","CANCER;GENETICS;PREVENTION;NUTRITION;RARE DISEASES;AGING;BREAST CANCER;DIGESTIVE DISEASES;CLINICAL RESEARCH;COLO-RECTAL CANCER;OBESITY;BIOTECHNOLOGY;CONTRACEPTION/REPRODUCTION;SUBSTANCE MISUSE;ALCOHOLISM, ALCOHOL USE AND HEALTH;HUMAN GENOME;LUNG;OVARIAN CANCER;TOBACCO;TOBACCO SMOKE AND HEALTH","31;23;23;13;13;9;9;9;8;7;7;6;6;6;5;5;5;5;5;5","CANCER;CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;STROKE;METABOLIC AND ENDOCRINE;NEUROLOGICAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;GENERIC HEALTH RELEVANCE;RESPIRATORY","41;11;7;7;2;2;2;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;5.1 PHARMACEUTICALS","18;3;2;2;2;2;1","BIOMEDICAL;CLINICAL;POPULATION & SOCIETY","13;6;1","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH;BASIC SCIENCE","28;17;14","BREAST CANCER;COLON AND RECTAL CANCER;LUNG CANCER;OVARIAN CANCER;NOT SITE-SPECIFIC CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;GENITAL SYSTEM, FEMALE;HEAD AND NECK CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;RESPIRATORY SYSTEM;THYROID CANCER","23;8;8;7;5;3;1;1;1;1;1;1","7 AFFORDABLE AND CLEAN ENERGY;3 GOOD HEALTH AND WELL BEING","6;1"
"IRCCS_TUMORIMILAN",2014,644,17.138198757764,3.83385093167702,0.358695652173913,0.338509316770186,0.453416149068323,3.40275862068966,1.54,2,1.69767441860465,0.481366459627329,3,411,111,45,44,0.64,0.17,0.07,0.07,37.13,0.982584517708205,7.15815815815818,0.524844720496894,0.881987577639752,0.54,0.502,0.471,0.483,"­ROSARIO ­TUMINO;ELIO RÍBOLI;ANNE TJØNNELAND;ANTONIA TRICHOPOULOU;ELISABETE WEIDERPASS;KIM OVERVAD;HEINER BOEING;KAY‐TEE KHAW;DOMENICO PALLI;FILIPPO DE BRAUD;SALVATORE PANICO;ANDREA NECCHI;NICHOLAS J. WAREHAM;PAOLO VINEIS;GIUSEPPE PROCOPIO;RUDOLF KAAKS;PETRA H. PEETERS;RUTH C. TRAVIS;MARÍA‐JOSÉ SÁNCHEZ;PAOLO CORRADINI","60;53;52;50;50;46;44;43;42;40;40;39;38;37;35;31;31;30;30;29","MAURA MASSIMINO;FILIPPO DE BRAUD;GIUSEPPE PROCOPIO;UGO PASTORINO;ANDREA FERRARI;ANDREA NECCHI;LARRY JUNCK;PAOLO CORRADINI;ROBERTO IACOVELLI;ALESSANDRO GRONCHI;GIUSEPPE PELOSI;ALESSANDRO M. GIANNI;LUIGI MARIANI;LISA LICITRA;ROMANO DEMICHELI;ISABELLA TESTA;­ROSARIO ­TUMINO;PATRIZIA GIANNATEMPO;ROBERTO SALVIONI;PAOLO G. CASALI","5.51;3.75;3.62;2.9;2.61;2.58;2.5;2.29;2.15;1.94;1.93;1.9;1.87;1.85;1.83;1.8;1.7;1.63;1.61;1.57","­ROSARIO ­TUMINO;ELIO RÍBOLI;ANNE TJØNNELAND;ANTONIA TRICHOPOULOU;ELISABETE WEIDERPASS;HEINER BOEING;KAY‐TEE KHAW;FILIPPO DE BRAUD;SALVATORE PANICO;ANDREA NECCHI;NICHOLAS J. WAREHAM;GIUSEPPE PROCOPIO;RUDOLF KAAKS;PETRA H. PEETERS;RUTH C. TRAVIS;MARÍA‐JOSÉ SÁNCHEZ;PAOLO CORRADINI;MARIE‐CHRISTINE BOUTRON‐RUAULT;ALESSANDRO M. GIANNI;LUIGI MARIANI","60;53;52;50;50;44;43;40;40;39;38;35;31;31;30;30;29;28;28;27","MAURA MASSIMINO;FILIPPO DE BRAUD;GIUSEPPE PROCOPIO;UGO PASTORINO;ANDREA FERRARI;ANDREA NECCHI;PAOLO CORRADINI;ROBERTO IACOVELLI;ALESSANDRO GRONCHI;GIUSEPPE PELOSI;ALESSANDRO M. GIANNI;LUIGI MARIANI;LISA LICITRA;ROMANO DEMICHELI;ISABELLA TESTA;­ROSARIO ­TUMINO;PATRIZIA GIANNATEMPO;ROBERTO SALVIONI;PAOLO G. CASALI;ANDREA BILLÈ","5.51;3.75;3.62;2.9;2.61;2.58;2.29;2.15;1.94;1.93;1.9;1.87;1.85;1.83;1.8;1.7;1.63;1.61;1.57;1.53","­ROSARIO ­TUMINO;ANNE TJØNNELAND;ELIO RÍBOLI;HEINER BOEING;ELISABETE WEIDERPASS;ANTONIA TRICHOPOULOU;KIM OVERVAD;DOMENICO PALLI;KAY‐TEE KHAW;NICHOLAS J. WAREHAM;RUDOLF KAAKS;SALVATORE PANICO;MARÍA‐JOSÉ SÁNCHEZ;PAOLO VINEIS;J. RAMÓN QUIRÓS;MARIE‐CHRISTINE BOUTRON‐RUAULT;PETRA H. PEETERS;DIMITRIOS TRICHOPOULOS;PAOLO CORRADINI;TIMOTHY J. KEY","3666;3642;3563;3397;3300;3258;3194;3145;3083;2819;2584;2482;2448;2302;2124;2093;2072;2031;1907;1803","PAOLO CORRADINI;VALERIA PALA;ALESSANDRO GRONCHI;VITTORIO KROGH;PAOLO G. CASALI;CLAUDIA AGNOLI;SARA GRIONI;LISA LICITRA;ANDREA NECCHI;FRANCESCO RASPAGLIESI;ROSALBA MICELI;SABINA SIERI;SILVIA STACCHIOTTI;FILIPPO DE BRAUD;SILVANA PILOTTI;FEDERICA PERRONE;PAOLO RADICE;MARCO A. PIEROTTI;SIRANOUSH MANOUKIAN;NADIA ZAFFARONI","1874;1579;1449;1329;1195;1010;955;954;790;760;717;676;638;624;606;597;596;582;576;557","FILIPPO DE BRAUD;GIUSEPPE PROCOPIO;ANDREA NECCHI;PAOLO CORRADINI;MAURA MASSIMINO;LUIGI MARIANI;ALESSANDRO M. GIANNI;ALESSANDRO GRONCHI;UGO PASTORINO;PAOLO G. CASALI;ROBERTO SALVIONI;PATRIZIA GIANNATEMPO;VITTORIO KROGH;VALERIA PALA;NICOLA NICOLAI;ROBERTO IACOVELLI;CLAUDIA AGNOLI;ELENA FARÈ;TULLIO TORELLI;DANIELE RAGGI","39;34;32;25;25;24;24;23;23;22;22;22;21;20;20;19;18;17;16;16","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;SOCIOLOGY;COMPUTER SCIENCE;MATHEMATICS;ECONOMICS;PSYCHOLOGY;POLITICAL SCIENCE;ART;BUSINESS;PHILOSOPHY;MATERIALS SCIENCE;ENGINEERING;HISTORY;ENVIRONMENTAL SCIENCE;GEOGRAPHY","587;247;74;48;33;31;22;18;15;12;10;10;10;9;8;7;3;3","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CANCER RESEARCH;GENETICS;GASTROENTEROLOGY;PATHOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;UROLOGY;PALEONTOLOGY;CELL BIOLOGY;RADIOLOGY;ENDOCRINOLOGY;NUCLEAR MEDICINE;PHARMACOLOGY;DEMOGRAPHY;NURSING;BIOINFORMATICS;GYNECOLOGY","498;299;170;143;118;117;114;91;83;61;55;41;37;33;26;26;24;23;22;21;21","CANCER;CHEMOTHERAPY;GENE;CONFIDENCE INTERVAL;POPULATION;CLINICAL TRIAL;RADIATION THERAPY;PROPORTIONAL HAZARDS MODEL;PROSPECTIVE COHORT STUDY;COHORT;LYMPHOMA;ODDS RATIO;LUNG CANCER;ADVERSE EFFECT;APOPTOSIS;COHORT STUDY;SARCOMA;RENAL CELL CARCINOMA;RANDOMIZED CONTROLLED TRIAL;STAGE (STRATIGRAPHY)","333;160;122;82;65;50;50;49;47;44;35;33;32;30;28;28;28;27;26;26","BREAST CANCER;COLORECTAL CANCER;HAZARD RATIO;CLINICAL ENDPOINT;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;METASTASIS;PROSTATE CANCER;CISPLATIN;SUNITINIB;PHASES OF CLINICAL RESEARCH;OVARIAN CANCER;PROGRESSION-FREE SURVIVAL;GENE EXPRESSION;MUTATION;DOCETAXEL;NEUTROPENIA;SORAFENIB;BLADDER CANCER;GENOTYPE;CARCINOGENESIS;GEMCITABINE;MICRORNA","81;56;52;44;35;33;30;29;25;23;22;22;21;20;19;18;18;16;16;15;15;15","KRAS;OXALIPLATIN;PAZOPANIB;CARBOPLATIN;IFOSFAMIDE;SINGLE-NUCLEOTIDE POLYMORPHISM;TRASTUZUMAB;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;ANDROGEN DEPRIVATION THERAPY;ESTROGEN RECEPTOR;DNA METHYLATION;GERMLINE MUTATION;VINCRISTINE;ANDROGEN RECEPTOR;CIRCULATING TUMOR CELL;GENE EXPRESSION PROFILING;IRINOTECAN;METASTATIC BREAST CANCER;TAXANE;ANAPLASTIC LYMPHOMA KINASE;ANTHRACYCLINE;CETUXIMAB;CYSTECTOMY;EPITHELIAL–MESENCHYMAL TRANSITION;POMALIDOMIDE;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;VEMURAFENIB","13;13;13;12;12;12;12;10;9;9;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5","HUMANS;FEMALE;;MALE;MIDDLE AGED;AGED;ADULT;ANTINEOPLASTIC AGENTS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;NEOPLASMS;LUNG NEOPLASMS;PROSPECTIVE STUDIES;NEOPLASM RECURRENCE, LOCAL;TREATMENT OUTCOME;ITALY;PROGNOSIS;RISK FACTORS;EUROPE;FOLLOW-UP STUDIES","392;276;244;239;219;188;166;112;96;95;92;75;75;65;65;61;61;61;60;60","RENAL CELL CARCINOMA;SARCOMA RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GLIOMAS;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;LYMPHOID NEOPLASMS;TESTICULAR GERM CELL TUMORS AND TREATMENT;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;ADVANCEMENTS IN LUNG CANCER RESEARCH;HER2 SIGNALING IN BREAST CANCER TREATMENT;CANCER STEM CELLS AND TUMOR METASTASIS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK","24;21;18;17;16;15;15;14;14;13;12;10;10;10;9;9;8;8;8;7","CLINICAL ENDPOINT;TREATMENT;BREAST CANCER;REGIMEN;PROGRESSION-FREE SURVIVAL;HEALTHY EATING INDEX;SOFT TISSUE SARCOMA;CANCER RISK;DIETARY PATTERNS;EVEROLIMUS;QUARTILE;TUMOR MICROENVIRONMENT;MELANOMA;PAZOPANIB;REFRACTORY (PLANETARY SCIENCE);RENAL CELL CARCINOMA;CANCER;CANCER THERAPY;CARBOPLATIN;CANCER SUSCEPTIBILITY","44;31;30;26;22;21;19;15;14;14;14;14;13;13;13;13;12;12;12;11","BREAST CANCER;CELL CARCINOMA;COLORECTAL CANCER;PATIENTS PTS;PHASE II;CANCER RISK;PROSTATE CANCER;RENAL CELL;CANCER PATIENTS;MULTIPLE MYELOMA;OVARIAN CANCER;PROSPECTIVE INVESTIGATION;EUROPEAN PROSPECTIVE;PHASE III;LUNG CANCER;EPIC COHORT;CELL TUMORS;METASTATIC RENAL;STEM CELL;GERM CELL;II TRIAL;II STUDY;SQUAMOUS CELL;PHASE STUDY;UROTHELIAL CARCINOMA;ADVANCED UROTHELIAL;COHORT STUDY;LOCALLY ADVANCED;PROGNOSTIC FACTORS;CELL TRANSPLANTATION","45;37;26;26;26;25;23;23;19;18;18;18;17;16;15;14;13;13;13;12;12;11;11;10;10;9;9;9;9;8","BREAST CANCER;CELL LINES;HR CI;PUBMED SCOPUS;CROSSREF PUBMED;CANCER RISK;EUROPEAN PROSPECTIVE;PROGRESSION-FREE SURVIVAL;COLORECTAL CANCER;CONFIDENCE INTERVAL;GENE EXPRESSION;ISTITUTO NAZIONALE;PROSPECTIVE INVESTIGATION;DEI TUMORI;NAZIONALE DEI;ABSTRACT AIM;LUNG CANCER;IRCCS ISTITUTO;MEDIAN AGE;TUMORI MILAN;MILAN ITALY;FONDAZIONE IRCCS;BLADDER CANCER;GROWTH FACTOR;RESPONSE RATE;ADVERSE EVENTS;INTERVAL CI;MEDIAN FOLLOW-UP;NUTRITION EPIC;PATIENTS TREATED","99;79;72;60;59;50;37;37;36;36;36;36;36;35;35;30;30;29;29;29;28;27;26;26;26;23;23;23;23;23",262,0.41,8.46,7,2,1,1,4,5.5,1.5,2,7,1,1,5,1,1,1,3,5,2,0,0,90.75,91,4,0,2,0,0,2,0,0,0,0,0,0,2,2,0,109.5,5.5,0.89,2.25,0,3,3,0,1,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BAKER JOFFRE B;BELVISI LAURA;CANEVARI SILVANA;CINGARLINI SARA;COLOMBATTI MARCO;COSSU FEDERICA;COUKOS GEORGE;DELIA DOMENICO;DRAGO CARMELO;FIGINI MARIANGELA","1;1;1;1;1;1;1;1;1;1","FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;CISI SCRL;FONDAZIONE CARIPLO;GENOMIC HEALTH INC;UNIVERSITA DEGLI STUDI DI MILANO;UNIVERSITA DEGLI STUDI DI VERONA;UNIVERSITY OF PENNSYLVANIA PENN","3;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY","7;4;3;1","CANCER;BIOTECHNOLOGY;GENETICS;OVARIAN CANCER;PROSTATE CANCER;RARE DISEASES;UROLOGIC DISEASES","4;1;1;1;1;1;1","5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","2;1","A61K39/00;A61K31/5517;A61K35/14;A61K35/17;A61K39/395;A61P35/00;C07D487/04;C07H21/04;C07K14/705;C07K16/00","2;1;1;1;1;1;1;1;1;1","A61P35/00;A61K38/00;C07K2317/622;A61K2035/124;A61K2039/505;A61K2039/5156;A61K2039/5158;A61K35/17;A61K38/06;A61K38/07","4;2;2;1;1;1;1;1;1;1",57,6.15,376.47,8.92,18,0.32,17.77,1,3,32,1,7,0,1,12,0,35,9,0,0,0,0,0,0,47,8,2,43,13,0,1,0,0,0,0,0,0,"Italy;Germany;United States;Belgium;United Kingdom;Japan;Netherlands","10;5;4;3;3;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3207 MEDICAL MICROBIOLOGY;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3215 REPRODUCTIVE MEDICINE;4205 NURSING;51 PHYSICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","56;39;23;7;3;3;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;DIGESTIVE DISEASES;HEMATOLOGY;ORPHAN DRUG;PATIENT SAFETY;PREVENTION;GENETICS;BREAST CANCER;LYMPHOMA;DENTAL/ORAL AND CRANIOFACIAL DISEASE;KIDNEY DISEASE;PEDIATRIC;REGENERATIVE MEDICINE;TRANSPLANTATION;UROLOGIC DISEASES;AGING;BIOMEDICAL IMAGING","44;39;29;19;6;6;6;6;6;5;4;4;3;3;3;3;3;3;2;2","CANCER;EYE;INFECTION;RENAL AND UROGENITAL","43;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;2.4 SURVEILLANCE AND DISTRIBUTION;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.1 INDIVIDUAL CARE NEEDS","35;17;6;4;2;2;1;1;1;1","SARCOMA;BLADDER CANCER;BREAST CANCER;NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;KIDNEY CANCER;SALIVARY GLAND CANCER;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;SKIN CANCER;THYROID CANCER;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;CERVICAL CANCER;HEAD AND NECK CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;PROSTATE CANCER;BLOOD CANCER;BRAIN TUMOR;ENDOMETRIAL CANCER","7;5;5;5;4;4;4;3;3;3;3;2;2;2;2;2;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;1.4 CANCER PROGRESSION AND METASTASIS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY","31;9;4;4;3;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,"PUBLIC LIBRARY OF SCIENCE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;KARGER PUBLISHERS","46;5;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3105 GENETICS;4203 HEALTH SERVICES AND SYSTEMS;34 CHEMICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;49 MATHEMATICAL SCIENCES;3202 CLINICAL SCIENCES;4202 EPIDEMIOLOGY;44 HUMAN SOCIETY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3204 IMMUNOLOGY;3210 NUTRITION AND DIETETICS;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;4905 STATISTICS;3103 ECOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3215 REPRODUCTIVE MEDICINE","53;33;23;21;9;8;6;5;5;3;3;3;2;2;2;2;2;1;1;1","CANCER;GENETICS;BIOTECHNOLOGY;PREVENTION;BREAST CANCER;HUMAN GENOME;RARE DISEASES;AGING;COLO-RECTAL CANCER;DIGESTIVE DISEASES;LUNG;LUNG CANCER;NUTRITION;PEDIATRIC;ALCOHOLISM, ALCOHOL USE AND HEALTH;CLINICAL RESEARCH;GENE THERAPY;GENETIC TESTING;IMMUNIZATION;KIDNEY DISEASE","16;14;7;7;6;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1","CANCER;ORAL AND GASTROINTESTINAL","19;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES","11;3;1;1;1;1","BIOMEDICAL;CLINICAL","9;3","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","13;8;2","BREAST CANCER;COLON AND RECTAL CANCER;OVARIAN CANCER;GASTROINTESTINAL TRACT;LUNG CANCER;NOT SITE-SPECIFIC CANCER;SARCOMA;BLADDER CANCER;GENITAL SYSTEM, FEMALE;KIDNEY CANCER;NON-HODGKIN'S LYMPHOMA;PROSTATE CANCER;STOMACH CANCER","12;3;3;2;2;2;2;1;1;1;1;1;1","7 AFFORDABLE AND CLEAN ENERGY","1"
"IRCCS_TUMORIMILAN",2015,662,18.3036253776435,4.44410876132931,0.370090634441088,0.374622356495468,0.469788519637462,3.44548651817116,1.31720430107527,2.15652173913043,1.42660550458716,0.540785498489426,5,428,106,55,36,0.65,0.16,0.08,0.05,64.81,1.73908788527723,7.20400837571046,0.528700906344411,0.86404833836858,0.54,0.547,0.528,0.524,"FILIPPO DE BRAUD;­ROSARIO ­TUMINO;ANDREA NECCHI;ELISABETE WEIDERPASS;ANNE TJØNNELAND;ANTONIA TRICHOPOULOU;ELIO RÍBOLI;HEINER BOEING;GIUSEPPE PROCOPIO;SALVATORE PANICO;KAY‐TEE KHAW;AMALIA MATTIELLO;LISA LICITRA;NICHOLAS J. WAREHAM;PAOLO CORRADINI;PATRIZIA GIANNATEMPO;KIM OVERVAD;GIOVANNA MASALA;MARÍA‐JOSÉ SÁNCHEZ;PETRA H. PEETERS","65;52;42;39;37;35;35;34;34;33;30;30;30;30;29;29;28;28;27;27","FILIPPO DE BRAUD;ANDREA NECCHI;MAURA MASSIMINO;LISA LICITRA;GIUSEPPE PROCOPIO;PAOLO BOSSI;PAOLO G. CASALI;PATRIZIA GIANNATEMPO;LUIGI MARIANI;UGO PASTORINO;PAOLO CORRADINI;LARRY JUNCK;FILIPPO PIETRANTONIO;VINCENZO MAZZAFERRO;NICOLA NICOLAI;DANIELE RAGGI;­ROSARIO ­TUMINO;AUGUSTO CARACENI;ELENA VERZONI;SILVIA STACCHIOTTI","4.98;3.2;3.08;2.97;2.86;2.4;2.31;2.28;2.16;2.07;2.03;2;1.95;1.92;1.87;1.81;1.77;1.74;1.73;1.71","FILIPPO DE BRAUD;­ROSARIO ­TUMINO;ANDREA NECCHI;GIUSEPPE PROCOPIO;SALVATORE PANICO;AMALIA MATTIELLO;LISA LICITRA;PAOLO CORRADINI;PATRIZIA GIANNATEMPO;MILENA SANT;LUIGI MARIANI;SABINA SIERI;VITTORIO KROGH;PAMELA MINICOZZI;DANIELE RAGGI;PAOLO G. CASALI;FRANCO BERRINO;NICOLA NICOLAI;FILIPPO PIETRANTONIO;PAOLO BOSSI","65;52;42;34;33;30;30;29;29;26;26;25;25;24;24;23;23;23;23;21","FILIPPO DE BRAUD;ANDREA NECCHI;MAURA MASSIMINO;LISA LICITRA;GIUSEPPE PROCOPIO;PAOLO BOSSI;PAOLO G. CASALI;PATRIZIA GIANNATEMPO;LUIGI MARIANI;UGO PASTORINO;PAOLO CORRADINI;FILIPPO PIETRANTONIO;VINCENZO MAZZAFERRO;NICOLA NICOLAI;DANIELE RAGGI;­ROSARIO ­TUMINO;AUGUSTO CARACENI;ELENA VERZONI;SILVIA STACCHIOTTI;ROBERTO SALVIONI","4.98;3.2;3.08;2.97;2.86;2.4;2.31;2.28;2.16;2.07;2.03;1.95;1.92;1.87;1.81;1.77;1.74;1.73;1.71;1.69","MARINA CHIARA GARASSINO;MARTIN RECK;SCOTT ANTONIA;JULIE R. BRAHMER;ADAM PŁUŻAŃSKI;BRIAN LESTINI;CHRISTINE BAUDELET;CHRISTOPHER HARBISON;DAVID R. SPIGEL;DAVID WATERHOUSE;ELENA PODDUBSKAYA;ESTHER HOLGADO;EVERETT E. VOKES;JOACHIM G.J.V. AERTS;JUSTIN F. GAINOR;KAREN L. RECKAMP;LIBOR HAVEL;LUCIO CRINÓ;LUÍS PAZ-ARES;MANUEL DÓMINE","7993;7894;7830;7758;7750;7750;7750;7750;7750;7750;7750;7750;7750;7750;7750;7750;7750;7750;7750;7750","MARINA CHIARA GARASSINO;GIUSEPPE PROCOPIO;VINCENZO MAZZAFERRO;UGO PASTORINO;FILIPPO DE BRAUD;LUCA ROZ;MILENA SANT;PAMELA MINICOZZI;LAURA BOTTA;VITTORIO KROGH;CLAUDIA AGNOLI;SABINA SIERI;VIRGINIA FERRARESI;LISA LICITRA;ROBERTO BUZZONI;LADISLAV DUŠEK;LAUFEY TRYGGVADÓTTÍR;NICOLA NICOLAI;ANNE–MARIE BOUVIER;S. BARA","7993;5376;2875;2552;2455;2107;1852;1669;1590;1455;1334;1316;1242;1210;1110;1093;1093;1051;1041;981","FILIPPO DE BRAUD;ANDREA NECCHI;GIUSEPPE PROCOPIO;LISA LICITRA;PAOLO CORRADINI;VITTORIO KROGH;LUIGI MARIANI;SABINA SIERI;PATRIZIA GIANNATEMPO;FILIPPO PIETRANTONIO;NICOLA NICOLAI;MILENA SANT;PAOLO G. CASALI;DANIELE RAGGI;CLAUDIA AGNOLI;PAOLO BOSSI;ROBERTO SALVIONI;UGO PASTORINO;PAMELA MINICOZZI;MARIA DI BARTOLOMEO","61;37;30;29;27;26;25;25;24;22;22;21;21;20;20;19;19;19;19;19","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;SOCIOLOGY;MATHEMATICS;PSYCHOLOGY;MATERIALS SCIENCE;POLITICAL SCIENCE;ECONOMICS;PHILOSOPHY;ENGINEERING;ART;BUSINESS;HISTORY;GEOLOGY;ENVIRONMENTAL SCIENCE;GEOGRAPHY","609;246;60;45;33;31;15;15;12;12;11;9;8;7;6;4;3;2;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;PATHOLOGY;CANCER RESEARCH;GENETICS;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;IMMUNOLOGY;PALEONTOLOGY;CELL BIOLOGY;UROLOGY;GYNECOLOGY;RADIOLOGY;BIOINFORMATICS;DEMOGRAPHY;OPTICS;FAMILY MEDICINE;NURSING","533;337;170;143;133;133;107;91;81;66;45;37;37;36;34;25;25;24;23;23","CANCER;CHEMOTHERAPY;GENE;CONFIDENCE INTERVAL;POPULATION;PROPORTIONAL HAZARDS MODEL;CLINICAL TRIAL;COHORT;PROSPECTIVE COHORT STUDY;RADIATION THERAPY;LUNG CANCER;STAGE (STRATIGRAPHY);RANDOMIZED CONTROLLED TRIAL;TRANSPLANTATION;ADVERSE EFFECT;COHORT STUDY;HEPATOCELLULAR CARCINOMA;ALTERNATIVE MEDICINE;LYMPHOMA;REGIMEN","355;158;130;87;74;58;54;48;48;41;35;34;33;29;27;27;27;26;26;25","BREAST CANCER;COLORECTAL CANCER;HAZARD RATIO;CLINICAL ENDPOINT;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;METASTASIS;CISPLATIN;PROSTATE CANCER;PHASES OF CLINICAL RESEARCH;PROGRESSION-FREE SURVIVAL;GENE EXPRESSION;DOCETAXEL;OVARIAN CANCER;PLACEBO;SUNITINIB;MICRORNA;MUTATION;NEUTROPENIA;CANCER REGISTRY;GENOTYPE;HEAD AND NECK CANCER","100;67;60;43;38;33;31;30;26;26;25;23;23;21;21;20;19;18;17;17;17","KRAS;RELATIVE SURVIVAL;DNA METHYLATION;ANDROGEN DEPRIVATION THERAPY;CARBOPLATIN;OXALIPLATIN;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;CETUXIMAB;PAZOPANIB;TAXANE;TRASTUZUMAB;SINGLE-NUCLEOTIDE POLYMORPHISM;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;IPILIMUMAB;METASTATIC BREAST CANCER;NIVOLUMAB;ANDROGEN RECEPTOR;CAPECITABINE;CYTOREDUCTIVE SURGERY;ESTROGEN RECEPTOR;IMATINIB MESYLATE;POMALIDOMIDE","16;14;12;11;11;11;11;10;10;10;10;9;8;8;8;8;7;7;7;7;7;7","HUMANS;FEMALE;;MALE;MIDDLE AGED;ADULT;AGED;BREAST NEOPLASMS;LUNG NEOPLASMS;ANTINEOPLASTIC AGENTS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BIOMARKERS, TUMOR;PROSPECTIVE STUDIES;RISK FACTORS;TREATMENT OUTCOME;ITALY;NEOPLASMS;AGED, 80 AND OVER;COLORECTAL NEOPLASMS;LIVER NEOPLASMS","383;280;274;224;212;175;175;157;138;120;96;76;74;71;71;68;67;59;58;56","SARCOMA RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;ADVANCEMENTS IN LUNG CANCER RESEARCH;LYMPHOID NEOPLASMS;RENAL CELL CARCINOMA;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;TESTICULAR GERM CELL TUMORS AND TREATMENT;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;GLIOMAS;CANCER STEM CELLS AND TUMOR METASTASIS;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;MAMMALIAN MAP KINASE SIGNALING PATHWAYS","22;17;17;15;14;14;14;13;13;12;11;11;11;11;10;10;10;9;9;9","CLINICAL ENDPOINT;BREAST CANCER;TREATMENT;PROGRESSION-FREE SURVIVAL;REGIMEN;HEALTHY EATING INDEX;CANCER RISK;DIETARY PATTERNS;CANCER;CANCER THERAPY;REFRACTORY (PLANETARY SCIENCE);EVEROLIMUS;MELANOMA;METASTATIC COLORECTAL CANCER;RELATIVE SURVIVAL;UNIVARIATE ANALYSIS;BIOMARKER ANALYSIS;DIET QUALITY;SOFT TISSUE SARCOMA;SURGICAL ONCOLOGY","43;33;28;26;25;21;18;17;15;15;14;13;13;13;13;13;12;12;12;12","BREAST CANCER;CANCER PATIENTS;CELL CARCINOMA;COLORECTAL CANCER;LUNG CANCER;PATIENTS PTS;PHASE II;PROSTATE CANCER;PHASE III;MULTIPLE MYELOMA;OVARIAN CANCER;PROSPECTIVE INVESTIGATION;SQUAMOUS CELL;CANCER RISK;EUROPEAN PROSPECTIVE;RENAL CELL;II STUDY;STEM CELL;PATIENTS TREATED;UROTHELIAL CARCINOMA;CELL LUNG;HEPATOCELLULAR CARCINOMA;RANDOMIZED PHASE;EPIC COHORT;EUROPE RESULTS;CELL TRANSPLANTATION;COHORT STUDY;METASTATIC RENAL;LOCALLY ADVANCED;LYMPH NODE","60;31;29;26;24;23;23;22;21;18;17;17;16;15;15;15;14;14;13;13;12;12;11;10;10;9;9;9;8;8","BREAST CANCER;MILAN ITALY;ISTITUTO NAZIONALE;PROGRESSION-FREE SURVIVAL;IRCCS ISTITUTO;FONDAZIONE IRCCS;CANCER RISK;HR CI;DEI TUMORI;NAZIONALE DEI;TUMORI MILAN;COLORECTAL CANCER;CONFIDENCE INTERVAL;LUNG CANCER;SURVIVAL OS;ADVERSE EVENTS;ITALY DEPARTMENT;PATIENTS TREATED;CELL LINES;RISK FACTORS;EUROPEAN PROSPECTIVE;PROSPECTIVE INVESTIGATION;GENE EXPRESSION;SURVIVAL PFS;OVARIAN CANCER;HAZARD RATIO;BOEHRINGER INGELHEIM;TUMOR CELLS;CANCER PATIENTS;PHASE II","153;65;64;60;57;55;52;52;51;51;50;47;44;43;40;39;37;37;36;36;35;34;31;31;30;29;28;28;27;27",305,0.46,12.35,10,2,2,1.5,4.25,2.25,0,2,11,1,1,7.75,1.25,1.25,2,4,6,3,0,0,102,101,5,0,3,0,0,2,0,2,0,0,0,0,3,4,0,18.5,3.57142857142857,0.85,1.85714285714286,2,4,3,0,0,2,0,0,4,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,1,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"GIANNI LUCA;SHAK STEVEN;BAKER JOFFRE B;BAKER JOFFRE;BELVISI LAURA;BOGNI ANNA;COSSU FEDERICA;DELIA DOMENICO;DRAGO CARMELO;LECIS DANIELE","3;3;2;1;1;1;1;1;1;1","FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;GENOMIC HEALTH INC;CISI SCRL;FONDAZIONE CARIPLO;UNIVERSITA DEGLI STUDI DI MILANO;UNIVERSITY OF PENNSYLVANIA PENN","6;3;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;51 PHYSICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3204 IMMUNOLOGY;3215 REPRODUCTIVE MEDICINE;5110 SYNCHROTRONS AND ACCELERATORS","9;4;3;2;1;1;1;1","CANCER;GENETICS;BREAST CANCER;CERVICAL CANCER;CLINICAL RESEARCH;COMPLEMENTARY AND INTEGRATIVE HEALTH;OVARIAN CANCER;RARE DISEASES;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN","4;2;1;1;1;1;1;1;1;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","1;1","C12Q1/68;A61F13/02;A61F6/14;A61K38/06;A61K38/07;A61K45/06;A61K51/04;A61K9/00;C07B59/00;C07B63/00","3;1;1;1;1;1;1;1;1;1","A61P35/00;A61P43/00;C12Q1/6886;C12Q2600/106;G01N2474/20;A61K38/00;A61K38/06;A61K38/07;A61K45/06;A61K51/0491","5;3;3;3;3;1;1;1;1;1",59,5.54,282.16,7.89,25,0.42,43.34,2,4,27,2,15,0,2,7,0,49,3,0,0,0,0,0,0,52,6,1,52,7,0,0,0,0,0,0,0,0,"Germany;United States;United Kingdom;Italy;Belgium;France;Japan;Switzerland;Denmark;Australia;Austria;Norway;Spain;Sweden","9;7;6;4;3;3;3;3;2;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;4205 NURSING;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;49 MATHEMATICAL SCIENCES;51 PHYSICAL SCIENCES;5105 MEDICAL AND BIOLOGICAL PHYSICS","57;41;33;4;3;3;3;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;DIGESTIVE DISEASES;PATIENT SAFETY;PREVENTION;ORPHAN DRUG;DENTAL/ORAL AND CRANIOFACIAL DISEASE;GENETICS;LUNG;PEDIATRIC;LUNG CANCER;NEUROSCIENCES;NUTRITION;HEMATOLOGY;LYMPHOMA;PANCREATIC CANCER;PEDIATRIC CANCER;BIOMEDICAL IMAGING","51;46;41;21;15;11;9;7;5;5;5;5;4;4;4;3;3;3;3;2","CANCER;ORAL AND GASTROINTESTINAL;NEUROLOGICAL;RENAL AND UROGENITAL;RESPIRATORY;SKIN","39;2;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS","39;7;5;4;1;1;1;1","LUNG CANCER;NOT SITE-SPECIFIC CANCER;PANCREATIC CANCER;SALIVARY GLAND CANCER;COLON AND RECTAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;KIDNEY CANCER;SARCOMA;STOMACH CANCER;BRAIN TUMOR;BREAST CANCER;HEAD AND NECK CANCER;LIVER CANCER;NON-HODGKIN'S LYMPHOMA;ORAL CAVITY AND LIP CANCER;OVARIAN CANCER;PHARYNGEAL CANCER;PROSTATE CANCER;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;CERVICAL CANCER","6;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.1 LOCALIZED THERAPIES - DISCOVERY AND DEVELOPMENT;1.4 CANCER PROGRESSION AND METASTASIS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;2.2 ENDOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","26;5;4;3;3;2;1;1;1;1;1",1,2987794,298779.4,5,10,5,1,40,1085538.11936974,0.609835793131205,"AGENCIA DE SALUD PÚBLICA DE BARCELONA;EUROPEAN NETWORK FOR SMOKING AND TOBACCO PREVENTION;FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;HOSPITAL UNIVERSITARIO DE LA PRINCESA;INSTITUT CATALÀ D'ONCOLOGIA;MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH;POLYTECHNIC UNIVERSITY OF CARTAGENA;TOBACCOFREE RESEARCH INSTITUTE;UNIVERSITY OF ABERDEEN;UNIVERSITY OF STIRLING","1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-HCO-2015 (CALL FOR PROPOSAL);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;4206 PUBLIC HEALTH","1;1;1","CANCER;HEALTH EFFECTS OF INDOOR AIR POLLUTION;LUNG;LUNG CANCER;PREVENTION;TOBACCO;TOBACCO SMOKE AND HEALTH","1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;RESPIRATORY","1;1;1","3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING","1","ESOPHAGEAL / OESOPHAGEAL CANCER;LUNG CANCER","1;1","2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;3.1 INTERVENTIONS TO PREVENT CANCER: PERSONAL BEHAVIORS THAT AFFECT CANCER RISK","1;1","A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE","1","3 GOOD HEALTH AND WELL BEING","1",42,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;TAYLOR & FRANCIS GROUP","22;11;8;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3105 GENETICS;4203 HEALTH SERVICES AND SYSTEMS;3210 NUTRITION AND DIETETICS;4206 PUBLIC HEALTH;46 INFORMATION AND COMPUTING SCIENCES;3204 IMMUNOLOGY;34 CHEMICAL SCIENCES;49 MATHEMATICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;4601 APPLIED COMPUTING;47 LANGUAGE, COMMUNICATION AND CULTURE;4905 STATISTICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES","54;28;25;17;10;9;6;4;4;3;3;3;2;2;2;2;2;2;1;1","CANCER;PREVENTION;GENETICS;BREAST CANCER;NUTRITION;CLINICAL RESEARCH;AGING;BIOTECHNOLOGY;RARE DISEASES;HEMATOLOGY;HUMAN GENOME;CARDIOVASCULAR;LYMPHOMA;STEM CELL RESEARCH;SUBSTANCE MISUSE;ACQUIRED COGNITIVE IMPAIRMENT;ATHEROSCLEROSIS;BRAIN DISORDERS;CHILDHOOD LEUKEMIA;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES","18;14;12;11;10;9;7;4;4;3;3;2;2;2;2;1;1;1;1;1","CANCER;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;STROKE","21;3;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES","7;4;2;1;1;1;1","BIOMEDICAL;POPULATION & SOCIETY;CLINICAL","7;4;2","PUBLIC HEALTH;CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","11;10;7","BREAST CANCER;LEUKEMIA / LEUKAEMIA;OVARIAN CANCER;COLON AND RECTAL CANCER;NOT SITE-SPECIFIC CANCER;HEAD AND NECK CANCER;KIDNEY CANCER;LARYNGEAL CANCER;LUNG CANCER;MELANOMA;NON-HODGKIN'S LYMPHOMA;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER","14;4;3;2;2;1;1;1;1;1;1;1;1","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_TUMORIMILAN",2016,756,18.1931216931217,4.23280423280423,0.382275132275132,0.362433862433862,0.503968253968254,3.61990950226244,1.55376344086022,2.40350877192982,1.61440677966102,0.571428571428571,5,531,121,44,24,0.7,0.16,0.06,0.03,54.87,1.68903925939982,7.34597670008126,0.542328042328042,0.878306878306878,0.554,0.541,0.522,0.513,"FILIPPO DE BRAUD;MAURA MASSIMINO;ANDREA NECCHI;­ROSARIO ­TUMINO;R. VALDAGNI;LISA LICITRA;ANTONIA TRICHOPOULOU;ELIO RÍBOLI;E. PIGNOLI;GIUSEPPE PROCOPIO;ALESSANDRO GRONCHI;FILIPPO PIETRANTONIO;ANNE TJØNNELAND;ELISABETE WEIDERPASS;VITTORIO KROGH;HEINER BOEING;DOMENICO PALLI;MARIA DI BARTOLOMEO;T. RANCATI;PAOLO CORRADINI","77;44;39;37;31;30;30;30;30;29;28;27;27;25;25;24;24;24;23;23","FILIPPO DE BRAUD;MAURA MASSIMINO;E. PIGNOLI;ANDREA NECCHI;UGO PASTORINO;R. VALDAGNI;LISA LICITRA;PAOLA PEREGO;ALESSANDRO GRONCHI;DOMENICA LORUSSO;PAOLO BOSSI;VINCENZO MAZZAFERRO;GIUSEPPE PROCOPIO;GABRIELLA SOZZI;T. RANCATI;NADIA ZAFFARONI;DANIELE RAGGI;PATRIZIA GIANNATEMPO;FILIPPO PIETRANTONIO;ELDA TAGLIABUE","5.63;4.52;2.9;2.81;2.45;2.44;2.41;2.35;2.16;2.07;2.02;2.01;1.94;1.9;1.86;1.83;1.82;1.82;1.82;1.75","FILIPPO DE BRAUD;MAURA MASSIMINO;ANDREA NECCHI;R. VALDAGNI;LISA LICITRA;E. PIGNOLI;GIUSEPPE PROCOPIO;ALESSANDRO GRONCHI;FILIPPO PIETRANTONIO;VITTORIO KROGH;MARIA DI BARTOLOMEO;T. RANCATI;PAOLO CORRADINI;MASSIMO MILIONE;PAOLO BOSSI;DANIELE RAGGI;SILVIA STACCHIOTTI;VINCENZO MAZZAFERRO;PATRIZIA GIANNATEMPO;LUIGI MARIANI","77;44;39;31;30;30;29;28;27;25;24;23;23;22;22;22;22;22;22;22","FILIPPO DE BRAUD;MAURA MASSIMINO;E. PIGNOLI;ANDREA NECCHI;UGO PASTORINO;R. VALDAGNI;LISA LICITRA;PAOLA PEREGO;ALESSANDRO GRONCHI;DOMENICA LORUSSO;PAOLO BOSSI;VINCENZO MAZZAFERRO;GIUSEPPE PROCOPIO;GABRIELLA SOZZI;T. RANCATI;NADIA ZAFFARONI;DANIELE RAGGI;PATRIZIA GIANNATEMPO;FILIPPO PIETRANTONIO;ELDA TAGLIABUE","5.63;4.52;2.9;2.81;2.45;2.44;2.41;2.35;2.16;2.07;2.02;2.01;1.94;1.9;1.86;1.83;1.82;1.82;1.82;1.75","JONATHAN E. ROSENBERG;ANDREA NECCHI;YOHANN LORIOT;JOSÉ LUIS PÉREZ‐GRACIA;SANJEEV MARIATHASAN;JOAQUIM BELLMUNT;MARGITTA RETZ;RICHARD W. JOSEPH;OYEWALE O. ABIDOYE;DANIEL P. PETRYLAK;DEAN F. BAJORIN;ARJUN VASANT BALAR;PETROS GRIVAS;RICHARD BOURGON;JEAN H. HOFFMAN-CENSITS;NANCY A. DAWSON;SANDY SRINIVAS;MATTHEW D. GALSKY;GREGG FINE;MICHIEL S. VAN DER HEIJDEN","5998;5559;5311;5297;5289;5284;5281;5256;5238;5237;5232;5225;5220;5220;5215;5215;5215;5201;5179;5179","ANDREA NECCHI;LISA LICITRA;NICCOLÒ BOLLI;FILIPPO DE BRAUD;MARINA CHIARA GARASSINO;DOMENICA LORUSSO;VITTORIO KROGH;PAOLO RADICE;ALESSANDRO GRONCHI;VINCENZO MAZZAFERRO;LUIGI MARIANI;SILVIA STACCHIOTTI;R. VALDAGNI;FILIPPO PIETRANTONIO;MAURA MASSIMINO;ROSALBA MICELI;GIULIA BIANCHI;ANDREA FERRARI;PAOLO G. CASALI;CARLO SPOSITO","5559;4769;3579;3428;2955;2562;2164;1313;1192;1149;1016;944;883;858;849;845;781;779;768;737","FILIPPO DE BRAUD;MAURA MASSIMINO;ANDREA NECCHI;R. VALDAGNI;LISA LICITRA;GIUSEPPE PROCOPIO;E. PIGNOLI;ALESSANDRO GRONCHI;FILIPPO PIETRANTONIO;VITTORIO KROGH;MARIA DI BARTOLOMEO;T. RANCATI;VINCENZO MAZZAFERRO;DANIELE RAGGI;PAOLO CORRADINI;PATRIZIA GIANNATEMPO;LUIGI MARIANI;PAOLO BOSSI;SILVIA STACCHIOTTI;ANDREA FERRARI","74;44;39;31;30;29;29;26;26;25;23;23;22;22;22;22;22;21;21;21","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;SOCIOLOGY;PSYCHOLOGY;ENGINEERING;MATERIALS SCIENCE;MATHEMATICS;ECONOMICS;POLITICAL SCIENCE;ART;PHILOSOPHY;ENVIRONMENTAL SCIENCE;BUSINESS;GEOGRAPHY;GEOLOGY;HISTORY","698;223;78;69;42;31;23;19;16;15;12;8;7;6;5;4;4;2;2","INTERNAL MEDICINE;ONCOLOGY;SURGERY;PATHOLOGY;CANCER RESEARCH;GENETICS;GASTROENTEROLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;RADIOLOGY;NUCLEAR MEDICINE;UROLOGY;IMMUNOLOGY;PALEONTOLOGY;OPTICS;ENDOCRINOLOGY;NURSING;MEDICAL PHYSICS;CELL BIOLOGY;GYNECOLOGY","588;379;204;152;146;131;118;87;87;63;55;54;49;44;39;34;30;29;28;26","CANCER;CHEMOTHERAPY;GENE;CLINICAL TRIAL;CONFIDENCE INTERVAL;POPULATION;RADIATION THERAPY;ADVERSE EFFECT;COHORT;RANDOMIZED CONTROLLED TRIAL;LUNG CANCER;PROPORTIONAL HAZARDS MODEL;PROSPECTIVE COHORT STUDY;SARCOMA;INCIDENCE (GEOMETRY);IMMUNOHISTOCHEMISTRY;COHORT STUDY;LYMPHOMA;STAGE (STRATIGRAPHY);TOXICITY","422;170;119;82;80;74;69;60;55;44;41;40;37;35;27;26;25;25;25;25","BREAST CANCER;CLINICAL ENDPOINT;COLORECTAL CANCER;IMMUNOTHERAPY;HAZARD RATIO;PROSTATE CANCER;PHASES OF CLINICAL RESEARCH;PROGRESSION-FREE SURVIVAL;MUTATION;CISPLATIN;METASTASIS;SOFT TISSUE SARCOMA;GENE EXPRESSION;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;HEAD AND NECK CANCER;PROSTATE;OVARIAN CANCER;BEVACIZUMAB;SUNITINIB;CYCLOPHOSPHAMIDE","93;72;64;58;54;52;36;36;31;29;27;26;25;23;23;23;22;20;19;18","NIVOLUMAB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;KRAS;IPILIMUMAB;SINGLE-NUCLEOTIDE POLYMORPHISM;OXALIPLATIN;CARBOPLATIN;CETUXIMAB;UROTHELIAL CARCINOMA;IRINOTECAN;PAZOPANIB;ANDROGEN DEPRIVATION THERAPY;CAPECITABINE;TAXANE;IFOSFAMIDE;PEMBROLIZUMAB;TRASTUZUMAB;TRIPLE-NEGATIVE BREAST CANCER;ANDROGEN RECEPTOR;ANTHRACYCLINE;BRENTUXIMAB VEDOTIN;ESTROGEN RECEPTOR;FEBRILE NEUTROPENIA;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;NEOADJUVANT THERAPY;SANGER SEQUENCING;TRANSCRIPTOME","30;21;18;16;16;15;14;12;12;11;11;10;10;10;8;8;8;8;7;7;7;7;7;7;7;7;7",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ANTINEOPLASTIC AGENTS;BREAST NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;LUNG NEOPLASMS;NEOPLASMS;NEOPLASM RECURRENCE, LOCAL;ITALY;AGED, 80 AND OVER;PROSTATIC NEOPLASMS;TREATMENT OUTCOME;EUROPE;PROGNOSIS;RETROSPECTIVE STUDIES","377;375;278;234;200;176;160;119;101;95;91;77;73;69;67;62;61;59;59;58","SARCOMA RESEARCH AND TREATMENT;GLIOMAS;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;RADIOTHERAPY PHYSICS AND TECHNOLOGY;CANCER IMMUNOTHERAPY;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;PROSTATE CANCER RESEARCH AND TREATMENT;HEALTH EFFECTS OF AIR POLLUTION;RENAL CELL CARCINOMA;TESTICULAR GERM CELL TUMORS AND TREATMENT;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;LYMPHOID NEOPLASMS;ADVANCEMENTS IN LUNG CANCER RESEARCH;CANCER STEM CELLS AND TUMOR METASTASIS","30;26;25;20;19;18;17;17;16;15;15;14;13;13;11;11;11;11;10;9","CLINICAL ENDPOINT;BREAST CANCER;PROGRESSION-FREE SURVIVAL;SOFT TISSUE SARCOMA;REGIMEN;METASTATIC COLORECTAL CANCER;TREATMENT;CANCER RISK;TUMOR MICROENVIRONMENT;REFRACTORY (PLANETARY SCIENCE);CONCOMITANT;RADIOTHERAPY;BIOMARKERS FOR IMMUNOTHERAPY;EVEROLIMUS;INTENSITY-MODULATED RADIOTHERAPY;CANCER SUSCEPTIBILITY;CARBOPLATIN;NEOADJUVANT THERAPY;UNIVARIATE ANALYSIS;INTRATUMOR HETEROGENEITY","72;36;36;29;23;20;20;19;18;17;16;16;15;15;15;14;14;14;14;13","BREAST CANCER;PROSTATE CANCER;PATIENTS PTS;CELL CARCINOMA;COLORECTAL CANCER;LUNG CANCER;CANCER PATIENTS;PHASE II;PHASE III;SOFT TISSUE;SQUAMOUS CELL;UROTHELIAL CARCINOMA;CANCER RISK;OVARIAN CANCER;METASTATIC COLORECTAL;NEUROENDOCRINE TUMORS;METASTATIC UROTHELIAL;MULTIPLE MYELOMA;EUROPEAN PROSPECTIVE;CASTRATION-RESISTANT PROSTATE;CELL LUNG;GERM CELL;PATIENTS TREATED;PHASE STUDY;PHASE TRIAL;PROSPECTIVE INVESTIGATION;EPIC COHORT;CANCER MCRPC;CELL TUMORS;LOCALLY ADVANCED","62;40;35;29;29;27;26;21;20;20;18;17;16;16;14;14;13;13;12;11;11;11;11;11;11;11;10;9;9;9","BREAST CANCER;CANCER RISK;PUBMED SCOPUS;HR CI;ADVERSE EVENTS;PROGRESSION-FREE SURVIVAL;LUNG CANCER;CANCER PATIENTS;CROSSREF PUBMED;OVARIAN CANCER;SNP RS;ISTITUTO NAZIONALE;MEDIAN AGE;MEDIAN FOLLOW-UP;PROSTATE CANCER;SURVIVAL OS;PATIENTS PTS;RESPONSE RATE;CELL LINES;RISK FACTORS;MEDIAN OS;SURVIVAL PFS;DEI TUMORI;DISEASE PROGRESSION;STATISTICALLY SIGNIFICANT;NAZIONALE DEI;CANCER RESEARCH;COLORECTAL CANCER;MEDIAN PFS;MONTHS CI","214;79;67;61;59;53;49;48;48;47;46;42;42;41;40;40;39;38;37;37;36;35;34;34;34;33;32;32;32;31",302,0.4,10.01,10,2,2,1.75,7,7,0,1,11.75,1,1,8,1,3,2,3,6,3,0,0,93.75,94,6,0,3,1,0,4,0,0,1,0,0,0,5,4,0,30,6,1.69,2.66666666666667,1,8,7,2,1,2,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,2,0,1,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BELVISI LAURA;COSSU FEDERICA;DELIA DOMENICO;DRAGO CARMELO;LECIS DANIELE;MAIORANA STEFANO;MANZONI LEONARDO PIERPAOLO;MASTRANGELO ELOISE;MILANI DE MAYO DE MARI MARIO;PEREGO PAOLA MARIA CHIARA","3;3;3;3;3;3;3;3;3;3","FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;UNIVERSITA DEGLI STUDI DI MILANO;CISI SCRL;FONDAZIONE CARIPLO;GENOMIC HEALTH INC;FOND IRCCS ST NAZ DEI TUMORI;I-20133 MILANO ITALY);UNIVERSITY OF PENNSYLVANIA PENN","8;4;3;3;3;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;34 CHEMICAL SCIENCES;31 BIOLOGICAL SCIENCES;3402 INORGANIC CHEMISTRY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3215 REPRODUCTIVE MEDICINE","9;4;4;3;2;1;1","CANCER;GENETICS;BIOTECHNOLOGY;BREAST CANCER;OVARIAN CANCER;RARE DISEASES","4;2;1;1;1;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","2;2;1","A61K31/5517;A61P35/00;C07D487/04;C07K5/083;C12Q1/68;C07K5/103;A61K31/167;A61K35/14;A61K35/17;A61K39/00","3;3;3;3;3;2;1;1;1;1","A61P35/00;A61K38/00;A61K45/06;A61K38/06;A61K38/07;C07D519/00;C07K5/0804;C07K5/0806;C07K5/0808;C07K5/1005","6;4;4;3;3;3;3;3;3;3",59,5.76,1308.22,7,33,0.56,51.37,2,6,17,2,16,0,1,15,0,45,9,0,0,0,0,0,0,50,8,1,52,5,0,2,0,0,0,0,0,0,"United States;Germany;Italy;Netherlands;Canada;France;Japan;United Kingdom;Denmark;Austria;China;Spain;Thailand","15;5;5;5;4;3;3;3;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;31 BIOLOGICAL SCIENCES;3105 GENETICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;4205 NURSING;4206 PUBLIC HEALTH;50 PHILOSOPHY AND RELIGIOUS STUDIES;5002 HISTORY AND PHILOSOPHY OF SPECIFIC FIELDS;51 PHYSICAL SCIENCES;5105 MEDICAL AND BIOLOGICAL PHYSICS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","58;40;32;7;6;6;4;1;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;LUNG;LUNG CANCER;PATIENT SAFETY;HEMATOLOGY;BREAST CANCER;DIGESTIVE DISEASES;PEDIATRIC;KIDNEY DISEASE;LYMPHOMA;PREVENTION;ORPHAN DRUG;BEHAVIORAL AND SOCIAL SCIENCE;NUTRITION;BRAIN DISORDERS;CERVICAL CANCER;COLO-RECTAL CANCER","53;48;39;23;10;10;9;8;6;6;6;5;5;5;4;3;3;2;2;2","CANCER;CARDIOVASCULAR;RESPIRATORY;GENERIC HEALTH RELEVANCE;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;STROKE","38;2;2;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;6.4 SURGERY;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.1 INDIVIDUAL CARE NEEDS;7.3 MANAGEMENT AND DECISION MAKING","39;10;5;4;1;1;1;1;1","LUNG CANCER;KIDNEY CANCER;BREAST CANCER;LEUKEMIA / LEUKAEMIA;SARCOMA;NON-HODGKIN'S LYMPHOMA;MELANOMA;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;STOMACH CANCER;CERVICAL CANCER;COLON AND RECTAL CANCER;ENDOMETRIAL CANCER;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;BRAIN TUMOR;EAR CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;GENITAL SYSTEM, FEMALE;HEAD AND NECK CANCER;LARYNGEAL CANCER","11;7;6;5;5;4;3;3;3;3;2;2;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;3.1 INTERVENTIONS TO PREVENT CANCER: PERSONAL BEHAVIORS THAT AFFECT CANCER RISK;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","36;6;3;2;2;2;1;1;1",4,3949016.5,562946.13,5,13,6.75,1,30.5,1327888.17058475,0.569325050668301,"FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;MINISTRY OF HEALTH;AMSTERDAM UMC LOCATION VUMC;ANDALUSIAN SCHOOL OF PUBLIC HEALTH;ARISTOTLE UNIVERSITY OF THESSALONIKI;ATHENS TECHNOLOGY CENTER (GREECE);BABEȘ-BOLYAI UNIVERSITY;CANCER SOCIETY OF FINLAND;EUROPEAN ORGANISATION FOR RARE DISEASES;EUROPEAN SOCIETY FOR PAEDIATRIC ONCOLOGY;EVONIK (GERMANY);FRAUNHOFER SOCIETY;FRENCH NATIONAL CANCER INSTITUTE;FUNDACIÓN PARA EL FOMENTO DE LA INVESTIGACIÓN SANITARIA Y BIOMÉDICA DE LA COMUNITAT VALENCIANA;FUNDACIÓN PARA LA FORMACIÓN E INVESTIGACIÓN SANITARIAS DE LA REGIÓN DE MURCIA;GERMAN CANCER SOCIETY;HEALTH SERVICE EXECUTIVE;HEINRICH HEINE UNIVERSITY DÜSSELDORF;HOSPITAL OF LITHUANIAN UNIVERSITY OF HEALTH SCIENCES KAUNAS CLINICS;HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO","4;3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;EUROPEAN RESEARCH COUNCIL","3;1","EC & ERC - EUROPEAN UNION;COALITION S","4;3","RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME);3RD HEALTH PROGRAMME (PROGRAMME);ERC-2015-STG (CALL FOR PROPOSAL);ERC-STG - STARTING GRANT (FUNDING SCHEME);H2020-EU.1.1. - EXCELLENT SCIENCE - EUROPEAN RESEARCH COUNCIL (ERC) (PROGRAMME);H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - LEADERSHIP IN ENABLING AND INDUSTRIAL TECHNOLOGIES – NANOTECHNOLOGIES (PROGRAMME);H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-NMP-2015-TWO-STAGE (CALL FOR PROPOSAL);H2020-PHC-2015-SINGLE-STAGE (CALL FOR PROPOSAL)","2;1;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3204 IMMUNOLOGY;4203 HEALTH SERVICES AND SYSTEMS","4;3;2;1;1","CANCER;RARE DISEASES;BIOENGINEERING;CLINICAL RESEARCH;DENTAL/ORAL AND CRANIOFACIAL DISEASE;HEALTH SERVICES;IMMUNIZATION;NANOTECHNOLOGY;NETWORKING AND INFORMATION TECHNOLOGY R&D (NITRD);ORPHAN DRUG;PREVENTION;VACCINE RELATED","3;2;1;1;1;1;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE","3;1","5.1 PHARMACEUTICALS;6.9 RESOURCES AND INFRASTRUCTURE (TREATMENT EVALUATION);7.3 MANAGEMENT AND DECISION MAKING","1;1;1","NOT SITE-SPECIFIC CANCER;HEAD AND NECK CANCER;ORAL CAVITY AND LIP CANCER;OVARIAN CANCER;PHARYNGEAL CANCER","2;1;1;1;1","4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.1 LOCALIZED THERAPIES - DISCOVERY AND DEVELOPMENT;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","1;1;1","A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;A01 CLINICAL MEDICINE;B08 CHEMISTRY","2;1;1","3 GOOD HEALTH AND WELL BEING;10 REDUCED INEQUALITIES","3;1",57,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;AMERICAN CHEMICAL SOCIETY;TAYLOR & FRANCIS GROUP","44;8;3;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3105 GENETICS;4202 EPIDEMIOLOGY;3202 CLINICAL SCIENCES;4206 PUBLIC HEALTH;4203 HEALTH SERVICES AND SYSTEMS;49 MATHEMATICAL SCIENCES;3210 NUTRITION AND DIETETICS;34 CHEMICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3203 DENTISTRY;3215 REPRODUCTIVE MEDICINE;38 ECONOMICS;3801 APPLIED ECONOMICS","56;31;27;16;13;11;8;6;5;4;3;3;2;2;1;1;1;1;1","CANCER;PREVENTION;DIGESTIVE DISEASES;GENETICS;CLINICAL RESEARCH;COLO-RECTAL CANCER;HUMAN GENOME;NUTRITION;BREAST CANCER;DIABETES;GENETIC TESTING;RARE DISEASES;CARDIOVASCULAR;OBESITY;BIOTECHNOLOGY;PANCREATIC CANCER;AGING;AUTOIMMUNE DISEASE;CERVICAL CANCER;HEART DISEASE","20;13;12;12;11;10;9;6;5;5;5;5;3;3;2;2;1;1;1;1","CANCER;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;RESPIRATORY;REPRODUCTIVE HEALTH AND CHILDBIRTH;STROKE","21;5;4;2;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.4 POPULATION SCREENING;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);5.1 PHARMACEUTICALS;5.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","15;2;2;1;1;1;1;1","CLINICAL;BIOMEDICAL;POPULATION & SOCIETY","6;5;2","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH;BASIC SCIENCE","21;11;8","COLON AND RECTAL CANCER;BREAST CANCER;LUNG CANCER;NOT SITE-SPECIFIC CANCER;PANCREATIC CANCER;BRAIN TUMOR;CERVICAL CANCER;GENITAL SYSTEM, FEMALE;HEAD AND NECK CANCER;KIDNEY CANCER;LARYNGEAL CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER","10;6;6;2;2;1;1;1;1;1;1;1;1;1",NA,NA
"IRCCS_TUMORIMILAN",2017,791,18.5891276864728,4.16687737041719,0.370417193426043,0.331226295828066,0.47787610619469,3.50265674814028,1.71345029239766,2.29824561403509,1.6875,0.623261694058154,4,524,124,70,16,0.66,0.16,0.09,0.02,46.75,1.58620639956075,7.9589627391742,0.549936788874842,0.893805309734513,0.587,0.507,0.502,0.49,"FILIPPO DE BRAUD;ANDREA NECCHI;LISA LICITRA;­ROSARIO ­TUMINO;ANNE TJØNNELAND;GIUSEPPE PROCOPIO;ANTONIA TRICHOPOULOU;FILIPPO PIETRANTONIO;DOMENICO PALLI;KIM OVERVAD;PAOLO G. CASALI;HEINER BOEING;PAOLO CORRADINI;ALESSANDRO GRONCHI;SALVATORE PANICO;DOMENICA LORUSSO;ELISABETE WEIDERPASS;FEDERICA PERRONE;KAY‐TEE KHAW;DANIELE RAGGI","61;55;48;45;36;35;35;35;32;31;31;30;28;28;27;27;27;26;26;26","ANDREA NECCHI;FILIPPO DE BRAUD;LISA LICITRA;MAURA MASSIMINO;GIUSEPPE PROCOPIO;DOMENICA LORUSSO;PATRIZIA GIANNATEMPO;LAURA D. LOCATI;DANIELE RAGGI;UGO PASTORINO;ALESSANDRO GRONCHI;PAOLO G. CASALI;FILIPPO PIETRANTONIO;LARRY JUNCK;ELENA TAMBORINI;SILVIA STACCHIOTTI;PAOLO GRASSI;LUIGI MARIANI;ELENA VERZONI;PAOLO CORRADINI","5;4.5;4.28;3.53;2.97;2.75;2.38;2.25;2.23;2.21;2.17;2.16;2.11;2;1.99;1.91;1.85;1.8;1.77;1.74","FILIPPO DE BRAUD;ANDREA NECCHI;LISA LICITRA;GIUSEPPE PROCOPIO;FILIPPO PIETRANTONIO;PAOLO G. CASALI;PAOLO CORRADINI;ALESSANDRO GRONCHI;DOMENICA LORUSSO;FEDERICA PERRONE;DANIELE RAGGI;SILVIA STACCHIOTTI;PATRIZIA GIANNATEMPO;LUIGI MARIANI;LAURA D. LOCATI;UGO PASTORINO;ROBERTO SALVIONI;VITTORIO KROGH;MAURA MASSIMINO;FEDERICA MORANO","61;55;48;35;35;31;28;28;27;26;26;26;26;25;23;23;23;23;23;21","ANDREA NECCHI;FILIPPO DE BRAUD;LISA LICITRA;MAURA MASSIMINO;GIUSEPPE PROCOPIO;DOMENICA LORUSSO;PATRIZIA GIANNATEMPO;LAURA D. LOCATI;DANIELE RAGGI;UGO PASTORINO;ALESSANDRO GRONCHI;PAOLO G. CASALI;FILIPPO PIETRANTONIO;ELENA TAMBORINI;SILVIA STACCHIOTTI;PAOLO GRASSI;LUIGI MARIANI;ELENA VERZONI;PAOLO CORRADINI;FEDERICA PERRONE","5;4.5;4.28;3.53;2.97;2.75;2.38;2.25;2.23;2.21;2.17;2.16;2.11;1.99;1.91;1.85;1.8;1.77;1.74;1.74","ANDREA NECCHI;CORA N. STERNBERG;DANIEL P. PETRYLAK;HOWARD GURNEY;DOMENICA LORUSSO;RONALD DE WIT;STÉPHANE CULINE;JAE‐LYUN LEE;JOAQUIM BELLMUNT;NICOLETTA COLOMBO;DEAN F. BAJORIN;TONI K. CHOUEIRI;DAVID I. QUINN;DAVID J. VAUGHN;LAWRENCE FONG;NICHOLAS J. VOGELZANG;RODOLFO F. PERINI;WINALD R. GERRITSEN;YVES FRADET;YABING MAI","5602;3917;3314;3152;3134;3086;3086;3078;3033;2993;2929;2929;2926;2926;2926;2926;2926;2926;2926;2921","ANDREA NECCHI;DOMENICA LORUSSO;FILIPPO DE BRAUD;ETTORE SEREGNI;VINCENZO MAZZAFERRO;LAURENCE GLADIEFF;LAURIE ELIT;LUC DIRIX;OLIVIER TRÉDAN;RONNIE SHAPIRA‐FROMMER;TAMAR SAFRA;TANJA NEUNHÖFFER;LISA LICITRA;MAURA MASSIMINO;VITTORIO KROGH;MARIO SANTINAMI;FILIPPO PIETRANTONIO;ALESSANDRO GRONCHI;MICHELE DEL VECCHIO;SILVIA STACCHIOTTI","5568;3134;2720;2450;1630;1432;1432;1432;1432;1432;1432;1432;1391;1329;1271;1260;1233;1142;1104;1057","FILIPPO DE BRAUD;ANDREA NECCHI;LISA LICITRA;GIUSEPPE PROCOPIO;FILIPPO PIETRANTONIO;PAOLO G. CASALI;ALESSANDRO GRONCHI;DOMENICA LORUSSO;PATRIZIA GIANNATEMPO;DANIELE RAGGI;SILVIA STACCHIOTTI;FEDERICA PERRONE;ROBERTO SALVIONI;MAURA MASSIMINO;VITTORIO KROGH;LUIGI MARIANI;UGO PASTORINO;LAURA D. LOCATI;NICOLA NICOLAI;PAOLO CORRADINI","57;54;47;34;33;28;27;26;25;25;25;24;23;23;23;23;22;22;21;21","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;SOCIOLOGY;POLITICAL SCIENCE;PSYCHOLOGY;MATHEMATICS;PHILOSOPHY;ECONOMICS;BUSINESS;MATERIALS SCIENCE;GEOGRAPHY;ART;ENGINEERING;ENVIRONMENTAL SCIENCE;HISTORY;GEOLOGY","756;268;64;62;36;28;22;22;18;13;9;8;8;7;6;6;4;3;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;PATHOLOGY;GASTROENTEROLOGY;CANCER RESEARCH;GENETICS;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;IMMUNOLOGY;PALEONTOLOGY;UROLOGY;ENDOCRINOLOGY;CELL BIOLOGY;RADIOLOGY;NURSING;OPTICS;NUCLEAR MEDICINE;FAMILY MEDICINE;DEMOGRAPHY","672;451;221;167;137;132;111;96;93;63;61;53;41;40;33;29;29;26;22;21","CANCER;CHEMOTHERAPY;GENE;CLINICAL TRIAL;POPULATION;ADVERSE EFFECT;CONFIDENCE INTERVAL;RADIATION THERAPY;COHORT;LUNG CANCER;RANDOMIZED CONTROLLED TRIAL;PROPORTIONAL HAZARDS MODEL;SARCOMA;PROSPECTIVE COHORT STUDY;STAGE (STRATIGRAPHY);IMMUNE SYSTEM;REGIMEN;TRANSPLANTATION;LYMPHOMA;ALTERNATIVE MEDICINE;RECEPTOR;RENAL CELL CARCINOMA","469;208;112;106;80;77;77;57;56;50;49;47;46;43;42;32;32;30;29;27;27;27","CLINICAL ENDPOINT;BREAST CANCER;IMMUNOTHERAPY;COLORECTAL CANCER;HAZARD RATIO;PHASES OF CLINICAL RESEARCH;PROGRESSION-FREE SURVIVAL;PROSTATE CANCER;CISPLATIN;OVARIAN CANCER;PROGRESSIVE DISEASE;DOCETAXEL;HEAD AND NECK CANCER;BLADDER CANCER;SOFT TISSUE SARCOMA;SUNITINIB;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;GENE EXPRESSION;CYCLOPHOSPHAMIDE;METASTASIS","97;85;78;74;56;51;46;38;34;33;32;31;31;30;30;27;26;26;22;21","NIVOLUMAB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;PAZOPANIB;PEMBROLIZUMAB;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;KRAS;UROTHELIAL CARCINOMA;CETUXIMAB;TRASTUZUMAB;ANDROGEN RECEPTOR;IFOSFAMIDE;CARBOPLATIN;DNA METHYLATION;SINGLE-NUCLEOTIDE POLYMORPHISM;ANDROGEN DEPRIVATION THERAPY;ESTROGEN RECEPTOR;TRABECTEDIN;VEMURAFENIB;VINCRISTINE;METASTATIC BREAST CANCER;TAXANE","46;40;23;22;19;15;15;14;14;12;12;11;11;11;10;10;10;10;10;9;9",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;LUNG NEOPLASMS;ANTINEOPLASTIC AGENTS;NEOPLASMS;PROSPECTIVE STUDIES;NEOPLASM RECURRENCE, LOCAL;BIOMARKERS, TUMOR;ITALY;AGED, 80 AND OVER;PROGNOSIS;RISK FACTORS;TREATMENT OUTCOME","396;387;293;246;221;178;159;121;121;115;84;72;68;64;58;58;57;57;57;57","SARCOMA RESEARCH AND TREATMENT;CANCER IMMUNOTHERAPY;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;RENAL CELL CARCINOMA;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;LYMPHOID NEOPLASMS;GLIOMAS;TESTICULAR GERM CELL TUMORS AND TREATMENT;MOLECULAR RESEARCH ON BREAST CANCER;RADIOTHERAPY PHYSICS AND TECHNOLOGY;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GASTRIC CANCER RESEARCH AND TREATMENT;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;MICRORNA REGULATION IN CANCER AND DEVELOPMENT","41;40;36;22;20;19;19;16;15;15;14;12;11;11;10;9;9;9;9;9","CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;BREAST CANCER;REGIMEN;TUMOR MICROENVIRONMENT;TREATMENT;SOFT TISSUE SARCOMA;PAZOPANIB;NEOADJUVANT THERAPY;REFRACTORY (PLANETARY SCIENCE);TOLERABILITY;METASTATIC COLORECTAL CANCER;BIOMARKERS FOR IMMUNOTHERAPY;DISCONTINUATION;EXPANDED ACCESS;HEALTHY EATING INDEX;CANCER RISK;EVEROLIMUS;UNIVARIATE ANALYSIS;ATEZOLIZUMAB","98;47;32;32;32;28;27;23;20;20;20;19;16;16;16;16;15;15;13;12","CELL CARCINOMA;BREAST CANCER;LUNG CANCER;CANCER PATIENTS;SQUAMOUS CELL;COLORECTAL CANCER;PATIENTS PTS;PHASE II;PROSTATE CANCER;OVARIAN CANCER;RENAL CELL;UROTHELIAL CARCINOMA;LOCALLY ADVANCED;CANCER RISK;METASTATIC COLORECTAL;METASTATIC RENAL;EXPANDED ACCESS;PHASE STUDY;PHASE TRIAL;SOFT TISSUE;CELL LUNG;METASTATIC UROTHELIAL;PATIENTS TREATED;PHASE III;GASTRIC CANCER;PROSPECTIVE INVESTIGATION;CELL TUMORS;EUROPEAN PROSPECTIVE;GERM CELL;NEUROENDOCRINE TUMORS","57;49;35;33;31;29;27;26;26;24;24;22;21;19;19;19;18;15;15;15;14;14;13;13;12;12;11;11;11;11","BREAST CANCER;HR CI;PROGRESSION-FREE SURVIVAL;BRISTOL-MYERS SQUIBB;ADVERSE EVENTS;LUNG CANCER;SURVIVAL OS;MEDIAN FOLLOW-UP;ENTITY RESPONSIBLE;LEGAL ENTITY;ADVISORY BOARD;ISTITUTO NAZIONALE;RESPONSE RATE;CLINICAL TRIAL;CANCER RISK;PRIMARY ENDPOINT;OVARIAN CANCER;SURVIVAL PFS;PATIENTS PTS;MEDIAN OS;CONFIDENCE INTERVAL;PATIENTS TREATED;PROSTATE CANCER;DISEASE PROGRESSION;CANCER INSTITUTE;HAZARD RATIO;PATIENTS RECEIVED;IRCCS ISTITUTO;MEDIAN AGE;AIR POLLUTION","158;117;97;93;90;82;78;75;71;71;67;67;65;62;60;57;55;55;54;52;51;51;51;50;48;48;46;45;44;43",349,0.44,9.5,9,2,2,1,10.25,4,0,2,11,1,1,8,1,2.75,2,4,6,4,0,0,83,82,6,0,7,0,0,3,0,0,1,0,0,0,8,3,0,6,4.54545454545455,1.52,1.90909090909091,1,8,6,2,1,3,0,1,3,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,7,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"APPIERTO VALENTINA;DAIDONE MARIA GRAZIA;DALLAVALLE SABRINA;FIGINI MARIANGELA;MUSSO LOANA;NICCOLINI ELISA;TIBERIO PAOLA;CANEVARI SILVANA;CATTOZZO MARGHERITA;DI CIOCCIO VITO","4;4;4;4;4;4;4;2;2;2","FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;UNIVERSITA DEGLI STUDI DI MILANO;ADVANCED ACCELERATOR APPLICATIONS SA;FOND IRCCS ST NAZ DEI TUMORI;UNIVERSITY OF PENNSYLVANIA PENN;GENOMIC HEALTH INC","10;4;2;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;34 CHEMICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3402 INORGANIC CHEMISTRY;3204 IMMUNOLOGY;3215 REPRODUCTIVE MEDICINE","14;8;5;4;3;2","CANCER;RARE DISEASES;IMMUNIZATION;ORPHAN DRUG;OVARIAN CANCER;VACCINE RELATED;BIOTECHNOLOGY;GENETICS","5;4;2;2;2;2;1;1","5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.2 CELLULAR AND GENE THERAPIES","6;1;1","C07K16/28;A61K31/167;A61K45/06;C07C251/60;C07C403/20;C07K14/725;A61K35/17;A61K39/00;A61P35/00;A61P35/02","6;4;2;2;2;2;1;1;1;1","A61P35/00;A61P43/00;A61K31/167;A61K45/06;A61P35/02;A61P35/04;C07C251/60;C07C2601/16;C07C403/20;C07K16/28","9;6;4;4;4;4;4;4;4;4",69,5.17,346.65,8.6,41,0.59,60.2,5,3,25,2,22,0,2,10,0,59,4,0,0,0,0,0,0,58,7,4,63,6,0,0,0,0,0,0,0,0,"United States;United Kingdom;Germany;Switzerland;Australia;Japan;Belgium;Italy;Netherlands;Norway;Spain","21;4;3;3;2;2;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;3215 REPRODUCTIVE MEDICINE;4203 HEALTH SERVICES AND SYSTEMS;3203 DENTISTRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4205 NURSING;4206 PUBLIC HEALTH","67;50;43;5;4;4;3;3;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;PATIENT SAFETY;DIGESTIVE DISEASES;ORPHAN DRUG;DENTAL/ORAL AND CRANIOFACIAL DISEASE;HEMATOLOGY;BREAST CANCER;LUNG;LUNG CANCER;PREVENTION;UROLOGIC DISEASES;GENETICS;LYMPHOMA;PROSTATE CANCER;AGING;BIOENGINEERING;INFECTIOUS DISEASES","58;55;41;25;13;11;9;7;7;6;6;6;6;6;5;4;4;3;3;3","CANCER;ORAL AND GASTROINTESTINAL;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM","45;2;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY","53;9;7;2;1;1;1","LUNG CANCER;ORAL CAVITY AND LIP CANCER;BREAST CANCER;HEAD AND NECK CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER;NON-HODGKIN'S LYMPHOMA;PROSTATE CANCER;STOMACH CANCER;LARYNGEAL CANCER;CERVICAL CANCER;COLON AND RECTAL CANCER;KIDNEY CANCER;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;SARCOMA;BLADDER CANCER;EAR CANCER;MYELOMA;NASAL CAVITY AND PARANASAL SINUS CANCER","9;7;6;6;6;6;5;5;5;4;3;3;3;3;3;3;2;2;2;2","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;3.2 NUTRITIONAL SCIENCE IN CANCER PREVENTION;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;3.1 INTERVENTIONS TO PREVENT CANCER: PERSONAL BEHAVIORS THAT AFFECT CANCER RISK;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","37;5;5;2;2;2;1;1;1",6,2724171.33,166429.32,4.5,11.8333333333333,5.66666666666667,0.666666666666667,37.2,1441382.33452408,0.548778752905403,"FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;DÉLÉGATION PARIS 11;ERASMUS MC;GERMAN CANCER RESEARCH CENTER;MAASTRICHT UNIVERSITY;ACADEMIC MEDICAL CENTER;ALLEANZA CONTRO IL CANCRO;AMGEN (BELGIUM);ASTRAZENECA (SWEDEN);BAMBINO GESÙ CHILDREN'S HOSPITAL;BAYER (GERMANY);BIOBANKING AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE - ERIC;BRIDGEPOINT (UNITED KINGDOM);CAREERS RESEARCH AND ADVISORY CENTRE (UNITED KINGDOM);CATHOLIC UNIVERSITY OF THE SACRED HEART;CENTRE FOR GENOMIC REGULATION;CF CONSULTING FINANZIAMENTI UNIONE EUROPEA;CHARITÉ - UNIVERSITY MEDICINE BERLIN;CHARLES RIVER LABORATORIES (GERMANY);DEUTSCHES INSTITUT FÜR NORMUNG","6;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;CANCER RESEARCH UK;NATIONAL CANCER INSTITUTE","4;1;1","COALITION S;EC & ERC - EUROPEAN UNION;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;AMRC - ASSOCIATION OF MEDICAL RESEARCH CHARITIES;NIH - NATIONAL INSTITUTES OF HEALTH;US FEDERAL FUNDERS","4;4;2;1;1;1","H2020-EU.1.3. - EXCELLENT SCIENCE - MARIE SKŁODOWSKA-CURIE ACTIONS (PROGRAMME);H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);MSCA-ITN-ETN - EUROPEAN TRAINING NETWORKS (FUNDING SCHEME);CSA - COORDINATION AND SUPPORT ACTION (FUNDING SCHEME);H2020-JTI-IMI2-2015-07-TWO-STAGE (CALL FOR PROPOSAL);H2020-MSCA-ITN-2016 (CALL FOR PROPOSAL);H2020-MSCA-ITN-2017 (CALL FOR PROPOSAL);R AND D CONTRACTS (FUNDING MECHANISM);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","2;2;2;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3105 GENETICS;3202 CLINICAL SCIENCES;3209 NEUROSCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","3;2;1;1;1;1;1;1;1;1","CANCER;CLINICAL RESEARCH;GENETICS;PEDIATRIC;RARE DISEASES;BIOENGINEERING;BIOTECHNOLOGY;BRAIN CANCER;BRAIN DISORDERS;CHRONIC PAIN;HUMAN GENOME;NETWORKING AND INFORMATION TECHNOLOGY R&D (NITRD);NEURODEGENERATIVE;NEUROSCIENCES;ORPHAN DRUG;PAIN RESEARCH;PEDIATRIC CANCER;PEDIATRIC RESEARCH INITIATIVE;PERIPHERAL NEUROPATHY;PREVENTION","4;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE","3;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;2.4 SURVEILLANCE AND DISTRIBUTION;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);5.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS","2;2;1;1;1;1;1;1;1","NOT SITE-SPECIFIC CANCER;NON-HODGKIN'S LYMPHOMA","3;1","6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.9 RESOURCES AND INFRASTRUCTURE RELATED TO CANCER CONTROL, SURVIVORSHIP, AND OUTCOMES RESEARCH","2;1;1;1;1;1","A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;B11 COMPUTER SCIENCE AND INFORMATICS;C23 EDUCATION","2;1;1;1","3 GOOD HEALTH AND WELL BEING","2",40,"PUBLIC LIBRARY OF SCIENCE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;SPRINGER NATURE;AMERICAN CHEMICAL SOCIETY;KARGER PUBLISHERS;TAYLOR & FRANCIS GROUP;WILEY","25;6;4;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;3105 GENETICS;4202 EPIDEMIOLOGY;4206 PUBLIC HEALTH;49 MATHEMATICAL SCIENCES;3202 CLINICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3210 NUTRITION AND DIETETICS;4905 STATISTICS;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3003 ANIMAL PRODUCTION;3101 BIOCHEMISTRY AND CELL BIOLOGY;3103 ECOLOGY;3106 INDUSTRIAL BIOTECHNOLOGY;3207 MEDICAL MICROBIOLOGY;34 CHEMICAL SCIENCES","45;19;17;15;8;7;5;5;5;4;2;2;2;1;1;1;1;1;1;1","CANCER;GENETICS;CLINICAL RESEARCH;BREAST CANCER;PREVENTION;NEUROSCIENCES;NUTRITION;OBESITY;PATIENT SAFETY;AGING;BIOTECHNOLOGY;BRAIN DISORDERS;COLO-RECTAL CANCER;DIABETES;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;GENETIC TESTING;HEMATOLOGY;HIV/AIDS;INFECTIOUS DISEASES","7;5;4;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CANCER;METABOLIC AND ENDOCRINE;INFECTION;NEUROLOGICAL;ORAL AND GASTROINTESTINAL;STROKE","7;3;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","6;1;1;1;1","BIOMEDICAL;CLINICAL","6;3","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","9;8;1","NOT SITE-SPECIFIC CANCER;BREAST CANCER;SARCOMA;BRAIN TUMOR;BLOOD CANCER;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;KAPOSI'S SARCOMA;NON-HODGKIN'S LYMPHOMA;PROSTATE CANCER","5;4;4;2;1;1;1;1;1;1","3 GOOD HEALTH AND WELL BEING","5"
"IRCCS_TUMORIMILAN",2018,862,18.4941995359629,3.65197215777262,0.329466357308585,0.31322505800464,0.409512761020882,3.55191873589165,1.57777777777778,2.25,1.78282828282828,0.583526682134571,6,607,134,33,24,0.7,0.16,0.04,0.03,46.06,1.50976599344166,7.89650507328068,0.5707656612529,0.933874709976798,0.591,0.564,0.511,0.545,"FILIPPO DE BRAUD;ANDREA NECCHI;ALESSANDRO GRONCHI;­ROSARIO ­TUMINO;FILIPPO PIETRANTONIO;SILVIA STACCHIOTTI;MARINA CHIARA GARASSINO;LISA LICITRA;ANTONIA TRICHOPOULOU;SALVATORE PANICO;PAOLO G. CASALI;PAOLO CORRADINI;GIUSEPPE PROCOPIO;ELIO RÍBOLI;RUDOLF KAAKS;HEINER BOEING;VINCENZO MAZZAFERRO;MARIA DI BARTOLOMEO;ELISABETE WEIDERPASS;ANNE TJØNNELAND","64;57;44;41;40;39;39;38;32;31;30;30;30;30;29;29;29;29;29;27","ANDREA NECCHI;FILIPPO DE BRAUD;ALESSANDRO GRONCHI;GIANCARLO PRUNERI;MARINA CHIARA GARASSINO;LISA LICITRA;GIUSEPPE PROCOPIO;PAOLO BOSSI;SILVIA STACCHIOTTI;LUIGI MARIANI;PAOLO CORRADINI;FILIPPO PIETRANTONIO;VINCENZO MAZZAFERRO;PAOLA COLLINI;MAURA MASSIMINO;DOMENICA LORUSSO;PAOLO G. CASALI;ANDREA FERRARI;R. VALDAGNI;UGO PASTORINO","4.26;4.14;4;3.01;3.01;2.67;2.64;2.51;2.22;2.21;2.16;2.09;2.05;1.93;1.9;1.87;1.87;1.86;1.77;1.74","FILIPPO DE BRAUD;ANDREA NECCHI;ALESSANDRO GRONCHI;­ROSARIO ­TUMINO;FILIPPO PIETRANTONIO;SILVIA STACCHIOTTI;MARINA CHIARA GARASSINO;LISA LICITRA;PAOLO G. CASALI;PAOLO CORRADINI;GIUSEPPE PROCOPIO;VINCENZO MAZZAFERRO;MARIA DI BARTOLOMEO;LUIGI MARIANI;R. VALDAGNI;PAOLA COLLINI;VITTORIO KROGH;DOMENICA LORUSSO;MAURA MASSIMINO;MASSIMO MILIONE","64;57;44;41;40;39;39;38;30;30;30;29;29;26;25;25;23;22;22;21","ANDREA NECCHI;FILIPPO DE BRAUD;ALESSANDRO GRONCHI;GIANCARLO PRUNERI;MARINA CHIARA GARASSINO;LISA LICITRA;GIUSEPPE PROCOPIO;PAOLO BOSSI;SILVIA STACCHIOTTI;LUIGI MARIANI;PAOLO CORRADINI;FILIPPO PIETRANTONIO;VINCENZO MAZZAFERRO;PAOLA COLLINI;MAURA MASSIMINO;DOMENICA LORUSSO;PAOLO G. CASALI;ANDREA FERRARI;R. VALDAGNI;UGO PASTORINO","4.26;4.14;4;3.01;3.01;2.67;2.64;2.51;2.22;2.21;2.16;2.09;2.05;1.93;1.9;1.87;1.87;1.86;1.77;1.74","MARINA CHIARA GARASSINO;SILVIA NOVELLO;MARTIN RECK;JHANELLE E. GRAY;ENRIQUETA FELIP;MANUEL DÓMINE;FRANCESCO GROSSI;RINA HUI;EDWARD B. GARON;EMILIO ESTEBAN;M. CATHERINE PIETANZA;MAXIMILIAN J. HOCHMAIR;MICHAEL BOYER;NIR PELED;STEVEN POWELL;SUSANNA Y. CHENG;JING YANG;SHIRISH M. GADGEEL;LEENA GANDHI;DELVYS RODRÍGUEZ‐ABREU","7811;5785;5781;5760;5715;5702;5373;5347;5279;5279;5279;5279;5279;5279;5279;5279;5275;5274;5270;5269","MARINA CHIARA GARASSINO;LISA LICITRA;PAOLO G. CASALI;ALESSANDRO GRONCHI;SILVIA STACCHIOTTI;ANDREA FERRARI;ANNA MARIA FREZZA;VINCENZO MAZZAFERRO;GENNARO CILIBERTO;MARIA DI BARTOLOMEO;SABINA SIERI;FILIPPO DE BRAUD;SARA GRIONI;LICIA RIVOLTINI;VITTORIO KROGH;CARLA RIPAMONTI;SHERRIE BHOORI;FILIPPO PIETRANTONIO;ANDREA NECCHI;CLAUDIA AGNOLI","7811;3755;3553;3507;3504;2948;2768;2660;1652;1567;1479;1441;1343;1247;1179;1074;947;929;917;886","ANDREA NECCHI;FILIPPO DE BRAUD;ALESSANDRO GRONCHI;MARINA CHIARA GARASSINO;FILIPPO PIETRANTONIO;SILVIA STACCHIOTTI;LISA LICITRA;GIUSEPPE PROCOPIO;MARIA DI BARTOLOMEO;VINCENZO MAZZAFERRO;PAOLO G. CASALI;PAOLO CORRADINI;LUIGI MARIANI;PAOLA COLLINI;VITTORIO KROGH;DOMENICA LORUSSO;DANIELE RAGGI;ANDREA FERRARI;FEDERICA MORANO;MASSIMO MILIONE","57;55;44;41;40;39;38;30;29;29;29;27;26;25;23;21;20;20;20;20","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;SOCIOLOGY;PSYCHOLOGY;MATHEMATICS;POLITICAL SCIENCE;ECONOMICS;ENGINEERING;PHILOSOPHY;BUSINESS;MATERIALS SCIENCE;HISTORY;ART;GEOGRAPHY;GEOLOGY","810;283;59;52;40;30;24;23;21;12;11;10;9;7;4;3;3;2","INTERNAL MEDICINE;ONCOLOGY;SURGERY;PATHOLOGY;CANCER RESEARCH;GASTROENTEROLOGY;GENETICS;ENVIRONMENTAL HEALTH;IMMUNOLOGY;BIOCHEMISTRY;PALEONTOLOGY;UROLOGY;RADIOLOGY;NURSING;CELL BIOLOGY;NUCLEAR MEDICINE;ENDOCRINOLOGY;OPTICS;GYNECOLOGY;FAMILY MEDICINE","716;476;235;169;165;156;144;119;85;84;61;58;44;37;36;34;33;29;24;22","CANCER;CHEMOTHERAPY;GENE;CLINICAL TRIAL;POPULATION;ADVERSE EFFECT;CONFIDENCE INTERVAL;RADIATION THERAPY;COHORT;LUNG CANCER;RANDOMIZED CONTROLLED TRIAL;PROPORTIONAL HAZARDS MODEL;SARCOMA;IMMUNE SYSTEM;PROSPECTIVE COHORT STUDY;STAGE (STRATIGRAPHY);RETROSPECTIVE COHORT STUDY;REGIMEN;DISEASE;ALTERNATIVE MEDICINE;LYMPHOMA;TRANSPLANTATION","512;228;120;103;99;85;85;81;78;61;61;52;47;44;44;41;38;36;34;31;31;31","IMMUNOTHERAPY;BREAST CANCER;CLINICAL ENDPOINT;COLORECTAL CANCER;HAZARD RATIO;CISPLATIN;PHASES OF CLINICAL RESEARCH;PROGRESSION-FREE SURVIVAL;MUTATION;OVARIAN CANCER;BLADDER CANCER;PROSTATE CANCER;SOFT TISSUE SARCOMA;TOLERABILITY;PLACEBO;METASTASIS;PROGRESSIVE DISEASE;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;DOCETAXEL;GENE EXPRESSION","120;111;105;89;64;51;50;49;34;34;33;33;33;33;31;28;28;27;25;25","PEMBROLIZUMAB;NIVOLUMAB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;CARBOPLATIN;CETUXIMAB;KRAS;UROTHELIAL CARCINOMA;TRASTUZUMAB;CYSTECTOMY;IRINOTECAN;OXALIPLATIN;PAZOPANIB;CYTOREDUCTIVE SURGERY;ESTROGEN RECEPTOR;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;METASTATIC BREAST CANCER;NEOADJUVANT THERAPY;GERMLINE MUTATION;IFOSFAMIDE;TRABECTEDIN","54;37;27;26;23;23;18;17;15;15;14;14;13;13;13;13;12;10;10;10",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;LUNG NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;NEOPLASMS;ANTINEOPLASTIC AGENTS;NEOPLASM RECURRENCE, LOCAL;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;CARCINOMA, NON-SMALL-CELL LUNG;ADOLESCENT;PROGNOSIS;SARCOMA;EUROPE","433;422;333;275;242;196;186;133;117;110;95;91;86;82;82;76;74;74;74;73","CANCER IMMUNOTHERAPY;SARCOMA RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;LYMPHOID NEOPLASMS;MANAGEMENT OF PERITONEAL CARCINOMATOSIS FROM DIGESTIVE TRACT;RENAL CELL CARCINOMA;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;NEUROBLASTOMA RESEARCH AND TREATMENT;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GLIOMAS;HEPATOCELLULAR CARCINOMA;HER2 SIGNALING IN BREAST CANCER TREATMENT;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;MOLECULAR RESEARCH ON BREAST CANCER;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA","58;48;42;26;18;17;17;16;14;13;13;13;11;11;11;11;11;11;10;9","CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;SOFT TISSUE SARCOMA;REGIMEN;TOLERABILITY;TREATMENT;BREAST CANCER;CARBOPLATIN;NEOADJUVANT THERAPY;RADIOTHERAPY;TUMOR MICROENVIRONMENT;METASTATIC COLORECTAL CANCER;BIOMARKERS FOR IMMUNOTHERAPY;REFRACTORY (PLANETARY SCIENCE);DISCONTINUATION;BIOMARKER ANALYSIS;HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY;UNIVARIATE ANALYSIS;METASTATIC UROTHELIAL CARCINOMA;NOMOGRAM","105;48;39;36;33;32;27;26;24;24;24;23;22;19;18;16;16;16;15;15","BREAST CANCER;PATIENTS PTS;CELL CARCINOMA;COLORECTAL CANCER;CANCER PATIENTS;PHASE II;LUNG CANCER;PROSTATE CANCER;SOFT TISSUE;METASTATIC COLORECTAL;PHASE STUDY;SQUAMOUS CELL;UROTHELIAL CARCINOMA;RENAL CELL;PHASE III;PATIENTS TREATED;PHASE TRIAL;CELL LUNG;LOCALLY ADVANCED;TISSUE SARCOMA;II STUDY;OVARIAN CANCER;EUROPEAN PROSPECTIVE;GROWTH FACTOR;NON-SMALL CELL;PEMBROLIZUMAB PEMBRO;PROSPECTIVE INVESTIGATION;CANCER RISK;METASTATIC RENAL;MULTICENTER STUDY","64;44;42;41;37;37;32;25;25;24;21;21;21;20;19;18;17;16;16;16;14;14;13;13;13;13;13;12;12;12","PUBMED SCOPUS;RESEARCH FUNDING;CROSSREF PUBMED;ADVISORY BOARD;BRISTOL-MYERS SQUIBB;ADVISORY COMMITTEES;ENTITYS BOARD;BREAST CANCER;LUNG CANCER;HR CI;SPEAKERS BUREAU;ENTITY RESPONSIBLE;LEGAL ENTITY;PROGRESSION-FREE SURVIVAL;CLIN ONCOL;RESPONSE RATE;ADVERSE EVENTS;CLINICAL TRIAL;PERSONAL FEES;CANCER PATIENTS;PATIENTS TREATED;SURVIVAL OS;HONORARIA MEMBERSHIP;CONFIDENCE INTERVAL;ONCOL -CROSSREF;MEDIAN FOLLOW-UP;ADVISORY ROLE;NOVARTIS PFIZER;SOFT TISSUE;CANCER RISK","282;193;191;146;126;116;113;110;100;86;80;78;78;74;71;70;69;67;67;66;62;62;59;58;56;53;51;51;51;48",389,0.45,13.45,14,2,2.5,1,4,2,1,1,17,1,1,13.75,2,1.5,2,5,9,5,0,0,80,80,4,0,6,0,0,5,0,0,0,0,0,0,6,5,0,1.5,4,1.4,1.18181818181818,2,2,5,1,0,4,0,1,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5,1,0,2,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"DI NICOLA MASSIMO;FIGINI MARIANGELA;GIANNI ALESSANDRO MASSIMO;SATTA ALESSANDRO;APPIERTO VALENTINA;DAIDONE MARIA GRAZIA;DALLAVALLE SABRINA;MUSSO LOANA;NICCOLINI ELISA;TIBERIO PAOLA","4;4;4;4;3;3;3;3;3;3","FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;UNIVERSITA DEGLI STUDI DI MILANO","11;2","32 BIOMEDICAL AND CLINICAL SCIENCES;34 CHEMICAL SCIENCES;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3402 INORGANIC CHEMISTRY;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;3215 REPRODUCTIVE MEDICINE","12;6;4;4;2;2;1","CANCER;IMMUNIZATION;VACCINE RELATED;BIOTECHNOLOGY;ORPHAN DRUG;RARE DISEASES;BIOENGINEERING","5;4;4;3;3;3;1","5.1 PHARMACEUTICALS","4","C07K16/28;A61K31/167;A61K39/395;A61K45/06;A61K9/70;C07C251/60;C07K16/40;A61K31/15;A61P35/00;C07C251/50","4;3;2;2;2;2;2;1;1;1","A61P35/00;A61K2039/505;A61K39/39558;C07K2317/56;A61K45/06;A61P1/00;A61P1/16;A61P11/00;A61P13/08;A61P15/00","11;6;6;6;5;4;4;4;4;4",74,5.3,453.62,9.45,40,0.54,57.92,3,2,38,1,18,0,0,12,0,56,10,0,0,0,0,0,0,62,12,0,66,8,0,0,0,0,0,0,0,0,"United States;Japan;United Kingdom;Germany;Italy;Switzerland;Belgium;France;Netherlands;Taiwan","25;8;6;5;5;3;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;3105 GENETICS;3215 REPRODUCTIVE MEDICINE;4205 NURSING;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","73;63;29;12;5;3;2;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;PATIENT SAFETY;BIOTECHNOLOGY;LUNG;BREAST CANCER;GENETICS;LUNG CANCER;ORPHAN DRUG;OVARIAN CANCER;DIGESTIVE DISEASES;HEMATOLOGY;KIDNEY DISEASE;PREVENTION;PEDIATRIC;BRAIN DISORDERS;DENTAL/ORAL AND CRANIOFACIAL DISEASE;IMMUNIZATION","61;60;48;19;8;7;7;6;6;6;6;6;5;5;5;5;4;3;3;3","CANCER;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM","53;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","56;12;11;2;1;1","LUNG CANCER;BREAST CANCER;KIDNEY CANCER;MELANOMA;OVARIAN CANCER;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;BLADDER CANCER;SARCOMA;CERVICAL CANCER;ENDOMETRIAL CANCER;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;COLON AND RECTAL CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;LEUKEMIA / LEUKAEMIA;SALIVARY GLAND CANCER;SKIN CANCER;STOMACH CANCER;MYELOMA","7;6;6;6;6;5;5;4;4;3;3;2;2;2;2;2;2;2;2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;1.4 CANCER PROGRESSION AND METASTASIS;2.2 ENDOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;3.3 CHEMOPREVENTION;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","46;11;2;2;1;1;1;1",1,22174,22174,2,1,1,0,0,1202575.65952408,0.716794817168627,"FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI","1","NATIONAL CANCER INSTITUTE","1","ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;NIH - NATIONAL INSTITUTES OF HEALTH;US FEDERAL FUNDERS","1;1;1","R AND D CONTRACTS (FUNDING MECHANISM)","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1;1","CANCER;CLINICAL RESEARCH;COLO-RECTAL CANCER;DIGESTIVE DISEASES;PATIENT SAFETY;PREVENTION","1;1;1;1;1;1","CANCER","1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1","COLON AND RECTAL CANCER;NOT SITE-SPECIFIC CANCER","1;1","6.2 SURVEILLANCE","1","A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE","1",NA,NA,55,"SPRINGER NATURE;PUBLIC LIBRARY OF SCIENCE;AMERICAN CHEMICAL SOCIETY;AMERICAN ASSOCIATION FOR CANCER RESEARCH;FRONTIERS;KARGER PUBLISHERS;MENDELEY DATA;SAGE JOURNALS","17;14;11;5;5;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;34 CHEMICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3204 IMMUNOLOGY;3202 CLINICAL SCIENCES;47 LANGUAGE, COMMUNICATION AND CULTURE;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;42 HEALTH SCIENCES;3105 GENETICS;4702 CULTURAL STUDIES;3103 ECOLOGY;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;3210 NUTRITION AND DIETETICS;3401 ANALYTICAL CHEMISTRY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3506 MARKETING;4202 EPIDEMIOLOGY","65;23;22;21;10;7;7;6;6;5;4;2;2;1;1;1;1;1;1;1","CANCER;RARE DISEASES;BIOTECHNOLOGY;BREAST CANCER;CLINICAL RESEARCH;IMMUNIZATION;VACCINE RELATED;DIGESTIVE DISEASES;GENETICS;NUTRITION;UROLOGIC DISEASES;COLO-RECTAL CANCER;LUNG;LUNG CANCER;PEDIATRIC;PREVENTION;PROSTATE CANCER","27;6;4;4;4;4;4;3;2;2;2;1;1;1;1;1;1","CANCER;INFLAMMATORY AND IMMUNE SYSTEM;CARDIOVASCULAR;GENERIC HEALTH RELEVANCE;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL","34;4;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;6.1 PHARMACEUTICALS;3.3 NUTRITION AND CHEMOPREVENTION","15;6;4;3;2;1","BIOMEDICAL;CLINICAL;POPULATION & SOCIETY","29;2;1","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","25;7;5","NOT SITE-SPECIFIC CANCER;LUNG CANCER;BREAST CANCER;PROSTATE CANCER;LIVER CANCER;MELANOMA;COLON AND RECTAL CANCER;BLADDER CANCER;SARCOMA;STOMACH CANCER","16;9;7;5;4;4;2;1;1;1",NA,NA
"IRCCS_TUMORIMILAN",2019,926,18.8671706263499,3.70194384449244,0.338012958963283,0.306695464362851,0.422246220302376,3.92554410080183,1.63020833333333,2.13533834586466,1.83568075117371,0.587473002159827,13,592,156,64,35,0.64,0.17,0.07,0.04,32.89,1.35264058644599,8.18037459283393,0.571274298056155,0.912526997840173,0.574,0.574,0.55,0.555,"FILIPPO DE BRAUD;ANDREA NECCHI;MARINA CHIARA GARASSINO;FILIPPO PIETRANTONIO;­ROSARIO ­TUMINO;LISA LICITRA;PAOLO CORRADINI;ALESSANDRO GRONCHI;ANTONIA TRICHOPOULOU;GIUSEPPE LO RUSSO;SALVATORE PANICO;DIEGO SIGNORELLI;CARLOTTA SACERDOTE;SARA LONARDI;HEINER BOEING;SILVIA STACCHIOTTI;DOMENICO PALLI;MARIA DI BARTOLOMEO;CHIARA CREMOLINI;ANNE TJØNNELAND","95;64;58;47;45;40;34;33;32;32;31;30;30;30;30;30;30;30;30;30","FILIPPO DE BRAUD;MARINA CHIARA GARASSINO;ANDREA NECCHI;LISA LICITRA;PAOLA PEREGO;MARIO P. COLOMBO;ALESSANDRO GRONCHI;FRANCESCO RASPAGLIESI;FILIPPO PIETRANTONIO;R. VALDAGNI;GIUSEPPE LO RUSSO;PAOLO BOSSI;GABRIELLA SOZZI;MAURA MASSIMINO;ROBERTO FERRARA;SILVIA STACCHIOTTI;DIEGO SIGNORELLI;PAOLO G. CASALI;GIANCARLO PRUNERI;ANDREA FERRARI","6.87;4.75;4.01;3.91;3.65;3.14;2.84;2.69;2.42;2.3;2.27;2.12;2.1;2.07;2.02;1.87;1.82;1.71;1.67;1.66","FILIPPO DE BRAUD;ANDREA NECCHI;MARINA CHIARA GARASSINO;FILIPPO PIETRANTONIO;LISA LICITRA;PAOLO CORRADINI;ALESSANDRO GRONCHI;GIUSEPPE LO RUSSO;DIEGO SIGNORELLI;SILVIA STACCHIOTTI;MARIA DI BARTOLOMEO;GIANCARLO PRUNERI;MAURA MASSIMINO;ROBERTO FERRARA;FRANCESCO RASPAGLIESI;MASSIMO MILIONE;GIOVANNI RANDON;GIULIA GALLI;GABRIELLA SOZZI;FEDERICA PERRONE","95;64;58;47;40;34;33;32;30;30;30;27;27;27;26;26;26;25;25;24","FILIPPO DE BRAUD;MARINA CHIARA GARASSINO;ANDREA NECCHI;LISA LICITRA;PAOLA PEREGO;MARIO P. COLOMBO;ALESSANDRO GRONCHI;FRANCESCO RASPAGLIESI;FILIPPO PIETRANTONIO;R. VALDAGNI;GIUSEPPE LO RUSSO;PAOLO BOSSI;GABRIELLA SOZZI;MAURA MASSIMINO;ROBERTO FERRARA;SILVIA STACCHIOTTI;DIEGO SIGNORELLI;PAOLO G. CASALI;GIANCARLO PRUNERI;ANDREA FERRARI","6.87;4.75;4.01;3.91;3.65;3.14;2.84;2.69;2.42;2.3;2.27;2.12;2.1;2.07;2.02;1.87;1.82;1.71;1.67;1.66","ANDREA NECCHI;FILIPPO DE BRAUD;IGNACE VERGOTE;ANTONIO GONZÁLEZ‐MARTÍN;DOMENICA LORUSSO;MARINA CHIARA GARASSINO;­ROSARIO ­TUMINO;ANDRÉS REDONDO;GILLES FREYER;BRADLEY J. MONK;SE HOON PARK;FLOOR J. BACKES;BENTE LUND;BHAVANA POTHURI;CHRISTOF VULSTEKE;KLAUS BAUMANN;PAUL HOSKINS;WHITNEY GRAYBILL;MANSOOR R. MIRZA;RICHARD G. MOORE","2816;2570;2335;2237;1877;1737;1725;1722;1681;1664;1660;1659;1657;1657;1657;1657;1657;1657;1651;1651","ANDREA NECCHI;FILIPPO DE BRAUD;DOMENICA LORUSSO;MARINA CHIARA GARASSINO;LISA LICITRA;ALESSANDRO GRONCHI;SILVIA STACCHIOTTI;LAURA D. LOCATI;GIUSEPPE PROCOPIO;GABRIELLA SOZZI;GIANCARLO PRUNERI;FRANCESCO RASPAGLIESI;UGO PASTORINO;MARIO P. COLOMBO;DIEGO SIGNORELLI;FILIPPO PIETRANTONIO;GIULIA BIANCHI;VITTORIO KROGH;VINCENZO MAZZAFERRO;MARIA DI BARTOLOMEO","2787;2451;1787;1737;1369;1275;1157;1078;1053;955;923;903;897;891;823;789;780;766;761;747","FILIPPO DE BRAUD;ANDREA NECCHI;MARINA CHIARA GARASSINO;FILIPPO PIETRANTONIO;LISA LICITRA;PAOLO CORRADINI;ALESSANDRO GRONCHI;GIUSEPPE LO RUSSO;SILVIA STACCHIOTTI;DIEGO SIGNORELLI;MARIA DI BARTOLOMEO;ROBERTO FERRARA;FRANCESCO RASPAGLIESI;GIOVANNI RANDON;GIANCARLO PRUNERI;MAURA MASSIMINO;GABRIELLA SOZZI;GIULIA GALLI;CLAUDIA PROTO;ALESSANDRA RAIMONDI","89;63;61;43;40;32;32;32;30;30;30;27;26;26;26;26;25;25;24;24","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;SOCIOLOGY;PSYCHOLOGY;MATHEMATICS;ECONOMICS;ENGINEERING;PHILOSOPHY;POLITICAL SCIENCE;BUSINESS;ART;MATERIALS SCIENCE;HISTORY;GEOGRAPHY;ENVIRONMENTAL SCIENCE;GEOLOGY","868;285;70;67;49;43;27;21;19;15;15;15;11;7;7;5;4;3;3","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CANCER RESEARCH;PATHOLOGY;GASTROENTEROLOGY;GENETICS;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;IMMUNOLOGY;RADIOLOGY;PALEONTOLOGY;UROLOGY;NUCLEAR MEDICINE;CELL BIOLOGY;GYNECOLOGY;OPTICS;ENDOCRINOLOGY;PEDIATRICS;FAMILY MEDICINE","768;525;233;174;173;155;135;107;93;83;61;57;43;40;38;33;32;30;30;29","CANCER;CHEMOTHERAPY;GENE;CONFIDENCE INTERVAL;CLINICAL TRIAL;POPULATION;COHORT;LUNG CANCER;RADIATION THERAPY;PROPORTIONAL HAZARDS MODEL;RANDOMIZED CONTROLLED TRIAL;PROSPECTIVE COHORT STUDY;ADVERSE EFFECT;IMMUNE SYSTEM;RETROSPECTIVE COHORT STUDY;STAGE (STRATIGRAPHY);SARCOMA;MULTIVARIATE ANALYSIS;ALTERNATIVE MEDICINE;DISEASE","562;207;135;110;98;98;83;83;79;66;63;56;54;47;45;43;40;38;37;37","IMMUNOTHERAPY;BREAST CANCER;COLORECTAL CANCER;CLINICAL ENDPOINT;HAZARD RATIO;PHASES OF CLINICAL RESEARCH;CISPLATIN;PROSTATE CANCER;PROGRESSION-FREE SURVIVAL;BLADDER CANCER;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;OVARIAN CANCER;GENE EXPRESSION;MUTATION;HEAD AND NECK CANCER;METASTASIS;PLACEBO;ADENOCARCINOMA;SOFT TISSUE SARCOMA;ALLELE;DOCETAXEL;GEMCITABINE","126;121;105;79;66;49;48;38;37;36;36;35;33;33;32;27;26;22;20;19;19;19","NIVOLUMAB;PEMBROLIZUMAB;CARBOPLATIN;KRAS;CETUXIMAB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;TRASTUZUMAB;OXALIPLATIN;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;UROTHELIAL CARCINOMA;DNA METHYLATION;MICROSATELLITE;PEMETREXED;IPILIMUMAB;IRINOTECAN;NEOADJUVANT THERAPY;CYSTECTOMY;CAPECITABINE;GERMLINE MUTATION;POLY ADP RIBOSE POLYMERASE","49;44;31;23;19;19;19;18;17;16;15;14;14;13;13;13;12;10;10;9",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;NEOPLASM RECURRENCE, LOCAL;LUNG NEOPLASMS;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;BIOMARKERS, TUMOR;PROGNOSIS;TREATMENT OUTCOME;ITALY;CARCINOMA, NON-SMALL-CELL LUNG;COLORECTAL NEOPLASMS;NEOPLASMS","469;448;339;285;252;220;192;176;132;129;125;93;90;89;85;84;83;70;69;67","CANCER IMMUNOTHERAPY;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;SARCOMA RESEARCH AND TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;LYMPHOID NEOPLASMS;RENAL CELL CARCINOMA;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GYNECOLOGIC ONCOLOGY;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GLIOMAS;HER2 SIGNALING IN BREAST CANCER TREATMENT;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;MOLECULAR RESEARCH ON BREAST CANCER;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;RADIOTHERAPY PHYSICS AND TECHNOLOGY","79;44;35;30;26;22;21;20;19;18;16;15;13;12;12;11;11;11;11;11","CLINICAL ENDPOINT;BIOMARKERS FOR IMMUNOTHERAPY;TUMOR MICROENVIRONMENT;PROGRESSION-FREE SURVIVAL;REGIMEN;BREAST CANCER;NEOADJUVANT THERAPY;CARBOPLATIN;METASTATIC COLORECTAL CANCER;CANCER RISK;SOFT TISSUE SARCOMA;PD-1 AND PD-L1;CHEMOTHERAPY REGIMEN;IMMUNE CHECKPOINT BLOCKADE;TREATMENT;INTRATUMOR HETEROGENEITY;MICROSATELLITE INSTABILITY;REFRACTORY (PLANETARY SCIENCE);BLADDER CANCER;CANCER IMMUNOEDITING","77;43;38;36;36;35;30;29;29;21;21;20;19;19;19;17;17;17;16;16","BREAST CANCER;LUNG CANCER;CELL CARCINOMA;COLORECTAL CANCER;PHASE II;CELL LUNG;CANCER PATIENTS;PHASE III;METASTATIC COLORECTAL;NON-SMALL CELL;SQUAMOUS CELL;PATIENTS PTS;OVARIAN CANCER;PROSTATE CANCER;UROTHELIAL CARCINOMA;PATIENTS TREATED;RENAL CELL;LOCALLY ADVANCED;ABSTRACT CT;MULTIPLE MYELOMA;CANCER RISK;EUROPEAN PROSPECTIVE;PROSPECTIVE INVESTIGATION;II STUDY;METASTATIC UROTHELIAL;POOLED ANALYSIS;BLADDER CANCER;NECK CANCER;SOFT TISSUE;ADVANCED NON-SMALL","59;54;44;40;39;38;33;31;30;30;29;27;24;22;22;21;20;19;18;18;16;16;16;15;15;14;13;13;13;12","ADVISORY CONSULTANCY;RESEARCH FUNDING;RESEARCH GRANT;GRANT FUNDING;ADVISORY COMMITTEES;ENTITYS BOARD;FUNDING INSTITUTION;SPEAKERS BUREAU;HR CI;CONSULTANCY HONORARIA;ACCOMMODATION EXPENSES;TRAVEL ACCOMMODATION;BREAST CANCER;EXPERT TESTIMONY;BUREAU EXPERT;SPEAKER BUREAU;CONSULTANCY RESEARCH;HONORARIA MEMBERSHIP;LUNG CANCER;PROGRESSION-FREE SURVIVAL;TRAVEL COSTS;SURVIVAL OS;PATIENTS TREATED;ADVERSE EVENTS;CONSULTANCY SPEAKER;CLINICAL TRIAL;RESPONSE RATE;ADVISORY BOARD;PERSONAL FEES;CANCER RISK","530;398;286;285;256;256;234;153;148;131;126;126;119;110;109;109;104;101;99;90;76;73;69;67;67;66;64;63;63;62",449,0.48,13,14,2,1,1,3,2,1,2,16,1,1,14,1.75,2.75,2,5,9,6,0,0,66,66,4,0,1,0,0,3,0,1,0,0,0,0,1,4,0,2,4.8,0.7,1.6,0,3,3,2,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,"DALLAVALLE SABRINA;FIGINI MARIANGELA;APPIERTO VALENTINA;CANEVARI SILVANA;COLOMBO MARIO PAOLO;COUKOS GEORGE;DAIDONE MARIA GRAZIA;DI NICOLA MASSIMO;E NICCOLINI;GIANNI ALESSANDRO MASSIMO","2;2;1;1;1;1;1;1;1;1","FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;UNIVERSITA DEGLI STUDI DI MILANO;UNIVERSITY OF PENNSYLVANIA PENN","5;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;34 CHEMICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;3402 INORGANIC CHEMISTRY;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;49 MATHEMATICAL SCIENCES;4901 APPLIED MATHEMATICS","5;4;2;1;1;1;1;1","CANCER;RARE DISEASES;BIOTECHNOLOGY;IMMUNIZATION;ORPHAN DRUG;OVARIAN CANCER;VACCINE RELATED","2;2;1;1;1;1;1","5.1 PHARMACEUTICALS","2","A61K31/167;A61K39/00;A61K39/395;A61K45/06;C07K16/28;A61K35/12;A61K35/17;A61P35/00;A61P35/02;C07C251/60","2;2;2;2;2;1;1;1;1;1","A61P35/00;A61K2039/505;A61K39/39558;A61K45/06;A61K31/167;A61P35/02;A61P35/04;A61P37/04;A61P43/00;C07C251/60","5;3;3;3;2;2;2;2;2;2",64,4.61,459.86,7.99,32,0.5,51.41,2,5,27,1,14,0,1,14,0,46,13,0,0,0,0,0,0,61,1,2,58,5,0,1,0,0,0,0,0,0,"United States;Italy;Japan;Germany;Netherlands;United Kingdom;Australia;China;Egypt;India;Spain;Switzerland","11;8;6;4;4;3;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4206 PUBLIC HEALTH","61;48;21;8;7;7;5;2","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;DIGESTIVE DISEASES;LUNG;LUNG CANCER;LYMPHOMA;UROLOGIC DISEASES;GENETICS;ORPHAN DRUG;PATIENT SAFETY;PREVENTION;LIVER DISEASE;BRAIN DISORDERS;COLO-RECTAL CANCER;PEDIATRIC;BIOMEDICAL IMAGING;BREAST CANCER","55;52;39;22;11;10;9;7;7;7;5;5;5;5;4;3;3;3;2;2","CANCER;RESPIRATORY;CARDIOVASCULAR;INFECTION;SKIN;STROKE","46;3;2;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;7.1 INDIVIDUAL CARE NEEDS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);5.1 PHARMACEUTICALS;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.3 MANAGEMENT AND DECISION MAKING","45;11;4;3;2;1;1;1;1;1;1;1;1","LUNG CANCER;BLADDER CANCER;BREAST CANCER;LIVER CANCER;NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;ESOPHAGEAL / OESOPHAGEAL CANCER;MELANOMA;SARCOMA;SKIN CANCER;GALLBLADDER CANCER;NOT SITE-SPECIFIC CANCER;PANCREATIC CANCER;PHARYNGEAL CANCER;STOMACH CANCER;KIDNEY CANCER;LARYNGEAL CANCER;MYELOMA;NASAL CAVITY AND PARANASAL SINUS CANCER","11;8;5;5;5;4;4;3;3;3;3;2;2;2;2;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;3.1 INTERVENTIONS TO PREVENT CANCER: PERSONAL BEHAVIORS THAT AFFECT CANCER RISK;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;1.4 CANCER PROGRESSION AND METASTASIS;3.2 NUTRITIONAL SCIENCE IN CANCER PREVENTION;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.2 SURVEILLANCE;6.4 COST ANALYSES AND HEALTH CARE DELIVERY","34;6;3;3;3;2;2;1;1;1;1;1;1",6,9043475.5,609790.31,4.83333333333333,6.16666666666667,3.16666666666667,0.833333333333333,29.3333333333333,1271233.06678903,0.728426615222458,"FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;AC CAMARGO HOSPITAL;ANDALUSIAN HEALTH SERVICE;AZIENDA OSPEDALIERA UNIVERSITARIA SENESE;BIOGEM;CENTRE LÉON BÉRARD;CHARITÉ - UNIVERSITY MEDICINE BERLIN;DÉLÉGATION PARIS 11;EUROPEAN INSTITUTE OF ONCOLOGY;GERMAN BREAST GROUP;HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ;INSTITUT GUSTAVE ROUSSY;INSTITUTO NACIONAL DE CANCEROLOGÍA;INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS;ISTITUTO ORTOPEDICO RIZZOLI;KAROLINSKA INSTITUTET;LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN;MASARYK MEMORIAL CANCER INSTITUTE;MASARYK UNIVERSITY;OSPEDALE POLICLINICO SAN MARTINO","6;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ITALIAN ASSOCIATION FOR CANCER RESEARCH;EUROPEAN COMMISSION","4;2","ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;COALITION S;EC & ERC - EUROPEAN UNION","4;2;2","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","6;6;3;1;1;1","CANCER;CLINICAL RESEARCH;RARE DISEASES;GENETICS;VACCINE RELATED;AGING;BRAIN DISORDERS;BREAST CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COLO-RECTAL CANCER;DIGESTIVE DISEASES;IMMUNIZATION;LUNG;LUNG CANCER;ORPHAN DRUG;PREVENTION;STEM CELL RESEARCH","6;4;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CANCER","6","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","3;2;1;1;1","BREAST CANCER;LUNG CANCER;MELANOMA;COLON AND RECTAL CANCER;SARCOMA","2;2;2;1;1","1.4 CANCER PROGRESSION AND METASTASIS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","2;1;1;1;1;1","A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","4;3",NA,NA,29,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;KARGER PUBLISHERS;SPRINGER NATURE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;TAYLOR & FRANCIS GROUP","21;2;2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3101 BIOCHEMISTRY AND CELL BIOLOGY;46 INFORMATION AND COMPUTING SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;3204 IMMUNOLOGY;4609 INFORMATION SYSTEMS;49 MATHEMATICAL SCIENCES;4904 PURE MATHEMATICS","45;12;8;6;5;5;3;2;2;1;1;1;1;1;1","CANCER;CLINICAL RESEARCH;RARE DISEASES;GENETICS;PATIENT SAFETY;BREAST CANCER;PREVENTION;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;NETWORKING AND INFORMATION TECHNOLOGY R&D (NITRD);AGING;ANTIMICROBIAL RESISTANCE;BIOTECHNOLOGY;COLO-RECTAL CANCER;DENTAL/ORAL AND CRANIOFACIAL DISEASE;HEMATOLOGY;HUMAN GENOME;NUTRITION;ORPHAN DRUG;PEDIATRIC","12;8;6;5;5;4;4;3;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE","14;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;8.4 RESEARCH DESIGN AND METHODOLOGIES (HEALTH SERVICES)","4;4;3;1;1","CLINICAL;BIOMEDICAL;POPULATION & SOCIETY","6;5;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","17;6","BREAST CANCER;LEUKEMIA / LEUKAEMIA;SARCOMA;BLOOD CANCER;COLON AND RECTAL CANCER;HEAD AND NECK CANCER;MYELOMA;NASAL CAVITY AND PARANASAL SINUS CANCER;NOT SITE-SPECIFIC CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;STOMACH CANCER","8;4;2;1;1;1;1;1;1;1;1;1","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_TUMORIMILAN",2020,1086,19.8572744014733,3.53038674033149,0.293738489871087,0.308471454880295,0.344383057090239,4.57517899761337,1.7431693989071,2.79166666666667,1.92783505154639,0.61878453038674,2,705,202,57,27,0.65,0.19,0.05,0.02,29.62,1.17534236960075,9.3502117148906,0.577348066298343,0.940147329650092,0.585,0.548,0.521,0.525,"ANDREA NECCHI;FILIPPO DE BRAUD;MARINA CHIARA GARASSINO;FRANCESCO RASPAGLIESI;GIUSEPPE PROCOPIO;ALESSANDRO GRONCHI;­ROSARIO ­TUMINO;MAURA MASSIMINO;LISA LICITRA;PAOLO CORRADINI;DANIELE RAGGI;LAURA MARANDINO;ALBERTO BRIGANTI;GIORGIO BOGANI;FRANCESCO MONTORSI;FILIPPO PIETRANTONIO;ELISABETE WEIDERPASS;DANIELE SANTINI;MARCO BANDINI;PAOLO A. ASCIERTO","93;74;64;47;46;42;38;38;36;36;36;35;35;34;34;33;33;33;31;30","ANDREA NECCHI;FRANCESCO RASPAGLIESI;FILIPPO DE BRAUD;MARINA CHIARA GARASSINO;GIORGIO BOGANI;ALESSANDRO GRONCHI;LISA LICITRA;MAURA MASSIMINO;GIUSEPPE PROCOPIO;ANTONINO DITTO;LAURA MARANDINO;PAOLO G. CASALI;DANIELE RAGGI;PAOLO CORRADINI;ANDREA FERRARI;ALBERTO BRIGANTI;ANNALISA TRAMA;GIANCARLO PRUNERI;FRANCESCO MONTORSI;MARCO FIORE","6.38;5.34;4.95;4.7;4.28;3.71;3.03;2.97;2.85;2.85;2.34;2.32;2.28;2.22;2.21;2.1;2.08;2.02;2;1.98","ANDREA NECCHI;FILIPPO DE BRAUD;MARINA CHIARA GARASSINO;FRANCESCO RASPAGLIESI;GIUSEPPE PROCOPIO;ALESSANDRO GRONCHI;MAURA MASSIMINO;LISA LICITRA;PAOLO CORRADINI;DANIELE RAGGI;LAURA MARANDINO;ALBERTO BRIGANTI;GIORGIO BOGANI;FRANCESCO MONTORSI;FILIPPO PIETRANTONIO;MARCO BANDINI;PAOLO A. ASCIERTO;PATRIZIA GIANNATEMPO;SILVIA STACCHIOTTI;DIEGO SIGNORELLI","93;74;64;47;46;42;38;36;36;36;35;35;34;34;33;31;30;30;29;28","ANDREA NECCHI;FRANCESCO RASPAGLIESI;FILIPPO DE BRAUD;MARINA CHIARA GARASSINO;GIORGIO BOGANI;ALESSANDRO GRONCHI;LISA LICITRA;MAURA MASSIMINO;GIUSEPPE PROCOPIO;ANTONINO DITTO;LAURA MARANDINO;PAOLO G. CASALI;DANIELE RAGGI;PAOLO CORRADINI;ANDREA FERRARI;ALBERTO BRIGANTI;ANNALISA TRAMA;GIANCARLO PRUNERI;FRANCESCO MONTORSI;MARCO FIORE","6.38;5.34;4.95;4.7;4.28;3.71;3.03;2.97;2.85;2.85;2.34;2.32;2.28;2.22;2.21;2.1;2.08;2.02;2;1.98","MARINA CHIARA GARASSINO;ENRIQUETA FELIP;FILIPPO DE BRAUD;ANDREA NECCHI;MAXIMILIAN J. HOCHMAIR;FRANCESCO GROSSI;NIELS REINMUTH;PAOLO A. ASCIERTO;LISA LICITRA;GIOVANNI CORRAO;MARTIN RECK;LEORA HORN;GIOVANNI APOLONE;LUÍS PAZ-ARES;JAN P. VAN MEERBEECK;ELISABETE WEIDERPASS;­ROSARIO ­TUMINO;GIUSEPPE CURIGLIANO;JULIEN MAZIÈRES;ELIO RÍBOLI","4314;2508;2153;2138;2072;1714;1628;1618;1616;1579;1530;1456;1380;1333;1332;1306;1298;1290;1288;1274","MARINA CHIARA GARASSINO;ANDREA NECCHI;FILIPPO DE BRAUD;LISA LICITRA;GIOVANNI APOLONE;GIUSEPPE PROCOPIO;ALESSANDRO GRONCHI;ANNALISA TRAMA;FRANCESCO RASPAGLIESI;ALESSANDRO DE TOMA;FEDERICO REA;GIOVANNI CORRAO;GIUSEPPE MANCIA;MONICA LUDERGNANI;MARCO FIORE;PAOLO CORRADINI;SILVIA STACCHIOTTI;FILIPPO PIETRANTONIO;VINCENZO MAZZAFERRO;GIUSEPPE VISCARDI","4283;2120;1722;1603;1380;1230;1172;1138;1107;1069;1056;1056;1056;1056;926;897;896;831;714;692","ANDREA NECCHI;MARINA CHIARA GARASSINO;FILIPPO DE BRAUD;FRANCESCO RASPAGLIESI;GIUSEPPE PROCOPIO;ALESSANDRO GRONCHI;MAURA MASSIMINO;DANIELE RAGGI;LISA LICITRA;GIORGIO BOGANI;FILIPPO PIETRANTONIO;LAURA MARANDINO;PAOLO CORRADINI;PATRIZIA GIANNATEMPO;SILVIA STACCHIOTTI;ANDREA FERRARI;DIEGO SIGNORELLI;GIUSEPPE LO RUSSO;ANTONINO DITTO;MICHELA CASANOVA","92;71;69;46;45;42;38;36;35;32;31;31;31;30;29;29;28;28;24;24","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;SOCIOLOGY;COMPUTER SCIENCE;MATHEMATICS;POLITICAL SCIENCE;PSYCHOLOGY;ECONOMICS;BUSINESS;PHILOSOPHY;ENGINEERING;GEOGRAPHY;HISTORY;ART;MATERIALS SCIENCE;ENVIRONMENTAL SCIENCE","1038;318;75;66;55;54;32;25;24;23;15;14;13;10;7;6;4;3","INTERNAL MEDICINE;ONCOLOGY;SURGERY;PATHOLOGY;GASTROENTEROLOGY;CANCER RESEARCH;ENVIRONMENTAL HEALTH;GENETICS;PALEONTOLOGY;BIOCHEMISTRY;RADIOLOGY;IMMUNOLOGY;UROLOGY;NURSING;NUCLEAR MEDICINE;OPTICS;GYNECOLOGY;FAMILY MEDICINE;INTENSIVE CARE MEDICINE;DEMOGRAPHY","932;596;305;226;196;160;149;128;107;95;83;81;70;48;45;45;41;38;35;34","CANCER;CHEMOTHERAPY;CONFIDENCE INTERVAL;POPULATION;GENE;CLINICAL TRIAL;DISEASE;COHORT;STAGE (STRATIGRAPHY);ADVERSE EFFECT;LUNG CANCER;PROPORTIONAL HAZARDS MODEL;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;RADIATION THERAPY;SARCOMA;PROSPECTIVE COHORT STUDY;INCIDENCE (GEOMETRY);OUTBREAK;MELANOMA","653;223;140;135;127;123;120;113;87;80;80;80;69;68;66;60;51;43;39;38","BREAST CANCER;IMMUNOTHERAPY;CLINICAL ENDPOINT;HAZARD RATIO;COLORECTAL CANCER;INFECTIOUS DISEASE (MEDICAL SPECIALTY);PROGRESSION-FREE SURVIVAL;BLADDER CANCER;PHASES OF CLINICAL RESEARCH;METASTASIS;CISPLATIN;PROGRESSIVE DISEASE;OVARIAN CANCER;PROSTATE CANCER;TOLERABILITY;2019-20 CORONAVIRUS OUTBREAK;PLACEBO;SOFT TISSUE SARCOMA;HEAD AND NECK CANCER;CERVICAL CANCER;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;UNIVARIATE ANALYSIS","167;157;112;105;95;66;66;58;48;44;41;35;34;34;34;31;27;27;25;23;23;23","PEMBROLIZUMAB;CORONAVIRUS DISEASE 2019 (COVID-19);NIVOLUMAB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;METASTATIC BREAST CANCER;CYSTECTOMY;IPILIMUMAB;UROTHELIAL CARCINOMA;KRAS;OXALIPLATIN;ESTROGEN RECEPTOR;TRASTUZUMAB;CARBOPLATIN;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;NEOADJUVANT THERAPY;MICROSATELLITE;SINGLE-NUCLEOTIDE POLYMORPHISM;TAMOXIFEN;SENTINEL NODE;CETUXIMAB;IFOSFAMIDE;IRINOTECAN;VEMURAFENIB","67;66;48;34;26;25;23;21;20;19;18;17;16;16;15;14;14;13;12;11;11;11;11",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ADULT;NEOPLASM RECURRENCE, LOCAL;BREAST NEOPLASMS;NEOPLASMS;LUNG NEOPLASMS;RETROSPECTIVE STUDIES;ITALY;COLORECTAL NEOPLASMS;PROGNOSIS;PROSPECTIVE STUDIES;CARCINOMA, NON-SMALL-CELL LUNG;AGED, 80 AND OVER;ANTIBODIES, MONOCLONAL, HUMANIZED","646;437;287;229;204;177;163;153;134;117;104;103;103;94;87;75;68;67;65;62","DIAGNOSIS AND TREATMENT OF BLADDER CANCER;CANCER IMMUNOTHERAPY;SARCOMA RESEARCH AND TREATMENT;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;RENAL CELL CARCINOMA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;GYNECOLOGIC ONCOLOGY;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;GLIOMAS;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;LYMPHOID NEOPLASMS;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;DIAGNOSIS AND TREATMENT OF LUNG CANCER;MOLECULAR RESEARCH ON BREAST CANCER;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS","64;62;53;47;28;25;25;24;21;17;16;16;16;15;15;15;14;14;13;13","CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;BIOMARKERS FOR IMMUNOTHERAPY;BREAST CANCER;NEOADJUVANT THERAPY;PANDEMIC;TOLERABILITY;TUMOR MICROENVIRONMENT;INTRATUMOR HETEROGENEITY;SOFT TISSUE SARCOMA;REGIMEN;2019-20 CORONAVIRUS OUTBREAK;METASTATIC BLADDER CANCER;CANCER;MELANOMA;TREATMENT;BLADDER CANCER;RADIOTHERAPY;ADJUVANT THERAPY;UNIVARIATE ANALYSIS","115;68;42;42;38;37;35;34;31;31;30;29;28;26;26;26;24;24;23;23","BREAST CANCER;CANCER PATIENTS;CELL CARCINOMA;LUNG CANCER;PHASE II;PATIENTS PTS;COLORECTAL CANCER;PHASE III;UROTHELIAL CARCINOMA;RENAL CELL;BLADDER CANCER;OVARIAN CANCER;SQUAMOUS CELL;PROSTATE CANCER;CELL LUNG;METASTATIC COLORECTAL;PATIENTS TREATED;METASTATIC RENAL;II STUDY;LOCALLY ADVANCED;NON-SMALL CELL;METASTATIC UROTHELIAL;CERVICAL CANCER;COHORT STUDY;ENDOMETRIAL CANCER;NEOADJUVANT CHEMOTHERAPY;ADVANCED BREAST;RANDOMIZED PHASE;SENTINEL NODE;SOFT TISSUE","87;59;56;54;50;47;38;32;32;28;27;27;25;24;23;22;21;20;19;19;19;18;15;15;15;15;14;14;14;14","CONSULTANCY HONORARIA;HR CI;RESEARCH FUNDING;ADVISORY COMMITTEES;ENTITYS BOARD;BREAST CANCER;PROGRESSION-FREE SURVIVAL;CANCER PATIENTS;SURVIVAL OS;PUBMED SCOPUS;RESPONSE RATE;MEDIAN FOLLOW-UP;SPEAKERS BUREAU;PATIENTS TREATED;LUNG CANCER;ADVERSE EVENTS;SURVIVAL PFS;DISEASE PROGRESSION;HAZARD RATIO;MONTHS CI;COMMITTEES SPEAKERS;HONORARIA MEMBERSHIP;PRIMARY ENDPOINT;CROSSREF PUBMED;OBJECTIVE RESPONSE;CONFIDENCE INTERVAL;MEDIAN AGE;PERFORMANCE STATUS;MEDIAN OS;CLINICAL TRIALS","189;188;146;121;121;117;117;116;110;108;101;98;89;86;85;84;79;74;74;72;62;62;61;58;58;57;55;52;51;50",596,0.55,11.78,13,2,2,0,3.25,2,1,1,15,1,1,14,1,3,2,5,9,6,0,0,55,55,6,0,1,0,2,4,0,0,0,0,0,0,3,4,0,3,3.57142857142857,0.65,1.14285714285714,1,1,3,0,2,2,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"FIGINI MARIANGELA;DI NICOLA MASSIMO;GIANNI ALESSANDRO MASSIMO;SATTA ALESSANDRO;CANEVARI SILVANA;CIANA PAOLO;COLOMBO MARIO PAOLO;COUKOS GEORGE;DE BRAUD FILIPPO GUGLIELMO;GAROFALO MARIANGELA","3;2;2;2;1;1;1;1;1;1","FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;UNIVERSITY OF PENNSYLVANIA PENN;INDIVIDUAL","5;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;3210 NUTRITION AND DIETETICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","10;3;2;1;1","CANCER;RARE DISEASES;OVARIAN CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;IMMUNIZATION;NUTRITION;ORPHAN DRUG;VACCINE RELATED","4;3;2;1;1;1;1;1;1","5.1 PHARMACEUTICALS;3.3 NUTRITION AND CHEMOPREVENTION;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.2 CELLULAR AND GENE THERAPIES","4;1;1;1","A61P35/00;C07K16/28;A61K39/395;C07K14/725;A23L33/00;A23L33/115;A23L33/125;A23L33/17;A23L33/20;A23L33/21","4;4;2;2;1;1;1;1;1;1","A61K2039/505;A61K39/39558;A61P35/00;A61P37/04;C07K2317/56;A61P1/00;A61P1/16;A61P11/00;A61P13/08;A61P15/00","4;4;4;3;3;2;2;2;2;2",73,4.71,527.99,9.43,43,0.59,82.53,5,7,19,1,24,0,1,15,1,58,12,0,0,0,0,0,0,66,3,4,68,3,1,1,0,0,0,0,0,0,"United States;Japan;United Kingdom;Netherlands;Belgium;Germany;Italy;Sweden;Switzerland","29;7;5;2;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4205 NURSING;3212 OPHTHALMOLOGY AND OPTOMETRY;40 ENGINEERING;4007 CONTROL ENGINEERING, MECHATRONICS AND ROBOTICS;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;44 HUMAN SOCIETY;4405 GENDER STUDIES;46 INFORMATION AND COMPUTING SCIENCES;4608 HUMAN-CENTRED COMPUTING","71;53;41;11;5;3;2;2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;PATIENT SAFETY;DIGESTIVE DISEASES;PEDIATRIC;LUNG;LUNG CANCER;UROLOGIC DISEASES;BREAST CANCER;COLO-RECTAL CANCER;HEMATOLOGY;PEDIATRIC CANCER;PREVENTION;BIOMEDICAL IMAGING;DENTAL/ORAL AND CRANIOFACIAL DISEASE;GENETICS;LIVER CANCER;LIVER DISEASE","65;59;52;23;19;9;9;8;7;6;5;5;5;4;4;3;3;3;3;3","CANCER;EYE","47;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);5.2 CELLULAR AND GENE THERAPIES;6.7 PHYSICAL;7.1 INDIVIDUAL CARE NEEDS","53;13;5;3;3;2;2;1;1;1","LUNG CANCER;COLON AND RECTAL CANCER;MELANOMA;BLADDER CANCER;BREAST CANCER;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;LIVER CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;PROSTATE CANCER;SARCOMA;CERVICAL CANCER;HEAD AND NECK CANCER;KIDNEY CANCER;LARYNGEAL CANCER;MYELOMA;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;SALIVARY GLAND CANCER;STOMACH CANCER","8;6;6;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;6.2 SURVEILLANCE","39;4;3;2;2;2;2;1;1",40,4263740.8,436118.55,4.075,2.425,1.825,0.2,4.75,1163263.96329764,0.933580025054147,"FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;MINISTRY OF HEALTH;DÉLÉGATION PARIS 11;ACTIVE FIBER SYSTEMS (GERMANY);AGENZIA PER L'ITALIA DIGITALE;CAMBRIDGE RAMAN IMAGING (ITALY);CAMBRIDGE RAMAN IMAGING (UNITED KINGDOM);CANDIOLO CANCER INSTITUTE;CASA SOLLIEVO DELLA SOFFERENZA;CENTRE LÉON BÉRARD;DEPARTMENT OF HEALTH;EQUALIS (SWEDEN);ERASMUS MC;ESSEN UNIVERSITY HOSPITAL;FEDERAL AGENCY FOR FOOD CHAIN SAFETY;FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES;FONDAZIONE EDO ED ELVO TEMPIA;FONDAZIONE POLITECNICO DI MILANO;FRENCH NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;GEMATIK GESELLSCHAFT FÜR TELEMATIKANWENDUNGEN DER GESUNDHEITSKARTE","40;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ITALIAN ASSOCIATION FOR CANCER RESEARCH;EUROPEAN COMMISSION","35;5","ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;COALITION S;EC & ERC - EUROPEAN UNION","35;5;5","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME);3RD HEALTH PROGRAMME (PROGRAMME);CSA - COORDINATION AND SUPPORT ACTION (FUNDING SCHEME);H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - LEADERSHIP IN ENABLING AND INDUSTRIAL TECHNOLOGIES - INFORMATION AND COMMUNICATION TECHNOLOGIES (ICT) (PROGRAMME)","3;3;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3101 BIOCHEMISTRY AND CELL BIOLOGY;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;51 PHYSICAL SCIENCES;3107 MICROBIOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4205 NURSING;4206 PUBLIC HEALTH;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","36;32;14;10;6;5;5;2;2;2;2;1;1;1;1;1;1;1","CANCER;CLINICAL RESEARCH;GENETICS;RARE DISEASES;BIOTECHNOLOGY;BREAST CANCER;PREVENTION;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HUMAN GENOME;LUNG;PEDIATRIC;IMMUNIZATION;LUNG CANCER;ORPHAN DRUG;UROLOGIC DISEASES;BIOMEDICAL IMAGING;BRAIN DISORDERS;HEMATOLOGY;PROSTATE CANCER;BIOENGINEERING","37;20;18;15;13;10;9;5;5;5;5;4;4;4;4;3;3;3;3;2","CANCER;INFECTION;GENERIC HEALTH RELEVANCE;RESPIRATORY","38;2;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES;3.4 VACCINES;4.4 POPULATION SCREENING;5.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;5.9 RESOURCES AND INFRASTRUCTURE (TREATMENT DEVELOPMENT);6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;6.9 RESOURCES AND INFRASTRUCTURE (TREATMENT EVALUATION);7.1 INDIVIDUAL CARE NEEDS","16;11;11;11;3;2;1;1;1;1;1;1;1","BREAST CANCER;LUNG CANCER;PROSTATE CANCER;BRAIN TUMOR;HEAD AND NECK CANCER;LEUKEMIA / LEUKAEMIA;NOT SITE-SPECIFIC CANCER;ORAL CAVITY AND LIP CANCER;OVARIAN CANCER;PHARYNGEAL CANCER;THYROID CANCER;BLADDER CANCER;LARYNGEAL CANCER;MELANOMA;NON-HODGKIN'S LYMPHOMA;SALIVARY GLAND CANCER;SARCOMA","12;5;4;2;2;2;2;2;2;2;2;1;1;1;1;1;1","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;1.4 CANCER PROGRESSION AND METASTASIS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;1.3 CANCER INITIATION: ONCOGENES AND TUMOR SUPPRESSOR GENES;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;2.2 ENDOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;3.4 VACCINES;5.1 LOCALIZED THERAPIES - DISCOVERY AND DEVELOPMENT;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.4 COST ANALYSES AND HEALTH CARE DELIVERY","13;10;9;8;4;4;4;3;2;1;1;1;1;1;1;1;1","A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;B12 ENGINEERING;A04 PSYCHOLOGY, PSYCHIATRY AND NEUROSCIENCE;B11 COMPUTER SCIENCE AND INFORMATICS;C19 POLITICS AND INTERNATIONAL STUDIES","33;3;2;1;1;1","3 GOOD HEALTH AND WELL BEING;4 QUALITY EDUCATION","9;1",54,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;ZENODO;AMERICAN ASSOCIATION FOR CANCER RESEARCH;SPRINGER NATURE;KARGER PUBLISHERS;SCIELO JOURNALS","15;13;12;6;6;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;3105 GENETICS;49 MATHEMATICAL SCIENCES;34 CHEMICAL SCIENCES;44 HUMAN SOCIETY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3215 REPRODUCTIVE MEDICINE;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;37 EARTH SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4206 PUBLIC HEALTH;4405 GENDER STUDIES;48 LAW AND LEGAL STUDIES;4804 LAW IN CONTEXT;4904 PURE MATHEMATICS","84;25;15;12;10;5;4;4;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;GENETICS;RARE DISEASES;BIOTECHNOLOGY;CLINICAL RESEARCH;VACCINE RELATED;CARDIOVASCULAR;HEART DISEASE;IMMUNIZATION;PREVENTION;HUMAN GENOME;OVARIAN CANCER;ARTHRITIS;DIGESTIVE DISEASES;DIGESTIVE DISEASES - (GALLBLADDER);HEMATOLOGY;HIV/AIDS;PATIENT SAFETY;UROLOGIC DISEASES;BREAST CANCER","22;13;7;6;6;6;4;4;4;4;3;3;2;2;2;2;2;2;2;1","CANCER;INFLAMMATORY AND IMMUNE SYSTEM;CARDIOVASCULAR;ORAL AND GASTROINTESTINAL","23;7;4;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;2.4 SURVEILLANCE AND DISTRIBUTION;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS","16;7;3;2;1;1;1;1","BIOMEDICAL;CLINICAL","21;4","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","19;18;3","NOT SITE-SPECIFIC CANCER;SARCOMA;THYROID CANCER;BREAST CANCER;LIVER CANCER;MELANOMA;OVARIAN CANCER;BRAIN TUMOR;EAR CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;LUNG CANCER;NASAL CAVITY AND PARANASAL SINUS CANCER;NEUROBLASTOMA;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;PROSTATE CANCER;SALIVARY GLAND CANCER","8;6;6;5;4;3;3;1;1;1;1;1;1;1;1;1;1;1",NA,NA
"IRCCS_TUMORIMILAN",2021,1003,20.7876370887338,3.54037886340977,0.281156530408774,0.283150548354935,0.35493519441675,4.50634517766497,1.54945054945055,2.4695652173913,1.74509803921569,0.692921236291127,7,565,228,44,46,0.56,0.23,0.04,0.05,21.68,1.40622209405251,9.63730322785826,0.572283150548355,0.936191425722832,0.569,0.506,0.511,0.489,"FILIPPO DE BRAUD;FRANCESCO RASPAGLIESI;MARINA CHIARA GARASSINO;ANDREA NECCHI;LISA LICITRA;ANDREA FERRARI;GIUSEPPE PROCOPIO;ALESSANDRO GRONCHI;GIORGIO BOGANI;FILIPPO PIETRANTONIO;MATTHIAS B. SCHULZE;PAOLO CORRADINI;UGO DE GIORGI;ELISABETE WEIDERPASS;­ROSARIO ­TUMINO;MASSIMO MILIONE;SILVIA STACCHIOTTI;ELENA VERZONI;ANNE TJØNNELAND;PAOLO G. CASALI","66;54;51;43;42;42;40;40;35;35;34;33;33;33;31;27;27;26;26;25","FRANCESCO RASPAGLIESI;GIORGIO BOGANI;FILIPPO DE BRAUD;ALESSANDRO GRONCHI;MARINA CHIARA GARASSINO;LISA LICITRA;ANDREA NECCHI;ANDREA FERRARI;GIUSEPPE PROCOPIO;PAOLA PEREGO;ELENA VERZONI;MAURA MASSIMINO;ANTONINO DITTO;MARCELLO DERACO;FILIPPO PIETRANTONIO;ROBERTO LILLINI;LORIS DE CECCO;VINCENZO MAZZAFERRO;ELDA TAGLIABUE;SILVIA STACCHIOTTI","4.97;4.09;3.88;3.5;3.31;3.01;2.93;2.78;2.68;2.62;1.95;1.94;1.93;1.85;1.83;1.79;1.79;1.67;1.63;1.62","FILIPPO DE BRAUD;FRANCESCO RASPAGLIESI;MARINA CHIARA GARASSINO;ANDREA NECCHI;LISA LICITRA;ANDREA FERRARI;GIUSEPPE PROCOPIO;ALESSANDRO GRONCHI;GIORGIO BOGANI;FILIPPO PIETRANTONIO;PAOLO CORRADINI;MASSIMO MILIONE;SILVIA STACCHIOTTI;ELENA VERZONI;PAOLO G. CASALI;MAURA MASSIMINO;MARIA DI BARTOLOMEO;LORIS DE CECCO;VINCENZO MAZZAFERRO;ALESSANDRO DE TOMA","66;54;51;43;42;42;40;40;35;35;33;27;27;26;25;25;24;23;22;22","FRANCESCO RASPAGLIESI;GIORGIO BOGANI;FILIPPO DE BRAUD;ALESSANDRO GRONCHI;MARINA CHIARA GARASSINO;LISA LICITRA;ANDREA NECCHI;ANDREA FERRARI;GIUSEPPE PROCOPIO;PAOLA PEREGO;ELENA VERZONI;MAURA MASSIMINO;ANTONINO DITTO;MARCELLO DERACO;FILIPPO PIETRANTONIO;ROBERTO LILLINI;LORIS DE CECCO;VINCENZO MAZZAFERRO;ELDA TAGLIABUE;SILVIA STACCHIOTTI","4.97;4.09;3.88;3.5;3.31;3.01;2.93;2.78;2.68;2.62;1.95;1.94;1.93;1.85;1.83;1.79;1.79;1.67;1.63;1.62","MARINA CHIARA GARASSINO;UGO DE GIORGI;GIUSEPPE PROCOPIO;ALESSANDRO GRONCHI;PIOTR RUTKOWSKI;ANDREA FERRARI;MARTIN RECK;ERIC WINQUIST;CAMILLO PORTA;SILVIA STACCHIOTTI;THOMAS POWLES;VIKTOR GRÜNWALD;JEAN‐YVES BLAY;MANUELA SCHMIDINGER;PAOLO G. CASALI;WINAN J. VAN HOUDT;GIOVANNI GRIGNANI;LEA DUTTA;SYLVIE BONVALOT;BOHUSLAV MELICHAR","2257;2008;1727;1638;1556;1549;1516;1503;1486;1468;1409;1409;1392;1391;1387;1361;1351;1338;1323;1316","MARINA CHIARA GARASSINO;GIUSEPPE PROCOPIO;ALESSANDRO GRONCHI;ANDREA FERRARI;SILVIA STACCHIOTTI;PAOLO G. CASALI;CLAUDIA SANGALLI;ANNALISA TRAMA;PAOLO CORRADINI;ANNA MARIA FREZZA;FILIPPO DE BRAUD;LISA LICITRA;MARIA DI BARTOLOMEO;FILIPPO PIETRANTONIO;FRANCESCO RASPAGLIESI;DOMENICA LORUSSO;ANNA GUIDETTI;GIULIA BIANCHI;ANDREA NECCHI;MARTINA DI MODICA","2249;1727;1638;1549;1468;1322;1184;1174;1157;1120;1102;1011;873;720;693;650;587;569;509;469","MARINA CHIARA GARASSINO;FILIPPO DE BRAUD;FRANCESCO RASPAGLIESI;ANDREA FERRARI;ALESSANDRO GRONCHI;GIUSEPPE PROCOPIO;LISA LICITRA;ANDREA NECCHI;GIORGIO BOGANI;FILIPPO PIETRANTONIO;PAOLO CORRADINI;MASSIMO MILIONE;SILVIA STACCHIOTTI;ELENA VERZONI;MAURA MASSIMINO;PAOLO G. CASALI;MARIA DI BARTOLOMEO;LORIS DE CECCO;MICHELA CASANOVA;ALESSANDRO DE TOMA","63;62;53;42;40;40;40;35;35;33;32;27;27;26;25;24;24;23;21;21","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;SOCIOLOGY;POLITICAL SCIENCE;MATHEMATICS;ECONOMICS;ENGINEERING;PSYCHOLOGY;PHILOSOPHY;BUSINESS;ART;MATERIALS SCIENCE;GEOGRAPHY;ENVIRONMENTAL SCIENCE;HISTORY;GEOLOGY","961;316;84;67;62;37;29;27;24;23;19;17;14;8;8;7;3;3;2","INTERNAL MEDICINE;ONCOLOGY;SURGERY;PATHOLOGY;CANCER RESEARCH;GASTROENTEROLOGY;GENETICS;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;IMMUNOLOGY;RADIOLOGY;PALEONTOLOGY;FAMILY MEDICINE;UROLOGY;OPTICS;PEDIATRICS;GYNECOLOGY;INTENSIVE CARE MEDICINE;ENDOCRINOLOGY;NUCLEAR MEDICINE","849;566;250;215;154;152;133;124;112;95;81;76;48;42;41;41;40;36;33;32","CANCER;CHEMOTHERAPY;GENE;CONFIDENCE INTERVAL;COHORT;POPULATION;CLINICAL TRIAL;DISEASE;LUNG CANCER;ADVERSE EFFECT;RETROSPECTIVE COHORT STUDY;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;STAGE (STRATIGRAPHY);PROPORTIONAL HAZARDS MODEL;SARCOMA;PROSPECTIVE COHORT STUDY;IMMUNE SYSTEM;LYMPHOMA;ALTERNATIVE MEDICINE","574;197;143;118;114;113;100;92;82;81;80;75;68;61;59;56;55;52;47;46","IMMUNOTHERAPY;BREAST CANCER;COLORECTAL CANCER;CLINICAL ENDPOINT;HAZARD RATIO;INFECTIOUS DISEASE (MEDICAL SPECIALTY);PHASES OF CLINICAL RESEARCH;OVARIAN CANCER;PROGRESSION-FREE SURVIVAL;CISPLATIN;PROSTATE CANCER;METASTASIS;PLACEBO;ALLELE;BLADDER CANCER;SOFT TISSUE SARCOMA;TOLERABILITY;ENDOMETRIAL CANCER;HEAD AND NECK CANCER;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION","130;127;102;89;76;56;50;47;44;39;37;34;29;26;26;26;26;25;25;24","CORONAVIRUS DISEASE 2019 (COVID-19);NIVOLUMAB;PEMBROLIZUMAB;MICROSATELLITE;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;KRAS;CARBOPLATIN;IPILIMUMAB;METASTATIC BREAST CANCER;CETUXIMAB;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;TRASTUZUMAB;UROTHELIAL CARCINOMA;CYTOREDUCTIVE SURGERY;NEOADJUVANT THERAPY;POLY ADP RIBOSE POLYMERASE;IRINOTECAN;LENVATINIB;SENTINEL NODE;ANDROGEN DEPRIVATION THERAPY;IFOSFAMIDE;IMMUNE CHECKPOINT;PTEN;REGORAFENIB;VINCRISTINE","56;51;47;23;23;22;19;16;16;14;14;14;14;12;12;12;10;10;10;9;9;9;9;9;9",";HUMANS;FEMALE;MALE;MIDDLE AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;AGED;ADULT;BREAST NEOPLASMS;LUNG NEOPLASMS;COLORECTAL NEOPLASMS;NEOPLASM RECURRENCE, LOCAL;RETROSPECTIVE STUDIES;NEOPLASMS;COVID-19;CARCINOMA, NON-SMALL-CELL LUNG;PROGNOSIS;ITALY;AGED, 80 AND OVER;ADOLESCENT","512;485;256;197;176;163;152;146;112;106;103;101;99;96;74;72;70;68;56;54","SARCOMA RESEARCH AND TREATMENT;CANCER IMMUNOTHERAPY;ADVANCEMENTS IN LUNG CANCER RESEARCH;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;RENAL CELL CARCINOMA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;LYMPHOID NEOPLASMS;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GYNECOLOGIC ONCOLOGY;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;RADIOMICS IN MEDICAL IMAGING ANALYSIS;PANCREATIC CANCER RESEARCH AND TREATMENT;MANAGEMENT OF PERITONEAL CARCINOMATOSIS FROM DIGESTIVE TRACT;MICRORNA REGULATION IN CANCER AND DEVELOPMENT","55;49;44;35;29;27;25;23;22;22;21;18;18;16;14;14;13;11;10;10","CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;TREATMENT;TUMOR MICROENVIRONMENT;PANDEMIC;REFRACTORY (PLANETARY SCIENCE);BIOMARKERS FOR IMMUNOTHERAPY;BREAST CANCER;REGIMEN;TOLERABILITY;METASTATIC COLORECTAL CANCER;NEOADJUVANT THERAPY;CANCER RISK;MICROSATELLITE INSTABILITY;UNIVARIATE ANALYSIS;DISCONTINUATION;SOFT TISSUE SARCOMA;CARBOPLATIN;SURGICAL ONCOLOGY;2019-20 CORONAVIRUS OUTBREAK","93;47;34;33;32;32;31;30;28;27;26;26;23;23;22;21;21;20;20;19","BREAST CANCER;CELL CARCINOMA;CANCER PATIENTS;LUNG CANCER;COLORECTAL CANCER;PHASE II;PATIENTS PTS;OVARIAN CANCER;RENAL CELL;METASTATIC COLORECTAL;PHASE III;PROSTATE CANCER;LOCALLY ADVANCED;PATIENTS TREATED;SQUAMOUS CELL;ENDOMETRIAL CANCER;CELL LUNG;SOFT TISSUE;NON-SMALL CELL;CANCER RISK;II TRIAL;II STUDY;PHASE STUDY;RANDOMIZED PHASE;IMMUNE CHECKPOINT;COVID- PANDEMIC;CHECKPOINT INHIBITORS;METASTATIC RENAL;TISSUE SARCOMA;CLINICAL PRACTICE","64;60;51;48;46;46;37;32;32;30;26;24;23;23;23;20;19;19;18;17;17;16;16;16;15;14;13;13;13;12","RESEARCH FUNDING;ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;HR CI;BREAST CANCER;PROGRESSION-FREE SURVIVAL;LUNG CANCER;CONSULTANCY HONORARIA;SURVIVAL OS;MONTHS CI;RESPONSE RATE;ADVERSE EVENTS;CONFIDENCE INTERVAL;PUBMED SCOPUS;SURVIVAL PFS;MEDIAN FOLLOW-UP;CANCER PATIENTS;ADVISORY BOARD;PATIENTS TREATED;HAZARD RATIO;MEDIAN AGE;INTERVAL CI;COLORECTAL CANCER;COVID- PANDEMIC;OBJECTIVE RESPONSE;PRIMARY ENDPOINT;PHASE II;CLINICAL PRACTICE;HONORARIA MEMBERSHIP","216;185;185;167;162;132;119;109;105;103;91;84;81;81;81;78;74;72;69;69;65;65;59;57;56;55;51;50;49;49",586,0.58,11.99,13,1.75,1,0,4,2,1,1,15,1,1,13,1.75,1,2,6,8,5,0,0,37,37,5,0,2,0,3,3,0,0,0,0,0,0,5,3,0,0,4.375,0.99,2.375,1,5,4,1,0,2,0,0,4,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"FIGINI MARIANGELA;BARTHEL MARKUS;CASSANI MARCO;DI NICOLA MASSIMO;ELSI PAOLO;GIANNI ALESSANDRO MASSIMO;GRANJA JUAN;ORLANDI ROSARIA;PATRICOLA PIETRO;PELLEGRINO TERESA","5;2;2;2;2;2;2;2;2;2","FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;CONSIGLIO NAZIONALE DELLE RICHERCHE CNR;COSMAR SRL;FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA;UNIVERSIDADE DE SANTIAGO DE COMPOSTELA;UNIVERSITA DEGLI STUDI DI GENOVA;UNIVERSITY OF PENNSYLVANIA PENN","7;2;2;2;2;2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;40 ENGINEERING;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3204 IMMUNOLOGY;4003 BIOMEDICAL ENGINEERING;4018 NANOTECHNOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3206 MEDICAL BIOTECHNOLOGY","9;6;3;2;2;2;2;1;1","CANCER;RARE DISEASES;OVARIAN CANCER;BIOENGINEERING;IMMUNIZATION;NANOTECHNOLOGY;VACCINE RELATED;CLINICAL RESEARCH;ORPHAN DRUG","5;5;4;2;2;2;2;1;1","5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES","5;1","C07K16/28;A61B10/00;A61B5/097;A61K47/68;A61P35/00;C07K14/725;G01N33/497;A61B5/08;A61K33/243;A61K35/12","4;2;2;2;2;2;2;1;1;1","A61P35/00;A61K2039/505;A61K39/39558;A61P37/04;A61B10/00;A61B10/0096;A61B2010/0087;A61B5/082;A61B5/097;A61K33/243","5;3;3;3;2;2;2;2;2;2",74,4.2,521.01,10,46,0.62,63.64,4,7,27,1,20,0,0,15,0,58,12,0,0,0,0,0,0,69,5,0,70,4,0,0,0,0,0,0,0,0,"United States;Japan;Italy;United Kingdom;Germany;Netherlands;Australia;Canada;Belgium;Denmark;Norway;Singapore;Switzerland","20;10;6;5;3;3;2;2;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3105 GENETICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4205 NURSING","74;51;42;7;4;4;2;2;2;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;PATIENT SAFETY;DIGESTIVE DISEASES;COLO-RECTAL CANCER;HEMATOLOGY;BIOTECHNOLOGY;VACCINE RELATED;GENETICS;LYMPHOMA;PREVENTION;BRAIN DISORDERS;INFECTIOUS DISEASES;LUNG;ORPHAN DRUG;PEDIATRIC;BREAST CANCER;DENTAL/ORAL AND CRANIOFACIAL DISEASE","70;66;54;19;15;12;9;8;7;7;6;6;6;5;5;5;4;4;3;3","CANCER;INFECTION;METABOLIC AND ENDOCRINE","49;4;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;3.4 VACCINES;5.2 CELLULAR AND GENE THERAPIES;7.2 END OF LIFE CARE;8.1 ORGANISATION AND DELIVERY OF SERVICES","55;11;4;3;3;2;1;1;1;1;1","COLON AND RECTAL CANCER;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;SARCOMA;MELANOMA;KIDNEY CANCER;LEUKEMIA / LEUKAEMIA;NOT SITE-SPECIFIC CANCER;STOMACH CANCER;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;BREAST CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;HEAD AND NECK CANCER;HODGKIN'S DISEASE;LARYNGEAL CANCER;ORAL CAVITY AND LIP CANCER;OVARIAN CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER;THYROID CANCER","9;6;6;6;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;1.4 CANCER PROGRESSION AND METASTASIS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;6.4 COST ANALYSES AND HEALTH CARE DELIVERY;6.6 END-OF-LIFE CARE","38;4;3;2;2;2;1;1;1;1;1",17,6924388.67,541082.22,3.76470588235294,3.11764705882353,2.29411764705882,0.176470588235294,5.5,1339936.5636296,0.748542899137768,"FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;ANTONI VAN LEEUWENHOEK HOSPITAL;ATOMIC ENERGY AND ALTERNATIVE ENERGIES COMMISSION;CAPITAL REGION OF DENMARK;CENTRE HOSPITALIER UNIVERSITAIRE DE GRENOBLE;CENTRE LÉON BÉRARD;CONCENTRIS (GERMANY);ESSEN UNIVERSITY HOSPITAL;EUROPEAN RESEARCH AND PROJECT OFFICE;EUROPEAN UNIVERSITY OF MADRID;FUNDACIÓ EURECAT;GERMAN CANCER RESEARCH CENTER;GERMAN SPORT UNIVERSITY COLOGNE;INSTITUT GUSTAVE ROUSSY;KAROLINSKA INSTITUTET;LJUBLJANA UNIVERSITY MEDICAL CENTRE;LUND UNIVERSITY;MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH;NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS;NATIONAL TECHNICAL UNIVERSITY OF UKRAINE “IGOR SIKORSKY KYIV POLYTECHNIC INSTITUTE”","17;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ITALIAN ASSOCIATION FOR CANCER RESEARCH;EUROPEAN COMMISSION","14;3","ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;COALITION S;EC & ERC - EUROPEAN UNION","14;3;3","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","3;3","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3202 CLINICAL SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4205 NURSING","16;14;6;4;4;2;1;1;1;1","CANCER;BIOTECHNOLOGY;BREAST CANCER;RARE DISEASES;GENETICS;CLINICAL RESEARCH;AGING;ORPHAN DRUG;HUMAN GENOME;OVARIAN CANCER;PEDIATRIC;PREVENTION;PROSTATE CANCER;UROLOGIC DISEASES;CARDIOVASCULAR;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIABETES;HEART DISEASE;HEMATOLOGY;LUNG","17;6;6;6;5;4;3;3;2;2;2;2;2;2;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;GENERIC HEALTH RELEVANCE","17;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.9 RESOURCES AND INFRASTRUCTURE (TREATMENT EVALUATION);4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.7 PHYSICAL;8.4 RESEARCH DESIGN AND METHODOLOGIES (HEALTH SERVICES)","11;9;6;2;1;1;1","BREAST CANCER;KIDNEY CANCER;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;PROSTATE CANCER;BRAIN TUMOR;LEUKEMIA / LEUKAEMIA;LUNG CANCER;MELANOMA;NEUROBLASTOMA;NON-HODGKIN'S LYMPHOMA","6;3;2;2;2;1;1;1;1;1;1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;1.4 CANCER PROGRESSION AND METASTASIS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;1.3 CANCER INITIATION: ONCOGENES AND TUMOR SUPPRESSOR GENES;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.1 LOCALIZED THERAPIES - DISCOVERY AND DEVELOPMENT;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","7;5;3;2;1;1;1;1;1","A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;B11 COMPUTER SCIENCE AND INFORMATICS","15;1;1","3 GOOD HEALTH AND WELL BEING","3",58,"FRONTIERS;AMERICAN ASSOCIATION FOR CANCER RESEARCH;ZENODO;PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;SAGE JOURNALS;TAYLOR & FRANCIS GROUP","19;14;10;8;5;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3204 IMMUNOLOGY;3202 CLINICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3210 NUTRITION AND DIETETICS;3105 GENETICS;4205 NURSING;4206 PUBLIC HEALTH;51 PHYSICAL SCIENCES;52 PSYCHOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;40 ENGINEERING;4008 ELECTRICAL ENGINEERING;47 LANGUAGE, COMMUNICATION AND CULTURE;49 MATHEMATICAL SCIENCES","92;28;17;13;13;11;9;7;5;2;2;2;2;1;1;1;1;1;1;1","CANCER;CLINICAL RESEARCH;GENETICS;PREVENTION;BIOTECHNOLOGY;CARDIOVASCULAR;HEART DISEASE;NUTRITION;HUMAN GENOME;LUNG;LUNG CANCER;RARE DISEASES;BASIC BEHAVIORAL AND SOCIAL SCIENCE;BEHAVIORAL AND SOCIAL SCIENCE;DENTAL/ORAL AND CRANIOFACIAL DISEASE;KIDNEY DISEASE;PATIENT SAFETY;PEDIATRIC;VACCINE RELATED;BREAST CANCER","25;18;13;10;9;7;7;7;5;5;5;4;3;3;3;3;3;3;3;2","CANCER;METABOLIC AND ENDOCRINE;GENERIC HEALTH RELEVANCE;RENAL AND UROGENITAL;INFLAMMATORY AND IMMUNE SYSTEM;MENTAL HEALTH;STROKE","29;7;2;2;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.1 INDIVIDUAL CARE NEEDS;6.7 PHYSICAL;8.4 RESEARCH DESIGN AND METHODOLOGIES (HEALTH SERVICES);1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;5.2 CELLULAR AND GENE THERAPIES;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY","16;5;4;3;3;3;2;2;1;1;1;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS;POPULATION & SOCIETY","19;10;2;2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH;HEALTH SERVICES RESEARCH","27;12;3;2","NOT SITE-SPECIFIC CANCER;LUNG CANCER;BREAST CANCER;KIDNEY CANCER;PROSTATE CANCER;STOMACH CANCER;HEAD AND NECK CANCER;LIVER CANCER;NON-HODGKIN'S LYMPHOMA;PHARYNGEAL CANCER;SALIVARY GLAND CANCER;SARCOMA;SKIN CANCER;BRAIN TUMOR;LEUKEMIA / LEUKAEMIA","21;5;4;4;4;3;2;2;2;2;2;2;2;1;1","3 GOOD HEALTH AND WELL BEING","4"
"IRCCS_TUMORIMILAN",2022,929,21.3304628632939,3.77610333692142,0.272335844994618,0.27556512378902,0.313240043057051,3.51503006012024,1.42937853107345,1.95419847328244,1.58152173913043,0.710441334768568,3,547,153,28,38,0.59,0.16,0.03,0.04,12.21,1.3681409708684,9.07291822955744,0.601722282023681,0.936490850376749,0.576,0.511,0.498,0.502,"FILIPPO DE BRAUD;MAURA MASSIMINO;FRANCESCO RASPAGLIESI;PAOLO CORRADINI;GIUSEPPE PROCOPIO;FILIPPO PIETRANTONIO;SILVIA STACCHIOTTI;SARA LONARDI;ALESSANDRO GRONCHI;ELISABETE WEIDERPASS;­ROSARIO ­TUMINO;MATTHIAS B. SCHULZE;ANNE TJØNNELAND;VERONICA BIASSONI;CHIARA CREMOLINI;VINCENZO MAZZAFERRO;GIANCARLO PRUNERI;LORIS DE CECCO;PAOLO VERDERIO;GIORGIO BOGANI","56;44;41;40;35;35;34;32;32;32;31;29;29;28;28;27;27;26;25;25","FRANCESCO RASPAGLIESI;ALESSANDRO GRONCHI;FILIPPO DE BRAUD;MAURA MASSIMINO;GIORGIO BOGANI;SILVIA STACCHIOTTI;EGIDIO RIGGIO;MARCO FIORE;LISA LICITRA;PAOLO CORRADINI;VERONICA BIASSONI;ROSALBA MICELI;VINCENZO MAZZAFERRO;LORIS DE CECCO;FILIPPO PIETRANTONIO;ANNALISA TRAMA;GIUSEPPE PROCOPIO;PAOLO VERDERIO;ANDREA FERRARI;PAOLA PEREGO","3.51;3.21;3.2;2.88;2.6;2.53;2.25;1.93;1.87;1.85;1.83;1.82;1.79;1.78;1.77;1.76;1.73;1.69;1.65;1.6","FILIPPO DE BRAUD;MAURA MASSIMINO;FRANCESCO RASPAGLIESI;PAOLO CORRADINI;GIUSEPPE PROCOPIO;FILIPPO PIETRANTONIO;SILVIA STACCHIOTTI;ALESSANDRO GRONCHI;VERONICA BIASSONI;VINCENZO MAZZAFERRO;GIANCARLO PRUNERI;LORIS DE CECCO;PAOLO VERDERIO;GIORGIO BOGANI;ANDREA FERRARI;MARIA DI BARTOLOMEO;LISA LICITRA;MASSIMO MILIONE;ELISABETTA SCHIAVELLO;GIUSEPPE LO RUSSO","56;44;41;40;35;35;34;32;28;27;27;26;25;25;25;24;23;22;22;22","FRANCESCO RASPAGLIESI;ALESSANDRO GRONCHI;FILIPPO DE BRAUD;MAURA MASSIMINO;GIORGIO BOGANI;SILVIA STACCHIOTTI;EGIDIO RIGGIO;MARCO FIORE;LISA LICITRA;PAOLO CORRADINI;VERONICA BIASSONI;ROSALBA MICELI;VINCENZO MAZZAFERRO;LORIS DE CECCO;FILIPPO PIETRANTONIO;ANNALISA TRAMA;GIUSEPPE PROCOPIO;PAOLO VERDERIO;ANDREA FERRARI;PAOLA PEREGO","3.51;3.21;3.2;2.88;2.6;2.53;2.25;1.93;1.87;1.85;1.83;1.82;1.79;1.78;1.77;1.76;1.73;1.69;1.65;1.6","MARINA CHIARA GARASSINO;PAOLO CORRADINI;LUÍS PAZ-ARES;MUSTAFA ÖZGÜROĞLU;PAOLO A. ASCIERTO;PIOTR RUTKOWSKI;HELEN MANN;GIUSEPPE PROCOPIO;MICHELE DEL VECCHIO;FILIPPO DE BRAUD;FILIPPO PIETRANTONIO;BYOUNG CHUL CHO;RINA HUI;MARTIN RECK;PAOLA QUEIROLO;C. FAIVRE‐FINN;MARIA DI BARTOLOMEO;DAVID PLANCHARD;SARA LONARDI;GEORGINA V. LONG","961;875;833;787;786;785;742;741;727;724;721;702;687;678;671;670;638;634;625;618","MARINA CHIARA GARASSINO;PAOLO CORRADINI;GIUSEPPE PROCOPIO;MICHELE DEL VECCHIO;FILIPPO PIETRANTONIO;FILIPPO DE BRAUD;MARIA DI BARTOLOMEO;FEDERICA MORANO;VINCENZO MAZZAFERRO;MARGHERITA AMBROSINI;MAURA MASSIMINO;FRANCESCO RASPAGLIESI;ANNA GUIDETTI;CARLA RIPAMONTI;GABRIELLA MARIANI;ALESSANDRO GRONCHI;PAOLO MANCA;MASSIMO MILIONE;GIANCARLO PRUNERI;MICHELA CASANOVA","926;843;736;727;721;678;638;374;348;335;306;297;287;274;273;271;263;233;229;228","FILIPPO DE BRAUD;MAURA MASSIMINO;FRANCESCO RASPAGLIESI;PAOLO CORRADINI;FILIPPO PIETRANTONIO;GIUSEPPE PROCOPIO;SILVIA STACCHIOTTI;ALESSANDRO GRONCHI;VERONICA BIASSONI;LORIS DE CECCO;GIANCARLO PRUNERI;ANDREA FERRARI;VINCENZO MAZZAFERRO;MARIA DI BARTOLOMEO;GIUSEPPE LO RUSSO;PAOLO VERDERIO;LISA LICITRA;ELISABETTA SCHIAVELLO;MASSIMO MILIONE;ROBERTO FERRARA","52;44;41;37;35;34;33;32;28;26;26;25;25;24;23;23;23;22;21;21","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;SOCIOLOGY;POLITICAL SCIENCE;MATHEMATICS;ENGINEERING;ECONOMICS;MATERIALS SCIENCE;PHILOSOPHY;PSYCHOLOGY;BUSINESS;ART;GEOGRAPHY;GEOLOGY;HISTORY;ENVIRONMENTAL SCIENCE","874;297;99;66;55;29;27;26;18;16;14;14;14;7;6;6;4;4;3","INTERNAL MEDICINE;ONCOLOGY;SURGERY;PATHOLOGY;CANCER RESEARCH;GENETICS;GASTROENTEROLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;PALEONTOLOGY;RADIOLOGY;CELL BIOLOGY;PEDIATRICS;NURSING;UROLOGY;FAMILY MEDICINE;GYNECOLOGY;OPTICS;GENERAL SURGERY","787;532;255;197;159;137;130;126;123;90;78;55;42;41;35;33;31;30;30;29","CANCER;CHEMOTHERAPY;GENE;CLINICAL TRIAL;POPULATION;CONFIDENCE INTERVAL;COHORT;DISEASE;ADVERSE EFFECT;RETROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;LUNG CANCER;RADIATION THERAPY;STAGE (STRATIGRAPHY);PROPORTIONAL HAZARDS MODEL;SARCOMA;PROSPECTIVE COHORT STUDY;IMMUNE SYSTEM;ALTERNATIVE MEDICINE;LYMPHOMA","540;207;163;115;114;104;89;85;79;79;76;70;67;61;59;59;51;43;39;39","IMMUNOTHERAPY;BREAST CANCER;COLORECTAL CANCER;CLINICAL ENDPOINT;HAZARD RATIO;PHASES OF CLINICAL RESEARCH;PROGRESSION-FREE SURVIVAL;CISPLATIN;INFECTIOUS DISEASE (MEDICAL SPECIALTY);OVARIAN CANCER;GENE EXPRESSION;PROSTATE CANCER;METASTASIS;PLACEBO;SOFT TISSUE SARCOMA;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;PROGRESSIVE DISEASE;TOLERABILITY;BEVACIZUMAB;MUTATION","124;108;103;91;72;48;47;45;38;38;36;36;31;31;31;25;25;24;23;23","NIVOLUMAB;PEMBROLIZUMAB;CORONAVIRUS DISEASE 2019 (COVID-19);KRAS;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;IPILIMUMAB;CARBOPLATIN;CETUXIMAB;TRASTUZUMAB;POLY ADP RIBOSE POLYMERASE;OXALIPLATIN;TRABECTEDIN;TRANSCRIPTOME;VINCRISTINE;DNA METHYLATION;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;IFOSFAMIDE;IRINOTECAN;MICROSATELLITE;TRIPLE-NEGATIVE BREAST CANCER","56;40;38;33;29;23;18;18;17;15;13;13;13;13;11;11;11;11;11;11",";HUMANS;RETROSPECTIVE STUDIES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;NEOPLASM RECURRENCE, LOCAL;FEMALE;SARCOMA;COLORECTAL NEOPLASMS;LUNG NEOPLASMS;PROSPECTIVE STUDIES;NEOPLASMS;MALE;BREAST NEOPLASMS;ADULT;MELANOMA;PROGNOSIS;COVID-19;KIDNEY NEOPLASMS;CARCINOMA, NON-SMALL-CELL LUNG;SOFT TISSUE NEOPLASMS","472;446;120;114;107;101;81;80;79;79;75;70;59;51;50;50;48;46;43;43","SARCOMA RESEARCH AND TREATMENT;CANCER IMMUNOTHERAPY;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;GLIOMAS;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;RENAL CELL CARCINOMA;LYMPHOID NEOPLASMS;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GYNECOLOGIC ONCOLOGY;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;CHOLANGIOCARCINOMA;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;CANCER SURVIVORSHIP AND QUALITY OF LIFE;GASTRIC CANCER RESEARCH AND TREATMENT","56;46;35;27;27;26;24;22;21;19;17;17;16;14;13;12;12;12;11;11","CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;BIOMARKERS FOR IMMUNOTHERAPY;REGIMEN;SOFT TISSUE SARCOMA;TUMOR MICROENVIRONMENT;BREAST CANCER;METASTATIC COLORECTAL CANCER;TOLERABILITY;DISCONTINUATION;REFRACTORY (PLANETARY SCIENCE);INTRATUMOR HETEROGENEITY;TREATMENT;SURGICAL ONCOLOGY;PANDEMIC;RHABDOMYOSARCOMA;UNIVARIATE ANALYSIS;MELANOMA;RADIOTHERAPY;CANCER THERAPY","92;48;34;29;29;29;27;27;25;24;24;23;23;21;20;20;20;19;19;18","BREAST CANCER;CANCER PATIENTS;LUNG CANCER;COLORECTAL CANCER;CELL CARCINOMA;PROSTATE CANCER;METASTATIC COLORECTAL;RENAL CELL;PHASE II;OVARIAN CANCER;PHASE III;CELL LUNG;PATIENTS PTS;NON-SMALL CELL;SOFT TISSUE;SQUAMOUS CELL;PHASE STUDY;METASTATIC RENAL;PATIENTS TREATED;ENDOMETRIAL CANCER;CANCER RISK;CIRCULATING TUMOR;FIRST-LINE TREATMENT;PHASE TRIAL;B-CELL LYMPHOMA;CERVICAL CANCER;EUROPEAN PROSPECTIVE;RETROSPECTIVE ANALYSIS;SOLID TUMORS;CYTOREDUCTIVE SURGERY","60;51;49;45;44;30;29;28;27;26;26;24;23;20;19;17;16;15;14;13;12;12;12;12;11;11;11;11;11;10","HR CI;PROGRESSION-FREE SURVIVAL;BREAST CANCER;CANCER PATIENTS;MEDIAN FOLLOW-UP;SURVIVAL OS;MONTHS CI;LUNG CANCER;PATIENTS TREATED;MEDIAN AGE;SURVIVAL PFS;CONFIDENCE INTERVAL;PATIENTS RECEIVED;PUBMED SCOPUS;RESPONSE RATE;ADVERSE EVENTS;CROSSREF PUBMED;DISEASE PROGRESSION;COLORECTAL CANCER;ENDOMETRIAL CANCER;HAZARD RATIO;INTERVAL CI;MEDIAN PFS;CANCER RISK;PATIENTS RECEIVING;PRIMARY ENDPOINT;RISK FACTORS;PATIENTS PTS;CELL CARCINOMA;CERVICAL CANCER","153;131;98;95;94;93;89;88;87;85;85;81;74;74;73;69;63;61;56;56;51;51;51;49;48;46;46;45;44;43",499,0.54,11.91,14,1,1.5,0,4,1,1,1,17,1,1,14,1,1,2,6,9,6,0,0,22,22,5,0,0,0,8,1,0,0,0,0,0,0,8,1,0,0,3.55555555555556,0.91,1.77777777777778,2,4,4,0,1,4,0,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CIANA PAOLO;DE BRAUD FILIPPO GUGLIELMO;GAROFALO MARIANGELA;MAGGI ADRIANA;MAZZAFERRO VINCENZO;RIVOLTINI LICIA;VERNIERI CLAUDIO;TOGNOLI EMILIANO;VILLA ALESSANDRO MARIA;ALESSANDRO MARIA VILLA","3;3;3;3;3;3;3;2;2;1","FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;UNIVERSITA DEGLI STUDI DI MILANO;CONSIGLIO NAZIONALE DELLE RICHERCHE CNR;FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA;UNIVERSIDADE DE SANTIAGO DE COMPOSTELA;UNIVERSITA DEGLI STUDI DI GENOVA","9;3;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3210 NUTRITION AND DIETETICS;31 BIOLOGICAL SCIENCES;40 ENGINEERING;46 INFORMATION AND COMPUTING SCIENCES;4601 APPLIED COMPUTING;3101 BIOCHEMISTRY AND CELL BIOLOGY;3206 MEDICAL BIOTECHNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","11;3;2;2;2;2;1;1;1","CANCER;NUTRITION;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BRAIN DISORDERS;PREVENTION;RARE DISEASES","3;3;2;2;1;1;1","3.3 NUTRITION AND CHEMOPREVENTION;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","3;2;2","A61P35/00;A23L33/00;A23L33/21;A61K47/69;A61K49/00;A23L33/185;A61K45/00;C12N5/078;G16H20/40;G16H40/63","4;3;3;3;3;2;2;2;2;2","A23L33/115;A23L33/185;A23L33/21;A23L33/40;A61K35/12;A61K45/00;A61K47/62;A61K47/6901;A61K49/0034;A61K49/0056","3;3;3;3;3;3;3;3;3;3",64,4.35,718.25,6.82,37,0.58,69.62,3,5,14,3,19,0,0,20,0,48,15,0,0,0,0,0,0,57,6,1,62,1,0,1,0,0,0,0,0,0,"United States;Italy;Germany;United Kingdom;Belgium;Spain;Australia;Finland;Norway;Switzerland","26;12;7;6;2;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3215 REPRODUCTIVE MEDICINE;4206 PUBLIC HEALTH;4205 NURSING;46 INFORMATION AND COMPUTING SCIENCES;4602 ARTIFICIAL INTELLIGENCE","62;46;24;12;8;6;4;2;2;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;DIGESTIVE DISEASES;LUNG;PATIENT SAFETY;LUNG CANCER;COLO-RECTAL CANCER;PREVENTION;BREAST CANCER;HEMATOLOGY;AGING;DENTAL/ORAL AND CRANIOFACIAL DISEASE;GENETICS;BEHAVIORAL AND SOCIAL SCIENCE;HEALTH SERVICES;ORPHAN DRUG;UROLOGIC DISEASES;BASIC BEHAVIORAL AND SOCIAL SCIENCE","61;57;46;16;13;11;10;9;8;7;6;6;4;4;4;3;3;3;3;2","CANCER;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;RESPIRATORY;STROKE","48;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;6.7 PHYSICAL;7.1 INDIVIDUAL CARE NEEDS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;4.4 POPULATION SCREENING;7.3 MANAGEMENT AND DECISION MAKING;8.1 ORGANISATION AND DELIVERY OF SERVICES","46;14;3;3;2;2;2;2;2;1;1;1;1;1","LUNG CANCER;COLON AND RECTAL CANCER;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;SARCOMA;HEAD AND NECK CANCER;NOT SITE-SPECIFIC CANCER;PHARYNGEAL CANCER;BLADDER CANCER;KIDNEY CANCER;MELANOMA;MYELOMA;ORAL CAVITY AND LIP CANCER;OVARIAN CANCER;RESPIRATORY SYSTEM;SALIVARY GLAND CANCER;STOMACH CANCER;BRAIN TUMOR;ENDOMETRIAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER","12;8;6;5;5;4;3;3;2;2;2;2;2;2;2;2;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;2.3 INTERACTIONS OF GENES AND/OR GENETIC POLYMORPHISMS WITH EXOGENOUS AND/OR ENDOGENOUS FACTORS;3.2 NUTRITIONAL SCIENCE IN CANCER PREVENTION;3.3 CHEMOPREVENTION;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.2 SURVEILLANCE;6.6 END-OF-LIFE CARE","38;6;3;3;2;2;2;1;1;1;1;1;1;1",16,5333913,452357.99,4,7.4375,4.75,0.625,2,2146523.90557659,0.432792757437498,"FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;OSLO UNIVERSITY HOSPITAL;CENTRE LÉON BÉRARD;EUROPEAN CANCER ORGANISATION;LEEDS TEACHING HOSPITALS NHS TRUST;MAASTRICHT UNIVERSITY;UNIVERSITY HOSPITAL IN MOTOL;UNIVERSITY OF EDINBURGH;UNIVERSITY OF LEEDS;VRIJE UNIVERSITEIT BRUSSEL;AALBORG UNIVERSITY;ACCELOPMENT (SWITZERLAND);AGE PLATFORM EUROPE;AGOSTINO GEMELLI UNIVERSITY POLYCLINIC;AIX-MARSEILLE UNIVERSITY;ALLEANZA CONTRO IL CANCRO;AMSTERDAM UMC LOCATION VUMC;ANTONI VAN LEEUWENHOEK HOSPITAL;ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;AUGUST PI I SUNYER BIOMEDICAL RESEARCH INSTITUTE","16;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;ITALIAN ASSOCIATION FOR CANCER RESEARCH;SARCOMA FOUNDATION OF AMERICA","9;6;1","COALITION S;EC & ERC - EUROPEAN UNION;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;HRA - HEALTH RESEARCH ALLIANCE","9;9;6;1","HORIZON.2.1 - HEALTH (PROGRAMME);HORIZON-RIA - HORIZON  RESEARCH AND INNOVATION ACTIONS (FUNDING SCHEME);HORIZON-HLTH-2021-DISEASE-04 (CALL FOR PROPOSAL);HORIZON-HLTH-2021-CARE-05 (CALL FOR PROPOSAL);EU4HEALTH PROGRAMME (EU4H) (PROGRAMME);HORIZON-AG - HORIZON ACTION GRANT BUDGET-BASED (FUNDING SCHEME);HORIZON-EIC - HORIZON EIC GRANTS (FUNDING SCHEME);HORIZON-EIC-2022-PATHFINDEROPEN-01 (CALL FOR PROPOSAL);HORIZON-HLTH-2021-TOOL-06 (CALL FOR PROPOSAL);HORIZON-MISS-2021-CANCER-02 (CALL FOR PROPOSAL);HORIZON.3.1 - THE EUROPEAN INNOVATION COUNCIL (EIC) (PROGRAMME);THE LAST MILE SARCOMA RESEARCH GRANT (FUNDING PROGRAM)","7;6;3;2;1;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;3204 IMMUNOLOGY;4205 NURSING;3202 CLINICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3106 INDUSTRIAL BIOTECHNOLOGY;40 ENGINEERING","9;7;7;7;4;3;3;2;1;1;1;1","CANCER;CLINICAL RESEARCH;GENETICS;HEALTH SERVICES;RARE DISEASES;BEHAVIORAL AND SOCIAL SCIENCE;BIOTECHNOLOGY;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HUMAN GENOME;BREAST CANCER;COMPARATIVE EFFECTIVENESS RESEARCH;COST EFFECTIVENESS RESEARCH;LUNG;LUNG CANCER;ORPHAN DRUG;PEDIATRIC;PREVENTION;REHABILITATION;AGING;BIOENGINEERING","16;11;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1","CANCER;GENERIC HEALTH RELEVANCE","15;2","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;7.2 END OF LIFE CARE;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.9 RESOURCES AND INFRASTRUCTURE (TREATMENT EVALUATION);7.1 INDIVIDUAL CARE NEEDS;8.1 ORGANISATION AND DELIVERY OF SERVICES","7;6;4;3;2;1;1;1","NOT SITE-SPECIFIC CANCER;BREAST CANCER;LUNG CANCER;KIDNEY CANCER;MELANOMA;OVARIAN CANCER;SARCOMA;THYROID CANCER","6;2;2;1;1;1;1;1","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.4 COST ANALYSES AND HEALTH CARE DELIVERY;1.4 CANCER PROGRESSION AND METASTASIS;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;6.6 END-OF-LIFE CARE;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.9 RESOURCES AND INFRASTRUCTURE RELATED TO CANCER CONTROL, SURVIVORSHIP, AND OUTCOMES RESEARCH;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","5;4;4;3;3;3;3;2;2;1;1","A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;B11 COMPUTER SCIENCE AND INFORMATICS;A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE;B12 ENGINEERING;C19 POLITICS AND INTERNATIONAL STUDIES","7;4;2;1;1;1","3 GOOD HEALTH AND WELL BEING;7 AFFORDABLE AND CLEAN ENERGY","3;1",82,"FRONTIERS;SPRINGER NATURE;PUBLIC LIBRARY OF SCIENCE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;ZENODO;KARGER PUBLISHERS;TAYLOR & FRANCIS GROUP","30;15;13;11;6;5;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;49 MATHEMATICAL SCIENCES;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;51 PHYSICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;4905 STATISTICS;3101 BIOCHEMISTRY AND CELL BIOLOGY;5105 MEDICAL AND BIOLOGICAL PHYSICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;34 CHEMICAL SCIENCES;3103 ECOLOGY;3106 INDUSTRIAL BIOTECHNOLOGY;3210 NUTRITION AND DIETETICS;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY","115;36;29;22;15;14;12;6;6;4;4;4;3;3;2;2;1;1;1;1","CANCER;CLINICAL RESEARCH;GENETICS;RARE DISEASES;PREVENTION;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;IMMUNIZATION;VACCINE RELATED;BREAST CANCER;BIOTECHNOLOGY;LYMPHOMA;PATIENT SAFETY;HUMAN GENOME;NUTRITION;AGING;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;NEUROSCIENCES","42;29;19;16;11;8;8;8;8;7;5;5;5;4;4;3;3;3;3;3","CANCER;CARDIOVASCULAR;INFECTION;METABOLIC AND ENDOCRINE;MUSCULOSKELETAL;INFLAMMATORY AND IMMUNE SYSTEM;ORAL AND GASTROINTESTINAL","38;4;3;2;2;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;3.4 VACCINES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;6.2 CELLULAR AND GENE THERAPIES;2.4 SURVEILLANCE AND DISTRIBUTION;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;7.1 INDIVIDUAL CARE NEEDS","12;7;6;3;3;3;2;2;1;1;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS;POPULATION & SOCIETY","22;21;1;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","31;20;3","BREAST CANCER;NOT SITE-SPECIFIC CANCER;MELANOMA;LEUKEMIA / LEUKAEMIA;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;OVARIAN CANCER;ENDOMETRIAL CANCER;HODGKIN'S DISEASE;PROSTATE CANCER;BRAIN TUMOR;COLON AND RECTAL CANCER;KIDNEY CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;GENITAL SYSTEM, FEMALE;HEAD AND NECK CANCER;LARYNGEAL CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER","10;10;8;7;5;5;5;3;3;3;2;2;2;1;1;1;1;1;1;1","3 GOOD HEALTH AND WELL BEING","5"
"IRCCS_TUMORIMILAN",2023,931,21.530612244898,3.50912996777658,0.27389903329753,0.262083780880773,0.322234156820623,3.77251732101617,1.49122807017544,2.05042016806723,1.57068062827225,0.68421052631579,2,532,177,30,41,0.57,0.19,0.03,0.04,6.12,1.39536379370832,8.57538594719382,0.575725026852846,0.954887218045113,0.561,0.529,0.513,0.531,"FILIPPO PIETRANTONIO;FILIPPO DE BRAUD;SARA LONARDI;GIUSEPPE PROCOPIO;LISA LICITRA;FRANCESCO RASPAGLIESI;CHIARA CREMOLINI;PAOLO CORRADINI;GIANCARLO PRUNERI;VINCENZO MAZZAFERRO;GIORGIO BOGANI;ANDREA FERRARI;ROSALBA MICELI;SEBASTIANO BUTI;ALESSANDRO GRONCHI;FRANCESCA BERGAMO;ELENA VERZONI;PAOLO A. ASCIERTO;ARSELA PRELAJ;GIUSEPPE LO RUSSO","60;55;46;42;41;40;40;34;34;33;30;30;27;26;26;25;25;24;23;23","FILIPPO PIETRANTONIO;LISA LICITRA;FRANCESCO RASPAGLIESI;FILIPPO DE BRAUD;GIORGIO BOGANI;SARA LONARDI;ALESSANDRO GRONCHI;ANDREA FERRARI;ROSALBA MICELI;CHIARA CREMOLINI;GIUSEPPE PROCOPIO;GIANCARLO PRUNERI;SERENA DI COSIMO;VINCENZO MAZZAFERRO;PAOLO CORRADINI;LORIS DE CECCO;FABIO MARTINELLI;ELENA VERZONI;MAURA MASSIMINO;T. RANCATI","3.48;3.16;2.86;2.81;2.66;2.29;2.19;2.17;1.99;1.98;1.97;1.88;1.7;1.61;1.54;1.52;1.51;1.5;1.48;1.46","FILIPPO PIETRANTONIO;FILIPPO DE BRAUD;GIUSEPPE PROCOPIO;LISA LICITRA;FRANCESCO RASPAGLIESI;PAOLO CORRADINI;GIANCARLO PRUNERI;VINCENZO MAZZAFERRO;GIORGIO BOGANI;ANDREA FERRARI;ROSALBA MICELI;ALESSANDRO GRONCHI;ELENA VERZONI;ARSELA PRELAJ;GIUSEPPE LO RUSSO;MICHELE DEL VECCHIO;ANDREA VINGIANI;GIUSEPPINA CALARESO;CLAUDIO VERNIERI;FEDERICO NICHETTI","60;55;42;41;40;34;34;33;30;30;27;26;25;23;23;22;22;22;21;21","FILIPPO PIETRANTONIO;LISA LICITRA;FRANCESCO RASPAGLIESI;FILIPPO DE BRAUD;GIORGIO BOGANI;ALESSANDRO GRONCHI;ANDREA FERRARI;ROSALBA MICELI;GIUSEPPE PROCOPIO;GIANCARLO PRUNERI;SERENA DI COSIMO;VINCENZO MAZZAFERRO;PAOLO CORRADINI;LORIS DE CECCO;FABIO MARTINELLI;ELENA VERZONI;MAURA MASSIMINO;T. RANCATI;UGO PASTORINO;ARSELA PRELAJ","3.48;3.16;2.86;2.81;2.66;2.19;2.17;1.99;1.97;1.88;1.7;1.61;1.54;1.52;1.51;1.5;1.48;1.46;1.45;1.37","FRANCESCO RASPAGLIESI;SARA LONARDI;MARIA DI BARTOLOMEO;FILIPPO PIETRANTONIO;LUCY GILBERT;DAVID CIBULA;MANSOOR RAZA MIRZA;GIORGIO VALABREGA;GIUSEPPE PROCOPIO;MARINA CHIARA GARASSINO;ELEFTHERIOS ZOGRAFOS;BRIAN M. SLOMOVITZ;BRADLEY J. MONK;ROBERT L. COLEMAN;BHAVANA POTHURI;ASHLEY STUCKEY;INGRID BOERE;JOSEPH BUSCEMA;LARS HANKER;MARK S. SHAHIN","704;533;436;414;390;383;382;376;376;369;367;362;361;355;348;342;342;342;342;342","FRANCESCO RASPAGLIESI;MARIA DI BARTOLOMEO;FILIPPO PIETRANTONIO;GIUSEPPE PROCOPIO;MARINA CHIARA GARASSINO;GIORGIO BOGANI;FILIPPO DE BRAUD;MICHELE DEL VECCHIO;FEDERICO CAPPUZZO;VALENTINA GUADALUPI;VINCENZO MAZZAFERRO;SABINA SIERI;ARSELA PRELAJ;SILVIA STACCHIOTTI;ROBERTO AGRESTI;LISA LICITRA;ALESSANDRO GRONCHI;MONICA NIGER;GIANCARLO PRUNERI;MICHELE PRISCIANDARO","661;436;414;367;266;251;235;198;181;180;180;174;169;139;133;131;122;116;114;113","FILIPPO PIETRANTONIO;FILIPPO DE BRAUD;LISA LICITRA;FRANCESCO RASPAGLIESI;GIUSEPPE PROCOPIO;GIANCARLO PRUNERI;VINCENZO MAZZAFERRO;PAOLO CORRADINI;ANDREA FERRARI;GIORGIO BOGANI;ALESSANDRO GRONCHI;ROSALBA MICELI;ELENA VERZONI;GIUSEPPE LO RUSSO;ARSELA PRELAJ;GIUSEPPINA CALARESO;MICHELE DEL VECCHIO;MONICA NIGER;ANDREA VINGIANI;LORIS DE CECCO","60;51;40;39;39;32;32;32;30;28;26;26;25;23;23;22;22;21;20;20","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;MATHEMATICS;PSYCHOLOGY;POLITICAL SCIENCE;SOCIOLOGY;ENGINEERING;ECONOMICS;PHILOSOPHY;MATERIALS SCIENCE;BUSINESS;HISTORY;ART;GEOGRAPHY;ENVIRONMENTAL SCIENCE;GEOLOGY","894;278;78;69;60;30;30;25;25;23;18;12;10;9;8;5;4;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;GASTROENTEROLOGY;PATHOLOGY;CANCER RESEARCH;GENETICS;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;IMMUNOLOGY;PALEONTOLOGY;RADIOLOGY;UROLOGY;OPTICS;NUCLEAR MEDICINE;GYNECOLOGY;FAMILY MEDICINE;NURSING;CELL BIOLOGY;GENERAL SURGERY","807;552;245;166;158;154;123;110;107;75;74;69;51;40;35;33;31;31;30;28","CANCER;CHEMOTHERAPY;GENE;CLINICAL TRIAL;CONFIDENCE INTERVAL;COHORT;POPULATION;RADIATION THERAPY;RETROSPECTIVE COHORT STUDY;PROPORTIONAL HAZARDS MODEL;LUNG CANCER;ADVERSE EFFECT;RANDOMIZED CONTROLLED TRIAL;DISEASE;STAGE (STRATIGRAPHY);PROSPECTIVE COHORT STUDY;LYMPHOMA;IMMUNE SYSTEM;SARCOMA;INCIDENCE (GEOMETRY)","552;193;138;118;117;112;102;81;74;65;63;62;62;55;52;42;40;38;38;35","BREAST CANCER;IMMUNOTHERAPY;COLORECTAL CANCER;CLINICAL ENDPOINT;HAZARD RATIO;PHASES OF CLINICAL RESEARCH;PROGRESSION-FREE SURVIVAL;ALLELE;CISPLATIN;OVARIAN CANCER;HEAD AND NECK CANCER;ADENOCARCINOMA;PROSTATE CANCER;GENE EXPRESSION;MUTATION;SOFT TISSUE SARCOMA;PROGRESSIVE DISEASE;TOLERABILITY;BEVACIZUMAB;CERVICAL CANCER;ENDOMETRIAL CANCER;GEMCITABINE;METASTASIS","138;135;116;93;87;53;53;32;29;29;28;27;27;26;25;25;21;21;19;19;19;19;19","NIVOLUMAB;PEMBROLIZUMAB;MICROSATELLITE;KRAS;IPILIMUMAB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;TRASTUZUMAB;NEOADJUVANT THERAPY;CORONAVIRUS DISEASE 2019 (COVID-19);HEAD AND NECK SQUAMOUS-CELL CARCINOMA;CETUXIMAB;METASTATIC BREAST CANCER;CARBOPLATIN;IRINOTECAN;ANDROGEN DEPRIVATION THERAPY;TRANSCRIPTOME;ANDROGEN RECEPTOR;GERMLINE MUTATION;IMMUNE CHECKPOINT;POLY ADP RIBOSE POLYMERASE","59;45;25;24;20;20;20;19;18;16;15;15;14;14;13;12;11;11;11;11",";HUMANS;RETROSPECTIVE STUDIES;FEMALE;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;LUNG NEOPLASMS;MALE;PROSPECTIVE STUDIES;COLORECTAL NEOPLASMS;NEOPLASM RECURRENCE, LOCAL;NEOPLASMS;ADULT;PROGNOSIS;SARCOMA;MIDDLE AGED;CARCINOMA, NON-SMALL-CELL LUNG;LIVER NEOPLASMS;KIDNEY NEOPLASMS;CHILD","495;430;133;132;113;81;79;71;69;65;65;65;53;45;43;41;40;40;37;36","SARCOMA RESEARCH AND TREATMENT;CANCER IMMUNOTHERAPY;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;RENAL CELL CARCINOMA;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;GYNECOLOGIC ONCOLOGY;LYMPHOID NEOPLASMS;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;MOLECULAR RESEARCH ON BREAST CANCER;RADIOMICS IN MEDICAL IMAGING ANALYSIS;CHOLANGIOCARCINOMA;HEPATOCELLULAR CARCINOMA;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;GASTRIC CANCER RESEARCH AND TREATMENT;MANAGEMENT OF PERITONEAL CARCINOMATOSIS FROM DIGESTIVE TRACT","47;40;34;28;25;25;22;22;22;22;18;17;17;16;16;15;14;13;13;13","CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;METASTATIC COLORECTAL CANCER;TUMOR MICROENVIRONMENT;BREAST CANCER;BIOMARKERS FOR IMMUNOTHERAPY;REGIMEN;TREATMENT;CANCER IMAGING;MICROSATELLITE INSTABILITY;REFRACTORY (PLANETARY SCIENCE);NEOADJUVANT THERAPY;CANCER IMMUNOEDITING;RADIOTHERAPY;MELANOMA;TOLERABILITY;INTERQUARTILE RANGE;SOFT TISSUE SARCOMA;CANCER RISK;CANCER THERAPY","105;58;43;42;37;34;32;29;28;27;27;26;22;22;21;21;20;20;19;19","BREAST CANCER;CELL CARCINOMA;COLORECTAL CANCER;CANCER PATIENTS;METASTATIC COLORECTAL;PHASE II;LUNG CANCER;RENAL CELL;SQUAMOUS CELL;PATIENTS PTS;PHASE III;LOCALLY ADVANCED;PROSTATE CANCER;COHORT STUDY;IMMUNE CHECKPOINT;OVARIAN CANCER;PATIENTS TREATED;II STUDY;METASTATIC RENAL;CHECKPOINT INHIBITORS;RETROSPECTIVE STUDY;SOFT TISSUE;CLINICAL OUTCOMES;ENDOMETRIAL CANCER;CANCER MCRC;CELL LUNG;CERVICAL CANCER;NECK CANCER;CANCER TREATED;CASTRATION-RESISTANT PROSTATE","79;63;54;46;46;45;42;32;28;25;23;22;20;19;18;18;18;17;16;15;15;15;14;14;13;13;13;13;11;11","HR CI;BREAST CANCER;PROGRESSION-FREE SURVIVAL;SURVIVAL OS;PATIENTS TREATED;MONTHS CI;MEDIAN FOLLOW-UP;SURVIVAL PFS;RESPONSE RATE;MEDIAN AGE;PRIMARY ENDPOINT;ADVERSE EVENTS;CONFIDENCE INTERVAL;LUNG CANCER;HAZARD RATIO;CANCER PATIENTS;MEDIAN OS;ADVISORY ROLE;INTERVAL CI;PATIENTS RECEIVED;PATIENTS PTS;CLINICAL PRACTICE;PHASE II;IMMUNE CHECKPOINT;OBJECTIVE RESPONSE;MEDIAN PFS;CELL CARCINOMA;STATISTICALLY SIGNIFICANT;DISEASE PROGRESSION;RATE ORR","161;146;127;111;105;96;92;85;82;78;73;69;66;65;63;58;48;47;47;46;45;44;44;42;42;41;39;38;37;37",374,0.4,12.32,14,1,1,0,6.75,1,1,1,16,1.75,1,13,1.75,1,2,6,9,6,0,0,10,10,9,0,0,0,5,4,0,0,1,0,0,0,6,4,0,0,3.3,1.01,1.8,2,5,3,0,3,4,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,1,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"FIGINI MARIANGELA;ARMANO MARIA TERESA;CANEVARI SILVANA;FERRARIS CRISTINA;FERRI FRANCESCA;APPIERTO VALENTINA;BARTHEL MARKUS;CASSANI MARCO;COUKOS GEORGE;DAIDONE MARIA GRAZIA","4;2;2;2;2;1;1;1;1;1","FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;CONSIGLIO NAZIONALE DELLE RICHERCHE CNR;FAMAFARM 50% SRL;FAMAFARM SRL;FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI 50%;FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA;UNIVERSIDADE DE SANTIAGO DE COMPOSTELA;UNIVERSITA DEGLI STUDI DI GENOVA;UNIVERSITA DEGLI STUDI DI MILANO;UNIVERSITY OF PENNSYLVANIA PENN","9;1;1;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;48 LAW AND LEGAL STUDIES;3211 ONCOLOGY AND CARCINOGENESIS;34 CHEMICAL SCIENCES;40 ENGINEERING;4806 PRIVATE LAW AND CIVIL OBLIGATIONS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3210 NUTRITION AND DIETETICS;3402 INORGANIC CHEMISTRY","11;4;3;2;2;2;1;1;1;1","CANCER;RARE DISEASES;OVARIAN CANCER;BIOENGINEERING;BIOTECHNOLOGY;COLO-RECTAL CANCER;DIGESTIVE DISEASES;IMMUNIZATION;NANOTECHNOLOGY;NUTRITION","5;3;2;1;1;1;1;1;1;1","5.1 PHARMACEUTICALS;3.3 NUTRITION AND CHEMOPREVENTION","2;1","A61P35/00;C07K16/28;A23L3/44;A23B9/08;A23L33/00;A23L33/185;A23L33/20;A23L33/21;A61K31/167;A61K33/243","4;4;2;1;1;1;1;1;1;1","A61P35/00;C07K16/28;A23B9/08;A23L3/44;A61K2039/505;A61K2236/00;A61K36/185;A61K39/39558;A61P37/04;C07K2317/92","7;3;2;2;2;2;2;2;2;2",38,4.11,514.95,4.58,11,0.29,46.87,3,1,8,2,10,0,0,14,0,28,10,0,0,0,0,0,0,29,6,3,38,0,0,0,0,0,0,0,0,0,"United States;United Kingdom;Denmark;France;Germany;Italy;Norway;Switzerland","9;3;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;31 BIOLOGICAL SCIENCES;3215 REPRODUCTIVE MEDICINE","37;28;15;5;5;3;3;2;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;PATIENT SAFETY;BIOMEDICAL IMAGING;DIGESTIVE DISEASES;LYMPHOMA;AGING;BREAST CANCER;GENETICS;LUNG;LUNG CANCER;PREVENTION;BEHAVIORAL AND SOCIAL SCIENCE;BIOTECHNOLOGY;COLO-RECTAL CANCER;HUMAN GENOME;NUTRITION","33;33;27;12;7;7;5;5;5;4;3;3;3;3;3;2;2;2;2;2","CANCER;CARDIOVASCULAR","31;1","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;6.4 SURGERY;6.6 PSYCHOLOGICAL AND BEHAVIOURAL;7.2 END OF LIFE CARE","22;4;4;4;2;2;1;1;1;1;1","MELANOMA;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;COLON AND RECTAL CANCER;LUNG CANCER;ENDOMETRIAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;MYELOMA;NOT SITE-SPECIFIC CANCER;PROSTATE CANCER;CERVICAL CANCER;EAR CANCER;GENITAL SYSTEM, FEMALE;HEAD AND NECK CANCER;HODGKIN'S DISEASE;KIDNEY CANCER;LARYNGEAL CANCER;LIVER CANCER;ORAL CAVITY AND LIP CANCER;PANCREATIC CANCER","5;5;4;4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;3.3 CHEMOPREVENTION;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.4 COST ANALYSES AND HEALTH CARE DELIVERY;6.6 END-OF-LIFE CARE","19;7;4;3;2;2;2;1;1;1;1;1",13,9443745.38,607805.7,3.76923076923077,14.0769230769231,8,0.615384615384615,1.5,2853603.11747239,0.32625419922608,"FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;ANTONI VAN LEEUWENHOEK HOSPITAL;EUROPEAN CANCER ORGANISATION;GERMAN CANCER RESEARCH CENTER;INSTITUT GUSTAVE ROUSSY;ALLEANZA CONTRO IL CANCRO;EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER;KAROLINSKA INSTITUTET;MEDICAL UNIVERSITY OF VIENNA;OSLO UNIVERSITY HOSPITAL;INSTITUTE CURIE;ISTITUTI FISIOTERAPICI OSPITALIERI;LUXEMBOURG INSTITUTE OF HEALTH;MINISTRY FOR HEALTH;MINISTRY OF HEALTH;NATIONAL INSTITUTE OF ONCOLOGY;ORGANISATION OF EUROPEAN CANCER INSTITUTES;RADBOUD UNIVERSITY NIJMEGEN MEDICAL CENTRE;SCIENSANO (BELGIUM);SISTERS OF CHARITY HOSPITAL","13;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","EUROPEAN COMMISSION;ITALIAN ASSOCIATION FOR CANCER RESEARCH","8;5","COALITION S;EC & ERC - EUROPEAN UNION;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP","8;8;5","HORIZON.2.1 - HEALTH (PROGRAMME);HORIZON-MISS-2022-CANCER-01 (CALL FOR PROPOSAL);HORIZON-CSA - HORIZON COORDINATION AND SUPPORT ACTIONS (FUNDING SCHEME);HORIZON-RIA - HORIZON  RESEARCH AND INNOVATION ACTIONS (FUNDING SCHEME);EU4HEALTH PROGRAMME (EU4H) (PROGRAMME);HORIZON-JU-IHI-2022-01-SINGLE-STAGE (CALL FOR PROPOSAL);HORIZON-JU-RIA - HORIZON JU RESEARCH AND INNOVATION ACTIONS (FUNDING SCHEME);HORIZON-MISS-2021-CANCER-02 (CALL FOR PROPOSAL);HORIZON-MSCA-2021-COFUND-01 (CALL FOR PROPOSAL);HORIZON-TMA-MSCA-COFUND-P - HORIZON TMA MSCA COFUND POSTDOCTORAL PROGRAMME (FUNDING SCHEME);HORIZON.1.2 - MARIE SKŁODOWSKA-CURIE ACTIONS (MSCA) (PROGRAMME);HORIZON.2.1.7 - INNOVATIVE HEALTH INITIATIVE (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","5;4;2;2;1;1;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4205 NURSING;44 HUMAN SOCIETY;4407 POLICY AND ADMINISTRATION;51 PHYSICAL SCIENCES;5105 MEDICAL AND BIOLOGICAL PHYSICS","9;9;6;5;4;3;1;1;1;1;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LUNG;RARE DISEASES;LUNG CANCER;COMPARATIVE EFFECTIVENESS RESEARCH;HEALTH SERVICES;AGING;BIOENGINEERING;BIOMEDICAL IMAGING;CARDIOVASCULAR;DIGESTIVE DISEASES;GENETICS;HEART DISEASE;KIDNEY DISEASE;LIVER DISEASE;NUTRITION;ORPHAN DRUG;PATIENT SAFETY","12;9;4;4;4;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CANCER","12","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.1 INDIVIDUAL CARE NEEDS","2;1;1;1;1;1","LUNG CANCER;NOT SITE-SPECIFIC CANCER;SARCOMA;KIDNEY CANCER;LIVER CANCER;PROSTATE CANCER","4;3;2;1;1;1","6.9 RESOURCES AND INFRASTRUCTURE RELATED TO CANCER CONTROL, SURVIVORSHIP, AND OUTCOMES RESEARCH;1.4 CANCER PROGRESSION AND METASTASIS;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;6.4 COST ANALYSES AND HEALTH CARE DELIVERY;5.1 LOCALIZED THERAPIES - DISCOVERY AND DEVELOPMENT;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","3;2;2;2;2;2;2;1;1;1","A01 CLINICAL MEDICINE;A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;C17 BUSINESS AND MANAGEMENT STUDIES","7;3;2;1","3 GOOD HEALTH AND WELL BEING;11 SUSTAINABLE CITIES AND COMMUNITIES","2;1",78,"FRONTIERS;AMERICAN ASSOCIATION FOR CANCER RESEARCH;PUBLIC LIBRARY OF SCIENCE;SAGE JOURNALS;ZENODO;FUTURE SCIENCE GROUP;TAYLOR & FRANCIS GROUP;SPRINGER NATURE","29;22;12;6;4;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;3105 GENETICS;3202 CLINICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;49 MATHEMATICAL SCIENCES;46 INFORMATION AND COMPUTING SCIENCES;3204 IMMUNOLOGY;3210 NUTRITION AND DIETETICS;44 HUMAN SOCIETY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;34 CHEMICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;4202 EPIDEMIOLOGY;4403 DEMOGRAPHY;4608 HUMAN-CENTRED COMPUTING","108;43;42;31;21;10;10;6;5;4;3;3;3;2;2;1;1;1;1;1","CANCER;GENETICS;CLINICAL RESEARCH;RARE DISEASES;PEDIATRIC;PEDIATRIC CANCER;HEMATOLOGY;BREAST CANCER;CHILDHOOD LEUKEMIA;PREVENTION;BIOTECHNOLOGY;LUNG;NUTRITION;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;GENETIC TESTING;HUMAN GENOME;AGING;BIOMEDICAL IMAGING;DENTAL/ORAL AND CRANIOFACIAL DISEASE","42;18;16;15;10;10;9;8;8;7;4;4;4;3;3;3;3;2;2;2","CANCER;METABOLIC AND ENDOCRINE","58;3","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.1 INDIVIDUAL CARE NEEDS","16;4;3;2;1;1;1;1;1","BIOMEDICAL;CLINICAL;POPULATION & SOCIETY","14;11;2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","25;17;5","BREAST CANCER;NOT SITE-SPECIFIC CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;HEAD AND NECK CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;THYROID CANCER;LARYNGEAL CANCER;SALIVARY GLAND CANCER;LIVER CANCER;MELANOMA;COLON AND RECTAL CANCER;GALLBLADDER CANCER;KIDNEY CANCER;NASAL CAVITY AND PARANASAL SINUS CANCER;NON-HODGKIN'S LYMPHOMA;PANCREATIC CANCER;PROSTATE CANCER;STOMACH CANCER","19;15;8;5;4;4;4;4;3;3;2;2;1;1;1;1;1;1;1;1","3 GOOD HEALTH AND WELL BEING","2"
"IRCCS_TUMORIMILAN",2024,726,20.8333333333333,3.69834710743802,0.279614325068871,0.289256198347107,0.334710743801653,3.2985257985258,1.31818181818182,1.85840707964602,1.41279069767442,0.550964187327824,4,400,125,26,25,0.55,0.17,0.04,0.03,1.14,1.19767989320239,7.00415183867139,0.557851239669422,0.928374655647383,0.545,0.503,0.47,0.487,"FILIPPO PIETRANTONIO;FRANCESCO RASPAGLIESI;ALESSANDRO GRONCHI;GIUSEPPE PROCOPIO;GIORGIO BOGANI;SARA LONARDI;SILVIA STACCHIOTTI;MAURA MASSIMINO;MICHELA CASANOVA;CHIARA CREMOLINI;ANDREA FERRARI;GIANCARLO PRUNERI;VINCENZO MAZZAFERRO;FILIPPO DE BRAUD;SEBASTIANO BUTI;LISA LICITRA;CLAUDIO VERNIERI;GIOVANNA MASALA;UGO DE GIORGI;PAOLO VERDERIO","40;36;34;33;29;27;26;26;24;24;24;22;21;20;20;20;19;19;19;18","FRANCESCO RASPAGLIESI;GIORGIO BOGANI;ALESSANDRO GRONCHI;FILIPPO PIETRANTONIO;LISA LICITRA;ANDREA FERRARI;GIOVANNI LUCA BERETTA;SANDRO PASQUALI;GIUSEPPE PROCOPIO;GIANCARLO PRUNERI;MAURA MASSIMINO;LEONARDO DURANTI;LUCA TAVECCHIO;UMBERTO LEONE ROBERTI MAGGIORE;SILVIA STACCHIOTTI;MICHELA CASANOVA;PAOLO VERDERIO;ALESSANDRA ALESSI;UGO PASTORINO;FABIO MARTINELLI","3.37;3.13;3.11;2.01;1.67;1.61;1.58;1.58;1.57;1.57;1.57;1.5;1.5;1.43;1.38;1.36;1.22;1.21;1.2;1.16","FILIPPO PIETRANTONIO;FRANCESCO RASPAGLIESI;ALESSANDRO GRONCHI;GIUSEPPE PROCOPIO;GIORGIO BOGANI;SILVIA STACCHIOTTI;MAURA MASSIMINO;MICHELA CASANOVA;ANDREA FERRARI;GIANCARLO PRUNERI;VINCENZO MAZZAFERRO;FILIPPO DE BRAUD;LISA LICITRA;CLAUDIO VERNIERI;PAOLO VERDERIO;ROSALBA MICELI;LORIS DE CECCO;PATRIZIA GIANNATEMPO;SANDRO PASQUALI;MASSIMO MILIONE","40;36;34;33;29;26;26;24;24;22;21;20;20;19;18;18;18;18;17;16","FRANCESCO RASPAGLIESI;GIORGIO BOGANI;ALESSANDRO GRONCHI;FILIPPO PIETRANTONIO;LISA LICITRA;ANDREA FERRARI;GIOVANNI LUCA BERETTA;SANDRO PASQUALI;GIUSEPPE PROCOPIO;GIANCARLO PRUNERI;MAURA MASSIMINO;LEONARDO DURANTI;LUCA TAVECCHIO;UMBERTO LEONE ROBERTI MAGGIORE;SILVIA STACCHIOTTI;MICHELA CASANOVA;PAOLO VERDERIO;ALESSANDRA ALESSI;UGO PASTORINO;FABIO MARTINELLI","3.37;3.13;3.11;2.01;1.67;1.61;1.58;1.58;1.57;1.57;1.57;1.5;1.5;1.43;1.38;1.36;1.22;1.21;1.2;1.16","BOHUSLAV MELICHAR;MANUELA SCHMIDINGER;TONI K. CHOUEIRI;ERIC WINQUIST;GIUSEPPE PROCOPIO;PIOTR RUTKOWSKI;THOMAS E. HUTSON;JAIME R. MERCHAN;ROBERT J. MOTZER;MICHELE DEL VECCHIO;LAURA BOTTA;KAIRE INNOS;PAOLO A. ASCIERTO;ROCCO GALASSO;ALEXANDER KATALINIC;FRANCESCO RASPAGLIESI;PAOLO BAILI;VANNA CHIARION‐SILENI;CAMILLO PORTA;UGO DE GIORGI","83;76;64;62;61;61;61;60;60;59;58;56;56;56;55;55;53;51;50;50","GIUSEPPE PROCOPIO;MICHELE DEL VECCHIO;LAURA BOTTA;FRANCESCO RASPAGLIESI;PAOLO BAILI;GIORGIO BOGANI;LISA LICITRA;FILIPPO PIETRANTONIO;PAOLO LASALVIA;SABINA SIERI;ALESSANDRO GRONCHI;MARINA CHIARA GARASSINO;MASSIMO MILIONE;VALENTINA CHIAPPA;PATRIZIA GIANNATEMPO;SILVIA STACCHIOTTI;MAURA MASSIMINO;ROSALBA MICELI;SERENA DI COSIMO;PAOLO VERDERIO","60;59;54;53;51;49;49;42;28;27;24;23;22;22;21;21;20;20;20;18","FILIPPO PIETRANTONIO;FRANCESCO RASPAGLIESI;ALESSANDRO GRONCHI;GIUSEPPE PROCOPIO;GIORGIO BOGANI;MAURA MASSIMINO;SILVIA STACCHIOTTI;MICHELA CASANOVA;ANDREA FERRARI;GIANCARLO PRUNERI;LISA LICITRA;VINCENZO MAZZAFERRO;LORIS DE CECCO;PAOLO VERDERIO;PATRIZIA GIANNATEMPO;ROSALBA MICELI;SANDRO PASQUALI;FILIPPO DE BRAUD;MARCO FIORE;CLAUDIO VERNIERI","40;34;33;32;27;26;26;24;24;20;20;19;18;18;18;18;17;17;16;16","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;CHEMISTRY;SOCIOLOGY;MATHEMATICS;POLITICAL SCIENCE;ENGINEERING;PHILOSOPHY;PSYCHOLOGY;ART;BUSINESS;ECONOMICS;MATERIALS SCIENCE;GEOGRAPHY;HISTORY;ENVIRONMENTAL SCIENCE;GEOLOGY","702;212;63;62;54;26;25;25;19;17;17;13;13;13;10;7;6;4;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CANCER RESEARCH;PATHOLOGY;GENETICS;RADIOLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;BIOCHEMISTRY;PALEONTOLOGY;GASTROENTEROLOGY;GENERAL SURGERY;GYNECOLOGY;BIOINFORMATICS;OPTICS;FAMILY MEDICINE;NURSING;COMPUTATIONAL BIOLOGY;MEDICAL PHYSICS","589;371;158;149;126;95;75;65;63;56;55;52;45;37;33;32;29;28;25;25","CANCER;CHEMOTHERAPY;GENE;RADIATION THERAPY;POPULATION;COHORT;CLINICAL TRIAL;RETROSPECTIVE COHORT STUDY;DISEASE;CONFIDENCE INTERVAL;IMMUNE SYSTEM;RANDOMIZED CONTROLLED TRIAL;STAGE (STRATIGRAPHY);LUNG CANCER;PROSPECTIVE COHORT STUDY;SARCOMA;PROPORTIONAL HAZARDS MODEL;INCIDENCE (GEOMETRY);RENAL CELL CARCINOMA;MELANOMA","409;104;86;59;55;53;47;43;42;40;36;35;35;34;34;33;29;24;23;22","BREAST CANCER;IMMUNOTHERAPY;COLORECTAL CANCER;HAZARD RATIO;CLINICAL ENDPOINT;OVARIAN CANCER;PROSTATE CANCER;GENE EXPRESSION;SOFT TISSUE SARCOMA;BLADDER CANCER;METASTASIS;HEAD AND NECK CANCER;PROGRESSION-FREE SURVIVAL;ADENOCARCINOMA;ENDOMETRIAL CANCER;CERVICAL CANCER;CISPLATIN;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;PHASES OF CLINICAL RESEARCH;PLACEBO","106;98;73;30;29;28;25;21;19;18;18;17;17;15;15;14;14;14;14;12","PEMBROLIZUMAB;NIVOLUMAB;UROTHELIAL CARCINOMA;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;IPILIMUMAB;KRAS;ANDROGEN RECEPTOR;METASTATIC BREAST CANCER;SYSTEMIC THERAPY;NEOADJUVANT THERAPY;IMMUNE CHECKPOINT;TRANSCRIPTOME;TRIPLE-NEGATIVE BREAST CANCER;CORONAVIRUS DISEASE 2019 (COVID-19);ESTROGEN RECEPTOR;LENVATINIB;POLY ADP RIBOSE POLYMERASE;SENTINEL LYMPH NODE;TRASTUZUMAB;UROTHELIAL CANCER","33;32;13;12;11;11;10;10;10;9;8;8;8;7;7;7;7;7;7;7",";HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;PROSPECTIVE STUDIES;PROGNOSIS;ADOLESCENT;NEOPLASMS;BREAST NEOPLASMS;MUTATION;TREATMENT OUTCOME;BIOMARKERS, TUMOR;CHILD","434;290;178;133;131;125;124;65;58;45;38;35;34;31;30;27;25;25;24;24","SARCOMA RESEARCH AND TREATMENT;CANCER IMMUNOTHERAPY;GYNECOLOGIC ONCOLOGY;RENAL CELL CARCINOMA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;ADVANCEMENTS IN LUNG CANCER RESEARCH;GLIOMAS;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;MANAGEMENT OF PERITONEAL CARCINOMATOSIS FROM DIGESTIVE TRACT;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;CHOLANGIOCARCINOMA;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;PEDIATRIC CANCER AND QUALITY OF LIFE;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;COLORECTAL CANCER RESEARCH AND TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;LYMPHOID NEOPLASMS;MOLECULAR RESEARCH ON BREAST CANCER","39;25;25;24;19;19;18;17;15;15;13;13;13;12;11;11;11;10;9;9","CLINICAL ENDPOINT;METASTATIC COLORECTAL CANCER;SOFT TISSUE SARCOMA;TREATMENT;BREAST CANCER;SURGICAL ONCOLOGY;PROGRESSION-FREE SURVIVAL;TUMOR MICROENVIRONMENT;CANCER IMAGING;CANCER IMMUNOEDITING;RADIOTHERAPY;NEOADJUVANT THERAPY;BIOMARKERS FOR IMMUNOTHERAPY;REFRACTORY (PLANETARY SCIENCE);COMBINATION THERAPIES;RENAL CELL CARCINOMA;RHABDOMYOSARCOMA;CANCER RISK;HEALTHY EATING INDEX;INTRATUMOR HETEROGENEITY","29;27;26;24;21;20;18;18;17;17;17;16;15;15;13;13;13;11;11;11","BREAST CANCER;CELL CARCINOMA;COLORECTAL CANCER;LUNG CANCER;CANCER PATIENTS;METASTATIC COLORECTAL;PROSTATE CANCER;RENAL CELL;SQUAMOUS CELL;PHASE III;SOFT TISSUE;ENDOMETRIAL CANCER;PHASE II;UROTHELIAL CARCINOMA;LOCALLY ADVANCED;OVARIAN CANCER;PHASE STUDY;PHASE TRIAL;CERVICAL CANCER;COHORT STUDY;EUROPEAN PROSPECTIVE;IMMUNE CHECKPOINT;NEOADJUVANT CHEMOTHERAPY;PATIENTS TREATED;PROSPECTIVE INVESTIGATION;RETROSPECTIVE STUDY;CELL LUNG;NECK SQUAMOUS;NON-SMALL CELL;TISSUE SARCOMA","57;37;36;27;23;21;21;19;17;15;15;14;14;13;12;12;11;11;10;10;10;10;10;10;10;10;9;9;9;9","HR CI;BREAST CANCER;PROGRESSION-FREE SURVIVAL;SURVIVAL OS;COLORECTAL CANCER;RESPONSE RATE;SURVIVAL PFS;GENETIC TESTING;CROSSREF PUBMED;PUBMED SCOPUS;MEDIAN FOLLOW-UP;PROSTATE CANCER;CANCER PATIENTS;LUNG CANCER;MEDIAN AGE;CELL CARCINOMA;PALLIATIVE CARE;CLINICAL PRACTICE;GENETIC COUNSELING;MEDIAN OS;MONTHS NA;CLINICAL TRIALS;DISEASE PROGRESSION;HAZARD RATIO;IMMUNE CHECKPOINT;PATIENTS TREATED;PRIMARY ENDPOINT;ADVERSE EVENTS;CONFIDENCE INTERVAL;PROGNOSTIC FACTORS","77;61;56;52;45;35;35;33;32;32;30;30;29;29;28;27;26;25;24;23;23;22;22;22;21;21;21;20;20;20",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,3,0.11,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"DE BRAUD FILIPPO GUGLIELMO;RIVOLTINI LICIA;VERNIERI CLAUDIO","1;1;1","FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3210 NUTRITION AND DIETETICS","2;1","CANCER;NUTRITION;PREVENTION","1;1;1","3.3 NUTRITION AND CHEMOPREVENTION","1","A23L33/00;A23L33/115;A23L33/185;A23L33/21","1;1;1;1","A23L33/115;A23L33/185;A23L33/21;A23L33/40;A61P35/00;A61P37/02","1;1;1;1;1;1",5,3.8,1147.2,0.65,0,0,97,0,0,0,0,3,0,0,2,0,3,2,0,0,0,0,0,0,5,0,0,5,0,0,0,0,0,0,0,0,0,"United States;Belgium;Denmark;France;Germany;Netherlands;Switzerland;United Kingdom","2;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","4;4;3;1;1;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;LUNG;LUNG CANCER;LYMPHOMA;AGING;GENETICS","5;5;3;3;2;2;2;2;1;1","CANCER","5","6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.1 INDIVIDUAL CARE NEEDS;7.2 END OF LIFE CARE","3;1;1;1","LUNG CANCER;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER","2;2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","3;2;1",1,2999835,749958.75,4,4,3,1,0,2893386.38915607,0.250917057853361,"FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;INSTITUTE FOR BIOENGINEERING OF CATALONIA;LUND UNIVERSITY;POLITECNICO DI MILANO","1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","HORIZON-EIC - HORIZON EIC GRANTS (FUNDING SCHEME);HORIZON-EIC-2023-PATHFINDEROPEN-01 (CALL FOR PROPOSAL);HORIZON.3.1 - THE EUROPEAN INNOVATION COUNCIL (EIC) (PROGRAMME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","1;1","CANCER;CLINICAL RESEARCH;LUNG;LUNG CANCER;RARE DISEASES;STEM CELL RESEARCH","1;1;1;1;1;1","CANCER","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1;1","LUNG CANCER","1",NA,NA,"A01 CLINICAL MEDICINE","1","3 GOOD HEALTH AND WELL BEING","1",10,"AMERICAN ASSOCIATION FOR CANCER RESEARCH;FRONTIERS","9;1","31 BIOLOGICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","18;9;3;2;2;1","CANCER;BEHAVIORAL AND SOCIAL SCIENCE;BIOTECHNOLOGY;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DENTAL/ORAL AND CRANIOFACIAL DISEASE;DIGESTIVE DISEASES;GENETICS;LUNG;LUNG CANCER;NUTRITION;PREVENTION;RARE DISEASES","2;1;1;1;1;1;1;1;1;1;1;1;1","CANCER","10","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.2 CELLULAR AND GENE THERAPIES;6.1 PHARMACEUTICALS","2;1;1;1","BIOMEDICAL;CLINICAL","5;1","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE","5;3","LUNG CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;NOT SITE-SPECIFIC CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER","9;1;1;1;1;1",NA,NA
